Provisional Applications in Blood Anticlot Technology,
Medications and Medical Devices

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

US PATENT APPLICATIONS IN BLOOD ANTICLOT DRUGS AND DEVICES PUBLISHED 2006 TO 2009



Application No.: US20060002973A1  Published: 05/Jan/2006

Title: Loading and release of water-insoluble drugs

Applicant/Assignee: SCIMED LIFE SYSTEMS, INC

Application No.: 11/188850   Filing Date: 26/Jul/2005

Abstract:A medical device, polymer composition, and method for delivering substantially water-insoluble drugs to tissue at desired locations within the body. At least a portion of the exterior surface of the medical device is provided with a polymer coating. Incorporated in the polymer coating is a solution of at least one substantially water-insoluble drug in a volatile organic solvent. The medical device is positioned to a desired target location within the body, whereupon the drug diffuses out of the polymer coating.

Priority: US2001-978763 Applic. Date: 2001-10-18; US1998-172026 Applic. Date: 1998-10-14; US1998-133603 Applic. Date: 1998-08-13; US1997-910136 Applic. Date: 1997-08-13

Inventor: BARRY JAMES J [US]; PALASIS MARIA [US]


Application No.: US20060008792A1  Published: 12/Jan/2006

Title: Process for improvement of virus-safe biological fluids

Applicant/Assignee: RELIANCE LIFE SCIENCES PVT., LTD RELIANCE LIFE SCIENCES PVT. LTD

Application No.: 11/171877   Filing Date: 29/Jun/2005

Abstract:The present invention relates to a process of disinfecting biological materials. In particular, a novel process is provided for removing detergent and/or solvent added to biological materials for the inactivation of viral contaminants. Safe, efficient, and economical methods for removing virucidal agents such as solvent-detergent from virus-inactivated pooled plasma by hydrophobic interaction chromatography are provided. Methods for clearing solvent-detergent from virus-inactivated biological materials in a single step are also provided.

Priority: IN2004MU00695 Applic. Date: 2004-06-29

Inventor: VISWANATHAN CHANDRA [IN]; KUPPUSAMY MOSUVAN [IN]; KAMATH MANJUNATH [IN]; BAIKAR VILAS [IN]; TANAVADE ARATI [IN]; PRASAD NARAHARI R [IN]


Application No.: US20060009799A1  Published: 12/Jan/2006

Title: Embolic filtering method and apparatus

Applicant/Assignee:

Application No.: 11/184069   Filing Date: 19/Jul/2005

Abstract:The present invention relates generally to a device and method for preventing the undesired passage of emboli from a venous blood pool to an arterial blood pool. The invention relates especially to a device and method for treating certain cardiac defects, especially patent foramen ovales and other septal defects, through the use of an embolic filtering device capable of instantaneously deterring the passage of emboli from the moment of implantation. The device consists of a frame, and a braided mesh of sufficient dimensions to prevent passage of emboli through the mesh. The device is preferably composed of shape memory allow, such as nitinol, which conforms to the shape and dimension of the defect to be treated.

Priority: US2004-847909 Applic. Date: 2004-05-19; US20030471555P Applic. Date: 2003-05-19

Inventor: KLESHINSKI STEPHEN J [US]; RUSSELL SCOTT M [US]


Application No.: US20060009841A1  Published: 12/Jan/2006

Title: Percutaneous aortic valve

Applicant/Assignee: REX MEDICAL REX MEDICAL, L.P

Application No.: 11/222570   Filing Date: 09/Sep/2005

Abstract:The present invention provides a valve configured for insertion on the proximal and distal sides of a heart valve annulus to replace the heart valve of a patient. The valve comprises a first substantially annular portion adapted to be positioned on a proximal side of the annulus of a patient and a second substantially annular portion adapted to be positioned on a distal side of the annulus of a patient, wherein at least one of the first and second substantially annular portions is movable towards the other portion to a clamped position to clamp around the annulus. The second portion has a flow restricting portion extending therefrom and is movable between a first position to permit the flow of blood and a second position to restrict the flow of blood.

In one embodiment, the valve has a suture joining the first and second portions to draw the first and second portions into closer proximity and a cinch member to secure the suture to maintain the first and second portions in the clamped position. In another embodiment, the first and second portions are connected by a first segment which biases the first and second portions toward the clamped position.

Priority: US2003-429536 Applic. Date: 2003-05-05

Inventor: MCGUCKIN JAMES F JR [US]; HINCHLIFFE PETER W [US]


Application No.: US20060013727A1  Published: 19/Jan/2006

Title: Reagent carrier

Applicant/Assignee: SCIL ANIMAL CARE COMPANY GMBH

Application No.: 11/183389   Filing Date: 18/Jul/2005

Abstract:A reagent carrier has a first chamber, which contains a reagent. The reagent carrier is characterized in that at least one second chamber is provided to hold blood, a third chamber is provided to hold a dye and a fourth chamber is designed as a measurement chamber.

Priority: DE200410034801 Applic. Date: 2004-07-19

Inventor: RUDLOFF PETER [DE]


Application No.: US20060014297A1  Published: 19/Jan/2006

Title: Clinical method for the genetic screening of newborns using tandem mass spectrometry

Applicant/Assignee: PERKINELMER GENETICS, INC

Application No.: 11/225615   Filing Date: 13/Sep/2005

Abstract:A method for screening newborns using electrospray tandem mass spectrometry. The method improves the current protocols that use tandem mass spectrometry by assuring accurate and consistent results at the clinical level through enhanced quality controls and quality assurance protocols as applied to the scan profiling and sample preparation of blood spots from newborns. Specific additives are used in precise concentrations of internal standards, employing detailed controls adapted to distinguish twenty metabolites, which are scanned and vigorously compared to known spectra results. Revealing peaks, metabolite concentration, and scan intensities in the quality assurance steps are then compared to a range of thresholds to determine whether or not the sample is contaminated, drug-ridden, diagnosable, or unacceptable.

All spectra results and quality assurance flags are organized in spreadsheet form and exported to a database where values are compiled and stored for daily output results and trend analysis. The method provides for high-throughput and quality results, having a consistent predictability for genetically testing newborns efficiently and accurately.

Priority: US2005-169158 Applic. Date: 2005-06-28; US2002-252115 Applic. Date: 2002-09-23; US1999-464132 Applic. Date: 1999-12-16; US1999-277119 Applic. Date: 1999-03-26; US19990117880P Applic. Date: 1999-01-30

Inventor: CHACE DONALD H [US]


Application No.: US20060014299A1  Published: 19/Jan/2006

Title: Method for analyzing blood for cholesterol components

Applicant/Assignee:

Application No.: 11/104285   Filing Date: 12/Apr/2005

Abstract:A method for detecting and quantifying lipoprotein subgroup concentration in a blood serum sample in a single spin cycle using a fluorescent dye and a self generating continuous gradient followed fluorescent dye detection and quantitation.

Priority: US20040561463P Applic. Date: 2004-04-12

Inventor: TROUP JAN M [US]


Application No.: US20060015074A1  Published: 19/Jan/2006

Title: Catheter flushing fluid lock system and method

Applicant/Assignee:

Application No.: 10/533749   Filing Date: 10/May/2005

Abstract:A catheter-flushing fluid lock system ( 100 ) for maintaining the patency of the lumen of an indwelling catheter ( 203 ). The system is comprised of a fluid locked system such as a tubing system ( 104 ) in fluid connection with an indwelling catheter, said tubing system defining an internal volume and at least one proximal terminal ( 106 ) for intermittent connection with an external fluid source

Priority: WO2002US35163 Applic. Date: 2002-11-04

Inventor: LYNN LAWRENCE A [US]


Application No.: US20060018200A1  Published: 26/Jan/2006

Title: Mediwatch

Applicant/Assignee:

Application No.: 10/796916   Filing Date: 02/Jul/2004

Abstract:A combined watch, storage container and a medical alert bracelet, thus eliminating the need for wearing a separate medical alert bracelet/necklace with separate alarms alerting the wearer when to take medication. The combined watch, pillbox storage container, with a locking device is hinged to the base, having a main face with four individual watch faces within. Control mechanisms fixedly mounted on the underside, of the lid and is adapted for tracking the time of day as well as the ability to set alarms independently and is powered by a battery. Fitting snuggly, the underside lid contains a two-sided removable disc for listing medications and important medical information. Storage device, which is the base housing, having bottom and peripheral walls coupled to and away from the peripheral edge and securely hinged to the lid.

Storage device has multiple removable divisional inserts, allowing the choice for number of compartments with a plastic covered, rotating shield, which the wearer spins to open over the selected compartment. The underside engraved base serves as a medical alert bracelet with medical information permanently engraved

Priority:

Inventor: PITOCCO THERESA A [US]; PITOCCO MICHELLE C [US]


Application No.: US20060018933A1  Published: 26/Jan/2006

Title: Novel drug delivery system

Applicant/Assignee:

Application No.: 11/134631   Filing Date: 19/May/2005

Abstract:A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

Priority: IN2002MU00698 Applic. Date: 2002-08-05; IN2002MU00696 Applic. Date: 2002-08-05; IN2003MU00081 Applic. Date: 2003-01-22; US2003-630348 Applic. Date: 2003-07-29

Inventor: VAYA NAVIN [IN]; KARAN RAJESH S [IN]; NADKARNI SUNIL S [IN]; GUPTA VINOD K [IN]


Application No.: US20060018934A1  Published: 26/Jan/2006

Title: Novel drug delivery system

Applicant/Assignee:

Application No.: 11/134632   Filing Date: 19/May/2005

Abstract:A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

Priority: IN2002MU00698 Applic. Date: 2002-08-05; IN2002MU00696 Applic. Date: 2002-08-05; IN2003MU00081 Applic. Date: 2003-01-22; US2003-630348 Applic. Date: 2003-07-29

Inventor: VAYA NAVIN [IN]; KARAN RAJESH S [IN]; NADKARNI SUNIL S [IN]; GUPTA VINOD K [IN]


Application No.: US20060019234A1  Published: 26/Jan/2006

Title: Modern blood banking employing improved cell preservation composition

Applicant/Assignee: SHANBROM TECHNOLOGIES, LLC

Application No.: 10/897632   Filing Date: 22/Jul/2004

Abstract:An improved anticoagulant is based on a higher level of citric acid than is usual (at least about 0.2% weight by volume). The higher citrate is combined with an amino acid as a counterion. The amino acid prevents cellular damage often caused by elevated citrate levels. The amino acid citrate mixture also serves to preserve platelet concentrates and platelet rich plasma during room incubation. Not only does the amino acid citrate combination enhance platelet integrity, it completely inhibits the growth of bacteria such as Staphylococcus epidermidis. Collecting blood of plasma into such higher levels of citrate prevents activation of blood proteins so that fractions made from the blood or plasma have superior characteristics.

Priority:

Inventor: SHANBROM EDWARD [US]


Application No.: US20060019319A1  Published: 26/Jan/2006

Title: Methods and apparatuses for conducting assays

Applicant/Assignee: MESO SCALE DIAGNOSTICS, LLC MESO SCALE TECHNOLOGIES, LLC

Application No.: 11/145528   Filing Date: 03/Jun/2005

Abstract:Disclosed are methods for conducting assays of samples, such as whole blood, that may contain cells or other particulate matter. Also disclosed are systems, devices, equipment, kits and reagents for use in such methods. One advantage of certain disclosed methods and systems is the ability to rapidly measure the concentration of an analyte of interest in blood plasma from a whole blood sample without blood separation and hematocrit correction.

Priority: US20040576710P Applic. Date: 2004-06-03

Inventor: BILLADEAU MARK A [US]; DEBAD JEFF D [US]; GLEZER ELI N [US]; LELAND JONATHAN K [US]; WIJAYAWARDHANA CHARLES A [US]


Application No.: US20060020227A1  Published: 26/Jan/2006

Title: Collection means and a method for collecting cord blood

Applicant/Assignee:

Application No.: 11/186415   Filing Date: 20/Jul/2005

Abstract:The invention provided herein comprises a kit, where the kit includes at least one collecting receptacle for collecting cord blood, and a pre-measured non-liquid anticoagulant which is optionally pre-loaded into the receptacle. The anticoagulant is preferably selected from the group consisting of heparin or heparin type additives, citrates, EDTA (ethylenediaminetetraacetic acid), and oxalates and any other anticoagulant that can be used to decrease the clotting ability of the blood. The invention provided herein also comprises a method for collecting cord blood, where the method comprises collecting a desired amount of cord blood from the umbilical cord using a collection receptacle of the invention, wherein the collection receptacle is pre-loaded with a pre-measured amount of non-liquid anticoagulant.

Priority: US20040590386P Applic. Date: 2004-07-20

Inventor: MOORE THOMAS E [US]; MAPOTHER BETH [US]


Application No.: US20060024365A1  Published: 02/Feb/2006

Title: Novel dosage form

Applicant/Assignee:

Application No.: 11/134633   Filing Date: 19/May/2005

Abstract:A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg

a process for preparing the dosage form.

Priority: IN2002MU00699 Applic. Date: 2002-08-05; IN2002MU00697 Applic. Date: 2002-08-05; IN2003MU00080 Applic. Date: 2003-01-22; IN2003MU00082 Applic. Date: 2003-01-22; US2003-630446 Applic. Date: 2003-07-29

Inventor: VAYA NAVIN [IN]; KARAN RAJESH S [IN]; SADANAND SUNIL [IN]; GUPTA VINOD K [IN]


Application No.: US20060024745A1  Published: 02/Feb/2006

Title: Variants of factor XllA

Applicant/Assignee:

Application No.: 10/539720   Filing Date: 18/Jul/2005

Abstract:Factor XIIa (activated Factor XII) exists in a variety of forms in the blood. Measurement of different forms provides information relevant for diagnosing, monitoring, or predicting the susceptibility to, progress of, or outcome of a disease or disorder, or of treatment of the disease or disorder in a subject having or suspected of having the disease or disorder.

Priority: GB20020029837 Applic. Date: 2002-12-20; GB20020029835 Applic. Date: 2002-12-20; GB20020029832 Applic. Date: 2002-12-20; GB20020029828 Applic. Date: 2002-12-20; WO2003GB05612 Applic. Date: 2003-12-22

Inventor: PRITCHARD DAVID J [GB]


Application No.: US20060028909A1  Published: 09/Feb/2006

Title: Device and method for flow mixing of a biological fluid and a solution

Applicant/Assignee:

Application No.: 11/196706   Filing Date: 03/Aug/2005

Abstract:The disclosure relates to a mixing machine, system, and method including: a measurement device able to measure a volume of a biological fluid

a pumping device able to pump an anticoagulant and/or preservation solution into the biological fluid

and a control system for the pumping device. The control system may include: a device for determining an actual volume of the solution previously pumped by the pumping device and an automatic control able to control a pumping speed of the pumping device. The automatic control may control the pumping speed by calculating a theoretical volume of the solution to be mixed with the biological fluid previously pumped by the pumping device as a function of a determined ratio of the biological fluid collected and the solution pumped

comparing the theoretical volume to the actual volume

and adjusting the pumping speed of the pumping device to approach the determined ratio.

Priority: FR20040051769 Applic. Date: 2004-08-03

Inventor: BEHAGUE MAURICE [FR]


Application No.: US20060029578A1  Published: 09/Feb/2006

Title: Composition and method for the repair and regeneration of cartilage and other tissues

Applicant/Assignee: BIO SYNTECH CANADA INC ECOLE POLYTECHNIQUE

Application No.: 11/031325   Filing Date: 07/Jan/2005

Abstract:The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention.

Priority: US2001-896912 Applic. Date: 2001-06-29; US20000214717P Applic. Date: 2000-06-29

Inventor: HOEMANN CAROLINE D [CA]; BUSCHMANN MICHAEL D [CA]; MCKEE MARC D [CA]


Application No.: US20060029923A1  Published: 09/Feb/2006

Title: Plasma or serum separation membrane and filter apparatus including the plasma or serum separation membrane

Applicant/Assignee: SEKISUI CHEMICAL CO., LTD

Application No.: 10/533539   Filing Date: 02/May/2005

Abstract:A Plasma or serum separation membrane that enables omitting centrifugal separation, is free from hemolysis attributed to destruction of red blood cells and realizes easy and rapid separation of plasma or serum from blood

and a filter apparatus including the plasma or serum separation membrane. In particular, a plasma or serum separation membrane being a membrane for separation of plasma or serum from blood and having a void ratio of 30% or below

and a filter apparatus comprising a filter member capable of attaining movement of plasma swifter than movement of blood cells and a plasma or serum separation membrane connected in series with a rear side of the filter member.

Priority: JP20020335606 Applic. Date: 2002-11-19; JP20020335607 Applic. Date: 2002-11-19; JP20030124335 Applic. Date: 2003-04-28; WO2003JP14625 Applic. Date: 2003-11-18

Inventor: TOGAWA KATSUYA [JP]; OKAMOTO RYUSUKE [JP]; ISOGAWA HIRONOBU [JP]


Application No.: US20060030051A1  Published: 09/Feb/2006

Title: Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same

Applicant/Assignee:

Application No.: 11/194056   Filing Date: 29/Jul/2005

Abstract:An erythrocyte sedimentation rate (ESR) measurement instrument having a Blood Collection Configuration and an ESR Measurement Configuration. The ESR measurement instrument comprises a sedimentation measurement tube having an hollow interior volume containing a predetermined quantity of blood sample diluting agent therewithin and being air/fluid sealed with respect to the ambient environment

and a blood collection tube having a hollow interior volume containing a predetermined quantity of anti-coagulant and being vacuum-sealed with respect to the ambient environment, and physically coupled to the air-sealed sedimentation measurement tube, by at least a portion of the sedimentation measurement tube being inserted within a portion of the hollow interior volume of the blood collection tube. The sedimentation measurement tube and the blood collection tube are maintained stationarily fixed relative to each other as a unitary assembly having a syringe-like form factor when the ESR measurement instrument is arranged in the Blood Collection Configuration. During this configuration, a needle-supporting connector can be connected to the blood collection tube and a sample of whole blood from a patient vacuum-drawn and injected into the blood collection tube. After the sample of anti-coagulated blood has been collected in the blood collection tube and the needle-supporting connector is disconnected therefrom, the air/fluid seal of the sedimentation measurement tube can be broken and then the sedimentation measurement tube can be manually plunged into and to the bottom of the hollow interior volume of said blood collection tube, using a single-handed operation to rearrange the ESR measurement instrument into the ESR Measurement Configuration. The anti-coagulated sample of blood fills up a substantially portion of the sedimentation measurement tube and mixes with the blood sample diluting agent to enable the blood plasma/erythrocyte cell (P/E) interface level within the sedimentation measurement tube to settle downwards toward the blood collection tube during a predetermined time period when said ESR measurement instrument is oriented in a gravity vertical position. By virtue of the present invention, the erythrocyte sedimentation rate (ESR) of the collected blood sample can be measured by determining how far the P/E interface level has moved against graduation markings formed along the length of the sedimentation measurement tube during the predetermined time period.

Priority: US2003-395860 Applic. Date: 2003-03-21

Inventor: BOUBOULIS DENIS A [US]


Application No.: US20060034847A1  Published: 16/Feb/2006

Title: Methods of treating a subject for a condition

Applicant/Assignee:

Application No.: 10/917270   Filing Date: 11/Aug/2004

Abstract:Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g., simultaneously. Also provided are kits for use in practicing the subject methods.

Priority:

Inventor: YUN ANTHONY J [US]; LEE PATRICK Y [US]


Application No.: US20060035816A1  Published: 16/Feb/2006

Title: Method and composition for inhibiting or slowing blood coagulation

Applicant/Assignee: BRIGHAM & WOMEN'S HOSPITAL, INC THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

Application No.: 10/516450   Filing Date: 02/Dec/2004

Abstract:A method and composition for inhibiting or slowing blood coagulation includes lactadherin, a fragment of lactadherin, a functional equivalent of lactadherin, or a functional equivalent of a fragment of lactadherin.

Priority: US20020386562P Applic. Date: 2002-06-07; WO2003US15404 Applic. Date: 2003-06-06

Inventor: GILBERT GARY E [US]; SHI JIALIN [US]


Application No.: US20060039950A1  Published: 23/Feb/2006

Title: Multi-functional biocompatible coatings for intravascular devices

Applicant/Assignee:

Application No.: 10/924102   Filing Date: 23/Aug/2004

Abstract:A polymeric coating is adapted to substantially eliminate thrombus formation when in contact with blood. The polymeric coating includes a first polymeric layer and a second polymeric layer. Interposed between the first and second polymeric layers is a polymeric matrix layer doped with at least one of a nitric oxide donor and a nitric oxide generator. The nitric oxide donor and/or the nitric oxide generator are capable of releasing or generating NO. A bioactive agent is either immobilized to the surface of the second polymeric layer or is incorporated into the polymeric matrix layer.

Priority:

Inventor: ZHOU ZHENGRONG [US]; MEYERHOFF MARK E [US]; REYNOLDS MELISSA M [US]


Application No.: US20060039990A1  Published: 23/Feb/2006

Title: Biological tissue regenerative agent and method for preparing same

Applicant/Assignee:

Application No.: 10/923237   Filing Date: 20/Aug/2004

Abstract:A biological tissue regenerative agent and method for preparing the same. The agent comprises the compounds that are usually found sequestered within platelets, along with platelet cytosolic components, and serum. The agent is prepared by preparing two quanta of blood. The first is clotted, the cells discarded and the serum retained. The second quantum undergoes concentration and lysis of the platelets therein, followed by recombination of the lysed platelets and platelet internal products with serum to form the agent. In a preferred embodiment, lysis of platelets is accomplished by providing an effective amount of calcium. The agent may be further purified and may be frozen or freeze dried for storage.

Priority:

Inventor: BARRUETA ALBERTO G [ES]; ELIZUNDIA JOSU S [ES]; BARBERA-GUILLEM EMILIO [US]


Application No.: US20060039991A1  Published: 23/Feb/2006

Title: Biological tissue regenerative agent and method for preparing and using same

Applicant/Assignee:

Application No.: 11/208231   Filing Date: 19/Aug/2005

Abstract:A biological tissue regenerative agent and method for preparing the same. The agent comprises the compounds that are usually found sequestered within platelets, along with platelet cytosolic components, and serum. The agent is prepared by preparing two quanta of blood. The first is clotted, the cells discarded and the serum retained. The second quantum undergoes concentration and lysis of the platelets therein, followed by recombination of the lysed platelets and platelet internal products with serum to form the agent. In a preferred embodiment, lysis of platelets is accomplished by providing an effective amount of calcium. The avoidance of a platelet release reaction and the presence of alpha-2 macroglobulin in the serum suppresses active TGF-beta in the agent. The agent may be further purified and may be frozen or freeze dried for storage.

Priority: US2004-923237 Applic. Date: 2004-08-20

Inventor: BARRUETA ALBERTO GORROCHATEGUI [ES]; ELIZUNDIA JOSU SIMON [ES]; BARBERA-GUILLEM EMILIO [US]


Application No.: US20060040772A1  Published: 23/Feb/2006

Title: Formulation for blood clot inhibitor for use with bow hunting broadheads and method for using same

Applicant/Assignee:

Application No.: 11/206463   Filing Date: 18/Aug/2005

Abstract:A method and formulation are disclosed toward the enhancing of a blood trail by a wounded target animal. A topical application for use with broadheads is disclosed as well as a method for using same.

Priority: US20040603691P Applic. Date: 2004-08-21

Inventor: JONES BRANDON C [US]


Application No.: US20060040953A1  Published: 23/Feb/2006

Title: Diketopiperazine salts for drug delivery and related methods

Applicant/Assignee: MANNKIND CORPORATION

Application No.: 11/210710   Filing Date: 23/Aug/2005

Abstract:Biologically active agent delivery compositions, which comprise diketopiperazine carboxylate salts are provided. Related methods for making and using the biologically active agent delivery compositions are also provided.

Priority: US20040603761P Applic. Date: 2004-08-23

Inventor: LEONE-BAY ANDREA [US]; MOYE-SHERMAN DESTARDI [US]; WILSON BRYAN R [US]


Application No.: US20060041216A1  Published: 23/Feb/2006

Title: Two stage hemofiltration that generates replacement fluid

Applicant/Assignee: KKJ, INC

Application No.: 10/922763   Filing Date: 20/Aug/2004

Abstract:The present invention relates to a system for two-stage blood dialysis of a patient. In one embodiment, the system comprises a first filtration device for receiving the blood from the patient and for producing a first filtrate and processed blood. The system further comprises a second filtration device for receiving the first filtrate and producing replacement fluid and waste product. At least one of the first and second filtration devices preferably comprises a Taylor vortex-enhanced blood filtration device.

Priority:

Inventor: MCLAUGHLIN JENNIFER K [US]; SCHOENDORFER DON [US]


Application No.: US20060046259A1  Published: 02/Mar/2006

Title: Differential expression of molecules associated with acute stroke

Applicant/Assignee: THE GOV. OF THE U.S.A AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

Application No.: 11/155835   Filing Date: 17/Jun/2005

Abstract:Methods are provided for evaluating a stroke, for example for determining whether a subject has had an ischemic stroke, determining the severity or likely neurological recovery of a subject who has had an ischemic stroke, and determining a treatment regimen for a subject who has had an ischemic stroke, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes screening for expression in ischemic stroke related genes (or proteins), such as white blood cell activation and differentiation genes (or proteins), genes (or proteins) related to hypoxia, genes (or proteins) involved in vascular repair, and genes (or proteins) related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment.

Also provided are methods of identifying one or more agents that alter the activity (such as the expression) of an ischemic stroke-related molecule.

Priority: WO2005US18744 Applic. Date: 2005-05-27; US20040575279P Applic. Date: 2004-05-27

Inventor: BAIRD ALISON E [US]; MOORE DAVID F [US]; GOLDIN EHUD [US]


Application No.: US20060047221A1  Published: 02/Mar/2006

Title: New method to reduce complete blood count variation of peripheral blood sample

Applicant/Assignee: HONEYWELL INTERNATIONAL, INC

Application No.: 10/924689   Filing Date: 24/Aug/2004

Abstract:The invention sets forth a method for reducing coagulation in a blood sample collected most conveniently from an acral body site such as the fingertip or heel, commonly referred to as capillary blood collection. The method includes the steps of applying an anticoagulant composition to the acral site, lancing the skin in contact with the anticoagulant composition and allowing blood and anticoagulant to mix on the skin at the site prior to collecting the blood for analysis.

Priority:

Inventor: GU YUANDONG [US]


Application No.: US20060047239A1  Published: 02/Mar/2006

Title: Ultrasound catheter devices and methods

Applicant/Assignee: FLOWCARDIA, INC

Application No.: 10/927966   Filing Date: 26/Aug/2004

Abstract:Ultrasound catheter devices and methods provide enhanced disruption of blood vessel obstructions. Generally, an ultrasound catheter device includes an elongate flexible catheter body with one or more lumens, an ultrasound transmission member extending longitudinally through the catheter body lumen and a distal head coupled with the transmission member and positioned adjacent the distal end of the catheter body for disrupting occlusions. A proximal housing of the catheter device may include one or more features for dissipating heat from the ultrasound transmission wire, such as a fluid inlet aperture for passage of fluid, use of heat conductive materials in the proximal housing, surface features to increase the housing's surface area, heat conductive members disposed adjacent the transmission member and the like.

Various irrigation fluids may be used, such as cooled, oxygen supersaturated or lubricious fluids.

Priority:

Inventor: NITA HENRY [US]; SARGE JEFF [US]; SPANO RICHARD [US]


Application No.: US20060051334A1  Published: 09/Mar/2006

Title: Injection of bone marrow-derived conditioned medium for angiogenesis

Applicant/Assignee: MYOCARDIAL THERAPEUTICS, INC

Application No.: 11/117607   Filing Date: 27/Apr/2005

Abstract:Methods are provided for promoting formation of collateral blood supply at an ischemic site in tissue by culturing early attaching cells derived from growth of bone marrow aspirate in vitro, collecting early attaching cells produced by the bone marrow culture and injecting conditioned medium produced by culture of the early attaching cells into an ischemic site in heart or limb. The preferred early attaching cells for use in the invention methods are marrow-derived stromal cells. Any donor's bone marrow can be used in preparation of the conditioned medium. Optionally, the early attaching cells can be transfected with an angiogenesis promoting transgene encoding hypoxia inducing factor 1 alpha, a fibroblast growth factor and/or a nitric oxide synthase. Conditioned media containing angiogenic cytokines produced such cells are also provided for injection into tissue, such as heart or peripheral limb muscle, requiring formation of collateral blood supply.

Priority: US2002-160514 Applic. Date: 2002-05-30; US2001-868411 Applic. Date: 2001-06-14; WO2000US08353 Applic. Date: 2000-03-30; US20040566332P Applic. Date: 2004-04-28; US19990138379P Applic. Date: 1999-06-09; US19990126800P Applic. Date: 1999-03-30

Inventor: KORNOWSKI RAN [IL]; FUCHS SHMUEL [US]; EPSTEIN STEPHEN [US]; LEON MARTIN B [US]


Application No.: US20060051828A1  Published: 09/Mar/2006

Title: Diagnostic test for determining the concentration of transient proteolytic activity in composite biological media

Applicant/Assignee: SYNAPSE B. V

Application No.: 10/514269   Filing Date: 01/Aug/2005

Abstract:A method is provided for determining in real time the course of thrombin activity in a sample of blood or plasma as it appears in and disappears from the simple which comprises adding a thrombin substrate to the sample that, per unit time, produces a detectable signal in a quantity that bears relation to the amount of thrombin present. Simultaneously, in a control sample of the same blood or plasma in which thrombin generation is not triggered, the activity of a standard preparation with invariable thrombin activity is measured. The exact molar amount of thrombin present at any moment is obtained by comparison of the activity measured in clotting blood and the simultaneously measured calibrator. The method is useful inter alia for diagnosing hyper- and hypo-coaguable states, either congenital, acquired or drug-induced in humans and animals. Also provided is a kit for use in this method.

Priority: EP20020076744 Applic. Date: 2002-05-01; WO2003EP04705 Applic. Date: 2003-05-01

Inventor: GIESEN PETER [NL]; HEMKER HENDRIK [NL]; AL DIERI RAED [NL]; BEGUIN SUZETTE L [NL]; WAGENVOORD ROBERT [NL]


Application No.: US20060052745A1  Published: 09/Mar/2006

Title: Blood contacting sensor

Applicant/Assignee: MEDTRONIC MINIMED, INC

Application No.: 10/935954   Filing Date: 08/Sep/2004

Abstract:The invention provides methods and apparatus for detecting an analyte in blood. The apparatus is particularly suited for bringing a sensor into direct contact with blood in vivo. The apparatus comprises a sensor that detects the presence of an analyte and an assembly means. The assembly means has a sensor end, wherein the sensor end of the assembly means is affixed to the sensor, and the assembly means is adapted for coupling with a venous flow device. By coupling with a venous flow device, the assembly means brings the sensor into direct contact with blood flowing through the venous flow device. Examples of venous flow devices that bring the sensor into direct contact with the blood of a subject include, but are not limited to, intravenous catheters and external blood loops, such as are used in extra corporeal membrane oxygenation or hemodialysis.

Priority:

Inventor: VAN ANTWERP NANNETTE M [US]; ENEGREN BRADLEY J [US]; MASTROTOTARO JOHN J [US]; SHAH RAJIV [US]; HOSS UDO [US]; ZHANG YANAN [US]; WANG JENN-HANN [US]; CLARK KENT L [US]


Application No.: US20060058167A1  Published: 16/Mar/2006

Title: Blood component separation system with stationary separation chamber

Applicant/Assignee:

Application No.: 11/167784   Filing Date: 27/Jun/2005

Abstract:Provided is a blood processing system having a stationary component separation chamber. Individual blood components as well as other particles and contaminates are separated from blood flowing through the separation chamber by optical traps configured to manipulate specific components are projected into the flow field of the chamber. Cells or particles of the selected components that are manipulated by the optical traps then may be directed from the flow field to individual reservoirs to collect quantities of the selected components.

Priority: US20040583929P Applic. Date: 2004-06-28

Inventor: RAGUSA MICHAEL [US]; STACEY GARY R [US]; PAGES ETIENNE [FR]


Application No.: US20060062768A1  Published: 23/Mar/2006

Title: Biocompatible hydrogel compositions

Applicant/Assignee:

Application No.: 10/948765   Filing Date: 23/Sep/2004

Abstract:Compositions, instruments, systems, and methods are providing for creating families of materials having diverse therapeutic indications and possessing enhanced biocompatibility. The genus platform for the families includes a biocompatible synthetic electrophilic component mixed with a nucleophilic component. The electrophilic component can include a functionalized electrophilic poly (anhydride ester) material. The nucleophilic material can include a natural, autologous protein. The components, when mixed in a liquid state, react by cross-linking, forming a solid matrix composition, or hydrogel.

Priority:

Inventor: HNOJEWYJ OLEXANDER [US]


Application No.: US20060067936A1  Published: 30/Mar/2006

Title: IL-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses

Applicant/Assignee: CENTOCOR, INC

Application No.: 11/234011   Filing Date: 23/Sep/2005

Abstract:An anti-IL-23 specific human Ig derived protein, isolated nucleic acids that encode at least one anti-IL-23 Ig derived protein, vectors, host cells, transgenic animals or plants, and methods of making and using thereof are useful as therapeutic and diagnostic compositions, methods and devices. The anti-IL-23 Ig derived protein preferably binds to one or more of the Seg 1, Seg 2, and Seg 3 epitopes of the p40 subunit of IL-23.

Priority: US20040612866P Applic. Date: 2004-09-24; US20040616832P Applic. Date: 2004-10-07

Inventor: BENSON JACQUELINE [US]; CUNNINGHAM MARK [US]; LUO JEFFREY [US]


Application No.: US20060068030A1  Published: 30/Mar/2006

Title: Individual need-based system for providing supplements

Applicant/Assignee: NUTRI-CHECK TECHNOLOGIES, LLC

Application No.: 10/541621   Filing Date: 06/Jul/2005

Abstract:A system for individual need-based determinations relative to the use of a substance is presented in various embodiments. As applied to supplements the system may be configured to present a test modality ( 6 ) which may be attached to a distribution container ( 1 ) within which supplements ( 2 ) or the like may be contained. The test modality ( 6 ) may be a user practical test modality that may be provided to a user with an information display ( 11 ) that may include an internal display ( 12 ) to educate the user on a particular test modality ( 6 ). Provisions for the options of a test result recordation enablement element ( 10 ) are provided in both manual and internet forms. The test modality ( 6 ) may be test strips compactly assembled and provided attached to the distribution container ( 1 ).

Priority: US20030438426P Applic. Date: 2003-01-06; WO2004US00179 Applic. Date: 2004-01-06

Inventor: JENSEN JAMES C [US]; SUGERMAN HERBERT L [US]


Application No.: US20060068373A1  Published: 30/Mar/2006

Title: Systems and methods of identifying biomarkers for subsequent screening and monitoring of diseases

Applicant/Assignee: VITRIMARK, INC

Application No.: 11/232597   Filing Date: 22/Sep/2005

Abstract:A system for generating an image of ultrastructural biomarkers from a biological sample is provided. The system includes a grid onto which a sample to be imaged may be placed and a cryogenic reservoir into which the grid and sample may be immersed for vitrification of the sample. The system also includes a stage onto which the grid and sample may be situated for subsequent imaging in a high contrast imager to permit identification of ultrastructural biomarkers therein. A method for generating an image of ultrastructural biomarkers from a biological sample is also provided. The generated image of ultrastructural biomarkers may be used subsequently for screening and monitoring diseases, evaluating drug and therapeutic efficacy, and assessing risks associated with a drug or therapeutic candidate, among other things.

Priority: US20040612713P Applic. Date: 2004-09-24

Inventor: BOSE ARIJIT [US]; AZIZ NAZNEEN [US]


Application No.: US20060069093A1  Published: 30/Mar/2006

Title: Substituted 2H-1,3-benzoxazin-4(3H)-ones

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 11/236051   Filing Date: 26/Sep/2005

Abstract:Substituted benzoxazin-4(3H)-ones are provided which are useful for treating thrombosis and for reducing the likelihood and/or severity of a secondary ischemic event in a patient.

Priority: US20040614564P Applic. Date: 2004-09-29

Inventor: SCARBOROUGH ROBERT M [US]; VENKATRAMAN MEENAKSHI S [US]; ZHANG XIAOMING [US]; PANDEY ANJALI [US]


Application No.: US20060073182A1  Published: 06/Apr/2006

Title: Conveniently implantable sustained release drug compositions

Applicant/Assignee:

Application No.: 11/236426   Filing Date: 27/Sep/2005

Abstract:This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

Priority: US20040614484P Applic. Date: 2004-10-01; US20050709665P Applic. Date: 2005-08-19

Inventor: WONG VERNON G [US]; WOOD LOUIS L [US]


Application No.: US20060073217A1  Published: 06/Apr/2006

Title: Methods of preventing weight gain

Applicant/Assignee: MOR RESEARCH APPLICATIONS LTD

Application No.: 11/283928   Filing Date: 22/Nov/2005

Abstract:Methods for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed.

Priority: IL20040161595 Applic. Date: 2004-04-22; WO2005IL00440 Applic. Date: 2005-04-21; US20050670290P Applic. Date: 2005-04-12

Inventor: BARAK NIR [IL]


Application No.: US20060073467A1  Published: 06/Apr/2006

Title: Biocompatible polymer and filter for selectively eliminating leucocytes using the same

Applicant/Assignee: ASAHI KASEI KURARAY MEDICAL CO., LTD

Application No.: 10/518351   Filing Date: 30/Aug/2005

Abstract:It is intended to provide a polymer which is scarcely eluted, has a high biocompatibility and is useful in a filter for selectively eliminating leucocytes. It is also intended to provide a filter for selectively eliminating leucocytes, a filtration apparatus for selectively eliminating leucocytes and a system for selectively eliminating leucocytes, each having the above-described polymer. The above objects can be achieved by providing a polymer which comprises from 8% by mol to 45% by mol of a unit originating in a polymerizable monomer having a polyalkylene oxide chain, from 30% by mol to 90% by mol of a unit originating in a polymerizable monomer having a hydrophobic group, and from 2% by mol to 50% by mol of a unit originating in polymerizable monomer having a hydroxyl group.

Priority: JP20020176332 Applic. Date: 2002-06-17; JP20020176333 Applic. Date: 2002-06-17; WO2003JP07687 Applic. Date: 2003-06-17

Inventor: KUNO SUSUMU [JP]; ONODERA HIROKAZU [JP]; SAKURAI MASAMI [JP]


Application No.: US20060074378A1  Published: 06/Apr/2006

Title: Device for draining the coronary sinus

Applicant/Assignee:

Application No.: 10/956973   Filing Date: 01/Oct/2004

Abstract:A device for draining a coronary sinus comprises a first catheter having a distal end, a proximal end, and a passage there through, the distal end adapted to be placed in a coronary sinus, a second catheter having a distal end, a proximal end, and a passage there through, the distal end adapted to be placed in a right side of a heart, and a control system for receiving signals indicative of a coronary sinus needing to be drained of blood, the control system comprising a pump for pumping blood from a coronary sinus through the first catheter to the second catheter into a right side of a heart.

Priority:

Inventor: STAMOS THOMAS S [US]


Application No.: US20060074410A1  Published: 06/Apr/2006

Title: Energy based devices and methods for treatment of anatomic tissue defects

Applicant/Assignee: CIERRA, INC

Application No.: 10/952492   Filing Date: 27/Sep/2004

Abstract:Methods for treating anatomic tissue defects such as patent foramen ovale (PFO) generally involve positioning a distal end of an elongate catheter device at the site of the anatomic defect, exposing an expandable housing and energy transmission member out of the distal end of the catheter device, engaging the housing with tissues at the site of the anatomic defect, applying suction to the tissues via the housing to bring the tissues together

and applying energy to the tissues with the energy transmission member to substantially close the anatomic defect acutely. Apparatus generally include an elongate catheter body, a housing extending from a distal end of the catheter body for engaging tissues at the site of the anatomic defect, and an energy transmission member adjacent a distal end of the housing, the energy transmission member having at least one substantially planar surface.

Priority: US2004-873348 Applic. Date: 2004-06-21

Inventor: MALECKI WILLIAM [US]; FRANCIS DAN [US]; HORNE KENNETH [US]; DEEM MARK E [US]; GIFFORD HANSON [US]; ALEJANDRO JOSE [US]


Application No.: US20060084686A1  Published: 20/Apr/2006

Title: Methods of food intake management

Applicant/Assignee: MOR RESEARCH APPLICATIONS LTD

Application No.: 11/283865   Filing Date: 22/Nov/2005

Abstract:Methods for regulating food intake in a human subject

for improving a compliance of a human subject to caloric restriction

and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.

Priority: IL20040161595 Applic. Date: 2004-04-22; US20050670290P Applic. Date: 2005-04-12

Inventor: BARAK NIR [IL]


Application No.: US20060094715A1  Published: 04/May/2006

Title: 5-Ht4 receptor antagonists for the treatment of heart failure

Applicant/Assignee:

Application No.: 10/514386   Filing Date: 26/Aug/2005

Abstract:This invention provides the use of a 5-HT4 receptor antagonist in the manufacture of a medicament for treating or preventing heart failure. Particular heart disorders to be treated are selected from the group comprising chronic heart failure, congestive heart failure, chronic congestive heart failure and heart failure resulting from ischaemic heart disease. Methods of treating heart failure using 5-HT4 receptor antagonists and pharmaceutical compositions containing 5-HT4 receptor antagonists are also provided.

Priority: GB20020011230 Applic. Date: 2002-05-16; WO2003GB02134 Applic. Date: 2003-05-16

Inventor: LEVY FINN O [NO]


Application No.: US20060094985A1  Published: 04/May/2006

Title: Autonomous, ambulatory analyte monitor or drug delivery device

Applicant/Assignee: ROSEDALE MEDICAL

Application No.: 11/311667   Filing Date: 20/Dec/2005

Abstract:The invention relates to analyte monitoring/drug (pharmaceutical agent) delivery device. The invention is suited for monitoring various blood constituents such as glucose. The device has a housing that at least partially encloses a plurality of microneedles disposed on a carrier and an electronics portion. Each microneedle is in fluid communication with a corresponding microchannel. Each microneedle is individually addressable. That is, each microneedle can be extended and retracted individually via an actuator. The electronics portion includes a processor and associated circuitry (e.g., memory, supporting electronics and the like), a motor or the like, a sensor, a power supply (e.g., battery) and optionally an interface. In general, the processor controls the operation of the device and is data communication with the actuator, motor, sensor and interface. The invention provides for autonomous operation, that is, without intervention of the user. The invention can optionally provide for calibration without intervention of the user. The invention can also provide for semi-continuous monitoring for day and night time. The invention can provide for up to four, or more, weeks of operation. The invention can provide for a device that is relative small in size, and therefore unobtrusive. The invention can also provide for device with remote control and interactive electronics. The invention may be also used for the delivery of various pharmaceutical agents including high potency drugs to minimize patient intervention and minimize discomfort.

Priority: US2002-131268 Applic. Date: 2002-04-23; US20020355195P Applic. Date: 2002-02-08

Inventor: ACETI JOHN G [US]; MCBRIDE STERLING E [US]; MORONEY RICHARD M [US]; GREGORY CHRISTOPHER C [US]; ZANZUCCHI PETER J [US]


Application No.: US20060104944A1  Published: 18/May/2006

Title: Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use

Applicant/Assignee:

Application No.: 11/018710   Filing Date: 20/Dec/2004

Abstract:The present invention relates to a method of treating a subject for a condition mediated by a deficiency in angiogenesis by administering to the subject a PAR2 agonist under conditions effective to promote angiogenesis and treat the conditions mediated by a deficiency in angiogenesis. A further aspect of the present invention is a method of treating a subject for condition mediated by excessive or pathological angiogenesis by administering to the subject a PAR2 antagonist or inhibitor under conditions effective to inhibit angiogenesis and treat the subject for the condition mediated by excessive or pathological angiogenesis.

Priority: US20040629190P Applic. Date: 2004-11-18

Inventor: MOUSA SHAKER A [US]


Application No.: US20060106331A1  Published: 18/May/2006

Title: Apparatus and method for in-vivo plasmapheresis using periodic backflush containing anticoagulant

Applicant/Assignee: TRANSVIVO INC

Application No.: 11/320866   Filing Date: 29/Dec/2005

Abstract:Method for in-vivo plasmapheresis utilizing a plurality of elongated hollow microporous filter fibers periodically interrupt diffusion of blood plasma from a patient, and, for a selected time, directing backflush fluid into the fibers at a pressure and interval sufficient to cleanse the fiber pores, after which plasma diffusion is resumed. The backflush fluid, preferably a normal saline solution, may contain an anticoagulant such as heparin, citrate or NO donor in suitable concentration for systemic anti-coagulation or for treating the fiber for thromboresistance.

Priority: US2003-408657 Applic. Date: 2003-04-04; US2001-754773 Applic. Date: 2001-01-04

Inventor: GORSUCH REYNOLDS G [US]; COOPER TOMMY G [US]; HANDLEY HAROLD H JR [US]; PETERS HAROLD W [US]


Application No.: US20060110368A1  Published: 25/May/2006

Title: Medium for culturing autologous human progenitor stem cells and applications thereof

Applicant/Assignee: INSTITUTO CIENTIFICO Y TECHNOLOGICO DE NAVARRA, SA

Application No.: 10/519974   Filing Date: 11/Jun/2003

Abstract:Described is a medium for the autologous culture of autologous human progenitor stem cells, which comprises: between 0.1 and 90 wt.-% autologous human serum

between 0.1 and 10,000 UI/ml heparin

between 0.1 and 10,000 UI/ml protamine

and a culture medium consisting of basic nutrients with or without glutamine, in a sufficient quantity to make up 100 wt.-%, which can be used to culture and expand autologous human progenitor stem cells. Compositions containing said cells can be implanted in the patient using an autologous cellular cardiomyoplasty method in order to create, regenerate and repair dysfunctional myocardial tissue.

Priority: ES20020001540 Applic. Date: 2002-07-02; WO2003ES00285 Applic. Date: 2003-06-11

Inventor: PROSPER CARDOSO FELIPE [ES]; GONZALEZ JESUS H [ES]


Application No.: US20060115449A1  Published: 01/Jun/2006

Title: Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 11/000572   Filing Date: 30/Nov/2004

Abstract:This document discloses a family of tyrosine carbonate polymers and polymer mixtures that may contain bioactive or biobeneficial polymers or constituents. Methods of making these polymers and mixtures are disclosed, as well. Also, implantable or partially implantable medical devies constructed with or from these polymers are disclosed.

Priority:

Inventor: PACETTI STEPHEN D [US]


Application No.: US20060115457A1  Published: 01/Jun/2006

Title: Biocompatible hydrogel compositions

Applicant/Assignee:

Application No.: 11/233737   Filing Date: 23/Sep/2005

Abstract:Compositions, instruments, systems, and methods are providing for creating families of materials having diverse therapeutic indications and possessing enhanced biocompatibility. One genus platform for the families includes a biocompatible synthetic electrophilic component mixed with a nucleophilic component. The electrophilic component can include a functionalized electrophilic poly (anhydride ester) material. The nucleophilic material can include a natural, autologous protein. The components, when mixed in a liquid state, react by cross-linking, forming a solid matrix composition, or hydrogel.

Priority: US2004-948765 Applic. Date: 2004-09-23

Inventor: HNOJEWYJ OLEXANDER [US]


Application No.: US20060115514A1  Published: 01/Jun/2006

Title: Chelating and binding chemicals to a medical implant, medical device formed, and therapeutic applications

Applicant/Assignee:

Application No.: 11/284832   Filing Date: 23/Nov/2005

Abstract:Chelating and binding chemicals to a medical implant, and therapeutic applications. Implantable metal chelated surface and chemical coated medical implant device-drug (or biological moiety) coated or drug eluting stent, prosthesis, or other, includes a medical implant component having metal surface (M) with chemical entity (X) bound via chelator (C) chelated to the metal surface in an (M)-(C)-(X) configuration. Chelator or/and chemical entity-drug (or biological moiety), linker bonded to a drug (or biological moiety), other, are bound at surface concentration greater than 100 picograms per cm<2>. Manufacturing the implantable medical device. Medical implant system including medical implant component and delivery device for delivering and implanting medical implant component in a subject. Implanting the medical device. Preventing or/and treating medical conditions, such as restenosis or/and thrombosis, by implanting the medical device, wherein activity of bound chemical entity exhibits efficacy towards the medical condition.

Priority: US20040630560P Applic. Date: 2004-11-26

Inventor: GENGRINOVITCH STELA [IL]


Application No.: US20060122552A1  Published: 08/Jun/2006

Title: Extracorporeal blood treatment and system having reversible blood pumps

Applicant/Assignee: CHF SOLUTIONS INC

Application No.: 11/002442   Filing Date: 03/Dec/2004

Abstract:An extracorporeal blood treatment system including: a blood circuit having a first blood passage coupled at a first end to a first end of a blood treatment device and a second blood passage coupled at a first end to a second end of the treatment device, wherein the first and second blood passages each have a second end adapted to be coupled to a vascular system of a human patient

a first blood pump connectable to the first blood passage and a second blood pump connectable to the second blood passage, wherein said first and second blood pumps are adapted to move blood through the first and second blood passages in a first direction and in a reverse direction, and a pump controller operatively connected to the first and second blood pumps, said controller operates the blood pumps to cyclically move blood through the first and second blood passages in the first direction and the reverse direction.

Priority:

Inventor: O'MAHONY JOHN J [IE]


Application No.: US20060122673A1  Published: 08/Jun/2006

Title: System and method for determining and controlling core body temperature

Applicant/Assignee: RADIANT MEDICAL,INC RADIANT MEDICAL, INC

Application No.: 10/525625   Filing Date: 03/Oct/2005

Abstract:Systems and methods for accurate temperature modification of a patient, or selected regions thereof, including inducing hypothermia. The temperature modification is accomplished using an in-dwelling heat exchange catheter within which a fluid heat exchange medium circulates. A heat exchange cassette attached to the circulatory flow lines of the catheter, the heat exchange cassette being sized to engage a cavity within a control unit. A temperature measurement scheme for obtaining body core temperature is provided, including methods of obtaining and analyzing temperature data to provide feedback to the control unit for use in controlling the heating and cooling of the heat exchange medium so as to heat or cool a patient to a desired target temperature.

Priority: US20020410096P Applic. Date: 2002-09-12; WO2003US28683 Applic. Date: 2003-09-12

Inventor: CALLISTER JEFFREY [US]; STULL PAUL M [US]; WU ANDREW E [US]; SCOTT DAVID J [US]


Application No.: US20060127389A1  Published: 15/Jun/2006

Title: Fused protein with the function of both hemolysis and anticoagulation and use of it

Applicant/Assignee:

Application No.: 10/526682   Filing Date: 10/Nov/2005

Abstract:This application relates to a fusion protein, which is composed of a thrombolytic protein, an anticoagulant protein, and a linker peptide. In particular, the fusion protein is composed of an anticoagulant protein and a protein molecule having plasminogen-activating activity, wherein said two proteins are linked together via a linker peptide, which can be recognized and cleaved by blood coagulation factors. The application also relates to the medical use of said fusion protein, and to the use of the linker peptide which can be recognized by blood coagulation factor in linking a thrombolytic protein and an anticoagulation protein.

Priority: WO2003CN00743 Applic. Date: 2003-09-03; CN20021029086 Applic. Date: 2002-09-03

Inventor: SHI BINGXING [CN]; WU ZUZE [CN]; YU AIPING [CN]; DONG CHUNNA [CN]


Application No.: US20060141450A1  Published: 29/Jun/2006

Title: Magnetism based rapid cell separation

Applicant/Assignee: CAPITALBIO CORPORATION TSINGHUA UNIVERSITY

Application No.: 10/538498   Filing Date: 31/Dec/2002

Abstract:This invention relates generally to the field of. In particular, the invention provides processes and kits for isolating a target cell, cellular organelle or virus from a sample, using inter alia, non- or low-specific binding between a target cell, cellular organelle or virus with a magnetic microbead.

Priority: CN20021053992 Applic. Date: 2002-12-09; WO2002CN00942 Applic. Date: 2002-12-31

Inventor: ZHANG XU [CN]; XIE XIN [CN]; CHEN DEPU [CN]; FEI WEIYANG [CN]; CHENG JING [CN]


Application No.: US20060141629A1  Published: 29/Jun/2006

Title: Method and system for determining platelet-mediated clot formation

Applicant/Assignee:

Application No.: 11/022339   Filing Date: 27/Dec/2004

Abstract:The present invention concerns methods for determining platelet medicated clot formation. Specifically, the invention provides a method for determining platelet-medicated clot formation in a blood sample comprising: (i) obtaining sample of blood, and optionally mixing same with an anti-coagulant in an amount effective to inhibit clot formation

(ii) in a vessel, mixing the sample with a minute amount of an initiator to obtain a mixed sample, the amount being effective to initiate coagulation

(iii) rotating the mixed sample inside the vessel, whereby shear forces are developed at the surface of said vessel in a manner and for a time sufficient to allow adhesion of platelets at the surface of said vessel

(iv) determining clot formation at the surface of said adherent platelets.

The method has different applications, among others, for determining a coagulation disorder in a subject having a coagulation factor dysfunction.

Priority:

Inventor: GITEL SANFORD N [IL]


Application No.: US20060142707A1  Published: 29/Jun/2006

Title: Apparatus and method for autologous normovolemic hemodilution

Applicant/Assignee: UNIVERSITY HOSPITALS OF CLEVELAND CASE WESTERN RESERVE UNIVERSITY

Application No.: 11/318286   Filing Date: 23/Dec/2005

Abstract:A system and method for autologous normovolemic hemodilution (ANH) are disclosed. The system can include a vacuum canister, which is sized to accept donor bags of a predetermined capacity. The vacuum canister is connected to a vacuum source which applies a suction to the donor bag within the canister. The system can include a canister having a self-generated vacuum, which includes compressible sidewalls that are spring-loaded to provide negative pressure needed to collect blood from a patient without the use of a gravity-induced siphon gradient. Also disclosed are ANH systems and kits that rely on a gravity-induced siphon gradient for blood collection.

Priority: US20040639246P Applic. Date: 2004-12-27

Inventor: TRICKETT JAMES R [US]


Application No.: US20060148901A1  Published: 06/Jul/2006

Title: Acylated 4-amidino-and-4-guanidinobenzylamines for inhibition of plasma kallikrein

Applicant/Assignee:

Application No.: 10/540958   Filing Date: 15/Jan/2004

Abstract:The invention relates to the use of acylated 4-amidino- or 4-guanidinobenzylamine in accordance with the general formula I P4-P3-P2-P1 (I), where P4 is a monosubstituted or polysubstituted or unsubstituted benzylsulfonyl group, P3 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural alpha-amino acid or alpha-imino acid in the D configuration, P2 is a monosubstituted or polysubstituted or unsubstituted, natural or unnatural alpha-amino acid or alpha-imino acid in the L configuration, and P1 is a monosubstituted or polysubstituted or unsubstituted 4-amidino- or 4-guanidinobenzylamine group, for inhibiting plasma kallikrein (PK), factor XIa and factor XIIa, in particular for preventing the activation of coagulation at synthetic surfaces and for systemic administration as anticoagulants/-antithrombotic agents, in particular for preventing the activation of coagulation at synthetic surfaces for the purpose of averting thromboembolic events.

Priority: DE20031001300 Applic. Date: 2003-01-15; WO2004EP00247 Applic. Date: 2004-01-15

Inventor: STURZEBECHER JORG [DE]; STEINMETZER TORSTEN [DE]; SCHWEINITZ ANDREA [DE]


Application No.: US20060149213A1  Published: 06/Jul/2006

Title: Self-sealing male connector device with collapsible body

Applicant/Assignee: CAREFUSION 303 INC

Application No.: 11/026002   Filing Date: 30/Dec/2004

Abstract:A self-sealing male connector device for connection with a female Luer connector. The device has an elongated male body configured with lengthwise relatively rigid and flexible wall segments cooperating to allow the body to be radially compressed from an expanded configuration to a contracted configuration. A closure cap formed with a resealable aperture is disposed on the distal end of the male body so as to be responsive to the compression of the male body. The relatively flexible wall segments may be installed within notches in the male body or be formed integral with the relatively rigid wall segments.

Priority:

Inventor: RAYBUCK JOHN [US]


Application No.: US20060149483A1  Published: 06/Jul/2006

Title: Method and apparatus for determining anticoagulant therapy factors

Applicant/Assignee: WADA, INC

Application No.: 11/359667   Filing Date: 22/Feb/2006

Abstract:Methods and apparatus are disclosed for determining a new anticoagulant therapy factor (nATF) for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. In one embodiment, the new anticoagulant therapy factor is based upon a determination of a new fibrinogen transformation rate (nFTR) which, in turn, is dependent on a maximum acceleration point (MAP) for fibrinogen (FBG) conversion. The new anticoagulant therapy factor quantity is also based upon the time to maximum acceleration from the time of reagent injection (TX) into a plasma sample, but does not require the difficulty of obtaining prior art International Normalized Ratio (INR) and International Sensitivity Index (ISI) parameters.

Other embodiments provide methods and apparatus for determining an anticoagulant therapy factor without requiring use of a mean normal prothrombin time determination or ISI.

Priority: US2003-662043 Applic. Date: 2003-09-12; US2003-428708 Applic. Date: 2003-05-02; US20050679423P Applic. Date: 2005-05-10

Inventor: CARROLL WALLACE E [US]; JACKSON R D [US]


Application No.: US20060151522A1  Published: 13/Jul/2006

Title: Patient usable emergency medical kit

Applicant/Assignee:

Application No.: 11/372838   Filing Date: 10/Mar/2006

Abstract:An emergency medical kit to be carried by a patient having a known high risk of suffering a sudden ischemic event such as a heart attack or a stroke. The kit includes a breathable oxygen delivery system configured for self administration of breathable oxygen by the patient. The breathable oxygen increases oxygen saturation in the blood upon the onset of symptoms of the sudden ischemic event. The kit also includes one or more medications specifically prescribed to the patient by a physician. The medications are of a type and dosage suitable for self administration include specific elements selected to prevent the death of the patient when taken in combination with breathable oxygen immediately upon the onset of symptoms of the sudden ischemic event. The kit includes a portable container to hold the breathable oxygen delivery system and the medication therein. The kit may be carried by the patient or stored near the patient.

Priority: US2002-075088 Applic. Date: 2002-02-16

Inventor: SPRUIELL GRAHAM L [US]


Application No.: US20060153716A1  Published: 13/Jul/2006

Title: Device for sucking liquid and method for sucking liquid

Applicant/Assignee:

Application No.: 10/524440   Filing Date: 01/Apr/2005

Abstract:When a plurality of liquids are simultaneously sucked using a plurality of suction paths connected to a single pump, one suction end may hinder other acts of suction. A multiple valve for connecting each suction path and the pump in a one-by-one manner is disposed between the plurality of suction paths and the pump. Suction is conducted while the communication between the suction paths and the pump is successively switched in a time-sharing manner. At a certain period of time, the pump and a given path is independent of other suction paths. Whereby, suction can be conducted without being influenced by suction ends of other suction paths.

Priority: WO2002JP09555 Applic. Date: 2002-09-18

Inventor: SHOJI YOSHIYUKI [JP]; YOKOBAYASHI TOSHIAKI [JP]


Application No.: US20060155236A1  Published: 13/Jul/2006

Title: Method and apparatus for collecting a blood component and performing a photopheresis treatment

Applicant/Assignee: THERAKOS, INC

Application No.: 11/304092   Filing Date: 15/Dec/2005

Abstract:Methods and apparatus for collecting and treating blood component. An apparatus and methods for improvement of an extracorporeal photopheresis treatment is described. A cassette having flexible tubes inside its housing and on the bottom surface outside the cassette housing for ease of manufacturing is operated with a centrifuge bowl having an inlet and two outlets, pressure domes for measuring pressures in tubes, an improved irradiation plate, and a dual chamber bag in an extracorporeal photopheresis treatment.

Priority: US20040637985P Applic. Date: 2004-12-21

Inventor: GARA STEPHEN [US]; STAR CYNTHIA [US]; BRIGGS DENNIS [US]; HUTCHINSON MICHAEL [US]; WATTERS TOM [US]


Application No.: US20060160165A1  Published: 20/Jul/2006

Title: Device and methods for identifying and treating aspirin non-responsive patients

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 11/304054   Filing Date: 14/Dec/2005

Abstract:The present invention relates to methods and compositions for identifying and treating subjects in need of antithrombotic therapies but who are not responsive to aspirin.

Priority: US20040636744P Applic. Date: 2004-12-14

Inventor: PHILLIPS DAVID R [US]; ANDRE PATRICK [US]; STEPHENS GILLIAN [US]


Application No.: US20060165649A1  Published: 27/Jul/2006

Title: Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases

Applicant/Assignee:

Application No.: 10/534324   Filing Date: 13/Apr/2003

Abstract:Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agent is capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of MPD. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Priority: US20020424731P Applic. Date: 2002-11-06; WO2003US11325 Applic. Date: 2003-04-13

Inventor: ZELDIS JEROME B [US]


Application No.: US20060165809A1  Published: 27/Jul/2006

Title: Oral pharmaceutical formulation in the form of a plurality of microcapsules for prolonged release of active principle(s) with slow solubility

Applicant/Assignee:

Application No.: 10/522252   Filing Date: 28/Jul/2003

Abstract:The invention concerns microcapsules with prolonged release of active principles with low solubility, consisting of a core containing the active principle and coated with a polymer layer which controls the release of the active principle. The aim is that said oral microcapsules containing hardly soluble active principles should have a coating film of sufficient thickness to ensure controlled permeability and should be adapted to industrial reproduction. This is achieved by the inventive microcapsules of mean diameter less than 1000 microns, and whereof the coating film contains a film-forming polymer (P1) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA). Said microcapsules are characterized in that their coating films represents at least 3% p/p of dry matter, relative to their total weight and their core contains a hardly soluble active principle and a solubilizing agent (polyoxyethylene hydrogenated castor oil) which provides the core wherein it is contained with properties such that the behaviour of the exposed core (non-coated) in a given dissolving test (TD), is as follows: release of 80% of active principle in less than two hours. The invention also concerns the use of such microcapsules in galenic formulation.

Priority: FR20020009532 Applic. Date: 2002-07-26; WO2003FR02382 Applic. Date: 2003-07-28

Inventor: GUIMBERTEAU FLORENCE [FR]; CASTAN CATHERINE [FR]; MEYRUEIX REMI [FR]


Application No.: US20060166239A1  Published: 27/Jul/2006

Title: Genetic variants predicting warfarin sensitivity

Applicant/Assignee: ACADEMIA SINICA

Application No.: 11/316406   Filing Date: 21/Dec/2005

Abstract:We discovered that a polymorphism in the promoter of the VKORC1 gene is associated with warfarin sensitivity. This polymorphism can explain both the inter-individual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. Thus, the promoter sequence or activity of the VKORC1 gene of a subject can be used to predict how much warfarin should be prescribed for the subject. Relevant methods and compositions are provided.

Priority: US20040638837P Applic. Date: 2004-12-21; US20050679694P Applic. Date: 2005-05-10

Inventor: CHEN YUAN-TSONG [TW]; YUAN HSIANG-YU [TW]; CHEN JIN-JER [TW]


Application No.: US20060166284A1  Published: 27/Jul/2006

Title: Novel tissue factor targeted antibodies as anticoagulants

Applicant/Assignee: CPS COLOR EQUIPMENT S.P.A BAYER SCHERING PHARMA AG

Application No.: 10/512215   Filing Date: 12/Jan/2005

Abstract:This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Priority: US20020376566P Applic. Date: 2002-05-01; WO2003US13521 Applic. Date: 2003-04-30

Inventor: LIGHT DAVID [US]; MCLEAN KIRK [US]


Application No.: US20060166932A1  Published: 27/Jul/2006

Title: Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione

Applicant/Assignee: CELGENE CORPORATION

Application No.: 11/371777   Filing Date: 08/Mar/2006

Abstract:Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Priority: US2003-411656 Applic. Date: 2003-04-11; US20020424730P Applic. Date: 2002-11-06

Inventor: ZELDIS JEROME B [US]


Application No.: US20060172931A1  Published: 03/Aug/2006

Title: Heparin-binding peptides and uses thereof

Applicant/Assignee: THOMAS JEFFERSON UNIVERSITY

Application No.: 10/551005   Filing Date: 29/Mar/2004

Abstract:Heparin-binding peptides are provided of the formula R1(X1B1B2X2B3X3Y1R2)nR3, R1(X1B1B2B3X2X3B4X4Y1R2)nR3, and C(X1B1B2B3X2X3B4X4)nC

wherein X1, X2, X3, and X4 are independently selected from the group consisting of hydropathic amino acids

B1, B2, B3, and B4 are independently selected from the group consisting of basic amino acids

C is cysteine

Y1 is zero or one to ten amino acid residues, wherein at least one amino acid residue is proline

n is an integer from one to ten

and R1, R2, and R3 are independently selected segments containing from zero to twenty amino acid residues, provided, at least one of the segments R1, R2, and R3 comprises at least one hydrophobic amino acid residue. The peptide C(X1B1B2B3X2X3B4X4)nC is optionally cyclized via a disulfide bond formed between cysteine residues.

The peptides are administered to reduce plasma LMWH and heparin levels and to reduce the anticoagulant effects of heparin and LMWH. The peptides are also administered to inhibit microbial growth and to inhibit mast cell serine proteases involved in various diseases and disorders. The peptides are also administered as carriers to deliver active agents.

Priority: US20030458241P Applic. Date: 2003-03-28; WO2004US09668 Applic. Date: 2004-03-29

Inventor: SAN ANTONIO JAMES D [US]; SCHICK BARBARA P [US]; VERRECCHIO ANGELA [US]


Application No.: US20060173378A1  Published: 03/Aug/2006

Title: Automatic blood sampling device

Applicant/Assignee:

Application No.: 11/341865   Filing Date: 30/Jan/2006

Abstract:The present invention relates to an automatic blood sampling device comprising a catheter part being operatively connected to a penetration member, the operatively connection between the catheter part and the penetration member being provided via one or more tube sections. The device further comprises pump means being adapted to pump blood through the catheter part and the penetration member and into a storage container, the storage container being adapted to contain a blood sample. The penetration member, typically a needle or a canulla, is adapted to penetrate a flexible member, typically a seal in the form of a rubber membrane, of the storage container. The blood sampling device can be preprogrammed to perform a series of preprogrammed events, such as taking independent blood samples on animals with certain time intervals.

Priority: US20050647778P Applic. Date: 2005-01-31

Inventor: FONSS ANDERS [DK]


Application No.: US20060177480A1  Published: 10/Aug/2006

Title: Drug-eluting biodegradable stent

Applicant/Assignee:

Application No.: 11/130787   Filing Date: 17/May/2005

Abstract:The present invention relates to a biodegradable stent comprising a luminal surface portion with a second degree of crosslink, an outer surface portion with a first degree of crosslink, and a wall between the luminal and outer surface portions, wherein the wall comprises a crosslinked material characterized by the first degree of crosslink not less than the second degree of crosslink.

Priority: US2005-906239 Applic. Date: 2005-02-10

Inventor: SUNG HSING-WEN [TW]; CHEN MEI-CHIN [TW]; TU HOSHENG [US]


Application No.: US20060177811A1  Published: 10/Aug/2006

Title: Composition for preserving platelets and method of using the same

Applicant/Assignee:

Application No.: 11/330132   Filing Date: 12/Jan/2006

Abstract:The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Priority: US20050643107P Applic. Date: 2005-01-12

Inventor: SEHGAL LAKSHMAN R [US]; MOUSA SHAKER [US]


Application No.: US20060178610A1  Published: 10/Aug/2006

Title: Clotting cascade initiating apparatus and methods of use and methods of closing wounds

Applicant/Assignee:

Application No.: 11/337278   Filing Date: 23/Jan/2006

Abstract:Wound closure methods and apparata are provided which utilize blood fluid by activating the clotting cascade of the blood fluid outside the body within a substantially enclosed sterile container then introducing the blood fluid to the wound site to complete clotting. Methods and apparata for providing ways of inhibiting anticoagulants and slowing fibrin clot degradation are also disclosed. Kits for practicing the invention singularly or in combination with and/or associated with preferred procedures are also disclosed.

Priority: US2002-291278 Applic. Date: 2002-11-08; US2000-732423 Applic. Date: 2000-12-07; US1998-212080 Applic. Date: 1998-12-15; US19970069834P Applic. Date: 1997-12-16

Inventor: NOWAKOWSKI KAROL L [US]


Application No.: US20060182685A1  Published: 17/Aug/2006

Title: Hollow fiber technique for in vivo study of cell populations

Applicant/Assignee:

Application No.: 11/221294   Filing Date: 06/Sep/2005

Abstract:The present invention relates to a method of using hollow fibers to evaluate cellular changes in vivo. A method for evaluating cellular changes in vivo in response to administration of a drug or drugs of interest is provided. The hollow fiber technique is also used to evaluate cellular changes in a microorganism in vivo. The technique is further used to evaluate cellular changes in a microorganism in vivo in response to administration of a drug or drugs of interest. A vaccine and method of vaccination are also provided.

Priority: US20040606939P Applic. Date: 2004-09-04

Inventor: BISHAI WILLIAM R [US]; KARAKOUSIS PETROS C [US]


Application No.: US20060182724A1  Published: 17/Aug/2006

Title: Method for expansion of stem cells

Applicant/Assignee:

Application No.: 11/353692   Filing Date: 14/Feb/2006

Abstract:A method of increasing the growth of stem cells by mixing the stem cells with a growth medium that has been conditioned by an incubation with placental tissue. The method increases the expansion of the stem cell population.

Priority: US20050653390P Applic. Date: 2005-02-15

Inventor: RIORDAN NEIL H [US]


Application No.: US20060183172A1  Published: 17/Aug/2006

Title: Diagnostic assay for thrombin-activatable fibrinolysis inhibitor (fafi)

Applicant/Assignee: AMERICAN DIAGNOSTICA, INC

Application No.: 10/526167   Filing Date: 29/Aug/2003

Abstract:The invention relates to a diagnostic assay for selectively measuring levels of the 35kD form of thrombin-activatable fibrinolysis inhibitor (TAFla or TAFlai), or a derivative or variant thereof, but not the TAFI proenzyme (TAFI) or the N-terminal activation peptide of TAFI.

Priority: US20020406756P Applic. Date: 2002-08-29; WO2003US27061 Applic. Date: 2003-08-29

Inventor: GREENFIELD ROBERT S [US]; AN SEOUNG S [US]


Application No.: US20060184002A1  Published: 17/Aug/2006

Title: Quantitative contrast enhanced black-blood imaging using quadruple-inversion recovery

Applicant/Assignee: UNIVERSITY OF WASHINGTON

Application No.: 11/385201   Filing Date: 21/Mar/2006

Abstract:A reduced field-of-view (FOV) imaging technique combines suppression of signals from outer volume and inflowing blood. Both outer volume and blood suppression are achieved using an SFQIR (Small-FOV Quadruple-inversion-Recovery) preparative pulse sequence including two double-inversion pulse pairs separated by appropriate delays. Within each pair, inversion pulses are successively applied to the imaged slice and the slab orthogonal to the imaging plane, with the thickness equal to the FOV size in the phase-encoding direction. Each double-inversion results in a reinversion of the magnetization in a central part of the FOV, while outer areas of the FOV and inflowing blood remain inverted. The SFQIR module was implemented for single-slice and multislice acquisition with a fast spin-echo readout sequence.

Timing parameters of the sequence corresponding to the maximal suppression efficiency can be found by niiziig variation of the normalized signal over the entire range of T1 occurring in tissues.

Priority: US2003-740354 Applic. Date: 2003-12-18; US20020435835P Applic. Date: 2002-12-19

Inventor: YARNYKH VASILY L [US]; YUAN CHUN [US]


Application No.: US20060184084A1  Published: 17/Aug/2006

Title: Medical fluid therapy flow balancing and synchronization method and apparatus

Applicant/Assignee: BAXTER INTERNATIONAL INC BAXTER HEALTHCARE S.A

Application No.: 11/356661   Filing Date: 16/Feb/2006

Abstract:A medical fluid therapy method includes: (a) establishing a communication link between a kidney dialysis/blood treatment machine and at least one remote pump controller

(b) using the link to synchronize operation of at least one pump housed integrally with the machine with at least one pump located remotely from the machine

(c) enabling an operator to enter a net fluid transfer amount

and (d) controlling the pumps to at least substantially achieve the entered amount.

Priority: US2003-685724 Applic. Date: 2003-10-15

Inventor: WARE LEE C [US]; BOEHNLEIN ARNOLD F [US]


Application No.: US20060188995A1  Published: 24/Aug/2006

Title: Process, composition and kit for providing a stable whole blood calibrator/control

Applicant/Assignee:

Application No.: 11/066620   Filing Date: 24/Feb/2005

Abstract:The present invention is directed toward a stable calibrator and/or control, kit and process for using in a glucose monitoring instrumentation. Principally, the instant invention teaches a glycolyzed red blood cell component, which has been treated with a glycolysis stabilizing effective amount of at least one non-crosslinking aldehyde compound. The glycolyzed red blood cell component may be added to fresh plasma along with an amount of glucose to form a simulated whole blood glucose control product, effective for maintaining a particular and essentially stable glucose concentration over a period of time sufficient for accurate measurement and calibration of a glucose measuring instrument.

Priority:

Inventor: RYAN WAYNE L [US]; HUNSLEY BRADFORD A [US]


Application No.: US20060189863A1  Published: 24/Aug/2006

Title: Analyte monitoring device and methods of use

Applicant/Assignee: ABBOTT DIABETES CARE, INC

Application No.: 11/265787   Filing Date: 01/Nov/2005

Abstract:An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.

Priority: US2003-420057 Applic. Date: 2003-04-18

Inventor: PEYSER THOMAS [US]; HELLER ADAM [US]


Application No.: US20060193920A1  Published: 31/Aug/2006

Title: NANOPARTICULATE COMPOSITIONS OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE INHIBITORS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/275069   Filing Date: 07/Dec/2005

Abstract:Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US2002-323736 Applic. Date: 2002-12-20; US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21; US2003-392303 Applic. Date: 2003-03-20; US20020365524P Applic. Date: 2002-03-20

Inventor: BOSCH H W [US]; CARY GRETA G [US]; HOVEY DOUGLAS C [US]; JAIN RAJEEV A [US]; KLINE LAURA J [US]; MERISKO-LIVERSIDGE ELAINE [US]; OSTRANDER KEVIN D [US]


Application No.: US20060198864A1  Published: 07/Sep/2006

Title: Biointerface membranes incorporating bioactive agents

Applicant/Assignee:

Application No.: 11/416825   Filing Date: 03/May/2006

Abstract:A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.

Priority: US2004-842716 Applic. Date: 2004-05-10; US2003-647065 Applic. Date: 2003-08-22; US20030472673P Applic. Date: 2003-05-21; US20040544722P Applic. Date: 2004-02-12

Inventor: SHULTS MARK [US]; BRAUKER JAMES H [US]; CARR-BRENDEL VICTORIA [US]; TAPSAK MARK [US]; MARKOVIC DUBRAVKA [US]


Application No.: US20060204532A1  Published: 14/Sep/2006

Title: Drug Delivery Systems and Methods for Modulating the Fetal Environment and Pregnancy Process

Applicant/Assignee:

Application No.: 11/160949   Filing Date: 15/Jul/2005

Abstract:Systems and Methods are described for treatment of fetal disorders, promotion of fetal health, and extension of the pregnancy period. A drug delivery system (DDS) can perform both bolus and continuous delivery of substances in accordance with sensed data reflecting the current state of a fetus. The methods and systems for promotion of healthy pregnancy and treatment of a developing fetus can alter the drug delivery, by evaluating the sensed data with respect to the age or physical characteristics of the fetus and/or mother.

Priority: US20040574195P Applic. Date: 2004-05-25; US20040587870P Applic. Date: 2004-07-15; US20030488133P Applic. Date: 2003-07-16

Inventor: JOHN MICHAEL S [US]


Application No.: US20060204536A1  Published: 14/Sep/2006

Title: Biointerface membranes incorporating bioactive agents

Applicant/Assignee:

Application No.: 11/416734   Filing Date: 03/May/2006

Abstract:A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen to induce vascularization and/or prevent barrier cell layer formation in vivo, and are advantageous when used with implantable devices wherein solutes are transported across the device-tissue interface.

Priority: US2004-842716 Applic. Date: 2004-05-10; US2003-647065 Applic. Date: 2003-08-22; US20030472673P Applic. Date: 2003-05-21; US20040544722P Applic. Date: 2004-02-12

Inventor: SHULTS MARK [US]; BRAUKER JAMES H [US]; CARR-BRENDEL VICTORIA [US]; TAPSAK MARK [US]; MARKOVIC DUBRAVKA [US]


Application No.: US20060204596A1  Published: 14/Sep/2006

Title: Formulation of a mixture of Free-B-Ring flavonoids and flavans as a therapeutic agent

Applicant/Assignee: UNIGEN PHARMACEUTICALS, INC

Application No.: 11/373576   Filing Date: 10/Mar/2006

Abstract:The present invention provides a composition of matter comprised of a mixture of two specific classes of compounds-Free-B-Ring flavonoids and flavans-referred to herein as UP736 for use in the prevention and treatment of diseases and conditions related to platelet aggregation and platelet-induced thrombosis. The invention further provides a novel composition of matter comprised of UP736 in combination with injectable or oral anticoagulants, antiplatelet agents, non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 selective inhibitors and a method for using said composition in the prevention and treatment of diseases and conditions related to platelet aggregation and platelet-induced thrombosis. Finally, this invention provides a method for using UP736 in combination with anti-platelet, anti-coagulant, prophylaxis agents and NSAIDs as a means for reducing the dosage of these agents, decreasing the side effects associated with acute or chronic administration of these agents

counteracting or antagonizing the risks of acute or chronic administration of these agents and for achieving additional and/or multiple clinical benefits.

Priority: US20050660564P Applic. Date: 2005-03-10

Inventor: JIA QI [US]; ZHAO YUAN [US]


Application No.: US20060206028A1  Published: 14/Sep/2006

Title: Apparatus and method for ablating deposits from blood vessel

Applicant/Assignee: QI YU

Application No.: 11/077942   Filing Date: 11/Mar/2005

Abstract:An apparatus for ablating deposits along the blood vessel of human and animals is disclosed. The apparatus has an extracting and pressurizing unit for extracting blood from a supply vessel and pressurizing it plus a downstream delivering and injecting unit for delivering and injecting the filtered and pressurized source blood into a blood vessel under treatment. Besides inducing a blood circulation and having ablation devices like ultrasound and RF heating, the apparatus ablates the deposits from a nearby portion of the vessel. The characteristics of selective ablation and self-termination make the proposed apparatus safe and effective in treating early-stage atherosclerosis. A DC discharging device can be included to neutralize excess surface charge generation on the wounded healthy tissues following ablation for disinfection and anti-inflammation. Placement of the blood extracting point just downstream of the blood injecting point insures thorough collection and removal of blood-clogging plaque and calcification fragments.

Priority:

Inventor: LEE YEE-CHUN [US]; YU QI [US]


Application No.: US20060210604A1  Published: 21/Sep/2006

Title: Ocular delivery of polymeric delivery formulations

Applicant/Assignee:

Application No.: 11/244438   Filing Date: 04/Oct/2005

Abstract:The present invention provides a flowable composition suitable for use as a controlled release implant. The flowable composition can be administered into the ocular region of a mammal. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid

(b) a biological agent, a metabolite thereof, a biological agently acceptable salt thereof, or a prodrug thereof

and (c) a biocompatible organic liquid, at standard temperature and pressure, in which the thermoplastic polymer is soluble. The present invention also provides methods of medical treatment that include administering the flowable composition into the ocular region of a mammal.

Priority: US20040615727P Applic. Date: 2004-10-04; US20040628630P Applic. Date: 2004-11-17; US20040629133P Applic. Date: 2004-11-18

Inventor: DADEY ERIC [US]; LINDEMANN CHRISTOPHER M [US]; WARREN STEPHEN L [US]; NORTON RICHARD L [US]


Application No.: US20060211072A1  Published: 21/Sep/2006

Title: Process, composition and kit for providing a stable whole blood calibrator/control

Applicant/Assignee: STRECK, INC

Application No.: 11/362362   Filing Date: 23/Feb/2006

Abstract:The present invention is directed toward a stable calibrator and/or control, kit and process for using in a glucose monitoring instrumentation. Principally, the instant invention teaches a glycolyzed red blood cell component which has been treated with a glycolysis stabilizing effective amount of at least one non-crosslinking aldehyde compound which may be added to fresh plasma along with an amount of glucose to form a simulated whole blood glucose control product, effective for maintaining a particular and essentially stable glucose concentration over a period of time sufficient for accurate measurement and calibration of a glucose measuring instrument.

Priority: US20050656154P Applic. Date: 2005-02-23

Inventor: RYAN WAYNE L [US]; HUNSLEY BRADFORD A [US]


Application No.: US20060211611A1  Published: 21/Sep/2006

Title: Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism

Applicant/Assignee: LEWIS S. COLEMAN, MD, INC

Application No.: 11/080709   Filing Date: 15/Mar/2005

Abstract:A theory has been presented that provides a simplified explanation of a cohesive mechanism of embryological development, hemostasis, coagulation, wound repair and tissue maintenance that operates continuously in the animal body to oppose the effects of stress. The theory endeavors to fit all known facts, and is based on the hypothesis that coagulation Factors VII and VIII are respectively local and systemic stress agents that regulate thrombin activity and synergize each other's effects. Stress Theory may explain the etiologies of several hitherto mysterious disease syndromes, and the stress mechanism lo and may play a more pervasive role in disease than is generally appreciated. The theory offers fresh avenues for research and clinical strategy.

Priority:

Inventor: COLEMAN LEWIS S [US]


Application No.: US20060212020A1  Published: 21/Sep/2006

Title: Sample collection system with caspase inhibitor

Applicant/Assignee:

Application No.: 10/530824   Filing Date: 19/Oct/2005

Abstract:A collection container and a method for collecting a biological sample, particularly whole blood, includes at least one stabilizing agent in an amount effective to inhibit apoptosis. The stabilizing agent comprises or consists of one or more caspase inhibitors.

Priority: US20020417531P Applic. Date: 2002-10-10; WO2003US32261 Applic. Date: 2003-10-10

Inventor: RAINEN LYNNE [US]; LIEBMANN-VINSON ANDRCA [US]


Application No.: US20060216687A1  Published: 28/Sep/2006

Title: Reconstitutable dried blood products

Applicant/Assignee:

Application No.: 10/540520   Filing Date: 24/Dec/2003

Abstract:The invention provides a process for the preparation of a dried particulate blood product the particles whereof comprise anuclear blood cells in a protective agent, said process comprising: obtaining a blood sample from a mammalian subject

adding an anticoagulant to said sample

concentrating the cells of said sample

recovering a concentrate containing anuclear blood cells from said sample

impregnating with said concentrate a particulate comprising a macromolecular protective material

drying the impregnated particulate at a temperature in the range of -20 to +120 DEG C.

and, optionally, packaging the dried particular in sealed containers.

Priority: GB20020030152 Applic. Date: 2002-12-24; WO2003GB05670 Applic. Date: 2003-12-24

Inventor: ALVES-FILHO ODILIO [NO]; BERGSLIEN OLA [NO]; BJORK PETER [NO]; EIKEVIK TRYGVE M [NO]; STROMMEN INGVALD [NO]


Application No.: US20060216829A1  Published: 28/Sep/2006

Title: Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same

Applicant/Assignee:

Application No.: 11/332776   Filing Date: 13/Jan/2006

Abstract:An erythrocyte sedimentation rate (ESR) measurement instrument having a Blood Collection Configuration and an ESR Measurement Configuration. The ESR measurement instrument comprises a sedimentation measurement tube having an hollow interior volume containing a predetermined quantity of blood sample diluting agent therewithin and being air/fluid sealed with respect to the ambient environment

and a blood collection tube having a hollow interior volume containing a predetermined quantity of anti-coagulant and being vacuum-sealed with respect to the ambient environment, and physically coupled to the air-sealed sedimentation measurement tube, by at least a portion of the sedimentation measurement tube being inserted within a portion of the hollow interior volume of the blood collection tube. The sedimentation measurement tube and the blood collection tube are maintained stationarily fixed relative to each other as a unitary assembly having a syringe-like form factor when the ESR measurement instrument is arranged in the Blood Collection Configuration. During this configuration, a needle-supporting connector can be connected to the blood collection tube and a sample of whole blood from a patient vacuum-drawn and injected into the blood collection tube. After the sample of anti-coagulated blood has been collected in the blood collection tube and the needle-supporting connector is disconnected therefrom, the air/fluid seal of the sedimentation measurement tube can be broken and then the sedimentation measurement tube can be manually plunged into and to the bottom of the hollow interior volume of said blood collection tube, using a single-handed operation to rearrange the ESR measurement instrument into the ESR Measurement Configuration. The anti-coagulated sample of blood fills up a substantially portion of the sedimentation measurement tube and mixes with the blood sample diluting agent to enable the blood plasma/erythrocyte cell (P/E) interface level within the sedimentation measurement tube to settle downwards toward the blood collection tube during a predetermined time period when said ESR measurement instrument is oriented in a gravity vertical position. By virtue of the present invention, the erythrocyte sedimentation rate (ESR) of the collected blood sample can be measured by determining how far the P/E interface level has moved against graduation markings formed along the length of the sedimentation measurement tube during the predetermined time period.

Priority: US2005-194056 Applic. Date: 2005-07-29; US2003-395860 Applic. Date: 2003-03-21

Inventor: BOUBOULIS DENIS [US]


Application No.: US20060217651A1  Published: 28/Sep/2006

Title: Control system for driving fluids through an extracorporeal blood circuit

Applicant/Assignee:

Application No.: 11/444745   Filing Date: 01/Jun/2006

Abstract:A control deck and system for controlling and driving blood fluids through an extracorporeal blood circuit kit. In one aspect, the invention is a deck having an improved mechanism for securing a cassette in place during treatment operations. The improved deck comprises catches for slidably receiving tabs of the cassette and one or more rotating clamps for locking and securing the cassette in a loaded position. In another aspect the invention is a system for controlling and driving blood fluids having infrared communication abilities to transmit and receive real time data. In still another aspect, the invention is a system for controlling and driving blood fluids having an upright tower design that reduces the footprint of the system. In this embodiment, a centrifuge chamber is positioned in an upper portion of the system while the control deck and photoactivation chamber are located in a base portion of the system.

Priority: US2003-654670 Applic. Date: 2003-09-03

Inventor: HUTCHINSON MICHAEL [US]; BRIGGS DENNIS [US]; GARA STEPHEN [US]; WATTERS TOM [US]


Application No.: US20060222561A1  Published: 05/Oct/2006

Title: Control system for driving fluids through an extracorporeal blood circuit

Applicant/Assignee: THERAKOS, INC

Application No.: 11/444721   Filing Date: 01/Jun/2006

Abstract:A control deck and system for controlling and driving blood fluids through an extracorporeal blood circuit kit. In one aspect, the invention is a deck having an improved mechanism for securing a cassette in place during treatment operations. The improved deck comprises catches for slidably receiving tabs of the cassette and one or more rotating clamps for locking and securing the cassette in a loaded position. In another aspect the invention is a system for controlling and driving blood fluids having infrared communication abilities to transmit and receive real time data. In still another aspect, the invention is a system for controlling and driving blood fluids having an upright tower design that reduces the footprint of the system.

In this embodiment, a centrifuge chamber is positioned in an upper portion of the system while the control deck and photoactivation chamber are located in a base portion of the system.

Priority: US2003-654670 Applic. Date: 2003-09-03

Inventor: HUTCHINSON MCHAEL [US]; BRIGGS DENNIS [US]; GARA STEPHEN [US]; WALTERS TOM [US]


Application No.: US20060226086A1  Published: 12/Oct/2006

Title: Centrifuge for blood processing systems

Applicant/Assignee:

Application No.: 11/102215   Filing Date: 08/Apr/2005

Abstract:Described herein is a continuous-flow centrifuge (CFC) which may be embodied in an automated system for collecting and separating whole blood into its components. The collection and separation system includes a console and a disposable set. Various blood processing procedures which produce specific blood products may be implemented by using a specific disposable set for each process. The disposable set may include a manifold, a CFC, and various components attached by tubing. These components may include one or more solution bags, blood product bags, bacterial filters, leukofilters, and a donor blood collection tube with access needle. The manifold and CFC disk may be included in a cassette that mounts onto the front panel of the console. The console may contain valve actuators, pressure transducers, ultrasonic sensors, a roller pump assembly, a CFC drive system, optical sensors, electronics, software, user interface components, a bar code reader and data acquisition components.

Priority:

Inventor: ROBINSON THOMAS C [US]; SAHINES THOMAS P [US]; D ELIA RICHARD R [US]; ZAMORA SALVADOR M [US]; LEWIS BRIAN D [US]; FERNANDEZ ROBERT K [US]; BRIONES VICTOR A [US]; NIER DAVID M [US]; MCNAMARA THOMAS N [US]


Application No.: US20060226088A1  Published: 12/Oct/2006

Title: Disposable set for separations of blood into its components

Applicant/Assignee: MISSION MEDICAL, INC

Application No.: 11/386441   Filing Date: 22/Mar/2006

Abstract:Described herein is a continuous-flow centrifuge (CFC) which may be embodied in an automated system for collecting and separating whole blood into its components. The collection and separation system includes a console and a disposable set. Various blood processing procedures which produce specific blood products may be implemented by using a specific disposable set for each process. The disposable set may include a manifold, a CFC, and various components attached by tubing. These components may include one or more solution bags, blood product bags, bacterial filters, leukofilters, and a donor blood collection tube with access needle. The manifold and CFC disk may be included in a cassette that mounts onto the front panel of the console. The console may contain valve actuators, pressure transducers, ultrasonic sensors, a roller pump assembly, a CFC drive system, optical sensors, electronics, software, user interface components, a bar code reader and data acquisition components.

Priority: US2005-102215 Applic. Date: 2005-04-08

Inventor: ROBINSON THOMAS C [US]; SAHINES THOMAS P [US]; D ELIA RICHARD R [US]; ZAMORA SALVADOR M [US]; LEWIS BRIAN D [US]; FERNANDEZ ROBERT K [US]; BRIONES VICTOR A [US]; NIER DAVID M [US]; MCNAMARA THOMAS N [US]


Application No.: US20060228452A1  Published: 12/Oct/2006

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee:

Application No.: 11/386469   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US2004-769243 Applic. Date: 2004-01-30; US2004-796243 Applic. Date: 2004-03-09; US1998-159945 Applic. Date: 1998-09-24; US20030453555P Applic. Date: 2003-03-10; US20050664328P Applic. Date: 2005-03-23; US20050727080P Applic. Date: 2005-10-14; US20050726878P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20050727196P Applic. Date: 2005-10-14; US2004-977288 Applic. Date: 2004-10-29; US2002-235572 Applic. Date: 2002-09-06; US2001-950307 Applic. Date: 2001-09-10; US1999-433001 Applic. Date: 1999-11-02

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]


Application No.: US20060228453A1  Published: 12/Oct/2006

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee:

Application No.: 11/386498   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US20050727196P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20050726878P Applic. Date: 2005-10-14; US20050727080P Applic. Date: 2005-10-14; US20050664328P Applic. Date: 2005-03-23; US19970060015P Applic. Date: 1997-09-25; US20030453555P Applic. Date: 2003-03-10; US1998-159945 Applic. Date: 1998-09-24; US1999-433001 Applic. Date: 1999-11-02; US2001-950307 Applic. Date: 2001-09-10; US2002-235572 Applic. Date: 2002-09-06; US2004-977288 Applic. Date: 2004-10-29; US2004-769243 Applic. Date: 2004-01-30

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]


Application No.: US20060228765A1  Published: 12/Oct/2006

Title: Method for detecting procoagulant phospholipid

Applicant/Assignee: HAEMATEX RESEARCH PTY LIMITED

Application No.: 11/384258   Filing Date: 21/Mar/2006

Abstract:The present invention relates to a method for determining the amount of procoagulant phospholipid in a sample, said method comprising steps (i) to (iii) performed in the following order: (i) forming an admixture of the sample and a substrate plasma which has been rendered free or substantially free of procoagulant phospholipid sufficient to at least reduce the capacity of the substrate plasma to coagulate, wherein said substrate plasma has been rendered free or substantially free of procoagulant phospholipid by treatment with a phospholipase

(ii) contacting the admixture with a reagent for activating coagulation of plasma in conditions were procoagulant phospholipids is the rate limiting component of the mixture

and (iii) determining the clotting time of the admixture.

Priority: AU20030905172 Applic. Date: 2003-09-22; WO2004AU01291 Applic. Date: 2004-09-22

Inventor: EXNER THOMAS [AU]


Application No.: US20060229661A1  Published: 12/Oct/2006

Title: Device for building up muscle

Applicant/Assignee:

Application No.: 10/552991   Filing Date: 13/Oct/2005

Abstract:To provide a muscle development device wherein a sufficient pressure can be applied to every part of the limb intended to be compressed, even under the influence of muscle movements. To provide a muscle development device comprising a hollow tight fitting band 1 having a tube 5 and a wire-like piece 6 provided therein

and fastening means for use in keeping a length of the tight fitting band 1 in a loop having a desired size, the muscle development device being used to develop muscles of a limb while restricting the blood flow therethrough by means of applying, with the tight fitting band 1 being wrapped around a predetermined compressed range of the limb and the tight fitting band 1 being fastened with the fastening means to have a desired size, a predetermined pressure to the limb around which the tight fitting band 1 is wrapped, the pressure being produced by introducing air to the tube 5 . The wire-like piece 6 is designed to limit the direction towards which the tube 5 is allowed to inflate as the tube 5 is filled with air, to against the muscles as determined with the tight fitting band 1 being rest on the muscles.

Priority: JP20030110903 Applic. Date: 2003-04-15; WO2004JP05249 Applic. Date: 2004-04-13

Inventor: SATO YOSHIAKI [JP]


Application No.: US20060233786A1  Published: 19/Oct/2006

Title: Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation

Applicant/Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA

Application No.: 10/513491   Filing Date: 05/Nov/2004

Abstract:Formulations for neutralizing the anticoagulant action of a human tissue factor inhibitor, comprising a blood coagulation factor complex product or an activated blood coagulation factor VII product as an active ingredient

and formulations for neutralizing the blood coagulation-promoting action of an activated blood coagulation factor VII product, comprising a human tissue factor inhibitor as an active ingredient.

Priority: JP20020149494 Applic. Date: 2002-05-23; WO2003JP06469 Applic. Date: 2003-05-23

Inventor: KITAZAWA TAKEHISA [JP]; HATTORI KUNIHIRO [JP]


Application No.: US20060240070A1  Published: 26/Oct/2006

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee:

Application No.: 11/386587   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US2004-769243 Applic. Date: 2004-01-30; US2004-796243 Applic. Date: 2004-03-09; US2004-977288 Applic. Date: 2004-10-29; US2002-235572 Applic. Date: 2002-09-06; US2001-950307 Applic. Date: 2001-09-10; US1999-433001 Applic. Date: 1999-11-02; US1998-159945 Applic. Date: 1998-09-24; US20030453555P Applic. Date: 2003-03-10; US20050664328P Applic. Date: 2005-03-23; US20050727080P Applic. Date: 2005-10-14; US20050726878P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20050727196P Applic. Date: 2005-10-14

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]


Application No.: US20060241017A1  Published: 26/Oct/2006

Title: Novel compounds with high therapeutic index

Applicant/Assignee:

Application No.: 11/343557   Filing Date: 30/Jan/2006

Abstract:The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

Priority: WO2004US24901 Applic. Date: 2004-07-29; US20030491331P Applic. Date: 2003-07-29

Inventor: CHANDRAN V R [US]


Application No.: US20060241148A1  Published: 26/Oct/2006

Title: Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls

Applicant/Assignee: JANSSEN PHARMACEUTICA N.V

Application No.: 11/385056   Filing Date: 21/Mar/2006

Abstract:The present invention describes compounds of Formula I or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal. The present invention also relates to a novel method of N-oxidation of nitrogen containing heteroaryls.

Priority: US20050673131P Applic. Date: 2005-04-20

Inventor: KREUTTER KEVIN [US]; LU TIANBAO [US]; LEE YU K [US]; TELEHA CHRISTOPHER [US]; PLAYER MARK [US]; ZHU XIZHEN [US]


Application No.: US20060241524A1  Published: 26/Oct/2006

Title: Intravascular ultrasound catheter device and method for ablating atheroma

Applicant/Assignee:

Application No.: 11/134983   Filing Date: 23/May/2005

Abstract:An intravascular catheter device having a catheter and an ultrasound ablation manifold is proposed for generating cavitations and acoustic jet streams in the blood to ablate atheroma. The ablation manifold has a power transducer and a coupled leaky acoustic cavity. The leaky acoustic cavity contains a first portion of ultrasonic power emission for intra-cavity ablation while allowing a second portion of ultrasonic power emission to leak outside for an extra-cavity ablation. The power transducer and the leaky acoustic cavity are configured to form a confocal resonant cavity. An intervening bird cage is coupled to the resonant cavity for stronger resonance while maintaining ultrasound leakage. A protective shield is mounted around the waist of bird cage to strengthen resonance and to prevent damaging the intima from an otherwise normal incidence of high intensity ultrasound. A microbubble releasing device and micro pump are also included to further increase the ablation efficacy.

Priority: US2005-077942 Applic. Date: 2005-03-11

Inventor: LEE YEE-CHUN [US]; CHIO SHIU-SHIN [US]; YU QI [US]


Application No.: US20060246046A1  Published: 02/Nov/2006

Title: Modified tridegins, production and use thereof as transglutaminase inihibitors

Applicant/Assignee:

Application No.: 10/498752   Filing Date: 10/Feb/2005

Abstract:The invention relates to modified tridegins, polypeptides derived from SEQ ID No. 1, in which the modification is replacement of a cysteine residue and/or one of the following amino acids-Lys2, Lys7, His10, Gly12, Leu24, Tyr31, Phe34, Arg39, Ile45, Met48, Asp50, Pro55, Phe58, Asn60, Pro65, Arg66, by another amino acid and/or N- or C-terminal deletion, whereby the remaining polypeptide comprises at least the amino acid sequence DDIYQRXVXFPXLPL (SEQ ID NO.89) and/or a covalent bonding to polyethylene glycol. Said polypeptides are novel inhibitors of transglutaminases, in particular of Factor XIIIa, of the terminal enzymes in the blood coagulation cascade. The invention further relates to methods for production of said inhibitors and the use thereof as transglutaminase inhibitors.

Priority: DE20011063333 Applic. Date: 2001-12-21; DE20021058159 Applic. Date: 2002-12-12; WO2002EP14684 Applic. Date: 2002-12-20

Inventor: GIERSIEFEN HELMUT [DE]; STOCKEL JOHANNES [DE]; PAMP TANJA [DE]; OHLMANN MARION [DE]


Application No.: US20060252837A1  Published: 09/Nov/2006

Title: Diamine derivatives

Applicant/Assignee: DAIICHI PHARMACEUTICAL CO., LTD

Application No.: 10/540259   Filing Date: 25/Dec/2003

Abstract:A compound represented by formula (1): Q<1>-Q<2>-T-N(R<1>)-Q<3>-N(R<2>)-T<1>-Q<4> ( 1 ) [wherein R<1 >and R<2 >are hydrogen atoms or the like

Q<1 >is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like

Q<2 >is a single bond or the like

Q<3 >represents the following group: (wherein Q<5 >is an alkylene group having 1 to 8 carbon atoms, or the like)

and T<0 >and T<1 >are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof.

The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Priority: JP20020373787 Applic. Date: 2002-12-25; JP20030379163 Applic. Date: 2003-11-07; WO2003JP16783 Applic. Date: 2003-12-25

Inventor: OHTA TOSHIHARU [JP]; KOMORIYA SATOSHI [JP]; YOSHINO TOSHIHARU [JP]; UOTO KOUICHI [JP]; NAKAMOTO YUMI [JP]; NAITO HIROYUKI [JP]; MOCHIZUKI AKIYOSHI [JP]; KANNO HIDEYUKI [JP]; HAGINOYA NORIYASU [JP]; YOSHIKAWA KENJI [JP]; NAGAMOCHI MASATOSHI [JP]; KOBAYASHI SYOZO [JP]; ONO MAKOTO [JP]


Application No.: US20060254962A1  Published: 16/Nov/2006

Title: Diagnostic whole blood and plasma apparatus

Applicant/Assignee: CHROMEDX INC

Application No.: 11/432616   Filing Date: 12/May/2006

Abstract:Some embodiments of the invention provide an apparatus suitable for measuring at least one plasma analyte in plasma extracted from a whole blood sample within the apparatus. The apparatus is adapted for insertion into a slot in a meter, which can preferably perform at least spectroscopic or biosensor measurement. The apparatus comprises a whole blood flow path, which begins at the inlet opening of the apparatus, and terminates at a vent or a suction chamber. Included in the blood flow path is a flow-through filtration chamber. The apparatus further comprises a plasma flow path, which begins at the filtration chamber, and terminates at a vent or a suction chamber. The plasma flow path includes a plasma analyte signal providing means. The signal is transmitted to a processor in the meter for preparing analyte measurements.

Priority: CA20052507323 Applic. Date: 2005-05-13

Inventor: SAMSOONDAR JAMES [CA]


Application No.: US20060257883A1  Published: 16/Nov/2006

Title: Detection and measurement of hematological parameters characterizing cellular blood components

Applicant/Assignee:

Application No.: 11/125937   Filing Date: 10/May/2005

Abstract:Systems and methods for the diagnostic analysis of blood samples. The present invention uses sensor technology useful in the analysis of headspace sample from blood to provide an efficient and accurate means for identifying the presence of a volatile marker associated with hematological diseases or conditions. In a preferred embodiment, the sensor technology of the present invention includes detecting means such as RNA oligonucleotide chains or aptamers.

Priority:

Inventor: BJORAKER DAVID G [US]; MELKER RICHARD J [US]; DENNIS DONN M [US]


Application No.: US20060257947A1  Published: 16/Nov/2006

Title: Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibdies and other binding agents

Applicant/Assignee:

Application No.: 10/525610   Filing Date: 20/Aug/2003

Abstract:The invention relates to thrombospondin fragments found in plasma, their use or use of portions thereof in diagnostic methods, as method calibrators, method indicators, and as immunogens, and as analytes for methods with substantial clinical utility

and their detection in plasma or other bodily fluids for purpose of diagnostic methods, especially for cancer.

Priority: US2003-419462 Applic. Date: 2003-04-21; US20020405495P Applic. Date: 2002-08-23; WO2003US26023 Applic. Date: 2003-08-20

Inventor: WILLIAMS KEVIN J [US]


Application No.: US20060257957A1  Published: 16/Nov/2006

Title: Methods to measure immunosuppressive tacrolimus, sirolimus, and cyclosporin a complexes in a blood sample

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 11/398997   Filing Date: 06/Apr/2006

Abstract:The present invention provides methods, diagnostic assays, and diagnostic kits based on said methods, to determine levels of immunosuppressive complexes containing immunosuppressive drugs tacrolimus, sirolimus and cyclosporine A separately and in combination, formed in the blood of a drug-treated patient or in a patient candidate to immunosuppressive drug therapy. These methods, assays and kits are especially useful when using automated systems.

Priority: US20050668714P Applic. Date: 2005-04-06

Inventor: DRENGLER SUSAN M [US]; BAUGHER BENNETT W [US]


Application No.: US20060259005A1  Published: 16/Nov/2006

Title: Methods and systems for delivering substances into luminal walls

Applicant/Assignee: ANGIOSCORE, INC

Application No.: 11/411635   Filing Date: 26/Apr/2006

Abstract:Angioplasty and other dilatation devices are provided with scoring elements which incorporate a drug to be delivered to a body lumen, typically a blood vessel. The scoring elements have drugs and other active substances coated over a portion thereof or incorporated within internal structure of the element so that the drug is released into the luminal wall closely associated diseased regions of the body lumen as the scoring structure is radially expanded into the wall.

Priority: US20050680450P Applic. Date: 2005-05-11

Inventor: KONSTANTINO EITAN [US]; KONSTANTINO MICHAL [US]


Application No.: US20060261005A1  Published: 23/Nov/2006

Title: Porous spun polymeric structures and method of making same

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 11/496187   Filing Date: 31/Jul/2006

Abstract:A non-woven polymeric matrix for separating leukocytes from a blood sample includes a non-woven three dimensional matrix formed from polymeric fibers having a predetermined pore volume fraction including a defined channel configuration, a predetermined pore size in the range of from about 10 mum to about 250 mum, and a plurality of connections between the plurality of fibers. The matrix is configured so as to remove at least about 98% of leukocytes from at least one unit of packed red blood cells. Methods of making and using the matrix are also provided.

Priority: US2002-331213 Applic. Date: 2002-12-30

Inventor: DAO KINH-LUAN LENNY D [US]; CHIN YEM [US]; ZHONG SHENG-PING SAMUEL [US]; MOHAN KSHITIJ [US]; VU LIEM [US]


Application No.: US20060271165A1  Published: 30/Nov/2006

Title: Drug-eluting stent cover and method of use

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 11/497652   Filing Date: 01/Aug/2006

Abstract:An intravascular stent includes an eluting sheath fabricated from a mesh for controlled release of therapeutic drugs and for delivery of the therapeutic drugs in localized drug therapy in a blood vessel. The eluting sheath is attached to at least a portion of an outside surface area of the stent structure and is fabricated from a mesh designed to neck down in response to a radially outward directed force resulting in the uniform expansion of the stent. The eluting sheath can be loaded with at least one therapeutic drug for the release thereof at a treatment site to facilitate repair of a damaged vessel. The stent has a high degree of flexibility in the longitudinal direction, yet has adequate vessel wall coverage and radial strength sufficient to hold open an artery or other body lumen.

Priority: US2002-334034 Applic. Date: 2002-12-30

Inventor: YIP PHILIP S [US]; JACOBS JAMES [US]; HOSSAINY SYED [US]; BECKER JON [US]; LIMON TIMOTHY A [US]


Application No.: US20060271167A1  Published: 30/Nov/2006

Title: Vascular prosthesis

Applicant/Assignee: UNIVERSITY OF SOUTH FLORIDA

Application No.: 10/561929   Filing Date: 28/Jun/2004

Abstract:The subject invention concerns vascular prosthetic devices and methods for ascending aorta and/or valve replacement in humans and animals. In one embodiment, a device of the invention includes a vessel-like structure having a first end adapted for surgical attachment to a left ventricle, a second end adapted for surgical attachment to an aorta, and, interposed between the first and second ends, a sinus portion configured in the shape of the sinuses of Valsalva in a human aortic valve.

Priority: US20030483035P Applic. Date: 2003-06-27; WO2004US21046 Applic. Date: 2004-06-28

Inventor: KNIGHT JOSEPH A [US]


Application No.: US20060275271A1  Published: 07/Dec/2006

Title: PLASMA-DEPLETED, NON-RED BLOOD CELL-DEPLETED CORD BLOOD COMPOSITIONS AND METHODS OF USE

Applicant/Assignee: STEMCYTE, INC

Application No.: 11/422017   Filing Date: 02/Jun/2006

Abstract:The umbilical cord blood (UCB) compositions of the present invention possess the unique features of having plasma that is substantially depleted from the UCB unit and red blood cells (RBC) that are not depleted from the UCB unit. Such UCB units can be prepared by a process that combines plasma depletion with cryopreservation, selection, thawing, and/or transplantation of hematopoietic stem cells to provide superior clinical outcome by maximizing post-processing cell recovery and post-thaw infusion cell dose. Methods for treating a wide variety of malignant diseases and benign diseases associated with the hematopoietic system by administering the UCB compositions of the present invention are also provided.

Priority: US2003-367339 Applic. Date: 2003-02-13; US20050733956P Applic. Date: 2005-11-03; US20050687127P Applic. Date: 2005-06-02; US20020357308P Applic. Date: 2002-02-14

Inventor: CHOW ROBERT [US]


Application No.: US20060275376A1  Published: 07/Dec/2006

Title: Microcapsules with modified release of active principles with low solubility for oral delivery

Applicant/Assignee:

Application No.: 10/522234   Filing Date: 28/Jul/2003

Abstract:The invention concerns microcapsules for reliably modified release and adapted to industrial reproduction of an active principle hardly water-soluble, other than anti-hyperglycemia agents Each of said microcapsules comprises a core of hardly soluble active principle and a coating film applied on the core. Their mean diameter is less than 1000 microns. The coating film contains a film-forming polymer (P1) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA). Said coating film represents at least 4% p/p of dry mraner of their total weight. and its components P1, P2. PL satisfy the following characteristics: dry weight mass fraction of PI relative to the total coating weight ranging between 40 and 90%

dry matter weight fraction of PL/P1+P2 ranging between 15 and 60%: dry matter weight fraction of PL/P1+P2 ranging between 1 and 30%. The invention also concerns the uses of said microcapsules in galenic formulation.

Priority: FR20020009530 Applic. Date: 2002-07-26; WO2003FR02384 Applic. Date: 2003-07-28

Inventor: GUIMBERTEAU FLORENCE [FR]; CASTAN CATHERINE [FR]; MEYRUEIX REMI [FR]; SOULA GERARD [FR]


Application No.: US20060276838A1  Published: 07/Dec/2006

Title: Vascular puncture sealing method, apparatus, and system

Applicant/Assignee:

Application No.: 11/354225   Filing Date: 13/Feb/2006

Abstract:Some embodiments of the invention provide a guidewire directed vascular sealing device for securing hemostasis within a vascular puncture and puncture tract extending from the epidermis into a blood vessel in a living being. In some instances, the puncture tract is created by a percutaneous access apparatus used in the performance of medical catheter based diagnostic and therapeutic techniques. In some embodiments, the apparatus includes a hemostatic compound or material designed to facilitate clot formation within the tract.

Priority: US20050688510P Applic. Date: 2005-06-07; US20050693706P Applic. Date: 2005-06-24; US20050723878P Applic. Date: 2005-10-05

Inventor: WENSEL JEFFREY P [US]; BERGIN PATRICK J [US]


Application No.: US20060278293A1  Published: 14/Dec/2006

Title: PRESSURE MEASURING LINE, PARTICULARLY FOR INVASIVE BLOOD PRESSURE MEASUREMENT

Applicant/Assignee: SMITHS MEDICAL DEUTSCHLAND GMBH

Application No.: 11/423858   Filing Date: 13/Jun/2006

Abstract:The invention relates to a pressure measuring line, particularly for invasive blood pressure measurement, which presents a wall made of a flexible material, which surrounds a passageway. The wall consists particularly of at least one inner hose and an outer hose enveloping the former, where the material of the inner hose is harder than the material of the outer hose, and the wall thickness of the inner hose is less than the wall thickness of the outer hose. The inner side of the outer hose is in full-surface contact with the outer side of the inner hose.

Priority: DE200520009293U Applic. Date: 2005-06-13

Inventor: WEBER JORG [DE]; BECK BERND [DE]


Application No.: US20060278588A1  Published: 14/Dec/2006

Title: Apparatus and method for separating and concentrating fluids containing multiple components

Applicant/Assignee:

Application No.: 11/442631   Filing Date: 26/May/2006

Abstract:An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.

Priority: US2004-932882 Applic. Date: 2004-09-02; US2003-445381 Applic. Date: 2003-05-23; US20020383013P Applic. Date: 2002-05-24

Inventor: WOODELL-MAY JENNIFER E [US]


Application No.: US20060280655A1  Published: 14/Dec/2006

Title: Intravascular diagnostic and therapeutic sampling device

Applicant/Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY

Application No.: 11/450862   Filing Date: 08/Jun/2006

Abstract:A device and methods for continuous precision blood sampling from a patient with a micro impedance pump as the driver in a microfluidic system. Depending on the needs of medical technologies, the micro impedance pump in the intravascular diagnostic and therapeutic sampling system serves in a forward pumping function for blood sampling, in a backward infusing for therapeutic treatment, and in a valving function for controlling fluid flow.

Priority: US20050688436P Applic. Date: 2005-06-08

Inventor: GHARIB MORTEZA [US]; RINDERKNECHT DEREK [US]; PETRASEK DANNY [US]


Application No.: US20060280768A1  Published: 14/Dec/2006

Title: Meniscal repair device and method

Applicant/Assignee:

Application No.: 11/151615   Filing Date: 13/Jun/2005

Abstract:Methods and apparatus for treating meniscal tissue damage are disclosed, including a biocompatible meniscal repair device comprising a stent. The tissue repair device is adapted to be placed in contact with a defect in the meniscus and can preferably provide a structure for supporting meniscal tissue and/or encouraging tissue growth through contact with vascularized portions of the meniscus or as a conduit for introduction of exogenous healing therapies.

Priority:

Inventor: HWANG JULIA [US]; KLADAKIS STEPHANIE [US]; KADIYALA SUDHAKAR [US]; BOWMAN STEVEN [US]


Application No.: US20060280795A1  Published: 14/Dec/2006

Title: Specific time-delayed burst profile delivery system

Applicant/Assignee: DEXCEL PHARMA TECHNOLOGIES, LTD

Application No.: 11/147388   Filing Date: 08/Jun/2005

Abstract:The invention provides a delivery device for the delayed release of an active agent in the gastrointestinal tract comprising a core, comprising an active agent

a first outer coating, comprising a relatively hydrophobic substantially water insoluble polymer having substantially water insoluble hydrophilic particles embedded therein

and a first inner coating layer, comprising an agent that can cause the dissolution of at least one of the water insoluble components of the outer coating, and optionally a water soluble polymer, such that the insoluble particles in the outer coating, upon absorption of liquid, form channels leading to the inner coating layer, thus enabling the dissolution thereof, whereby the agents contained therein are released to cause the dissolution and/or degradation (destruction) of the outer coating, and the release of the pharmaceutically acceptable active agent from the core of the device.

Priority:

Inventor: PENHASI ADEL [IL]; GOMBERG MILA [IL]; GOMBERG MAXIM [IL]


Application No.: US20060281152A1  Published: 14/Dec/2006

Title: Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation

Applicant/Assignee:

Application No.: 11/440749   Filing Date: 24/May/2006

Abstract:Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity obtained by a process comprising the preparation of the K5 polysaccharide from Escherichia coli, N-deacetilation/N-sulfation, C-5 epimerization, supersulfation, selective O-desulfation, selective 6-O sulfation and N-sulfation, wherein said epimerization is carried out using the glucuronosyl C-5 epimerase enzyme in solution or in immobilized form in presence of specific divalent cations.

Priority: IT2000MI00665 Applic. Date: 2000-03-30; US2002-240606 Applic. Date: 2002-12-21; WO2001EP03461 Applic. Date: 2001-03-27

Inventor: ZOPPETTI GIORGIO [IT]; ORESTE PASQUA [IT]; CIPOLLETTI GIOVANNI [IT]


Application No.: US20060286141A1  Published: 21/Dec/2006

Title: Systems for gel-based medical implants

Applicant/Assignee:

Application No.: 10/587580   Filing Date: 28/Jul/2006

Abstract:Systems, including methods and apparatus, for medical implants including a gel.

Priority: US20030529470P Applic. Date: 2003-12-15; US20030529479P Applic. Date: 2003-12-15; US20030529489P Applic. Date: 2003-12-15; US20030529534P Applic. Date: 2003-12-15; WO2004US42474 Applic. Date: 2004-12-15

Inventor: CAMPBELL TODD D [US]


Application No.: US20060286614A1  Published: 21/Dec/2006

Title: METHOD FOR MONITORING COAGULABILITY AND HYPERCOAGULABLE STATES

Applicant/Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION

Application No.: 10/028741   Filing Date: 20/Dec/2001

Abstract:The assay of soluble endothelial protein C receptor (sEPCR) is useful to monitor effective thrombin levels and a hypercoagulable state. An assay for sEPCR is therefore useful to monitor ongoing effectiveness of anticoagulant therapy. A sEPCR ELISA assay is particularly useful for this purpose. A state of hypercoagulability in patients or normal individuals can also be identified by such an assay.

Priority: US20010270066P Applic. Date: 2001-02-20

Inventor: KUROSAWA SHINICHIRO [US]; STEARNS-KUROSAWA DEBORAH J [US]


Application No.: US20060287244A1  Published: 21/Dec/2006

Title: L-Threonine derivatives of high therapeutic index

Applicant/Assignee: SIGNATURE R&D HOLDINGS, LLC

Application No.: 11/442027   Filing Date: 26/May/2006

Abstract:The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the derivatives of the present invention enhance at least one or more therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

Priority: US2006-343557 Applic. Date: 2006-01-30; WO2004US24901 Applic. Date: 2004-07-29; US20030491331P Applic. Date: 2003-07-29

Inventor: CHANDRAN V R [US]


Application No.: US20060287315A1  Published: 21/Dec/2006

Title: Pyrazinedicarboxamides and their use

Applicant/Assignee: BAYER HEALTHCARE AG

Application No.: 11/299342   Filing Date: 08/Dec/2005

Abstract:The present invention relates to novel pyridinedicarboxamides, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.

Priority: DE200410059219 Applic. Date: 2004-12-09

Inventor: ROHRIG SUSANNE [DE]; JESKE MARIO [DE]; AKBABA METIN [DE]; ROSENTRETER ULRICH [DE]; BOYER STEPHEN [US]; FISCHER KARIN [DE]; POHLMANN JENS [CH]; TUCH AROUNARITH [FR]; PERZBORN ELISABETH [DE]; GERDES CHRISTOPH [DE]; SCHLEMMER KARL-HEINZ [DE]; BURKHARDT NILS [DE]; ALLERHEILIGEN SWEN [DE]; NELL PETER [DE]; ARNDT SABINE [DE]; LOBELL MARIO [DE]


Application No.: US20060287628A1  Published: 21/Dec/2006

Title: Blood component collection apparatus and method

Applicant/Assignee: TERUMO KABUSHIKI KAISHA

Application No.: 11/453840   Filing Date: 16/Jun/2006

Abstract:A blood component collection apparatus comprises a blood component collecting circuit which includes an anticoagulant line for feeding an anticoagulant and a line for collecting an initial flow of collected blood. In the blood component collection apparatus, air is intermediately present between the anticoagulant and the blood in the passage of a blood collection needle side line, after a priming operation is performed in which anticoagulant is supplied from the anticoagulant line toward the side of a centrifugal separator in the blood collection needle side line through a branch connector and after an initial flow collecting operation is performed in which the initial flow of blood is collected.

Priority: JP20050178316 Applic. Date: 2005-06-17

Inventor: HIRABUKI MAKOTO [JP]


Application No.: US20060287709A1  Published: 21/Dec/2006

Title: Drug-eluting stent and methods of making the same

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 11/510431   Filing Date: 25/Aug/2006

Abstract:An intravascular stent having a prefabricated, patterned polymeric sleeve for controlled release of therapeutic drugs and for delivery of the therapeutic drugs in localized drug therapy in a blood vessel is disclosed. The polymeric sleeve is attached to at least a portion of an outside surface area of the stent structure. Alternatively, a plurality of individual microfilament strands are longitudinally attached to an outer surface of a stent structure in a spaced apart orientation and loaded with at least one therapeutic drug for the release thereof at a treatment site. The stent has a high degree of flexibility in the longitudinal direction, yet has adequate vessel wall coverage and radial strength sufficient to hold open an artery or other body lumen. Methods for making the same are also disclosed.

Priority: US2002-293108 Applic. Date: 2002-11-13

Inventor: RAO K T V [US]


Application No.: US20060293733A1  Published: 28/Dec/2006

Title: Method of making selective organ cooling catheter

Applicant/Assignee:

Application No.: 11/389879   Filing Date: 27/Mar/2006

Abstract:A heat transfer device has first and second elongated, articulated segments, each having a turbulence-inducing exterior surface. A flexible joint connects the first and second elongated, articulated segments. An inner coaxial lumen is disposed within the first and second elongated, articulated segments. The inner coaxial lumen is capable of transporting a pressurized working fluid to a distal end of the first elongated, articulated segment.

Priority: US2003-749140 Applic. Date: 2003-12-29; US2001-836585 Applic. Date: 2001-04-16; US2000-566531 Applic. Date: 2000-05-08; US1998-103342 Applic. Date: 1998-06-23

Inventor: DOBAK JOHN D III [US]; LASHERAS JUAN C [US]


Application No.: US20070004736A1  Published: 04/Jan/2007

Title: Imidazole derivative, process for producing the same, and use

Applicant/Assignee:

Application No.: 10/535268   Filing Date: 20/Nov/2003

Abstract:There is provided an imidazole derivative useful as a thrombosis treating agent, which is represented by the formula (I): wherein R represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent linear hydrocarbon group, X represents an optionally substituted divalent hydrocarbon group, Y represents -CO-, -S(O)-, -S(O)2- or a bond, ring A represents an optionally substituted pyrrolidine ring, an optionally substituted piperidine ring or an optionally substituted perhydroazepine ring, Z<1 >and Z<3 >independently represent a bond or an optionally substituted divalent linear hydrocarbon group, Z<2 >represents -N(R<1>)-, -O-, -S(O)-, -S(O)2-, -CO-, -CH(R<1>)- or a bond, ring B represents an optionally substituted imidazole ring, wherein a substituent which the optionally substituted imidazole ring represented by ring B may have may be taken together with R<1 >to form an optionally substituted ring, and a represents 0, 1 or 2.

Priority: JP20020338939 Applic. Date: 2002-11-22; WO2003JP14793 Applic. Date: 2003-11-20

Inventor: KUBO KEIJI [JP]; KUROITA TAKANOBU [JP]; IMAEDA YASUHIRO [JP]; KAWAMURA MASAKI [JP]


Application No.: US20070005121A1  Published: 04/Jan/2007

Title: Central nervous system cooling catheter

Applicant/Assignee:

Application No.: 11/418849   Filing Date: 05/May/2006

Abstract:The invention provides a method and apparatus for performing selective hypothermia to the brain and spinal cord for injury protection without the need for systemic cooling. A flexible catheter is inserted into the cerebral lateral ventricle or spinal subdural space. The catheter has lumens with a heat transfer element. The lumens of the catheter circulate a coolant and communicate at the distal heat transfer element for transfer of heat from the cerebrospinal fluid. Furthermore a method of maintaining catheter patency and providing blood clot hemolysis and drainage is also provided through the use of ultrasonic and/or laser energy delivered through the catheter.

Priority: US2002-136003 Applic. Date: 2002-04-29

Inventor: KHANNA ROHIT [US]


Application No.: US20070009470A1  Published: 11/Jan/2007

Title: Topical/on-the-skin estrogen cream, lotion, ointment, hair tonic, shampoo and wound healing powder

Applicant/Assignee:

Application No.: 11/475797   Filing Date: 27/Jun/2006

Abstract:The Claimed Invention is the topical-to-skin use of generic estradiol, estriol, conjugated estrogens, or any other synthetic estrogen within a non-absorbable generic vehicle of cream, lotion, ointment, shampoo, hair tonic, and wound-healing powder, having no absorbents or deconstructors in their formulas. This invention causes skin basal cells to produce increased quantities of collagen and to retain skin-water resulting in increased skin-thickness. This increased thickness results in improved resilience, resistance to injury, trauma and infection. The target of this invention is the skin and skin only. Specifically, there is no intended absorption of hormone into the circulation to result in side effects or risk. Any possible unintended and minimal quantity of hormone absorbed would be metabolized normally by the liver and excreted in the urine without risk or awareness to the user. Improving skin health and healing existing injuries/disease can save individuals from mid 30's and older, and society in general millions of dollars annually in skin-related health care costs.

Priority: US20050595451P Applic. Date: 2005-07-06

Inventor: JUNG KIN [US]


Application No.: US20070009934A1  Published: 11/Jan/2007

Title: Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer

Applicant/Assignee:

Application No.: 11/416470   Filing Date: 02/May/2006

Abstract:This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

Priority: WO1997US03479 Applic. Date: 1997-03-14; US2004-912367 Applic. Date: 2004-07-23; US2001-013294 Applic. Date: 2001-12-10; US2001-013868 Applic. Date: 2001-10-30; US1998-155152 Applic. Date: 1998-09-22

Inventor: KOPRESKI MICHAEL S [US]


Application No.: US20070010528A1  Published: 11/Jan/2007

Title: Thiazoline derivative and use of the same

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 10/574048   Filing Date: 12/May/2006

Abstract:A thiazoline derivative represented by Formula (I): wherein R is a cyclic hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted

X is a bond or a divalent chain hydrocarbon group which may be substituted

X' is a bond or -N(R<5>)-

Y is a divalent hydrocarbon group which may be substituted

Y' is a bond or -C(-O)-

ring A is a nitrogen-containing heterocycle which may be substituted

Z<1 >and Z<3 >are each independently a bond or a divalent chain hydrocarbon group which may be substituted

Z<2 >is a bond or -N(R<6>)-

and B is a group represented by the formula: which is useful as a therapeutic drug for thrombosis, is provided.

Priority: JP20030341430 Applic. Date: 2003-09-30; WO2004JP14685 Applic. Date: 2004-09-29

Inventor: KUBO KEIJI [JP]; KUROITA TAKANOBU [JP]; KAWAMURA MASAKI [JP]; SAKAMOTO HIROKI [JP]


Application No.: US20070012323A1  Published: 18/Jan/2007

Title: Compositions and methods for treating a damaged cardiovascular element

Applicant/Assignee:

Application No.: 11/443594   Filing Date: 31/May/2006

Abstract:In the present invention, the applicants describe methods and compositions of treating damaged cardiovascular elements and cardiovascular conditions including hypotension, atherosclerotic lesions, vulnerable plaque, and acute myocardial infarct. The applicants demonstrate the ability of a biomembrane sealing agent to accumulate on the walls of damaged blood vessels and help improving mean arterial pressure following tissue injury. The applicants describe the use of formulations comprising at least one biomembrane sealing agent and one bioactive agent for prophylactic treatment such as they could be administered concurrently to an invasive therapeutic intervention or after the insult (i.e. post-injury or post-surgery). Alternatively, these methods and compositions could be used to reduce the severity of cardiovascular diseases after onset.

Priority: US20050685831P Applic. Date: 2005-05-31

Inventor: ROY JOSEE [US]; AYALA HEZI-YAMIT [US]; SULLIVAN CAROL [US]; CHEN MINGFEI [US]


Application No.: US20070014733A1  Published: 18/Jan/2007

Title: Hydroxylated nebivolol metabolites

Applicant/Assignee:

Application No.: 11/342497   Filing Date: 30/Jan/2006

Abstract:Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6'difluoro-, 4-hydroxy-5-phenol-6,6'difluoro-, and 4-hydroxy-8-pheno-6,6'difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

Priority: US20050648551P Applic. Date: 2005-01-31; US20060755856P Applic. Date: 2006-01-03

Inventor: O'DONNELL JOHN P [US]; OWENS WALTER [US]; DUNCAN JOSEPH [US]; SHAW ANDREW [US]; WU JINN [US]


Application No.: US20070014734A1  Published: 18/Jan/2007

Title: Glucuronidated nebivolol metabolites

Applicant/Assignee:

Application No.: 11/342889   Filing Date: 30/Jan/2006

Abstract:This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol and/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also provides methods of treating and/or preventing vascular diseases, by administering at least one glucuronidated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one glucuronidated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

Priority: US20050648552P Applic. Date: 2005-01-31; US20060755755P Applic. Date: 2006-01-03

Inventor: O'DONNELL JOHN P [US]; OWENS WALTER [US]; DUNCAN JOSEPH [US]; SHAW ANDREW [US]


Application No.: US20070014779A1  Published: 18/Jan/2007

Title: PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS

Applicant/Assignee: GENENTECH, INC

Application No.: 11/533305   Filing Date: 19/Sep/2006

Abstract:A solution is provided comprising about 0.01-0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline. Such solution is useful for delivery from a catheter and for treating a thrombotic disorder by exposing fibrin-rich fluid from the disorder to an effective amount thereof, as well as in kits. In a preferred embodiment, peripheral thrombosis is treated in a mammal comprising delivering to the mammal via a catheter an effective amount of this solution.

Priority: US2003-697142 Applic. Date: 2003-10-30; US20020426616P Applic. Date: 2002-11-14

Inventor: SEMBA CHARLES P [US]


Application No.: US20070016089A1  Published: 18/Jan/2007

Title: Implantable device for vital signs monitoring

Applicant/Assignee:

Application No.: 11/181969   Filing Date: 15/Jul/2005

Abstract:An implantable medical device is provided for subcutaneous implantation within a human being. The implantable medical device includes a pair of electrodes for sensing electrical signals from the human being's heart. Electronic circuitry having digital memory is provided with the electronic circuitry designed to record the electrical signals from the heart. The electronics of the electronic circuitry are housed in a case having a tapered shape to facilitate implantation and removal of the implantable medical device.

Priority:

Inventor: FISCHELL DAVID R [US]; FISCHELL TIM A [US]; HARWOOD JONATHAN [US]; JOHNSON STEVEN R [US]; TURI GREGG [US]


Application No.: US20070020607A1  Published: 25/Jan/2007

Title: Methods for the storage and deglycerolization of red blood cells

Applicant/Assignee: MISSION MEDICAL, INC

Application No.: 11/187521   Filing Date: 22/Jul/2005

Abstract:The present invention relates to improved methods for the anticoagulation of whole blood and the subsequent refrigerated storage of red blood cells and to improved methods for removing glycerol from frozen-thawed red blood cells.

Priority:

Inventor: MERYMAN HAROLD T [US]; HOGMAN CLAES F [SE]


Application No.: US20070021338A1  Published: 25/Jan/2007

Title: Stabilised compositions of Factor VII

Applicant/Assignee: NOVO NORDISK HEALTHCARE A/G

Application No.: 11/450783   Filing Date: 09/Jun/2006

Abstract:The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.

Priority: DK20030001901 Applic. Date: 2003-12-19; WO2004EP53587 Applic. Date: 2004-12-17

Inventor: HANSEN BIRTHE L [DK]; JENSEN MICHAEL B [DK]; KORNFELT TROELS [DK]


Application No.: US20070021458A1  Published: 25/Jan/2007

Title: Selective resonance of bodily agents

Applicant/Assignee: SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE

Application No.: 11/441786   Filing Date: 26/May/2006

Abstract:Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs.

Priority: US2005-186633 Applic. Date: 2005-07-21

Inventor: ISHIKAWA MURIEL Y [US]; JUNG EDWARD K [US]; LEUTHARDT ERIC C [US]; MYHRVOLD NATHAN P [US]; WOOD LOWELL L JR [US]


Application No.: US20070027370A1  Published: 01/Feb/2007

Title: Analyte sensor

Applicant/Assignee:

Application No.: 11/503367   Filing Date: 10/Aug/2006

Abstract:Biointerface membranes are provided which can be utilized with implantable devices, such as devices for the detection of analyte concentrations in a biological sample. More particularly, methods for monitoring glucose levels in a biological fluid sample using an implantable analyte detection device incorporating such membranes are provided.

Priority: US2006-439630 Applic. Date: 2006-05-23; US2005-077715 Applic. Date: 2005-03-10; US20040587787P Applic. Date: 2004-07-13; US20040587800P Applic. Date: 2004-07-13; US20040614683P Applic. Date: 2004-09-30; US20040614764P Applic. Date: 2004-09-30; US20050683923P Applic. Date: 2005-05-23

Inventor: BRAUKER JAMES H [US]; BOOCK ROBERT [US]; RIXMAN MONICA [US]; SIMPSON PETER C [US]; BRISTER MARK [US]


Application No.: US20070027529A1  Published: 01/Feb/2007

Title: Biological artificial blood vessel and method of making

Applicant/Assignee:

Application No.: 11/494817   Filing Date: 28/Jul/2006

Abstract:A prosthetic device for implantation into a human body is made by a method that includes the steps of providing a natural animal tissue that has a substrate, crosslinking and fixing the substrate, minimizing the antigens from the substrate, tanning the substrate to improve its mechanical properties, and coupling an anticoagulant to an inner surface of the substrate to form an anticoagulant surface layer.

Priority: CN20051036175 Applic. Date: 2005-07-29

Inventor: XU GUO-FENG [CN]


Application No.: US20070029257A1  Published: 08/Feb/2007

Title: Multiple laminar flow-based particle and cellular separation with laser steering

Applicant/Assignee: ARRYX, INC

Application No.: 11/543773   Filing Date: 06/Oct/2006

Abstract:The invention provides a method, apparatus and system for separating blood and other types of cellular components, and can be combined with holographic optical trapping manipulation or other forms of optical tweezing. One of the exemplary methods includes providing a first flow having a plurality of blood components

providing a second flow

contacting the first flow with the second flow to provide a first separation region

and differentially sedimenting a first blood cellular component of the plurality of blood components into the second flow while concurrently maintaining a second blood cellular component of the plurality of blood components in the first flow. The second flow having the first blood cellular component is then differentially removed from the first flow having the second blood cellular component.

Holographic optical traps may also be utilized in conjunction with the various flows to move selected components from one flow to another, as part of or in addition to a separation stage.

Priority: US2004-934597 Applic. Date: 2004-09-03; US2004-867328 Applic. Date: 2004-06-13; US20040571141P Applic. Date: 2004-05-14; US20030499957P Applic. Date: 2003-09-04; US20030511458P Applic. Date: 2003-10-15

Inventor: MUETH DANIEL [US]; PLEWA JOSEPH [US]; SHIREMAN JESSICA [US]; ANDERSON AMY [US]; GRUBER LEWIS [US]; ROSENBAUM NEIL H [US]


Application No.: US20070032424A1  Published: 08/Feb/2007

Title: Stimulators of Factor X activated (FXa) as new topical antihemorrhagic agents

Applicant/Assignee: THROMBOTARGETS CORPORATION

Application No.: 11/498590   Filing Date: 03/Aug/2006

Abstract:The activated coagulation Factor X (FXa) stimulating agents may be used in the treatment of hemorrhages in a subject. Compounds and combinations are described which are particularly useful for the topical treatment of hemorrhaging in healthy subjects or in patients with hemorrhagic diathesis.

Priority: EP20050380179 Applic. Date: 2005-08-03; US20050719643P Applic. Date: 2005-09-21

Inventor: EGEA JAVIER P [ES]; CATASUS LUIS C [US]


Application No.: US20070036766A1  Published: 15/Feb/2007

Title: Tissue graft composition comprising autologous bone marrow and purified autologous thrombin

Applicant/Assignee:

Application No.: 11/200535   Filing Date: 09/Aug/2005

Abstract:A method for the preparation of an autologous tissue graft composition is disclosed. Bone marrow is harvested from the patient. In one embodiment, the nucleated cells of the bone marrow are subsequently concentrated. Autologous thrombin is purified from a volume of whole blood also taken from the patient. The bone marrow aspirate or bone marrow concentrate is then combined with the purified autologous thrombin to form a coagulated tissue graft material that may be used alone or in conjunction with other graft materials.

Priority:

Inventor: KEVY SHERWIN [US]; JACOBSON MAY [US]; ELLSWORTH JAMES [US]; BENOIT KEVIN [US]


Application No.: US20070037737A1  Published: 15/Feb/2007

Title: Composition and method for the repair and regeneration of cartilage and other tissues

Applicant/Assignee:

Application No.: 11/584870   Filing Date: 23/Oct/2006

Abstract:The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention.

Priority: US2005-031325 Applic. Date: 2005-01-07; US2001-896912 Applic. Date: 2001-06-29; US20000214717P Applic. Date: 2000-06-29

Inventor: HOEMANN CAROLINE D [CA]; BUSCHMANN MICHAEL D [CA]; MCKEE MARC D [CA]


Application No.: US20070038277A1  Published: 15/Feb/2007

Title: Inhibition of platelet activation, aggregation and/or adhesion by hypothermia

Applicant/Assignee: RADIANT MEDICAL, INC ZOLL CIRCULATION, INC

Application No.: 11/501442   Filing Date: 08/Aug/2006

Abstract:A method for treating acute coronary syndromes (i.e., unstable angina or non-Q-wave MI) or transient ischemic attacks in a human or animal patient by placing a heat exchange apparatus in the patient's vasculature and using that heat exchange apparatus to cool the patient to a temperature (e.g. 30-36 DEG C.) at which platelet inhibition (i.e., inhibition of platelet activation and/or aggregation and/or adhesion) occurs. Anti-shivering drugs or anesthesia may be administered to patients whose body temperature is cooled below that patient's shivering threshold (typically approximately 35.5 C).

If it is determined that platelet inhibition is no longer desirable, such as when the patient is about to undergo a surgical or interventional procedure wherein bleeding could be problematic, the hypothermia-induced platelet inhibition may be rapidly reversed by using the intravascular heat exchange apparatus to re-warm the patient's body to normothermia or near normothermia.

Priority: US2003-408617 Applic. Date: 2003-04-07; US2001-790249 Applic. Date: 2001-02-21

Inventor: DAE MICHAEL W [US]; MACHOLD TIMOTHY R [US]; KELLER WADE A [US]


Application No.: US20070042049A1  Published: 22/Feb/2007

Title: Nanoparticulate benidipine compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LIMITED

Application No.: 11/446589   Filing Date: 05/Jun/2006

Abstract:The present invention relates to nanoparticulate benidipine compositions having improved bioavailability. The compositions comprise benidipine particles having an effective average particle size of less than about 2000 nm and may be useful in the prevention and treatment of hypertension, renal parenchymal hypertension and angina pectoris.

Priority: US20050687145P Applic. Date: 2005-06-03

Inventor: LIVERSIDGE GARY G [US]; JENKINS SCOTT [US]


Application No.: US20070042961A1  Published: 22/Feb/2007

Title: Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity

Applicant/Assignee:

Application No.: 11/589371   Filing Date: 30/Oct/2006

Abstract:Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Three examples of such recombinant APC mutants are KKK191-193AAA-APC, RR229/230AA-APC, and RR229/230AA plus KKK191-193AAA-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of APC's anticoagulant activity. These subjects include patients at risk of damage to blood vessels or tissue in various organs caused, at least in part, by apoptosis. At risk patients include, for example, those suffering (severe) sepsis, ischemia/reperfusion injury, ischemic stroke, acute myocardial infarction, acute or chronic neurodegenerative diseases, or those undergoing organ transplantation or chemotherapy, among other conditions. Methods of screening for variants of recombinant protein C or APC that are useful in accordance with the invention are also provided.

Priority: US2004-886766 Applic. Date: 2004-07-08; US20030485792P Applic. Date: 2003-07-08

Inventor: GRIFFIN JOHN H [US]; MOSNIER LAURENT O [US]; GALE ANDREW J [US]


Application No.: US20070043328A1  Published: 22/Feb/2007

Title: Cord blood and placenta collection kit

Applicant/Assignee:

Application No.: 11/589018   Filing Date: 27/Oct/2006

Abstract:The present invention provides an improved kit for the collection of umbilical cord blood and placental blood, and collection of the placenta from which such blood is obtained. The kit improves upon existing kits in that it provides for improved user convenience, provides for the collection of the placenta itself, and better maintains the internal temperature of the container in which the collected blood and placenta are shipped to a blood bank or registry. The invention further provides a method of collecting umbilical cord and placental blood, and the placenta from which such blood is obtained, comprising using the kit described herein.

Priority: US2005-230760 Applic. Date: 2005-09-20; US20040612408P Applic. Date: 2004-09-23

Inventor: GOODMAN CHRIS B [US]; ROBINSON WAYNE M [US]; FEINGOLD BARNETT D [US]


Application No.: US20070049739A1  Published: 01/Mar/2007

Title: Method and system for extracting blood-derived growth factors

Applicant/Assignee: BIOMET MANUFACTURING CORP

Application No.: 11/214661   Filing Date: 30/Aug/2005

Abstract:Methods for extracting heparin-binding growth factors from whole blood comprising contacting whole blood with a heparin-conjugated system to immobilize a conjugated fraction comprising the heparin-binding growth factors

separating a non-conjugated fraction from the system

and releasing the heparin-binding growth factors are provided. Kits include a heparin-conjugate immobilized to the surface of a substrate

and a device to withdraw whole blood from a human or animal subject. Methods of promoting tissue health with the growth factors are also provided.

Priority:

Inventor: TROXEL KAREN S [US]; PALACIOS FELIPE [US]


Application No.: US20070056595A1  Published: 15/Mar/2007

Title: Method for treatment of ischaemic tissue

Applicant/Assignee:

Application No.: 10/554427   Filing Date: 03/Nov/2003

Abstract:A method for treating ischaemic tissue comprising cutting the tissue to form a wound, and locating a sponge-like element ( 1 ) structured to receive blood and to comply with the movement of the tissue, in contact with a source of blood whereby the element ( 1 ) receives blood from the source of blood to thereby promote tissue growth and angiogenesis throughout and beyond the element ( 1 ).

Priority: AU20030902037 Applic. Date: 2003-04-24; WO2003AU01449 Applic. Date: 2003-11-03

Inventor: MCLACHLAN CRAIG [AU]


Application No.: US20070062861A1  Published: 22/Mar/2007

Title: Citrate anticoagulation system for extracorporeal blood treatments

Applicant/Assignee:

Application No.: 11/602827   Filing Date: 21/Nov/2006

Abstract:A hemofiltration system and method for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.

Priority: EP19990201302 Applic. Date: 1999-04-26; US2003-742137 Applic. Date: 2003-12-19; US2001-959543 Applic. Date: 2001-10-23; WO2000EP03583 Applic. Date: 2000-04-20; US20050739086P Applic. Date: 2005-11-22

Inventor: LANNOY JEAN-MICHEL [FR]


Application No.: US20070062885A1  Published: 22/Mar/2007

Title: Method and apparatus for fractionating blood

Applicant/Assignee:

Application No.: 10/554565   Filing Date: 28/Apr/2004

Abstract:A method and an apparatus for processing blood in a closed system in order to obtain fractionation of the corpusculate part and preferably the separation of the white cells from the red cells according to their sedimentation rate and maintain a high degree of vitality of the cells. The white blood cells are sequestered from the remaining cell population of the blood by placing the blood in a container, preventing its coagulation and separating the blood by means of a sedimentation agent in at least two compartments, one of which is extremely rich in white cells.

Priority: IT2003MI00897 Applic. Date: 2003-04-30; WO2004EP04474 Applic. Date: 2004-04-28

Inventor: STRISINO CESARE [IT]


Application No.: US20070065853A1  Published: 22/Mar/2007

Title: Nucleic acid preparation from whole blood for use in diagnosis of transmissible spongiform encephalopathy

Applicant/Assignee: ROCHE DIAGNOSTICS OPERATIONS, INC

Application No.: 11/514776   Filing Date: 01/Sep/2006

Abstract:The present invention deals with a method of preparing nucleic acids, particularly RNA, from a whole blood sample. The nucleic acids purified by the method of the invention are particularly suited for detection of nucleic acid marker molecules. Preferred are markers for the diagnosis of transmissible spongiform encephalopathy (TSE). Such diagnosis is based on the detection, by means of real-time PCR, of certain mRNAs of the TSE-infected organism. Said mRNAs specifically originate as splicing variants and are isolated from whole blood by the method of the invention.

Priority: EP20050019479 Applic. Date: 2005-09-07

Inventor: KNOLL MICHAEL [DE]; EBERLE WALTER [DE]; KIRSCHBAUM THOMAS [DE]


Application No.: US20070066615A1  Published: 22/Mar/2007

Title: Heterocyclic compounds

Applicant/Assignee: BAYER HEATHCARE AG

Application No.: 10/557168   Filing Date: 06/May/2004

Abstract:The present invention relates to the area of blood clotting. The invention relates in particular to certain heterocyclic compounds, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases.

Priority: DE20031022469 Applic. Date: 2003-05-19; WO2004EP04836 Applic. Date: 2004-05-06

Inventor: GERDES CHRISTOPH [DE]; PERZBORN ELISABETH [DE]; POHLMANN JENS [CH]; ROHRIG SUSANNE [DE]; STRAUB ALEXANDER [DE]; THOMAS CHRISTIAN R [DE]; TUCH AROUNARITH [FR]; SCHLEMMER KARL-HEINZ [DE]


Application No.: US20070066928A1  Published: 22/Mar/2007

Title: Automation and optimization of CRRT treatment using regional citrate anticoagulation

Applicant/Assignee:

Application No.: 11/525800   Filing Date: 21/Sep/2006

Abstract:A system or method automates and optimizes citrate anticoagulant supplementation in a blood filtration circuit during CRRT. A processor-based control system interfaces with a blood filtration circuit to detect patient blood flow into the circuit, detect fluid loss through a hemofilter, and sense vital electrolyte concentrations in the blood flow, and in response, control the addition of citrate, substitution fluid, and electrolyte supplements to ensure stability of plasma concentrations in post-dilution flow returned to the patient. The controller executes the method embodied as process control algorithms for calculating an optimal citrate flow rate as a function of selected, detected, and calculated system parameters. Citrate may be added to the circuit separately, or as part of a substitution solution or a dialysate.

Priority: US20050719718P Applic. Date: 2005-09-22

Inventor: LANNOY JEAN-MICHEL [FR]


Application No.: US20070067855A1  Published: 22/Mar/2007

Title: Production of human glycosylated proteins in transgenic insects

Applicant/Assignee: CHESAPEAKE PERL, INC

Application No.: 10/577528   Filing Date: 28/Oct/2004

Abstract:This invention relates, e.g., to transgenic insects, or progeny thereof, whose cells contain at least one genomically integrated, expressible, nucleic acid encoding two or more of a set of Nglycosylation enzymes that can glycosylate a heterologous protein with a mammalianized (e.g., humanized) glycosylation pattern. The glycosylation genes are preferably expressed in the insect cells in catalytic amounts. Also described are methods to use such a transgenic insect to produce heterologous, mammalianized polypeptides of interest.

Priority: US20030514741P Applic. Date: 2003-10-28; WO2004US35553 Applic. Date: 2004-10-28

Inventor: JARVIS DONALD [US]; BEEK NIKOLAI V [US]; FRASER MALCOLM [US]


Application No.: US20070073039A1  Published: 29/Mar/2007

Title: Peptides that inhibit viral infections

Applicant/Assignee:

Application No.: 11/541488   Filing Date: 29/Sep/2006

Abstract:The present application is directed to peptides that inhibit infection of a virus from the Flaviviridae family, methods of using these peptides to inhibit viral infections, and pharmaceutical compositions and combinations, as well as articles of manufacture comprising these peptides.

Priority: US20050722502P Applic. Date: 2005-09-29; US20060840328P Applic. Date: 2006-08-25

Inventor: CHISARI FRANCIS V [US]


Application No.: US20070073268A1  Published: 29/Mar/2007

Title: Integrated Infusion and Aspiration System and Method

Applicant/Assignee:

Application No.: 11/560754   Filing Date: 16/Nov/2006

Abstract:An integrated infusion and aspiration system includes of a flow control system and a catheter assembly. The catheter assembly includes an infusion catheter and an aspiration catheter, each having ports located at the distal end of thereof. The distal ends of the catheters are separated so that the aspiration catheter ports can be positioned on an opposing side of a surgical wound site from the infusion catheter ports. Methods of operation of the integrated infusion and aspiration system provides for uninterrupted aspiration with concurrent controlled delivery of an infusion solution such that the infusion solution is substantially evenly dispersed of over the wound site.

Priority: US2004-896515 Applic. Date: 2004-07-22; US2002-218106 Applic. Date: 2002-08-12

Inventor: GOBLE E M [US]; HOWARD MARK E [US]; MASON JEFFREY T [US]; FALLIN T W [US]


Application No.: US20070073383A1  Published: 29/Mar/2007

Title: Drug-eluting stent cover and method of use

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 11/497706   Filing Date: 01/Aug/2006

Abstract:An intravascular stent includes an eluting sheath fabricated from a mesh for controlled release of therapeutic drugs and for delivery of the therapeutic drugs in localized drug therapy in a blood vessel. The eluting sheath is attached to at least a portion of an outside surface area of the stent structure and is fabricated from a mesh designed to neck down in response to a radially outward directed force resulting in the uniform expansion of the stent. The eluting sheath can be loaded with at least one therapeutic drug for the release thereof at a treatment site to facilitate repair of a damaged vessel. The stent has a high degree of flexibility in the longitudinal direction, yet has adequate vessel wall coverage and radial strength sufficient to hold open an artery or other body lumen.

Priority: US2002-334034 Applic. Date: 2002-12-30

Inventor: YIP PHILIP S [US]; JACOBS JAMES [US]; HOSSAINY SYED [US]; BECKER JON [US]; LIMON TIMOTHY A [US]


Application No.: US20070081947A1  Published: 12/Apr/2007

Title: Solid active ingredient formulation

Applicant/Assignee: BAYER TECHNOLOGY SERVICE GMBH

Application No.: 10/577608   Filing Date: 19/Oct/2004

Abstract:The present invention relates to novel solid active substance formulations comprising solid active substances, dispersants, and polymers which together result in a fine-particle, predominantly amorphous mixture, to a process for the preparation thereof and to the use thereof for application of the contained bioactive active substances.

Priority: DE20031051087 Applic. Date: 2003-10-31; WO2004EP11807 Applic. Date: 2004-10-19

Inventor: EBLE AXEL [DE]; BAUR PETER [DE]; REIZLEIN KARL [DE]


Application No.: US20070081989A1  Published: 12/Apr/2007

Title: Treatment of B cell diseases using anti-germline antibody binding agents

Applicant/Assignee:

Application No.: 11/524531   Filing Date: 19/Sep/2006

Abstract:Methods for reducing the number of pathologic antibody producing B cells in a patient suffering from an autoimmune disease by administration of an anti-germline antibody are described. Methods for removing pathologic antibodies and B cells and plasma cells producing pathologic antibodies from the body of a patient suffering from autoimmune disease are provided, comprising contacting the blood or plasma of the patient with an immunoadsorbent having specific binding for an epitope present on germline antibodies, particularly VH4-34 antibodies, wherein said contacting results in the reduction in the amount of germline antibodies present in the blood or bone marrow or lymphoid tissue of the patient or the amount of germline antibody producing B cells present in the blood, lymphoid tissues or bone marrow of the patient. Methods for treating a patient suffering from a B cell cancer expressing cell surface germline antibodies by similar methods are also provided. Methods for ex vivo purging bone marrow of pathologic antibody producing B-cells and cancerous B-cells expressing germline antibodies are provided. Methods for monitoring the efficacy of a therapeutic treatment in a patient suffering from an autoimmune disease or B cell cancer are also provided. Kits and uses in preparation of a medicament are also described.

Priority: US20050718796P Applic. Date: 2005-09-19

Inventor: SANDERS MARTIN E [US]


Application No.: US20070082020A1  Published: 12/Apr/2007

Title: Blood clot filter having coating

Applicant/Assignee:

Application No.: 11/248024   Filing Date: 11/Oct/2005

Abstract:The present invention is directed to a blood clot filter for implantation in a patient comprising a blood clot filter having a coating comprising one or more pharmaceutically active compounds.

Priority:

Inventor: PICCONE VINCENT A JR [US]


Application No.: US20070088218A1  Published: 19/Apr/2007

Title: Surgical device and method for performing combination revascularization and therapeutic substance delivery to tissue

Applicant/Assignee:

Application No.: 11/543505   Filing Date: 05/Oct/2006

Abstract:The present invention contemplates a surgical device for both ablating a channel in a patient's tissue and also delivering a therapeutic agent. The device includes an elongated multi-lumen tube, an elongated tissue ablating assembly, and a therapeutic agent delivery assembly. The therapeutic agent is capable of being delivered into the channel and/or to the surrounding tissue. The device may further include a second multi-lumen tube also capable of delivering therapeutic agents. Although suitable for many operations, the device is particularly well suited for transmyocardial revascularization operations. The present invention also contemplates a procedure for using such a surgical device to ablate a channel in a patient's tissue and also deliver a therapeutic agent.

Priority: US20050727325P Applic. Date: 2005-10-17

Inventor: MCINTYRE JOHN [US]; TZENG ELBERT [US]


Application No.: US20070088246A1  Published: 19/Apr/2007

Title: Medical assembly with transducer for local delivery of a therapeutic substance and method of using same

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 11/636097   Filing Date: 08/Dec/2006

Abstract:A medical Assembly is used to delivery a therapeutic substance to a treatment area. The medical assembly comprises a catheter having a distal end and a proximal end, a transducer supported by at least a portion of the distal end of the catheter assembly, and a delivery lumen mounted on the catheter for delivery of a therapeutic substance. Support for the transducer is provided at a preselected number of anchoring points, wherein an inner surface of the transducer is positioned at a preselected distance from an outer surface of the catheter. The preselected distance defines a gap that is occupied by a low density material such as a gas which reflects acoustic pressure waves directed toward the gap by a transducer when a voltage is applied to the transducer. The reflected pressure wave increases the energy in the system, enhancing transport of therapeutic substances from the delivery lumen to the surrounding tissues and/or cells to be treated. The medical assembly may optionally be used in conjunction with both macroporous and microporous balloons. The medical assembly may optionally be modified so that a plurality of transducers are used, wherein the distal end of a transducer is positioned at a preselected distance from the proximal end of an adjacent transducer.

Priority: US1999-475548 Applic. Date: 1999-12-30

Inventor: STEWARD JEFFREY A [US]; GOSIENGFIAO BRANDON [US]


Application No.: US20070093446A1  Published: 26/Apr/2007

Title: Orally bioavailable compounds and methods for inhibiting platelet aggregation

Applicant/Assignee: INSPIRE PHARMACEUTICALS, INC

Application No.: 11/595837   Filing Date: 09/Nov/2006

Abstract:This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae III, IIIa, and IIIb, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae IIIa and IIIb, which are potent and have a good oral bioavailability.

Priority: WO2006US17781 Applic. Date: 2006-05-05; US2005-124619 Applic. Date: 2005-05-05; US2004-971766 Applic. Date: 2004-10-21; US20030513845P Applic. Date: 2003-10-21

Inventor: DOUGLASS JAMES G III [US]; WATSON PAUL S [US]; SAMUELSON CARL A [US]; CREAN CHRISTOPHER S [US]


Application No.: US20070093501A1  Published: 26/Apr/2007

Title: Urea derivative, process for producing the same, and use

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 10/583046   Filing Date: 15/Dec/2004

Abstract:The present invention provides a urea derivative or a salt thereof, which is useful as a therapeutic agent for thrombosis. The derivative is represented by Formula (I): wherein Cy is an aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted

R<1 >is a hydrogen atom or a hydrocarbon group which may be substituted

V is -C(O)-, -S(O)-, or -S(O)2-

W is -N(R<2>)-, -O-, or a bond (wherein R<2 >is a hydrogen atom or a hydrocarbon group which may be substituted)

X is alkylene which may be substituted

Y is -C(O)-, -S(O)-, or -S(O)2-

Z is a bond, a chain hydrocarbon group which may be substituted, or -N-

ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted

ring B is a nitrogen-containing heterocyclic ring which may be substituted

and [Chemical formula 2] custom character, custom character are each independently a single bond or a double bond

provided that R<1 >may be bonded to R<2 >to form a non-aromatic nitrogen-containing heterocyclic ring and that R<2 >may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted.

Priority: JP20030420031 Applic. Date: 2003-12-17; WO2004JP18717 Applic. Date: 2004-12-15

Inventor: KUBO KEIJI [JP]; IMAEDA YASUHIRO [JP]


Application No.: US20070098805A1  Published: 03/May/2007

Title: Methods of making and using novel griseofulvin compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LIMITED

Application No.: 11/546378   Filing Date: 12/Oct/2006

Abstract:The present invention is directed to nanoparticulate compositions comprising griseofulvin. The griseofulvin particles of the composition preferably have an effective average particle size of less than about 2 microns.

Priority: US2003-683154 Applic. Date: 2003-10-14; US2002-175851 Applic. Date: 2002-06-21; US1997-815346 Applic. Date: 1997-03-11

Inventor: LIVERSIDGE GARY G [US]


Application No.: US20070100272A1  Published: 03/May/2007

Title: METHOD FOR COLLECTING A DESIRED BLOOD COMPONENT AND PERFORMING A PHOTOPHERESIS TREATMENT

Applicant/Assignee:

Application No.: 11/613021   Filing Date: 19/Dec/2006

Abstract:An improved method for separating whole blood into components and collecting a desired blood component. The method allows a desired blood component to be subjected to centrifugal forces within a separator for prolonged periods of time, yielding a cleaner cut and higher yield of the desired blood component. Whole blood is drawn from a source and pumped into a separator, the undesired blood components are removed from the separator at rates so as to build up the desired blood component in the separator. The desired blood component is only removed after a predetermined amount of the desired blood component has built up in the separator. It is preferred that the desired blood component be buffy coat and that the method be used to perform photopheresis treatments. In another aspect, the invention is a method of performing a full photopheresis treatment to treat diseases in a reduced time, preferably less than about 70 minutes, and more preferably less than about 45 minutes.

Priority: US2003-654803 Applic. Date: 2003-09-03; US2003-375629 Applic. Date: 2003-02-27; US20020361287P Applic. Date: 2002-03-04

Inventor: BRIGGS DENNIS [US]


Application No.: US20070106129A1  Published: 10/May/2007

Title: Dietary monitoring system for comprehensive patient management

Applicant/Assignee: CARDIAC PACEMAKERS, INC

Application No.: 11/269771   Filing Date: 07/Nov/2005

Abstract:A patient management system includes a device, an interactive display, a repeater unit, and a host. The device assesses at least one dietary condition of a patient. The interactive display receives patient input related to the patient's dietary conditions and communicates dietary feedback to the patient. The system may also include at least one sensor configured to assess at least one dietary condition of the patient. The repeater unit collects information from the device, the interactive display and the sensors. The host communicates with the repeater through a network. The patient's own input of dietary information into the system can be useful for verifying sources of measured data and enhancing feedback given to the patient. The system is configured to perform accurately even in the absence of patient input or the input of incorrect information by the patient.

Priority:

Inventor: SRIVATHSA MURALIDHARAN [US]; JOHNSON DAVID C [US]; GOSCHA DONALD L [US]; BROCKWAY MARINA [US]; KADHIRESAN VEERICHETTY A [US]


Application No.: US20070106214A1  Published: 10/May/2007

Title: Systems and methods for securing cardiovascular tissue, including via asymmetric inflatable members

Applicant/Assignee: COAPTUS MEDICAL CORPORATION

Application No.: 11/582205   Filing Date: 16/Oct/2006

Abstract:Systems and methods for securing cardiovascular tissue, including via asymmetric inflatable members, are disclosed. A device in accordance with one embodiment includes a catheter having a proximal end and a distal end, with a working portion positioned toward the distal end and being elongated along a terminal axis. An energy transmitter and an inflatable member are positioned at the working portion, with the inflatable member being inflatable under fluid pressure from a generally collapsed configuration to an inflated configuration. In the inflated configuration, the inflatable member can be asymmetric relative to the terminal axis.

Priority: US20050727678P Applic. Date: 2005-10-17; US20060811866P Applic. Date: 2006-06-07; US20060811993P Applic. Date: 2006-06-07; US20060811864P Applic. Date: 2006-06-07; US20060811999P Applic. Date: 2006-06-07; US20060812002P Applic. Date: 2006-06-07; US2006-581848 Applic. Date: 2006-10-16; US2006-581869 Applic. Date: 2006-10-16; US2006-582210 Applic. Date: 2006-10-16; US2006-582253 Applic. Date: 2006-10-16

Inventor: GRAY WILLIAM [US]; GENAU CHRISTOPHER C [US]


Application No.: US20070106249A1  Published: 10/May/2007

Title: Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia

Applicant/Assignee: MERCATOR MEDSYSTEMS INC

Application No.: 11/607168   Filing Date: 01/Dec/2006

Abstract:Methods and kits for delivering pharmaceutical agents to the adventitia surrounding a blood vessel utilize a catheter having a microneedle. The microneedle is positioned in the perivascular space and delivers an amount of pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally along the blood vessel and in some cases to the adventitia surrounding other blood vessels.

Priority: US2003-350314 Applic. Date: 2003-01-22; US20020430993P Applic. Date: 2002-12-03; US20020370602P Applic. Date: 2002-04-05; US20020356670P Applic. Date: 2002-02-13; US20020350564P Applic. Date: 2002-01-22

Inventor: SEWARD KIRK P [US]; BARR LYNN M [US]; WILBER JUDITH C [US]; CAFFERATA ROBERT [US]


Application No.: US20070111947A1  Published: 17/May/2007

Title: Fibrin targeted therapeutics

Applicant/Assignee:

Application No.: 11/581677   Filing Date: 16/Oct/2006

Abstract:Fibrin targeted therapeutic agents for the treatment of thromboembolism, infection, and cancer are provided.

Priority: US20060800152P Applic. Date: 2006-05-12; US20050726632P Applic. Date: 2005-10-14

Inventor: MCMURRY THOMAS J [US]; KOLODZIEJ ANDREW [US]; CARPENTER ALAN P JR [US]; JONES SIMON [US]; GRAHAM PHILIP [US]; LOOBY RICHARD [US]; NAIR SHRIKUMAR A [US]; WANG XIFANG [US]; OVEROYE-CHAN KIRSTEN [US]; BARRETT JOHN A [US]


Application No.: US20070114172A1  Published: 24/May/2007

Title: Multiple laminar flow-based rate zonal or isopycnic separation with holographic optical trapping of blood cells and other static components

Applicant/Assignee: ARRYX, INC

Application No.: 11/594094   Filing Date: 08/Nov/2006

Abstract:The invention provides a method and apparatus for separating blood into components, may be expanded to include other types of cellular components, and can be combined with holographic optical manipulation or other forms of optical tweezing. One of the exemplary methods includes providing a first flow having a plurality of blood components

providing a second flow

contacting the first flow with the second flow to provide a first separation region

and differentially sedimenting a first blood cellular component of the plurality of blood components into the second flow while concurrently maintaining a second blood cellular component of the plurality of blood components in the first flow. The second flow having the first blood cellular component is then differentially removed from the first flow having the second blood cellular component.

Holographic optical traps may also be utilized in conjunction with the various flows to move selected components from one flow to another, as part of or in addition to a separation stage.

Priority: US2004-867328 Applic. Date: 2004-06-13; US2003-630904 Applic. Date: 2003-07-31

Inventor: MUETH DANIEL M [US]; SHIREMAN JESSICA [US]; ANDERSON AMY [US]


Application No.: US20070116710A1  Published: 24/May/2007

Title: Methods of treating hemolytic anemia

Applicant/Assignee:

Application No.: 11/595118   Filing Date: 08/Nov/2006

Abstract:Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.

Priority: US2005-050543 Applic. Date: 2005-02-03; US2004-771552 Applic. Date: 2004-02-03; US20060783070P Applic. Date: 2006-03-15

Inventor: BELL LEONARD [US]; ROTHER RUSSELL P [US]


Application No.: US20070118070A1  Published: 24/May/2007

Title: Device with anchoring elements for transdermal delivery or sampling of agents

Applicant/Assignee:

Application No.: 11/668157   Filing Date: 29/Jan/2007

Abstract:A percutaneous agent delivery or sampling device comprising a sheet having a plurality of microblades for piercing and anchoring to the skin for increasing transdermal flux of an agent and for improving the attachment of the device to the skin.

Priority: US1997-877155 Applic. Date: 1997-06-17; US19960019990P Applic. Date: 1996-06-18

Inventor: CORMIER MICHEL J [US]; NEUKERMANS ARMAND P [US]; BLOCK BARRY [US]; THEEUWES FELIX T [US]; AMKRAUT ALFRED A [US]


Application No.: US20070122440A1  Published: 31/May/2007

Title: Methods for producing nanoparticles

Applicant/Assignee:

Application No.: 11/486620   Filing Date: 14/Jul/2006

Abstract:The present invention relates to methods of preparing nanoparticles from reactively formed block and/or graft copolymers and nanoparticles derived therefrom

Priority: US20050700855P Applic. Date: 2005-07-20

Inventor: MACOSKO CHRISTOPHER W [US]; HOYE THOMAS R [US]; ANACKER JESSICA [US]; PRUD HOMME ROBERT K [US]


Application No.: US20070122824A1  Published: 31/May/2007

Title: Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime

Applicant/Assignee:

Application No.: 11/530826   Filing Date: 11/Sep/2006

Abstract:A method of determining a personalised therapeutic regime, comprising: receiving genetic information relating to a patient

determining genetic criteria relevant to a personalised therapeutic regime for the patient using the genetic information

receiving personal information relating to the patient

determining personal criteria relevant to the personalised therapeutic regime using the personal information

and combining the genetic criteria and the personal criteria to determine the personalised therapeutic regime for the patient.

Priority: US20050715936P Applic. Date: 2005-09-09

Inventor: TUCKER MARK R [GB]; WALTON ROBERT [GB]; MATTHEWS HUBERT [GB]; MISKIN ANTHONY [GB]


Application No.: US20070122884A1  Published: 31/May/2007

Title: Factor VII glycoforms

Applicant/Assignee: NOVO NORDISK HEALTHCARE A/G

Application No.: 11/643607   Filing Date: 21/Dec/2006

Abstract:The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.

Priority: DK20010000751 Applic. Date: 2001-05-14; DK20010000430 Applic. Date: 2001-03-14; DK20010000262 Applic. Date: 2001-02-16; DK20000001456 Applic. Date: 2000-10-02; US2003-725843 Applic. Date: 2003-12-02; US2001-969357 Applic. Date: 2001-10-02; US20010276322P Applic. Date: 2001-03-16; US20010271581P Applic. Date: 2001-02-26; US20000238944P Applic. Date: 2000-10-10

Inventor: PINGEL HANS K [DK]; KLAUSEN NIELS K [DK]


Application No.: US20070123547A1  Published: 31/May/2007

Title: [4-(6-HALO-7-SUBSTITUTED-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREAS AND FORMS AND METHODS RELATED THERETO

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 11/556490   Filing Date: 03/Nov/2006

Abstract:The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.

Priority: US20050733650P Applic. Date: 2005-11-03

Inventor: SCARBOROUGH ROBERT [US]; HUANG WOLIN [US]; MEHROTRA MUKUND [US]; ZHANG XIAOMING [US]; CANNON HILARY [GB]; GRANT CRAIG M [GB]; SCARBOROUGH CARROLL A C [US]


Application No.: US20070123964A1  Published: 31/May/2007

Title: MAGNETICALLY GUIDABLE ENERGY DELIVERY APPARATUS AND METHOD OF USING SAME

Applicant/Assignee: BAYLIS MEDICAL COMPANY

Application No.: 11/627406   Filing Date: 26/Jan/2007

Abstract:An energy delivery apparatus for delivering electrical energy at a target location, the energy delivery apparatus being usable in combination with a magnetic field. The energy delivery apparatus includes an electrical conductor, the electrical conductor having a substantially elongated configuration

an electrode for delivering the electrical energy at the target location, the electrode being electrically coupled to the electrical conductor and located at a predetermined location therealong

and a guiding element mounted to the electrical conductor in a substantially spaced apart relationship relative to the electrode, the guiding element including a magnetically responsive material. The energy delivery apparatus is constructed such that a movement of the guiding element causes a corresponding movement of the electrode. The magnetic field is used to move the guiding element in order to position the electrode substantially adjacent to the target location.

Priority: US2006-520754 Applic. Date: 2006-09-14; US2005-265304 Applic. Date: 2005-11-03; US2003-666301 Applic. Date: 2003-09-19; US2004-760479 Applic. Date: 2004-01-21; US2003-666288 Applic. Date: 2003-09-19; US2003-347366 Applic. Date: 2003-01-21; US20050596297P Applic. Date: 2005-09-14; US20060743181P Applic. Date: 2006-01-27; US20060827458P Applic. Date: 2006-09-29

Inventor: DAVIES GARETH [CA]; ALBERT KELLY [CA]; MUNGER GARETH T [US]; PANDEY ASHWINI [US]; VISWANATHAN RAJU [US]


Application No.: US20070128181A1  Published: 07/Jun/2007

Title: Methods of Preventing Morbidity and Mortality by Perioperative Administration of a Blood Clotting Inhibitor

Applicant/Assignee:

Application No.: 11/462282   Filing Date: 03/Aug/2006

Abstract:The present invention provides methods of using a blood clotting inhibitor to reduce post-surgical morbidity and mortality. In particular, perioperative use of a blood clotting inhibitor decreases surgical complications without significant adverse effects and is cost effective.

Priority: US2002-272187 Applic. Date: 2002-10-15

Inventor: MANGANO DENNIS T [US]


Application No.: US20070129371A1  Published: 07/Jun/2007

Title: Novel ethylenediamine derivatives

Applicant/Assignee: DAIICHI PHARMACEUTICAL CO., LTD

Application No.: 10/539995   Filing Date: 24/Dec/2003

Abstract:A compound represented by the following formula (1): Q<1>-Q<2>-T-N(R<1>)-Q<3>-N(R<2>)-T<1>-Q<4> ( 1 ) [wherein, R<1 >and R<2 >are hydrogen atoms or the like

Q<1 >is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may have a substituent, or the like

Q<2 >is a single bond or the like

Q<3 >represents the following group: -C(R<3a>)(R<4a>)-{C(R<3b>)(R<4b>)}m<1>-{C(R<3c>)(R<4c>)}m<2>-{C(R<3d>)(R<4d>)}m<3>-{C(R<3e>)(R<4e>)}m<4>-C (R<3f>)(R<4f>)- (in which, R<3a >to R<4e >represent hydrogen or the like)

T<0 >represents a carbonyl group or the like

and T<1 >represents -COCONR- or the like]

or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Priority: JP20020373025 Applic. Date: 2002-12-24; WO2003JP16556 Applic. Date: 2003-12-24

Inventor: NAKAMOTO YUMI [JP]; YOSHINO TOSHIHARU [JP]; NAITO HIROYUKI [JP]; NAGATA TSUTOMU [JP]; YOSHIKAWA KENJI [JP]; SUZUKI MAKOTO [JP]


Application No.: US20070134348A1  Published: 14/Jun/2007

Title: MULTI-PART SUBSTITUTION INFUSION FLUIDS AND MATCHING ANTICOAGULANTS

Applicant/Assignee: BAXTER INTERNATIONAL INC BAXTER HEALTHCARE S.A

Application No.: 11/678525   Filing Date: 23/Feb/2007

Abstract:A multi-part substitution infusion fluid for an extracorporeal blood treatment and methods for using same are provided. Generally, the multi-part substitution fluid comprises a first solution composed of electrolites but without divalent cations and a second solution comprising divalent cations. Another embodiment includes a third solution comprising a matching citrate/citric acid anticoagulant. The described methods of using the multi-part substitution infusion fluids significantly reduce risks associated with various extracorporeal blood treatments.

Priority: EP19990201302 Applic. Date: 1999-04-26; US2003-742137 Applic. Date: 2003-12-19; US2001-959543 Applic. Date: 2001-10-23; WO2000EP03583 Applic. Date: 2000-04-20

Inventor: CHANG PETER C [NL]; LANNOY JEAN-MICHEL [FR]


Application No.: US20070135382A1  Published: 14/Jun/2007

Title: Use of peroxisome proliferator-activated receptor gamma (ppary) and/or retinoic acid receptor (rxr) agonists to inhibit platelet functions

Applicant/Assignee:

Application No.: 10/576824   Filing Date: 22/Oct/2004

Abstract:Methods of inhibiting mammalian platelet release of CD40 ligand, thromboxanes, or prostaglandin E2, or surface expression of CD40 ligand that involve contacting mammalian platelets with an effective amount of a PPARgamma agonist, an RXR agonist, or a combination thereof. As a consequence of inhibiting CD40 ligand and thromboxane release, the present invention allows for inhibition of thrombus fon-nation by (or clotting activities of) activated platelets, as well as treating or preventing CD40 ligand-mediated conditions and/or thromboxane-mediated conditions. Use of PPARgamma agonist, RXR agonist, and/or inducers of PPARgamma agonist in preparing a stored blood product, and for diagnostic testing of patient samples is also disclosed.

Priority: US20030513372P Applic. Date: 2003-10-22; US20040553657P Applic. Date: 2004-03-16; US20040567397P Applic. Date: 2004-04-30; WO2004US35065 Applic. Date: 2004-10-22

Inventor: PHIPPS RICHARD P [US]; SIME PATRICIA J [US]; BLUMBERG NEIL [US]


Application No.: US20070135677A1  Published: 14/Jun/2007

Title: Wrap

Applicant/Assignee: SUNSHINE HEART COMPANY PTY LTD

Application No.: 10/595602   Filing Date: 28/Oct/2004

Abstract:A wrap ( 20 ) for securing about a blood vessel ( 36 ) by encasing a section of the vessel. The wrap ( 20 ) being of thin flexible construction having two ends ( 22, 24 ) and two sides ( 26, 28 ). The wrap ( 20 ) is more elastic or stretchable at, near, or along at least some of its sides ( 22, 24 ) compared to at, near, or along its centre, to provide strain relief from wrapped to unwrapped aorta. The wrap ( 20 ) is not inelastic, so that loss of aortic compliance is minimised or enhanced. The wrap ( 20 ) is adapted to apply, in use, less compressive force at, near, or along at least some of its sides ( 22, 24 ) compared to at, near, or along its centre.

Priority: AU20030905992 Applic. Date: 2003-10-30; WO2004AU01484 Applic. Date: 2004-10-28

Inventor: MILLER SCOTT H [AU]; PETERS WILLIAM S [NZ]; DE PLATER GEMMA L [AU]


Application No.: US20070141159A1  Published: 21/Jun/2007

Title: METHODS OF MAKING NANOPARTICULATE DRUG COMPOSITIONS COMPRISING COPOLYMERS OF VINYL PYRROLIDONE AND VINYL ACETATE AS SURFACE STABILIZERS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/213765   Filing Date: 30/Aug/2005

Abstract:The present invention is directed to nanoparticulate compositions comprising a poorly soluble drug and at least one copolymer of vinyl pyrrolidone and vinyl acetate as a surface stabilizer adsorbed to the surface of the drug. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate composition of the invention, methods of making and using such nanoparticulate and pharmaceutical compositions.

Priority: US2003-345312 Applic. Date: 2003-01-16; US2000-715117 Applic. Date: 2000-11-20; US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21

Inventor: BOSCH H W [US]; RYDE NIELS P [US]


Application No.: US20070142280A1  Published: 21/Jun/2007

Title: Factor VII or VIIa-like molecules

Applicant/Assignee:

Application No.: 11/448143   Filing Date: 07/Jun/2006

Abstract:Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Priority: DK20000000218 Applic. Date: 2000-02-11; US2004-950747 Applic. Date: 2004-09-27; US2001-782578 Applic. Date: 2001-02-12; US20000241916P Applic. Date: 2000-10-18; US20000184036P Applic. Date: 2000-02-22; DK20000001558 Applic. Date: 2000-10-18

Inventor: PEDERSEN ANDERS H [DK]; ANDERSEN KIM V [DK]; BORNAES CLAUS [DK]


Application No.: US20070148232A1  Published: 28/Jun/2007

Title: Stabilized pharmaceutical solid compositions of low-solubility drugs and poloxamers, and stabilizing polymers

Applicant/Assignee: PFIZER INC

Application No.: 10/596885   Filing Date: 20/Dec/2004

Abstract:Solid compositions with improved physical stability comprise an amorphous, low-solubility drug, a poloxamer, and a stabilizing polymer. The compositions provide good physical stability during storage and concentration enhancement of dissolved drug when administered to an aqueous environment of use.

Priority: US20030533848P Applic. Date: 2003-12-31; WO2004IB04260 Applic. Date: 2004-12-20

Inventor: CREW MARSHALL D [US]; FRIESEN DWAYNE T [US]; MILLER WARREN K [US]; SHANKER RAVI M [US]; SMITHEY DANIEL T [US]


Application No.: US20070155828A1  Published: 05/Jul/2007

Title: Coumarin analog compounds for safer anticoagulant treatment

Applicant/Assignee: NEW CENTURY PHARMACEUTICALS, INC

Application No.: 11/708004   Filing Date: 20/Feb/2007

Abstract:The present invention relates to the albumin-guided development of coumarin analogs and the analogs developed thereby. The coumarin analogs of the present invention are identified and isolated by the fact that they have binding sites to albumin which are different than the binding sites of conventional coumarin analogs such as sodium warfarin, and as a result will be less prone to be displaced since the binding site of sodium warfarin is shared by numerous drugs such as aspirin. The coumarin analogs of the invention are advantageous because they can achieve the effects of the prior coumarin analogs with a minimum of metabolic complications and undesirable side effects.

Priority: US2003-629858 Applic. Date: 2003-07-30; US20020399126P Applic. Date: 2002-07-30

Inventor: CARTER DANIEL C [US]


Application No.: US20070160678A1  Published: 12/Jul/2007

Title: Microcapsules with modified release of active principles with low solubility for oral delivery

Applicant/Assignee:

Application No.: 11/583940   Filing Date: 20/Oct/2006

Abstract:The present invention is directed to microcapsules for reliably modified release and adapted to industrial reproduction of an active principle hardly water-soluble, other than anti-hyperglycemia agents. Each of said microcapsules comprises a core of hardly soluble active principle and a coating film applied on the core. Their mean diameter is less than 1000 microns. The coating film contains a film-forming polymer (PI) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA). Said coating film represents at least 4% p/p of dry matter of their total weight, and its components P1, P2, PL satisfy the following characteristics: dry weight mass fraction of PI relative to the total coating weight ranging between 40 and 90%

dry matter weight fraction of PL/P1 +P2 ranging between 15 and 60%

dry matter weight fraction of PL/P1+P2 ranging between 1 and 30%. The present invention is also directed to the uses of said microcapsules in galenic formulation.

Priority: FR20020009530 Applic. Date: 2002-07-26; US2006-358047 Applic. Date: 2006-02-22; WO2003FR02384 Applic. Date: 2003-07-28

Inventor: GUIMBERTEAU FLORENCE [FR]; CASTAN CATHERINE [FR]; MEYRUIEX REMI [FR]; SOULA GERARD [FR]


Application No.: US20070161076A1  Published: 12/Jul/2007

Title: Methods and systems for sampling, screening, and diagnosis

Applicant/Assignee: THE JOHNS HOPKINS UNIVERSITY

Application No.: 10/587927   Filing Date: 04/Feb/2005

Abstract:Apparatus, systems, and methods for detecting, screening and sampling of cells are disclosed.

Priority: US20040541781P Applic. Date: 2004-02-04; US20040577790P Applic. Date: 2004-06-08; US20040619621P Applic. Date: 2004-10-18; WO2005US03369 Applic. Date: 2005-02-04

Inventor: HALDEN ROLF U [US]


Application No.: US20070163963A1  Published: 19/Jul/2007

Title: Blood cell sorting methods and systems

Applicant/Assignee:

Application No.: 11/646985   Filing Date: 28/Dec/2006

Abstract:The invention relates to methods of isolating white blood cells (WBCs) from a sample, e.g., whole blood, using magnetic particles that specifically bind to WBCs and a series of specific steps and conditions. The methods can include one or more of decreasing the viscosity of the sample prior to WBC isolation, agitating the sample at specified frequencies, and/or using a sample container arranged such that all of the sample is placed in close proximity (e.g., within 5, 2, 1, or 0.5 mm) to the source of the magnetic field. The new methods provide for isolation of WBC preparations with high yield, purity, and viability. The methods are designed for compatibility with automation protocols for rapid processing of multiple samples.

Priority: US20050754426P Applic. Date: 2005-12-28

Inventor: FAUSTMAN DENISE L [US]; BURGER DOUGLAS E [US]


Application No.: US20070167853A1  Published: 19/Jul/2007

Title: System and method for monitoring health using exhaled breath

Applicant/Assignee:

Application No.: 11/301911   Filing Date: 13/Dec/2005

Abstract:The present invention includes systems and methods for monitoring endogenous compound concentration in blood by detecting markers, such as odors, upon exhalation by a patient, wherein such markers are the endogenous compound itself or result from the endogenous compound. In the case of olfactory markers, the invention preferably utilizes electronic sensor technology, such as the commercial devices referred to as "artificial" or "electronic" noses or tongues, to non-invasively monitor endogenous compound levels in blood. The invention further includes a reporting system capable of tracking endogenous compound concentrations in blood (remote or proximate locations) and providing the necessary alerts with regard to emergent or harmful conditions in a patient.

Priority: WO2005US06355 Applic. Date: 2005-02-28; US2004-788501 Applic. Date: 2004-02-26; US2002-178877 Applic. Date: 2002-06-24; US2002-054619 Applic. Date: 2002-01-22

Inventor: MELKER RICHARD J [US]; DENNIS DONN M [US]; BJORAKER DAVID G [US]; GOLD MARK S [US]


Application No.: US20070170080A1  Published: 26/Jul/2007

Title: Medical device package

Applicant/Assignee:

Application No.: 11/340912   Filing Date: 26/Jan/2006

Abstract:The present disclosure provides a package containing a sealable pouch for a medical device and a sealed port positioned adjacent a periphery of the sealable pouch for permitting the passage of at least one agent to the medical device contained therein from outside the sealable pouch.

Priority:

Inventor: STOPEK JOSHUA [US]; HOTTER JOSEPH [US]; COHEN MATTHEW D [US]


Application No.: US20070172517A1  Published: 26/Jul/2007

Title: Compositions capable of facilitation penetration across a biological barrier

Applicant/Assignee:

Application No.: 10/572249   Filing Date: 17/Sep/2004

Abstract:This invention relates to novel pharmaceutical compositions capable of facilitating penetration of at least one effector across biological barriers. The invention also relates to methods of treating or preventing diseases by administering these compositions to affected subjects.

Priority: US2003-665184 Applic. Date: 2003-09-17; US2003-664989 Applic. Date: 2003-09-17; US20030503615P Applic. Date: 2003-09-17; WO2004IB04452 Applic. Date: 2004-09-17

Inventor: BEN-SASSON SHMUEL A [IL]; GALAMIDI-COHEN EINAT [IL]


Application No.: US20070173481A1  Published: 26/Jul/2007

Title: Compositions and methods for preventing infection

Applicant/Assignee: LA JOLLA BIOSCIENCES LLC

Application No.: 11/637960   Filing Date: 11/Dec/2006

Abstract:This invention relates to cholesterol-sequestering agents and methods of using cholesterol-sequestering agents to prevent infection. The compositions of the invention can be used to reduce or prevent maternal to fetal transmission of a microorganism and/or to reduce or eliminate a microorganism present in a blood sample or a blood product.

Priority: US2003-667727 Applic. Date: 2003-09-22; US20020412399P Applic. Date: 2002-09-20

Inventor: SCHEELE GEORGE A [US]; HILDRETH JAMES E [US]


Application No.: US20070178104A1  Published: 02/Aug/2007

Title: Methods and means for treating solid tumors

Applicant/Assignee:

Application No.: 11/399281   Filing Date: 06/Apr/2006

Abstract:The present invention relates to method and means for treating a vascularized solid tumor using a number of, in vitro prepared, anticellular agent(s)-carrying blood platelets to induce a thrombus formation within the tumor vasculature, and at the same time to deliver a high concentration of an anticellular agent within the tumor. The blood platelets are targeted and attached to the tumor vasculature using in vivo assembled binding complexes, each having at least one binding site specifically binding to tumor cells or to tumor-associated vasculature, and at least one binding site specifically binding to a blood platelet surface. The platelet-mediated thrombus formed within the tumor vasculature leads to occlusion of the tumor vasculature, with ultimate destruction of the centrally located tumor cells. This is followed by destruction or suppressing the growth or cell division of the peripherally located tumor cells, by the anticellular agent(s) carried by the blood platelets.

Priority: US2006-343694 Applic. Date: 2006-01-31

Inventor: AWDALLA ESSAM T [US]


Application No.: US20070178436A1  Published: 02/Aug/2007

Title: Method of inactivating virus in circular blood and its applications in treating viral diseases

Applicant/Assignee: BEIJING JINGJING MEDICAL EQUIPMENT CO., LTD

Application No.: 10/551334   Filing Date: 21/May/2004

Abstract:The present invention relates to a method for illuminating the viruses in a circulatory blood, comprising the following steps of: 1) Adding an anticoagulant into a whole blood source and establishing a circulation system for the whole blood source

2) Withdrawing the whole blood with the anticoagulant into a plasma-separating device for a separation, when finished, directly pumping the red-blood cells back into the whole blood source and transporting the plasma into a mixing transport pump after the separation

3) Meanwhile, pumping a photosensitizer methylene blue into the mixing transport pump so that the methylene blue is mixed with the plasma and pumped together into a plasma container

4) Using an illumination device to illuminate the plasma in the plasma container for virus illumination, and pumping the virus-illuminated plasma into a removing device for removing off the photosensitizer

5) The methylene blue being absorbed by the removing device and the plasma illuminated being transfused back into the whole blood system

6) Repeating the step 2 to the step 5 until the virus content in the whole blood source is reduced by 99.99%. The present invention can process blood in a batch, as a pipeline, and can utilize aseptic and disposable sealed systems isolated from the outside environment for processing. The processed plasma flows back into the whole blood source and can be directly transfused into the human body. Still, the invention may be further used to treat virus-diseases such as Hepatitis B, Hepatitis C, AIDS and etc., and to eliminate the viruses of organ transplantation recipient.

Priority: CN20031036647 Applic. Date: 2003-05-22; WO2004CN00516 Applic. Date: 2004-05-21

Inventor: WU WEIXING [CN]; KAM YUEN [CN]


Application No.: US20070179423A1  Published: 02/Aug/2007

Title: ADJUSTING PH IN A METHOD OF SEPARATING WHOLE BLOOD

Applicant/Assignee: GAMBRO BCT, INC

Application No.: 11/668715   Filing Date: 30/Jan/2007

Abstract:This invention is directed to a method of collecting and separating whole blood into components. The method includes the steps of adding an anticoagulant having an acidic pH to a bag for collecting and/or separating whole blood, collecting whole blood in the bag, loading the bag containing anticoagulated whole blood on a rotor, spinning the bag on the rotor to separate the whole blood into at least one component

and squeezing the bag on the rotor to push the component from the separation bag into at least one satellite bag.

Priority: US20060766586P Applic. Date: 2006-01-30

Inventor: FELT THOMAS [US]; GIBBS BRUCE [US]; PIHLSTEDT PETER [SE]


Application No.: US20070179424A1  Published: 02/Aug/2007

Title: High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjunction therewith

Applicant/Assignee:

Application No.: 11/640138   Filing Date: 15/Dec/2006

Abstract:A therapeutic product formed from a high concentration of white blood cells having a high degree of cell viability. The white blood cells are sequestered from their normal population presence in whole blood by placing the blood into a container and preventing coagulation of the blood, separating the blood into two components, one of which is extremely rich in white blood cells through the use of a reagent and centrifugation, sequestering the white cell concentration, and freezing the white cells.

Priority: US2001-855789 Applic. Date: 2001-05-15; US1999-313816 Applic. Date: 1999-05-18; US1998-128208 Applic. Date: 1998-08-03; US1994-349747 Applic. Date: 1994-12-05

Inventor: RUBINSTEIN PABLO [US]; COELHO PHILIP H [US]; STEVENS CLADD E [US]


Application No.: US20070184496A1  Published: 09/Aug/2007

Title: MONOCYTE ACTIVATION TEST BETTER ABLE TO DETECT NON-ENDOTOXIN PYROGENIC CONTAMINANTS IN MEDICAL PRODUCTS

Applicant/Assignee: NATIONAL BIOLOGICAL STANDARDS BOARD

Application No.: 11/613866   Filing Date: 20/Dec/2006

Abstract:An improved monocyte activation test is described that is better able to detect non-endotoxin pyrogens in medical products, in which a sample is incubated with a monocyte-containing reagent in an assay system comprising at least one surface comprising polypropylene. The invention also concerns assay systems for use in these tests that include at least one microtiter well having at least one interior surface comprising polypropylene and having a shape such that monocyte-containing reagent is concentrated in the well to provide greater cell to cell contact. The invention also relates to a diagnostic kit that can be used to test for the presence of non-endotoxin pyrogens in a sample.

Priority: US20050752970P Applic. Date: 2005-12-22

Inventor: POOLE STEPHEN [GB]; PATEL MEHUL [US]


Application No.: US20070190154A1  Published: 16/Aug/2007

Title: Method for the production of emulsion-based micro particles

Applicant/Assignee: PR PHAMACEUTICALS

Application No.: 10/553003   Filing Date: 12/Apr/2004

Abstract:The apparatus and methods of the present invention are of use for the production of emulsion-based microparticles containing a biological or chemical agent. In particular, the apparatus provides a vessel

packing material situated inside such vessel and may further provide material capable of insertion into both ends of said vessel for enclosure of the packing material. In a particular embodiment, the apparatus is a packed bed apparatus. The methods include production of emulsion based microparticles containing a biological or chemical agent. The usefulness of the present invention is that the apparatus and methods of the present invention provide for a low-shear, non-turbulent, production of emulsion-based microparticles that provides a narrow, reproducible, particle size distribution, capable of use with both large and small volumes that is capable of being conveniently scaled up while providing predictable emulsion properties.

Priority: US20030461860P Applic. Date: 2003-04-10; WO2004US11485 Applic. Date: 2004-04-12

Inventor: ZEIGERSON EHUD [US]


Application No.: US20070190160A1  Published: 16/Aug/2007

Title: Nanoparticles for drug-delivery

Applicant/Assignee:

Application No.: 10/570461   Filing Date: 02/Sep/2004

Abstract:This invention relates to polymeric nanoparticles useful for drug delivery with target molecules bonded to the surface of the particles and having sizes of up to 1000 nm, preferably 1 nm to 400 nm, more preferably 1 nm to 200 nm, that are dispersed homogeneously in aqueous solution. The target drug/target substance is covalently bonded to the novel polymeric nanoparticles to secure them from outer intervention in vivo or cell culture in vitro until they are exposed at the target site within the cell. This invention also relates to microemulsion polymerization techniques useful for preparing the novel nanoparticles.

Priority: US20030499904P Applic. Date: 2003-09-02; US20030500750P Applic. Date: 2003-09-04; US20040568746P Applic. Date: 2004-05-06; WO2004US28995 Applic. Date: 2004-09-02

Inventor: TUROS EDWARD [US]; SHIM JEUNG-YEOP [US]


Application No.: US20070202174A1  Published: 30/Aug/2007

Title: New mandelic acid derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 11/520063   Filing Date: 13/Sep/2006

Abstract:There is provided a compound of formula (I) wherein R, R<1>, R<2>, Y and R<3 >have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g., thrombosis) or as anticoagulants.

Priority: SE20000004458 Applic. Date: 2000-12-01; SE20010000965 Applic. Date: 2001-03-19; SE20010001239 Applic. Date: 2001-04-06; SE20010002921 Applic. Date: 2001-08-30; US2003-432411 Applic. Date: 2003-05-21; WO2001SE02657 Applic. Date: 2001-11-30

Inventor: INGHARDT TORD [SE]; JOHANSSON ANDERS [SE]; SVENSSON ARNE [SE]


Application No.: US20070202189A1  Published: 30/Aug/2007

Title: Acellular bioabsorbable tissue regeneration matrices

Applicant/Assignee:

Application No.: 11/588840   Filing Date: 26/Oct/2006

Abstract:The present invention provides methods and compositions useful in the regeneration of damaged, lost and/or degenerated tissue in humans and animals. In certain embodiments, the present invention provides an acellular bioabsorbable tissue regeneration matrix, methods of making such a matrix, and methods of using such a matrix for the regeneration of damaged, lost and/or degenerated tissue. In certain embodiments, methods and compositions of the present invention are useful in the treatment of damaged, lost and/or degenerated nerve tissue.

Priority: US20050730614P Applic. Date: 2005-10-26

Inventor: AHLFORS JAN-ERIC [US]


Application No.: US20070207058A1  Published: 06/Sep/2007

Title: System, method and apparatus for use in blood testing through luminescence

Applicant/Assignee: GEMOSCAN CANADA, INC

Application No.: 11/364273   Filing Date: 01/Mar/2006

Abstract:The present invention seeks to provide an express-control system for analysing the compatibility of blood with other substances. The present invention relates to a system, method and apparatus for use in blood testing and more specifically, food intolerance testing through analysis of blood using luminescence. The present invention utilises a blood testing system and apparatus, which includes a displacement assembly, a blood divider assembly, a reagent divider assembly, an electro-optical multiplier assembly and a central controller. A sample of blood is added to a corresponding one of a plurality of canisters containing a test substance. Thereafter a luminescent reagent is added and the plurality of canisters are moved in the blood testing apparatus until the canisters begin to luminese.

The amount of luminescence is measured and analysed an indicator of compatibility of the blood with the test substance and more specifically as an indicator of the presence and activity of neutrophil in the blood and more specifically the granulacy of the blood.

Priority:

Inventor: OSTROVSKY ALEKSANDR [CA]; LEIBOVSKI MIKHAIL [CA]


Application No.: US20070212417A1  Published: 13/Sep/2007

Title: Compressible resilient granules and formulations prepared therefrom

Applicant/Assignee:

Application No.: 11/715821   Filing Date: 07/Mar/2007

Abstract:Methods and compositions having resilient, self-adhered granules are disclosed and described. In one embodiment, a resilient, self-adhering granule, which includes a combination of a polysaccharide in an amount of about 10 wt % to about 30 wt %

a sugar alcohol in an amount of about 15 wt % to about 35 wt %

and a binder having a viscosity from about 5000 mPa.s to about 250,000 mPa.s in an amount of from about 10 wt % to about 35 wt %, is capable of low-pressure, reversible agglomeration. In other embodiments, an oral dosage form of such granules and methods of administering said forms are provided.

Priority: US20060780304P Applic. Date: 2006-03-07

Inventor: CHERUKURI S R [US]


Application No.: US20070212674A1  Published: 13/Sep/2007

Title: Blood Co-Processing For Contingent Autologous Leukocyte Transplantation

Applicant/Assignee: LIFEFORCE GROUP PLC

Application No.: 10/573872   Filing Date: 28/Sep/2004

Abstract:A process for producing a leukocyte bank suitable for CAT therapy comprising the steps of providing a blood sample from a healthy donor individual

selectively separating and collecting leukocytes from the sample

selectively separating and collecting red blood cells and/or platelets and/or plasma from the sample

and cryogenically preserving the leukocytes (and optionally the red blood cells and/or platelets and/or plasma)

wherein steps are conducted with an automated leukapheresis device comprising a separation device (e.g. a centrifuge rotor or filter), a leukapheresis tubing set and one or more pumps for conveying the sample through the tubing set and the separated leukocytes into a collection vessel.

Priority: GB20030022791 Applic. Date: 2003-09-30; WO2004GB04173 Applic. Date: 2004-09-28

Inventor: SPIERS WILLIAM A [GB]


Application No.: US20070212743A1  Published: 13/Sep/2007

Title: Assays for Determining Anticoagulant Cofactor Activity

Applicant/Assignee:

Application No.: 11/560502   Filing Date: 16/Nov/2006

Abstract:Methods are disclosed for determining, in a sample derived from a human, the functional activity of a component of the human blood coagulation system, which activity can be correlated to conversion of a substrate specific for activated Protein C (APC), by measuring in an assay medium containing the sample and a substrate for APC, the conversion of the substrate by APC and correlating the conversion to the functional activity of the component. When the component is anticoagulant Factor V, at least one of exogenous APC, Protein S or an inhibitor of Protein S activity is added to the medium. When the component is Protein C, APC, or Protein S, exogenous anticoagulant Factor V or an inhibitor of anticoagulant activity of Factor V is added to the medium. Methods are also disclosed for diagnosing a blood coagulation/anticoagulation disorder or for determining a predisposition thereto in a human by determining anticoagulant Factor V activity in an assay medium containing a sample derived from the human.

Priority: SE19930000300 Applic. Date: 1993-01-29; SE19930002457 Applic. Date: 1993-07-20; US1995-500917 Applic. Date: 1995-10-20; WO1994SE00070 Applic. Date: 1994-01-28

Inventor: DAHLBAECK BJOERN [SE]


Application No.: US20070213295A1  Published: 13/Sep/2007

Title: METHODS AND COMPOSITIONS FOR INDUCING TORPOR IN A SUBJECT

Applicant/Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Application No.: 11/623625   Filing Date: 16/Jan/2007

Abstract:The present invention relates to the discovery the 5'-AMP and analogues thereof can be used to induce a state of torpor or suspended animation in subjects, as exemplified by studies carried out in laboratory mice. In these studies, mice were injected with high doses of 5'-AMP, which was found to result in a decoupling of the animals' body temperature regulation mechanism accompanied by a reduction in the animals' core body temperature, which tended to lower towards the ambient environmental temperature. It was further discovered that the introduction of high levels of 5'-AMP resulted in an induction of fat regulation genes such as procolipase (Clps) in tissues and organs that do not normally express Clps, this in turn was accompanied by a shift in metabolism from a primarily glycolytic energy metabolism (which is inhibited at lower temperatures) to one that relied primarily on the liberation and metabolism of free fatty acids. Substantial medical and other applications that arise out of this discovery are also disclosed.

Priority: US20060821521P Applic. Date: 2006-08-04; US20060759480P Applic. Date: 2006-01-16

Inventor: LEE CHENG C [US]; ZHANG JIANFA [US]


Application No.: US20070218136A1  Published: 20/Sep/2007

Title: New mandelic acid derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 11/520052   Filing Date: 13/Sep/2006

Abstract:There is provided a compound of formula (I) wherein R, R<1>, R<2>, Y and R<3 >have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g., thrombosis) or as anticoagulants.

Priority: SE20000004458 Applic. Date: 2000-12-01; SE20010000965 Applic. Date: 2001-03-19; SE20010001239 Applic. Date: 2001-04-06; SE20010002921 Applic. Date: 2001-08-30; US2003-432411 Applic. Date: 2003-05-21; WO2001SE02657 Applic. Date: 2001-11-30

Inventor: INGHARDT TORD [SE]; JOHANSSON ANDERS [SE]; SVENSSON ARNE [SE]


Application No.: US20070224588A1  Published: 27/Sep/2007

Title: TROPHOBLAST PRESERVATION/PRETREATMENT MEDIUM AND METHOD

Applicant/Assignee: BIOCEPT, INC

Application No.: 11/277218   Filing Date: 22/Mar/2006

Abstract:An aqueous preservation medium for the selective preservation of trophoblasts obtained in a sample of cervical mucus which permits transportation of such sample to a laboratory facility for analysis and selectively preserves fetal trophoblasts in said sample while presenting conditions that are antagonistic to many maternal cells.

Priority:

Inventor: PIRCHER TONY [US]


Application No.: US20070224631A1  Published: 27/Sep/2007

Title: Device and method for high-throughput quantification of mRNA from whole blood

Applicant/Assignee:

Application No.: 11/803593   Filing Date: 15/May/2007

Abstract:Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.

Priority: US2004-796298 Applic. Date: 2004-03-09; US2003-698967 Applic. Date: 2003-10-30; WO2003US12895 Applic. Date: 2003-04-24; US20020375472P Applic. Date: 2002-04-24

Inventor: MITSUHASHI MASATO [US]


Application No.: US20070225282A1  Published: 27/Sep/2007

Title: PYRIDINES AND PYRIDINE N-OXIDES AS MODULATORS OF THROMBIN

Applicant/Assignee: JANSSEN PHARMACEUTICA NV

Application No.: 11/685544   Filing Date: 13/Mar/2007

Abstract:The present invention describes compounds of Formula I: wherein W, X, Y, Z, and Q are defined herein, or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal.

Priority: US20060784361P Applic. Date: 2006-03-21

Inventor: PLAYER MARK R [US]; LU TIANBAO [US]; HU HUAPING [US]; ZHU XIZHEN [US]; TELEHA CHRISTOPHER [US]; KREUTTER KEVIN [US]


Application No.: US20070233212A1  Published: 04/Oct/2007

Title: Methods and apparatus for regional and whole body temperature modification

Applicant/Assignee: RADIANT MEDICAL INC ZOLL CIRCULATION, INC

Application No.: 11/724075   Filing Date: 13/Mar/2007

Abstract:Methods and apparatus for temperature modification of selected body regions including an induced state of local hypothermia of the brain region for neuroprotection. A heat exchange catheter is provided with heat transfer fins projecting or extending outward from the catheter which may be inserted into selected blood vessels or body regions to transfer heat with blood or fluid in the selected blood vessels or body regions. Another aspect of the invention further provides methods and apparatus for controlling the internal body temperature of a patient. By selectively heating or cooling a portion of the catheter lying within a blood vessel, heat may be transferred to or from blood flowing within the vessel to increase or decrease whole body temperature or the temperature of a target region.

Feed back from temperature sensors located within the patient's body allow for control of the heat transfer from the catheter to automatically control the temperature of the patient or of the target region within the patient. The apparatus may include a blood channeling sleeve that directs body fluid over a heat exchanger where the body fluid's temperature is altered, and then is discharged out the distal end of the sleeve to a desired location, for example, cooled blood to the brain for neuroprotection. The catheter may be used alone or in conjunction with other heat exchangers to cool one region of a patient's body while heating another.

Priority: US2003-626007 Applic. Date: 2003-07-24; US1998-138830 Applic. Date: 1998-08-24; US1996-584013 Applic. Date: 1996-01-08; US1994-324853 Applic. Date: 1994-10-18; US1993-015714 Applic. Date: 1993-02-09

Inventor: GINSBURG ROBERT [US]; GINSBURG ARLENE S [US]; MACHOLD TIMOTHY R [US]; DINEEN MICHAEL T [US]


Application No.: US20070239096A1  Published: 11/Oct/2007

Title: ANTI-CLOTTING APPARATUS AND METHODS FOR FLUID HANDLING SYSTEM

Applicant/Assignee: OPTISCAN BIOMEDICAL CORPORATION

Application No.: 11/734242   Filing Date: 11/Apr/2007

Abstract:Methods and apparatus are provided for determining the concentration of an analyte in a sample, such as an analyte in a sample of bodily fluid. In some embodiments, a method for maintaining clear passageways in an extracorporeal blood flow system includes intermittently providing one or more anti-clotting agents to a passageway of the extracorporeal blood flow system. In some embodiments, an extracorporeal blood flow system includes a passageway and a device operatively connected to provide one or more anti-clotting agents to a least a portion of said passageway.

Priority: US20060791621P Applic. Date: 2006-04-11

Inventor: KEENAN RICHARD [US]; CHIOU JEFF [US]


Application No.: US20070243632A1  Published: 18/Oct/2007

Title: Methods for measuring platelet reactivity of patients that have received drug eluting stents

Applicant/Assignee:

Application No.: 11/742684   Filing Date: 01/May/2007

Abstract:A method is providing for measuring platelet reactivity of a PCI patient that has a (DES). A blood sample is obtained from the patient. The blood sample is mixed in combination with 1) an anticoagulant

2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation

3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface

4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the mixture. The absence of agglutination indicates that the patient has reduced ability to form platelet thrombi.

Priority: US20030485703P Applic. Date: 2003-07-08; US2004-886155 Applic. Date: 2004-07-06

Inventor: COLLER BARRY S [US]; DURBIN DENNIS [US]


Application No.: US20070244118A1  Published: 18/Oct/2007

Title: Cyclic Amide Derivative, and Its Production and Use

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 11/596089   Filing Date: 20/May/2005

Abstract:The present invention provides a cyclic amide derivative useful as a drug for treating thrombosis, which is represented by the formula (I)-: wherein R<1 >represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent chain hydrocarbon group, a represents 0, 1, or 2, X<1 >represents an optionally substituted lower alkylene or an optionally substituted lower alkenylene, Y<1 >represents -C(O)-, -S(O)- or -S(O)2-, A represents a piperazine ring which may be further substituted or a piperidine ring which may be further substituted, X<2 >represents a bond or an optionally substituted lower alkylene, Y<2 >represents -C(O)-, -S(O)-, -S(O)2- or -C(-NR<7>)-, X<3 >represents an optionally substituted C1-4 alkylene or an optionally substituted C2-4 alkenylene, Z<3 >represents -N(R<4>)-,

-O- or a bond, Z<1 >represents -C(R<2>)(R<2'>)-, -N(R<2>)-, etc., and Z<2 >represents -C(R<3>)(R<3'>)-, -N(R<3>)-, etc., or a salt thereof.

Priority: JP20040152000 Applic. Date: 2004-05-21; WO2005JP09711 Applic. Date: 2005-05-20

Inventor: KUBO KEIJI [JP]; IMAEDA YASUHIRO [JP]


Application No.: US20070248676A1  Published: 25/Oct/2007

Title: Use of nitric oxide adducts

Applicant/Assignee: NITROMED, INC

Application No.: 11/819513   Filing Date: 27/Jun/2007

Abstract:The invention provides a method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device

coated per se on a surface of the medical device

directly or indirectly bound to reactive sites on a surface of the medical device

or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.

Priority: US2003-646713 Applic. Date: 2003-08-25; US2002-253977 Applic. Date: 2002-09-25; US2000-621610 Applic. Date: 2000-07-21; US1999-433550 Applic. Date: 1999-11-04; US1995-460465 Applic. Date: 1995-06-02; US1993-123331 Applic. Date: 1993-09-17

Inventor: STAMLER JONATHAN [US]; LOSCALZO JOSEPH [US]; FOLTS JOHN D [US]


Application No.: US20070248942A1  Published: 25/Oct/2007

Title: METHOD FOR SELECTIVELY REMOVING VIRUS AND LEUKOCYTES, REMOVING MATERIAL AND REMOVING APPARATUS

Applicant/Assignee: ASAHI MEDICAL CO., LTD ASAHI KASEI KURARAY MEDICAL CO., LTD

Application No.: 11/772448   Filing Date: 02/Jul/2007

Abstract:It is intended to provide a method whereby a virus and leukocytes can be simultaneously eliminated from virus-containing blood and platelets can be recovered at a high yield, and a material and an apparatus therefor. A water-soluble carrier having surface which is capable of capturing a virus and leukocytes in blood but allows the permeation of platelets therethrough is brought into contact with virus-containing blood. Thus the virus and leukocytes can be simultaneously removed from the blood while platelets can be recovered at a high yield.

Priority: JP20010318512 Applic. Date: 2001-10-16; US2004-492652 Applic. Date: 2004-09-03; WO2002JP10766 Applic. Date: 2002-10-16

Inventor: ONODERA HIROKAZU [JP]; YOSHIDA MAKOTO [JP]


Application No.: US20070249578A1  Published: 25/Oct/2007

Title: New amidino derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB

Application No.: 11/808122   Filing Date: 06/Jun/2007

Abstract:There is provided compounds of formula I wherein R<1>, Rx, Y, R, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Priority: SE19980004313 Applic. Date: 1998-12-14; WO1999SE02316 Applic. Date: 1999-12-10; US2004-815954 Applic. Date: 2004-04-02; US2000-509032 Applic. Date: 2000-03-21

Inventor: INGHARDT TORD [SE]; KARLSSON OLLE [SE]; LINSCHOTEN MARCEL [SE]; NYSTROM JAN-ERIK [SE]


Application No.: US20070250106A1  Published: 25/Oct/2007

Title: SELF-FLUSHING MEDICAL APPARATUS

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 11/379884   Filing Date: 24/Apr/2006

Abstract:An apparatus for use in a therapeutic medical procedure that may include an elongate sheath having a longitudinal axis, an outer surface a distal end and a proximal end, the elongate sheath having a first lumen having a first cross-sectional area running from an first opening at the distal end to a first point proximal the distal end and a second lumen fluidly connected to the first lumen, the second lumen having a distal end at or proximal the first point and a second cross-sectional area less than the first cross-sectional area, the second lumen having a portion running generally along the elongate axis

and an elongate member having a first portion having a third cross-sectional area, a proximal end and a distal end and having a therapeutic device disposed on the elongate member proximate the distal end, the therapeutic device having a first configuration having a fourth cross-sectional area, wherein the elongate member is disposed in the first and second lumens and the distal protection device is disposed in the first lumen, wherein when the distal protection device is disposed in the first lumen, the elongate sheath has a second opening proximate and proximal the distal protection device and a third opening proximal the second opening in which the elongate member is partially disposed, and wherein the second opening is in fluid communication with the third opening when the distal protection device is disposed in the first lumen.

Priority:

Inventor: KIM ELIOT T [US]


Application No.: US20070255197A1  Published: 01/Nov/2007

Title: Method of Treatment for Undesired Effect Following Transdermal or Topical Drug Delivery

Applicant/Assignee: ACRUX DDS PTY LTD

Application No.: 10/581991   Filing Date: 09/Dec/2004

Abstract:This invention relates to a method for inhibiting the percutaneous absorption of a physiologically active agent topically applied to a transdermal administration site of a subject, the method including the step of applying to skin of the subject at the transdermal administration site, a device ( 1, 7 ) comprising a membrane ( 8 ) for contacting the skin of the subject coated on the skin contacting side thereof ( 11 ) with a layer of an adhesive ( 10 ).

Priority: AU20030906842 Applic. Date: 2003-12-10; WO2004AU01738 Applic. Date: 2004-12-09

Inventor: HUMBERSTONE ANDREW J [AU]; WILKINS NINA F [AU]; GONDA IGOR [AU]


Application No.: US20070258894A1  Published: 08/Nov/2007

Title: System and Method for Real-Time Diagnosis, Treatment, and Therapeutic Drug Monitoring

Applicant/Assignee:

Application No.: 10/588749   Filing Date: 28/Feb/2005

Abstract:Systems and methods for diagnosing and/or treating diseases as well as monitoring disease treatment. For diagnosis, the present invention uses nanoparticle-based assemblies, which comprise a nanoparticle

a surrogate marker

and a means for detecting a specific chemical entity. In certain embodiments, nanoparticle-based assemblies include a payload for simultaneous diagnosis and treatment of disease. In further embodiments, a therapeutic drug and therapeutic drug marker are administered to a patient to monitor disease treatment. Bodily fluid samples are analyzed using sensor technology to detect the presence of surrogate and/or therapeutic drug markers to provide an efficient and accurate means for diagnosing a disease and/or monitoring disease treatment.

Priority: US2000-708789 Applic. Date: 2000-11-08; WO2005US06355 Applic. Date: 2005-02-28

Inventor: MELKER RICHARD J [US]; SACKELLARES JAMES C [US]; GOLD MARK S [US]; DENNIS DONN M [US]


Application No.: US20070259809A1  Published: 08/Nov/2007

Title: Methods of Using High Affinity Atiii Variants

Applicant/Assignee:

Application No.: 10/584640   Filing Date: 10/Jan/2005

Abstract:Disclosed are compositions and methods related to binding of ATIII under low and high shear rate conditions.

Priority: US20040535360P Applic. Date: 2004-01-09; US20040618746P Applic. Date: 2004-10-14; WO2005US00843 Applic. Date: 2005-01-10

Inventor: BOCK SUSAN C [US]


Application No.: US20070264194A1  Published: 15/Nov/2007

Title: Peptides That Bind To Atherosclerotic Lesions

Applicant/Assignee: THE SCRIPPS RESEARCH INSTITUTE

Application No.: 10/486318   Filing Date: 09/Aug/2002

Abstract:The present invention provides peptides that selectively bind to mammalian atherosclerotic lesions. The present invention also provides methods for in vivo identification of peptides capable of binding to biomolecules as well as methods for identifying the targets of such binding moieties. Methods to diagnose or treat pathologic conditions that involve atherosclerotic lesions are also provided by the invention that involve administering to a mammal a peptide attached to a reporter molecule or a therapeutic agent, respectively.

Priority: US20010311507P Applic. Date: 2001-08-10; WO2002EP08942 Applic. Date: 2002-08-09

Inventor: LIU CHENG [US]; EDGINGTON THOMAS S [US]; PRESCOTT MARGARET F [US]


Application No.: US20070265615A1  Published: 15/Nov/2007

Title: Electrosurgical instrument with suction, irrigation and means to collect blood

Applicant/Assignee:

Application No.: 11/473103   Filing Date: 23/Jun/2006

Abstract:An electrosurgical instrument with electrode, suction, optional irrigation and means to bend the distal part of the surrounding suction tube is described. A distal part of the suction tube (around the electrode) has two members, whereas one member can be engaged inside the other-to various degrees-in order to control the length of the suction tube and its relation to the tip of the electrode. Means to fixate the electrode within the suction tube are described. Also described are means to evacuate smoke, blood, irrigation anticoagulant fluid and debris via a suction tube to a separation chamber and evacuation of the gaseous portions by a vacuum machine. The separation chamber serves as a blood collection container (the blood could then be re-infused to the patient!). Irrigation means of isotonic fluid with blood-anticoagulant combined with the suction are described. Combination of the various functions and options could be utilized for building various useful surgical instruments.

Priority: IL20060175493 Applic. Date: 2006-05-09

Inventor: BEN-SIMHON HAIM [IL]


Application No.: US20070270939A1  Published: 22/Nov/2007

Title: Drug Delivery Device

Applicant/Assignee: TAYSIDE FLOW TECHNOLOGIES LTD

Application No.: 10/597677   Filing Date: 04/Feb/2005

Abstract:A drug delivery device ( 1 ) is disclosed. The device comprises a vascular implant having a helical formation ( 4 ) that is capable of inducing helical flow of blood passing it. A drug is releasably associated with the helical formation.

Priority: GB20040002736 Applic. Date: 2004-02-06; WO2005GB00379 Applic. Date: 2005-02-04

Inventor: HOOD ROBERT G [GB]; DUFF CRAIG M [GB]


Application No.: US20070275889A1  Published: 29/Nov/2007

Title: Gene Expression Technique

Applicant/Assignee: DELTA BIOTECHNOLOGY LIMITED

Application No.: 10/584424   Filing Date: 23/Dec/2004

Abstract:The present invention provides a method for producing heterologous protein comprising: (a) providing a host cell comprising a 2 mum-family plasmid, the plasmid comprising a gene encoding a protein comprising the sequence of a chaperone protein and a gene encoding a heterologous protein

(b) culturing the host cell in a culture medium under conditions that allow the expression of the gene encoding the chaperone protein and the gene encoding a heterologous protein

(c) purifying the thus expressed heterologous protein from the cultured host cell or the culture medium.

Priority: GB20030029681 Applic. Date: 2003-12-23; WO2004GB05462 Applic. Date: 2004-12-23

Inventor: SLEEP DARRELL [GB]; SHUTTLEWORTH GILLIAN [GB]; FINNIS CHRISTOPHER JOHN A [GB]


Application No.: US20070282280A1  Published: 06/Dec/2007

Title: Intravascular Line and Port Cleaning Methods, Methods of Administering an Agent Intravascularly, Methods of Obtaining/Testing Blood, and Devices for Performing Such Methods

Applicant/Assignee: HYPROTEK, INC

Application No.: 11/745843   Filing Date: 08/May/2007

Abstract:An intravascular port access device includes a first component having a chamber configured to attach reversibly to an intravenous line port. A second component reversibly attaches to the first component and contains a disinfecting agent and an applicator material. The second component is configured to be reversibly received over external surfaces of the intravenous line port. A method of cleansing an intravenous line port includes providing a port cleaning device having a first component with a chamber containing a first cleaning agent. A second component includes a second cleaning agent. A third component has a microbiocidal agent and is reversibly attached to the first component. The second component is removed from the device, the external surfaces of the port are contacted with the second cleaning agent, the first cleaning agent is ejected from the chamber into the port, and the third component is used to cap the port.

Priority: US20060842194P Applic. Date: 2006-08-31; US20060747606P Applic. Date: 2006-05-18; US20070895621P Applic. Date: 2007-03-19

Inventor: TENNICAN PATRICK O [US]


Application No.: US20070284298A1  Published: 13/Dec/2007

Title: PLASMA EXTRACTION APPARATUS

Applicant/Assignee: CHROMEDX INC

Application No.: 11/835631   Filing Date: 08/Aug/2007

Abstract:Some analyzers cannot measure blood analytes from a sample of whole blood, but can measure the analytes in plasma extracted from the whole blood. Some embodiments of the invention provide a disposable apparatus that is suitable for extracting plasma from whole blood received from a blood supply. The blood supply includes one of a tube containing blood, a syringe containing blood, a drop of blood on the skin resulting from a pin prick, a vein, an artery, and an arterial line. The apparatus includes a housing, and arranged within the housing is a porous membrane, a filtration chamber, and a plasma collection chamber. The porous membrane forms a barrier between the whole blood and the plasma extracted from the whole blood. The filtration chamber receives the whole blood for plasma extraction, and the plasma collection chamber collects the plasma extracted from the whole blood.

The apparatus also includes a blood flow path within the housing, and the blood flow path includes the filtration chamber. Means for enabling blood flow in the blood flow path are provided, and means for enabling plasma extraction and plasma removal from the housing are also provided.

Priority: CA20052507323 Applic. Date: 2005-05-13; US2006-432616 Applic. Date: 2006-05-12

Inventor: SAMSOONDAR JAMES [CA]


Application No.: US20070292490A1  Published: 20/Dec/2007

Title: Production of tissue factor in plants

Applicant/Assignee:

Application No.: 11/165590   Filing Date: 22/Jun/2005

Abstract:The instant invention provides transgenic plants that express mammalian, e.g., human, recombinant tissue factor (rhTF) as well as methods for making rhTF. The invention further provides rhTF or functional fragment thereof that are obtained from a transgenic plant. The invention also provides methods of treating a subject using the rhTF or a fragment thereof.

Priority: US20040583187P Applic. Date: 2004-06-25

Inventor: NEGROUK VALENTIN [US]; WONG HING C [US]; TAYLOR DEAN [US]; HAN KAI-PING [US]


Application No.: US20070298021A1  Published: 27/Dec/2007

Title: Methods and Compositions for the Treatment or Prevention of Secondary Ischemic Injury

Applicant/Assignee: INDEX PHARMACEUTICALS AB

Application No.: 10/589842   Filing Date: 21/Feb/2005

Abstract:After a primary ischemic injury, which predominantly results in necrosis, there is a secondary injury in the neighbouring tissue, due at least to some extent to apoptosis. This secondary damage is usually not evident until several days after the initial ischemic event. The present invention provides methods of preventing, treating and/or alleviating secondary ischemic damage in a mammalian organ or tissue, comprising a step of administering an effective amount of an NF-kappaB inhibitor to said organ or tissue. Compositions for this purpose are also disclosed.

Priority: SE20040000399 Applic. Date: 2004-02-20; US20040546723P Applic. Date: 2004-02-20; WO2005SE00231 Applic. Date: 2005-02-21

Inventor: VON STEIN OLIVER [SE]; PETTERSSON SVEN [SE]; LIM SAI K [SG]


Application No.: US20080000484A1  Published: 03/Jan/2008

Title: Apparatus for vascular and nerve tissue histogenesis and enhancement

Applicant/Assignee:

Application No.: 11/477175   Filing Date: 28/Jun/2006

Abstract:An apparatus for delivering decompressive energy to soft tissues to stimulate cellular expansion through deep penetration of said applied decompressive energy to said soft tissues to stimulate a predetermined reaction to application of said decompressive energy comprising a vessel having an open end and adapted to encompass the soft tissue to be stimulated. A source of decompressive energy in communication with said vessel and a flexible mass affixed to said open end of said vessel to absorb the pressure exerted by delivery of said decompressive energy to said soft tissue, thereby acting as a seal and force diffuser between said vessel and the soft tissue adjacent the periphery of said vessel.

Priority:

Inventor: KAISER DANIEL E [US]


Application No.: US20080000801A1  Published: 03/Jan/2008

Title: Automated system, method, and kit for immediate treatment of acute medical condition

Applicant/Assignee:

Application No.: 11/300104   Filing Date: 13/Dec/2005

Abstract:A system, method, and kit for immediate and initial treatment of an acute medical condition. The system, method, and kit may be self-administered in the event of an acute medical condition.

Priority: US20040635800P Applic. Date: 2004-12-13

Inventor: MACKIE ROBERT W JR [US]


Application No.: US20080003214A1  Published: 03/Jan/2008

Title: Medicaments Comprising Carbonyl Compounds, And The Use Thereof

Applicant/Assignee:

Application No.: 11/575711   Filing Date: 24/Aug/2005

Abstract:Use of compounds of the formula (I) in which D, E, G, W, X, Y, T, R<1 >and R<2 >have the meaning indicated in Patent Claim 1 , for the prophylaxis and/or therapy of thromboembolic diseases

Priority: DE200410045796 Applic. Date: 2004-09-22; WO2005EP09124 Applic. Date: 2005-08-24

Inventor: CEZANNE BERTRAM [DE]; DORSCH DIETER [DE]; MEDERSKI WERNER [DE]; TSAKLAKIDIS CHRISTOS [DE]; GLEITZ JOHANNES [DE]


Application No.: US20080003231A1  Published: 03/Jan/2008

Title: Method of medically treating an individual

Applicant/Assignee:

Application No.: 11/478070   Filing Date: 29/Jun/2006

Abstract:A method immunizing an individual that minimizes the amount of antigen or attenuated organism needed and the number of doses and clinic visits required, while making possible polyvalent simultaneous immunizations. The method comprises the steps of obtaining a sample of blood. Exposing at least a portion of this sample to at least one immunogenic antigen, attenuant or other immunogen. Incubating the exposed sample under specified optimal conditions and introducing this exposed sample into the individual to effect immunization thereof. The method of the invention also provides a method of delivery of materials, other than antigens, throughout an individual's body such as therapeutic drugs, virus vectors, genes, DNA, RNA, isotopes, and other therapeutic substances. A method for the delivery of treatment material to an individual is also provided by this method.

Priority:

Inventor: NALIN DAVID R [US]


Application No.: US20080003564A1  Published: 03/Jan/2008

Title: SAMPLE PROCESSING

Applicant/Assignee: IQUUM, INC

Application No.: 11/674117   Filing Date: 12/Feb/2007

Abstract:A sample processing tubule may include at least three segments. Each segment may be defined by the tubule, may be fluidly isolated, at least in part by a breakable seal, may be so expandable as to receive a volume of fluid expelled from another segment, and may be so compressible as to contain substantially no fluid when so compressed. At least one segment may contain at least a control reagent. At least one segment may contain at least one of a nucleic acid amplification reagent and a detection reagent.

Priority: US20060743292P Applic. Date: 2006-02-14

Inventor: CHEN SHUQI [US]; CHEN LINGJUN [US]


Application No.: US20080008693A1  Published: 10/Jan/2008

Title: PLASMA-DEPLETED, NON-RED BLOOD CELL-DEPLETED CORD BLOOD COMPOSITIONS AND METHODS OF USE

Applicant/Assignee: STEMCYTE, INC

Application No.: 11/771942   Filing Date: 29/Jun/2007

Abstract:The umbilical cord blood (UCB) compositions of the present invention possess the unique features of having plasma that is substantially depleted from the UCB unit and red blood cells (RBC) that are not depleted from the UCB unit. Such UCB units can be prepared by a process that combines plasma depletion with cryopreservation, selection, thawing, and/or transplantation of hematopoietic stem cells to provide superior clinical outcome by maximizing post-processing cell recovery and post-thaw infusion cell dose. Methods for treating a wide variety of malignant diseases and benign diseases associated with the hematopoietic system by administering the UCB compositions of the present invention are also provided.

Priority: US2006-422017 Applic. Date: 2006-06-02; US20050733956P Applic. Date: 2005-11-03; US20050687127P Applic. Date: 2005-06-02

Inventor: CHOW ROBERT [US]


Application No.: US20080008744A1  Published: 10/Jan/2008

Title: Novel tissue support

Applicant/Assignee:

Application No.: 11/825478   Filing Date: 06/Jul/2007

Abstract:The present disclosure provides tissue supports which may be utilized by themselves or in combination with other tissue closure means to enhance wound closure and healing. The tissue supports are made of a material which shrinks upon application of heat or light to further support the tissue and/or wound to which it is applied.

Priority: US20060819152P Applic. Date: 2006-07-07

Inventor: PROMMERSBERGER MEGAN [US]


Application No.: US20080009009A1  Published: 10/Jan/2008

Title: Device and method for high-throughput quantification of mRNA from whole blood

Applicant/Assignee:

Application No.: 11/803663   Filing Date: 15/May/2007

Abstract:Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.

Priority: US2004-796298 Applic. Date: 2004-03-09; US2003-698967 Applic. Date: 2003-10-30; WO2003US12895 Applic. Date: 2003-04-24; US20020375472P Applic. Date: 2002-04-24

Inventor: MITSUHASHI MASATO [US]


Application No.: US20080009935A1  Published: 10/Jan/2008

Title: STENT DESIGN WITH SHEATH ATTACHMENT MEMBERS

Applicant/Assignee: BOSTON SCIENTIFIC SCIMED, INC

Application No.: 11/857531   Filing Date: 19/Sep/2007

Abstract:A stent is provided having attachment members for allowing attachment of a sheath or sheaths. Accordingly, a practitioner is able to selectively choose a desirable sheath, such as a polymeric sleeve, a biomaterial, or a natural blood vessel, at a point-of-use and attach it to the sheath. The attachment members may be bendable tabs and/or secondary support stents.

Priority: US2001-974653 Applic. Date: 2001-10-10

Inventor: BICEK ANDREW D [US]; GIRTON TIMOTHY S [US]


Application No.: US20080014148A1  Published: 17/Jan/2008

Title: Perturbed membrane-binding compounds and methods of using the same

Applicant/Assignee: APOSENSE LTD

Application No.: 11/882490   Filing Date: 02/Aug/2007

Abstract:The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes.

Priority: US2004-799586 Applic. Date: 2004-03-15; US20040536493P Applic. Date: 2004-01-15; US20040537289P Applic. Date: 2004-01-20

Inventor: ZIV ILAN [IL]; SHIRVAN ANAT [IL]


Application No.: US20080015487A1  Published: 17/Jan/2008

Title: System and Method for Delivery of Regional Citrate Anticoagulation to Extracorporeal Blood Circuits

Applicant/Assignee: HENRY FORD HEALTH SYSTEM

Application No.: 11/829261   Filing Date: 27/Jul/2007

Abstract:The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.

Priority: WO2007US62589 Applic. Date: 2007-02-22; US20060775729P Applic. Date: 2006-02-22; US20060775728P Applic. Date: 2006-02-22; US20060790882P Applic. Date: 2006-04-11; US20060791055P Applic. Date: 2006-04-11; US20060845646P Applic. Date: 2006-09-19

Inventor: SZAMOSFALVI BALAZS [US]; FRINAK STANLEY [US]; YEE JERRY [US]


Application No.: US20080015598A1  Published: 17/Jan/2008

Title: Novel skin staples

Applicant/Assignee:

Application No.: 11/827278   Filing Date: 11/Jul/2007

Abstract:The present disclosure provides composite staples which include legs made of a bioabsorbable shape memory material capable of gripping tissue upon application in vivo and holding the staple in place.

Priority: US20060819965P Applic. Date: 2006-07-11

Inventor: PROMMERSBERGER MEGAN [US]


Application No.: US20080017577A1  Published: 24/Jan/2008

Title: Membrane-based Double-layer Tube for Sample Collections

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 11/459076   Filing Date: 21/Jul/2006

Abstract:The fluid sample collection device is adapted to collect and separate a fluid sample into constituent parts such as separating plasma or serum from a blood sample. The device includes an evacuated outer container and an inner container. The outer container has a first open end and a second closed end. A pierceable closure closes the first open end thereby defining a first interior chamber. The inner container is contained within the outer container and separates the first interior chamber into an upper chamber portion and lower chamber portion in fluid communication. The inner container defines a second interior chamber separated from the lower chamber portion through a porous membrane. A port is provided for placing the second interior chamber in fluid communication with the first interior chamber. Another aspect of the device relates to a method of using the device to separate plasma or serum from a blood sample.

Priority:

Inventor: YI JIZU [US]; LIN FU CHUNG [US]; MANOUSSAKIS DIMITRIOS [US]; GELFAND CRAIG [US]


Application No.: US20080019985A1  Published: 24/Jan/2008

Title: NOVEL TISSUE FACTOR TARGETED THROMBOMODULIN FUSION PROTEINS AS ANTICOAGULANTS

Applicant/Assignee: BAYER SCHERING AG BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Application No.: 11/766155   Filing Date: 21/Jun/2007

Abstract:This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Priority: US2003-427805 Applic. Date: 2003-04-30; US20020376566P Applic. Date: 2002-05-01

Inventor: LIGHT DAVID [US]; MCLEAN KIRK [US]


Application No.: US20080020965A1  Published: 24/Jan/2008

Title: NOVEL TISSUE FACTOR TARGETED THROMBOMODULIN FUSION PROTEINS AS ANTICOAGULANTS

Applicant/Assignee: BAYER SCHERING AG BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Application No.: 11/766160   Filing Date: 21/Jun/2007

Abstract:This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or in combination with at least one other TM domain selected from the group consisting of the N-terminal hydrophobic region domain, the EGF123 domain, the interdomain loop between EGF3 and EGF4, and the O-glycosylated Ser/Thr-rich domain, or analogs, fragments, derivatives or variants thereof. The fusion protein binds at the site of injury and prevents the initiation of thrombosis. The fusion protein can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.

Priority: US2003-427805 Applic. Date: 2003-04-30; US20020376566P Applic. Date: 2002-05-01

Inventor: LIGHT DAVID [US]; MCLEAN KIRK [US]


Application No.: US20080021065A1  Published: 24/Jan/2008

Title: NOVEL BENZAMIDINE COMPOUND

Applicant/Assignee: AJINOMOTO CO. INC AJINOMOTO CO., INC

Application No.: 11/832895   Filing Date: 02/Aug/2007

Abstract:Compounds represented by formula (1) and pharmaceutically acceptable salt thereofs: wherein each symbol is as defined in the specification, are useful as inhibitors of an activated blood coagulation factor X. Compositions which contain, as an active ingredient, an FXa selective low-molecular weight FXa inhibitor having a short serum half-life are particularly useful as anticoagulants for an extracorporeal blood circuit.

Priority: JP20050026949 Applic. Date: 2005-02-02; WO2006JP302202 Applic. Date: 2006-02-02

Inventor: TAKAYANAGI MASARU [JP]; TAKEHANA SHUNJI [JP]; OTANI KAYO [JP]; SAITOU YUKI [JP]


Application No.: US20080021366A1  Published: 24/Jan/2008

Title: WEARABLE ULTRAFILTRATION DEVICE

Applicant/Assignee: NATIONAL QUALITY CARE, INC FRESENIUS MEDICAL CARE HOLDINGS, INC

Application No.: 11/830695   Filing Date: 30/Jul/2007

Abstract:An ultrafiltration device adapted to be worn on a portion of the body of a patient includes a blood inlet tube leading from a first blood vessel, a blood pump, an anticoagulant reservoir for infusing anticoagulants into the blood, a blood filter including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube leading to a second blood vessel.

Priority: US2002-251937 Applic. Date: 2002-09-19; US2001-085349 Applic. Date: 2001-11-16

Inventor: GURA VICTOR [US]; RAMBOD EDMOND [US]


Application No.: US20080023399A1  Published: 31/Jan/2008

Title: Apparatus and method for continuous particle separation

Applicant/Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY

Application No.: 11/809559   Filing Date: 31/May/2007

Abstract:The invention is directed to an apparatus and a method of separating particles, such as cells, from a heterogeneous fluid, such as blood, where the particles have a large range of sizes.

Priority: US20060809933P Applic. Date: 2006-06-01

Inventor: INGLIS DAVID W [AU]; DAVIS JOHN [US]; AUSTIN ROBERT [US]; STURM JAMES [US]


Application No.: US20080025872A1  Published: 31/Jan/2008

Title: Disposable Fluid Sample Collection Device

Applicant/Assignee:

Application No.: 10/578453   Filing Date: 05/Nov/2004

Abstract:A fluid sampling device ( 100 ) that operates by a combination of capillary action to collect a small fluid sample, and by pressure differential when inserted into an analyzer ( 200 ) to expose the fluid sample for testing by the analyzer ( 200 ). The device is especially suited for use as a disposable blood sampling unit designed to interface with a blood analyzer, albeit the concept of the invention may be employed for sampling and testing virtually any fluids.

Priority: US20030517573P Applic. Date: 2003-11-05; WO2004US36909 Applic. Date: 2004-11-05

Inventor: DYKES CHRIS [US]; LANE BEN [US]


Application No.: US20080026474A1  Published: 31/Jan/2008

Title: ASSAY FOR DIFFERENTIATING COMPOUNDS THAT MODULATE THE EXTRINSIC AND/OR INTRINSIC COAGULATION PATHWAYS

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 11/782660   Filing Date: 25/Jul/2007

Abstract:Methods for differentiating compounds that modulate the extrinsic and/or intrinsic coagulation pathways are provided. Also provided are methods for identifying a compound that modulates the extrinsic coagulation pathway. In addition, methods for determining an effective dosage of an anticoagulant in a patient are provided.

Priority: US20060833674P Applic. Date: 2006-07-27

Inventor: WANG XINKANG [US]; HSU MEI-YIN [US]; WONG PANCRAS C [US]


Application No.: US20080031874A1  Published: 07/Feb/2008

Title: Treatment of endotoxemia using endotoxin neutralizing agents

Applicant/Assignee:

Application No.: 11/703538   Filing Date: 06/Feb/2007

Abstract:Methods and compositions for selecting a patient suffering from endotoxemia for treatment with an endotoxin neutralizing agent are disclosed comprising: (a) determining the level of endotoxin in the patient's blood

and (b) comparing the endotoxin level in the patient's blood to a predetermined threshold endotoxin level to determine if the patient has elevated endotoxin levels. The methods can further comprise treating patients identified as having elevated levels of endotoxin with an endotoxin neutralizing therapy. The methods provide increased safety and a reduction in risk for critically ill patients.

Priority: US20060765996P Applic. Date: 2006-02-06

Inventor: SANDERS MARTIN E [US]


Application No.: US20080031934A1  Published: 07/Feb/2008

Title: Processes for the production of solid dressings for treating wounded tissue

Applicant/Assignee:

Application No.: 11/882872   Filing Date: 06/Aug/2007

Abstract:Disclosed are processes for preparing solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen and liquid compositions useful for preparing the haemostatic layer(s) of these dressings or for treating wounded tissue in a mammal.

Priority: US20060835423P Applic. Date: 2006-08-04

Inventor: MACPHEE MARTIN [US]; BEALL DAWSON [US]


Application No.: US20080033331A1  Published: 07/Feb/2008

Title: Solid dressing for treating wounded tissue

Applicant/Assignee:

Application No.: 11/882874   Filing Date: 06/Aug/2007

Abstract:Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings.

Priority: US20060835423P Applic. Date: 2006-08-04

Inventor: MACPHEE MARTIN [US]; BEALL DAWSON [US]


Application No.: US20080033332A1  Published: 07/Feb/2008

Title: Solid dressing for treating wounded tissue

Applicant/Assignee:

Application No.: 11/882876   Filing Date: 06/Aug/2007

Abstract:Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of fibrinogen and a fibrinogen activator, wherein the fibrinogen is present in an amount between 3.0 mg/cm<2 >of the wound facing surface of the dressing and 13.0 mg/cm<2 >of the wound facing surface of the dressing. Also disclosed are methods for treating wounded tissue.

Priority: US20060835423P Applic. Date: 2006-08-04

Inventor: MACPHEE MARTIN [US]; BEALL DAWSON [US]


Application No.: US20080033333A1  Published: 07/Feb/2008

Title: Solid dressing for treating wounded tissue

Applicant/Assignee:

Application No.: 11/882879   Filing Date: 06/Aug/2007

Abstract:Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and thrombin, wherein the thrombin is present in an amount between 0.250 Units/mg of fibrinogen component and 0.062 Units/mg of fibrinogen component. Also disclosed are methods for treating wounded tissue.

Priority: US20060835423P Applic. Date: 2006-08-04

Inventor: MACPHEE MARTIN [US]; BEALL DAWSON [US]


Application No.: US20080038316A1  Published: 14/Feb/2008

Title: Conveniently implantable sustained release drug compositions

Applicant/Assignee:

Application No.: 11/826833   Filing Date: 18/Jul/2007

Abstract:This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

Priority: US2005-236426 Applic. Date: 2005-09-27; US20050709665P Applic. Date: 2005-08-19; US20040614484P Applic. Date: 2004-10-01; US20060831991P Applic. Date: 2006-07-19

Inventor: WONG VERNON G [US]; WOOD LOUIS L [US]


Application No.: US20080038351A1  Published: 14/Feb/2008

Title: Flowable carrier matrix

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 11/504363   Filing Date: 14/Aug/2006

Abstract:A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Priority:

Inventor: BEALS NEAL [US]; SCIFERT JEFFREY L [US]; BODEN SCOTT D [US]


Application No.: US20080038764A1  Published: 14/Feb/2008

Title: COMPOSITIONS, KIT AND ONE-STEP METHOD FOR MONITORING COMPOUNDS HAVING ANTI-FACTOR Xa AND/OR ANTI FACTOR IIa ACTIVITIES

Applicant/Assignee:

Application No.: 11/841684   Filing Date: 20/Aug/2007

Abstract:Provided are compositions and methods for accurate determination of the concentration of anticoagulant in a sample such as a blood or plasma sample. The compositions can contain a Factor X compound and Factor V compound, and additional components as well. Methods for performing the assay include one-step methods in which a sample is added to a coagulation assay composition, and time is monitored from the point of adding the sample and coagulation assay composition to an endpoint, such as clot formation.

Priority: US2005-127540 Applic. Date: 2005-05-11; US20040570312P Applic. Date: 2004-05-11

Inventor: YIN THYE [US]


Application No.: US20080038828A1  Published: 14/Feb/2008

Title: Protocol for Monitoring Direct Thrombin Inhibition

Applicant/Assignee: HAEMOSCOPE CORPORATION

Application No.: 11/753071   Filing Date: 24/May/2007

Abstract:A hemostasis analyzer, such as the Thrombelastograph(R) (TEG(R)) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit evaluation of hemostasis therapies including anticoagulation therapies such as direct thrombin inhibition therapies.

Priority: US2006-608174 Applic. Date: 2006-12-07; US2003-384345 Applic. Date: 2003-03-07; US2000-591371 Applic. Date: 2000-06-09; US1999-255099 Applic. Date: 1999-02-22; US20060803184P Applic. Date: 2006-05-25

Inventor: COHEN ELI [US]; COHEN ROSLYN [US]


Application No.: US20080039373A1  Published: 14/Feb/2008

Title: Pegylated Factor VII Glycoforms

Applicant/Assignee: NOVO NORDISK A/S

Application No.: 11/845175   Filing Date: 27/Aug/2007

Abstract:The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked oligosaccharide chains, and wherein at least one oligosaccharide group is covalently attached to at least one polymeric group.

Priority: DK20020000964 Applic. Date: 2002-06-21; US2003-609701 Applic. Date: 2003-06-30; WO2003DK00420 Applic. Date: 2003-06-20; US20020394778P Applic. Date: 2002-07-01

Inventor: KLAUSEN NIELS K [DK]; BJORN SOREN [DK]; BEHRENS CARSTEN [DK]; GARIBAY PATRICK W [DK]


Application No.: US20080045881A1  Published: 21/Feb/2008

Title: DEVICES AND METHODS FOR REMOVING A MATTER FROM A BODY CAVITY OF A PATIENT

Applicant/Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA

Application No.: 11/829879   Filing Date: 27/Jul/2007

Abstract:Disclosed are systems and methods for removing a matter from a body cavity of a patient. Exemplary systems of the present invention generally comprise a delivery catheter device, a central matter retrieval device and a device retriever. The central matter retrieval device has an elongated body and shape memory foam attached thereon. In use, the central matter retrieval device is housed within a parking segment of the delivery catheter and delivered to a desired body cavity in a patient. The retriever device is separately deployed to securely remove the matter and the central matter retrieval device from the patient.

Priority: US2005-087780 Applic. Date: 2005-03-23; WO2005US09658 Applic. Date: 2005-03-24; US20040556993P Applic. Date: 2004-03-26; US20040611684P Applic. Date: 2004-09-20; US20060820671P Applic. Date: 2006-07-28

Inventor: TEITELBAUM GEORGE P [US]; LARSEN DONALD W [US]


Application No.: US20080045985A1  Published: 21/Feb/2008

Title: COMPOSITIONS AND METHODS FOR JOINING NON-CONJOINED LUMENS

Applicant/Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Application No.: 11/766779   Filing Date: 21/Jun/2007

Abstract:Disclosed are compositions, methods, and kits for joining together non-conjoined lumens in a patient's body including vascular lumens. More particularly, in various aspects, this invention provides compositions, methods, and kits for joining such non-conjoined lumens, including small lumens typically requiring microsurgical technique

Priority: US20060805425P Applic. Date: 2006-06-21; US20060806242P Applic. Date: 2006-06-29; US20070914635P Applic. Date: 2007-04-27

Inventor: GURTNER GEOFFREY C [US]; FULLER GERALD G [US]; LONGAKER MICHAEL T [US]; RAJADAS JAYAKUMAR [US]


Application No.: US20080047898A1  Published: 28/Feb/2008

Title: Sealed Sterile System and Method for Filtering Biological or Medical Fluids, in Particular Whole Blood

Applicant/Assignee: GERATEZENTRALE FUR BLUTTRANSFUSION DES OSTERREICHI

Application No.: 11/632823   Filing Date: 14/Jun/2005

Abstract:The invention relates to a sealed, sterile system for filtering fluids, in particular whole blood. The system comprises a first collapsible container for receiving the fluid to be filtered and a second collapsible container for receiving the filtered fluid, both containers interconnected by a fluid line, in which a filter and a third container, for deaeration, are located. The first collapsible container contains a predetermined quantity of air, which is sufficient to ensure that no blood remains in the filter and the adjacent tube line sections when the whole blood is transferred from the first container into the second container. The air that is present in the second container, after the whole blood has been filtered, is transferred to the deaeration container.

Priority: DE200410035352 Applic. Date: 2004-07-21; WO2005EP06338 Applic. Date: 2005-06-14

Inventor: SOMMER CHRISTIAN [AT]; KURZ MICHAEL [AT]; MAYER GUNTER [AT]


Application No.: US20080047908A1  Published: 28/Feb/2008

Title: Tool for Recovering Biological Samples and Method for Recovering Biological Samples

Applicant/Assignee: EIKEN KAGAKU KABUSHIKI KAISHA

Application No.: 11/597412   Filing Date: 25/May/2005

Abstract:This invention provides a tool for recovering biological samples for realizing more simple and accurate clinical testing with the use of a trace amount of the blood sample, a kit comprising the same, and a method for recovering and separating biological samples using the same. Such tool comprises: a recovery container body composed of an upper container portion having a medium-accommodating portion, provided with an upper opening, for accommodating and conserving an absorption medium to be impregnated with the recovered biological samples and a lower container portion for accommodating the biological samples separated from the medium

and a lid for closing the upper opening of the medium-accommodating portion, the bottom of such medium-accommodating portion being provided with an open area in communication with the lower container portion.

Priority: JP20040158290 Applic. Date: 2004-05-27; WO2005JP09534 Applic. Date: 2005-05-25

Inventor: SEKINE KAZUHITO [JP]; HIRAHARA SHIN [JP]; ICHIKAWA YOSHIHARU [JP]; TAKAHASHI TOMOYOSHI [JP]; OYAMA TAKAO [JP]; TAKAHASHI MASAMI [JP]


Application No.: US20080050389A1  Published: 28/Feb/2008

Title: Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots

Applicant/Assignee: TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Application No.: 11/640737   Filing Date: 18/Dec/2006

Abstract:Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.

Priority: US2002-253518 Applic. Date: 2002-09-23; US1999-454666 Applic. Date: 1999-12-03; WO1999US10547 Applic. Date: 1999-05-12; US19980086262P Applic. Date: 1998-05-21

Inventor: MUZYKANTOV VLADIMIR R [US]; HIGAZI ABD A [US]; MURCIANO JUAN C [ES]; CINES DOUGLAS [US]; TAYLOR RONALD P [US]


Application No.: US20080050394A1  Published: 28/Feb/2008

Title: System and device for medically treating an individual

Applicant/Assignee:

Application No.: 11/507876   Filing Date: 22/Aug/2006

Abstract:A system for medically treating/vaccinating an individual comprising a first syringe, containing an anticoagulant material therein, for drawing a sample of blood from the individual. A centrifuge means for centrifuging the sample of blood contained within the first syringe to obtain a buffy coat. A second syringe comprising a second plunger and at least one microtubule member containing one of a treatment agent and a vaccine antigen. At least one open end formed within the at least one microtubule member for drawing a portion of the buffy coat therein and exposing the buffy coat to one of the treatment agent and vaccine antigen. A second needle capable of being attached onto the second syringe for introducing the exposed sample into the individual to effect treatment/vaccination thereof.

This system is capable of allowing a plurality of treatment agents and/or vaccine antigens to be simultaneously applied to an individual.

Priority:

Inventor: NALIN DAVID R [US]


Application No.: US20080050461A1  Published: 28/Feb/2008

Title: NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/928250   Filing Date: 30/Oct/2007

Abstract:Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US2003-392403 Applic. Date: 2003-03-20; US20020365540P Applic. Date: 2002-03-20; US20020366542P Applic. Date: 2002-03-25

Inventor: MERISKO-LIVERSIDGE ELAINE [US]; BOSCH H WILLIAM [US]; CARY GRETA G [US]; PRUITT JOHN [US]; RYDE TUULA [US]; JAIN RAJEEV [US]; WALTERS AMY [US]


Application No.: US20080051689A1  Published: 28/Feb/2008

Title: WEARABLE ULTRAFILTRATION DEVICE

Applicant/Assignee: NATIONAL QUALITY CARE, INC

Application No.: 11/933569   Filing Date: 01/Nov/2007

Abstract:An ultrafiltration device adapted to be worn on a portion of the body of a patient includes a blood inlet tube leading from a first blood vessel, a blood pump, an anticoagulant reservoir for infusing anticoagulants into the blood, a blood filter including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube leading to a second blood vessel.

Priority: US2004-846618 Applic. Date: 2004-05-17; US2001-085349 Applic. Date: 2001-11-16

Inventor: GURA VICTOR [US]; RAMBOD EDMOND [US]


Application No.: US20080056933A1  Published: 06/Mar/2008

Title: Self-Propelled Sterilization Robot and Method

Applicant/Assignee:

Application No.: 11/468157   Filing Date: 29/Aug/2006

Abstract:A sterilization apparatus ( 200 ) comprises a robot ( 201 ), at least one germicidal energy source ( 202 ), and at least one motive capability ( 203 ). The sterilization apparatus may optionally further comprise numerous additional components, including a filtration unit ( 204 ), at least one power source ( 209 ), a power connector ( 210 ), an environmental sampling device ( 211 ), at least one sensor ( 212 ), a control system ( 213 ), an audio output device ( 214 ), a data transmitter ( 215 ), a global positioning satellite (GPS) receiver ( 216 ), a radio frequency identification (RFID) tag ( 217 ), a vacuum device ( 218 ), a floor washing device ( 219 ), an activator ( 220 ), a waterproof housing ( 221 ), and/or a padded housing ( 222 ).

Priority:

Inventor: MOORE BARRETT H [US]; BOTOS MATTHEW J [US]


Application No.: US20080057101A1  Published: 06/Mar/2008

Title: MEDICAL DEVICES FOR CONTROLLED DRUG RELEASE

Applicant/Assignee:

Application No.: 11/839093   Filing Date: 15/Aug/2007

Abstract:The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.

Priority: US20060823057P Applic. Date: 2006-08-21; US20060823061P Applic. Date: 2006-08-21; US20060823063P Applic. Date: 2006-08-21; US20060823067P Applic. Date: 2006-08-21; US20060823069P Applic. Date: 2006-08-21; US20060823071P Applic. Date: 2006-08-21

Inventor: ROORDA WOUTER [US]


Application No.: US20080057102A1  Published: 06/Mar/2008

Title: METHODS OF MANUFACTURING MEDICAL DEVICES FOR CONTROLLED DRUG RELEASE

Applicant/Assignee:

Application No.: 11/839104   Filing Date: 15/Aug/2007

Abstract:The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.

Priority: US20060823057P Applic. Date: 2006-08-21; US20060823061P Applic. Date: 2006-08-21; US20060823063P Applic. Date: 2006-08-21; US20060823067P Applic. Date: 2006-08-21; US20060823069P Applic. Date: 2006-08-21; US20060823071P Applic. Date: 2006-08-21; US2007-839093 Applic. Date: 2007-08-15; US2007-839121 Applic. Date: 2007-08-15

Inventor: ROORDA WOUTER [US]


Application No.: US20080057103A1  Published: 06/Mar/2008

Title: METHODS OF USING MEDICAL DEVICES FOR CONTROLLED DRUG RELEASE

Applicant/Assignee:

Application No.: 11/839121   Filing Date: 15/Aug/2007

Abstract:The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.

Priority: US20060823057P Applic. Date: 2006-08-21; US20060823061P Applic. Date: 2006-08-21; US20060823063P Applic. Date: 2006-08-21; US20060823067P Applic. Date: 2006-08-21; US20060823069P Applic. Date: 2006-08-21; US20060823071P Applic. Date: 2006-08-21; US2007-839093 Applic. Date: 2007-08-15; US2007-839104 Applic. Date: 2007-08-15

Inventor: ROORDA WOUTER [US]


Application No.: US20080058695A1  Published: 06/Mar/2008

Title: Autotransfusion Method and Autotransfusion Device with Phase Separation and Concentration, Comprising Removable Bags

Applicant/Assignee: DIRECTION ET PRIORITES SA

Application No.: 11/660323   Filing Date: 04/Aug/2005

Abstract:A process for treating the haemorrhage fluids of a patient at the time of a surgical procedure with the aim of carrying out an autotransfusion, includes a stage for recovering the haemorrhage fluids with simultaneous introduction of agents such as anticoagulant and/or diluting agents, at least one stage for the mechanical separation/concentration of this haemodiluted haemorrhage fluid in order to concentrate its content in red blood cells and partially purify it, this phase being collected in a sterile manner so as to be fit for injecting back to the patient. Also described is the related device.

Priority: WO2005FR50648 Applic. Date: 2005-08-04

Inventor: PEROVITCH PHILIPPE [FR]; GADRAT FRANCIS [FR]; CHASTENET BERTRAND [FR]


Application No.: US20080058696A1  Published: 06/Mar/2008

Title: WEARABLE CONTINUOUS RENAL REPLACEMENT THERAPY DEVICE

Applicant/Assignee: NATIONAL QUALITY CARE, INC

Application No.: 11/933533   Filing Date: 01/Nov/2007

Abstract:A continuous renal replacement therapy (CRRT) device adapted to be worn on a portion of the body of a patient. The CRRT device is worn by the patient and operates on rechargeable batteries for more than 5 hours. Dialysate is used to remove impurities from the blood. The dialysate is recycled and refreshed by a filter section. Less than one liter of dialysate is required to circulate through the wearable CRRT device.

Priority: US2004-940862 Applic. Date: 2004-09-14; US2001-085349 Applic. Date: 2001-11-16

Inventor: GURA VICTOR [US]; RAMBOD EDMOND [US]


Application No.: US20080063695A1  Published: 13/Mar/2008

Title: Thin film dressing

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 11/900301   Filing Date: 11/Sep/2007

Abstract:Multi-layer articles are provided which are suitable for use as medical dressings. The articles include a hydrophilic layer, a hydrophobic layer, a delivery layer, and a release layer. In embodiments, the articles may also include adhesive tapes, stabilizer layers, and absorbent materials which may be included in an existing layer or applied as a separate absorbent layer.

Priority: US20060844008P Applic. Date: 2006-09-12

Inventor: VITARIS RONALD F [US]


Application No.: US20080063708A1  Published: 13/Mar/2008

Title: Pharmaceutical Compositions of Amorphous Dispersions of Drugs and Lipophilic Microphase-Forming Materials

Applicant/Assignee:

Application No.: 11/924988   Filing Date: 26/Oct/2007

Abstract:A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material. Alternatively, a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer is co-administered with a lipophilic microphase-forming material to an in vivo use environment.

Priority: WO2003IB00335 Applic. Date: 2003-01-28; US2003-355747 Applic. Date: 2003-01-31; US20020354081P Applic. Date: 2002-02-01

Inventor: PERLMAN MICHAEL E [US]; SHANKER RAVI M [US]; BABCOCK WALTER C [US]; FRIESEN DWAYNE T [US]; RABENSTEIN MARK D [US]; SMITHEY DAN T [US]


Application No.: US20080066741A1  Published: 20/Mar/2008

Title: METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION

Applicant/Assignee:

Application No.: 11/689315   Filing Date: 21/Mar/2007

Abstract:Systems and methods for delivery of a drug to the respiratory system of a patient are provided, where the drug is supplied in purified air at a positive pressure relative to atmospheric pressure. With the systems and methods of the present disclosure, medication available in a variety of forms is introduced in a controlled fashion into the purified air stream in aerosol, nebulized, or vaporized form.

Priority: US2007-627692 Applic. Date: 2007-01-26; US2006-552871 Applic. Date: 2006-10-25; US20060826271P Applic. Date: 2006-09-20

Inventor: LEMAHIEU EDWARD [US]; JONES CHARLES [US]; STERN TOM [US]; HEBRANK JACK [US]; HUNTER CHARLES ERIC [US]; DUVALL LYNDELL [US]; HARTLEY CHRIS [US]; BALLOU BERNARD L [US]; HUNTER JOCELYN [US]; MCNEIL LAURIE [US]; WETZEL PAUL [US]; CRISS RON [US]


Application No.: US20080069889A1  Published: 20/Mar/2008

Title: Compressible resilient granules and formulations prepared therefrom

Applicant/Assignee:

Application No.: 11/899601   Filing Date: 05/Sep/2007

Abstract:The present invention provides resilient self-adhering granules which comprise a polysaccharide present in an amount from about 10 wt % to about 90 wt % and a binder having a viscosity from about 5,000 mPa.s to about 250,000 mPa.s present in an amount from about 90 wt % to about 10 wt %, wherein the granule is capable of reversible agglomeration at or below 6,500 kilonewtons/m<2>. The present invention also provides oral dosage compositions comprising the resilient self-adhering granules and methods for making and using the resilient self-adhering granules.

Priority: US2007-715821 Applic. Date: 2007-03-07; US20060780304P Applic. Date: 2006-03-07

Inventor: CHERUKURI S R [US]


Application No.: US20080075691A1  Published: 27/Mar/2008

Title: Permucosal Composition and Method of Improving Permucosal Absorption

Applicant/Assignee: OTSUKA PHARMACEUTICAL CO., LTD

Application No.: 11/662094   Filing Date: 12/Sep/2005

Abstract:An object of the invention is to provide a composition for transmucosal administration that enables pharmacologically active peptides and proteins to be efficiently absorbed through the mucosa such as the pulmonary mucosa, nasal mucosa, oral mucosa, vaginal mucosa, gastric mucosa, gastrointestinal mucosa or the like. A composition for transmucosal administration are prepared by adding (i) at least one member selected from the group consisting of peptides and proteins having pharmacological activity

and (ii) at least one member selected from the group consisting of chitosan oligosaccharides having a polymerization degree of from 2 to 20, derivatives thereof, glucosamine, and salts thereof.

Priority: JP20040268891 Applic. Date: 2004-09-15; WO2005JP16739 Applic. Date: 2005-09-12

Inventor: YAMAMOTO AKIRA [JP]; YAMADA KEIGO [JP]


Application No.: US20080075772A1  Published: 27/Mar/2008

Title: PHARMACEUTICAL COMPOSITIONS HAVING NOVEL SCORING PATTERNS AND METHODS OF USING THOSE COMPOSITIONS

Applicant/Assignee:

Application No.: 11/735268   Filing Date: 13/Apr/2007

Abstract:The invention provides novel scoring patterns for a wide variety of tablets that contain specific drugs or contain drugs in certain drug classes, and methods of treatment with layered tablets and fractional tablets derived from breaking said tablets.

Priority: US20060791834P Applic. Date: 2006-04-13; US20060792601P Applic. Date: 2006-04-17; US20060792933P Applic. Date: 2006-04-18; US20060861898P Applic. Date: 2006-11-30

Inventor: SOLOMON LAWRENCE [US]; KAPLAN ALLAN S [US]


Application No.: US20080075788A1  Published: 27/Mar/2008

Title: DIAMMONIUM PHOSPHATE AND OTHER AMMONIUM SALTS AND THEIR USE IN PREVENTING CLOTTING

Applicant/Assignee:

Application No.: 11/859291   Filing Date: 21/Sep/2007

Abstract:The present invention relates to products, methods, and processes of various ammonium salts and their use as anti-coagulants.

Priority: US20060846312P Applic. Date: 2006-09-21

Inventor: LEE SAMUEL [US]; LOUIE STEPHANIE [US]; SCHWARDT JEFFREY D [US]; SLATER THOMAS A [US]; WENZ ROBERT [DE]


Application No.: US20080086107A1  Published: 10/Apr/2008

Title: DEVICES FOR DELIVERING SUBSTANCES THROUGH AN EXTRA-ANATOMIC OPENING CREATED IN AN AIRWAY

Applicant/Assignee: BRONCUS TECHNOLOGIES, INC

Application No.: 11/538950   Filing Date: 05/Oct/2006

Abstract:Devices and methods for delivering substances to lung tissue through an extra-anatomic passage created in an airway.

Priority:

Inventor: ROSCHAK EDMUND J [US]


Application No.: US20080090800A1  Published: 17/Apr/2008

Title: Mandelic acid derivatives and their use as thrombin inhibitors

Applicant/Assignee: ASTRAZENECA AB ASTRAZENECA

Application No.: 11/797656   Filing Date: 04/May/2007

Abstract:There is provided a compound of formula (I) wherein R, R<1>, R<2>, Y and R<3 >have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g., thrombosis) or as anticoagulants.

Priority: SE20000004458 Applic. Date: 2000-12-01; SE20010000965 Applic. Date: 2001-03-19; SE20010001239 Applic. Date: 2001-04-06; SE20010002921 Applic. Date: 2001-08-30; US2006-520063 Applic. Date: 2006-09-13; US2003-432411 Applic. Date: 2003-05-21; WO2001SE02657 Applic. Date: 2001-11-30

Inventor: INGHARDT TORD [SE]; JOHANSSON ANDERS [SE]; SVENSSON ARNE [SE]


Application No.: US20080090807A1  Published: 17/Apr/2008

Title: LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY BRISTOL-MEYERS SQUIBB COMPANY

Application No.: 11/955678   Filing Date: 13/Dec/2007

Abstract:The present application describes lactam-containing compounds and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Priority: US2005-198801 Applic. Date: 2005-08-05; US2004-850587 Applic. Date: 2004-05-20; US2002-245122 Applic. Date: 2002-09-17; US20010324165P Applic. Date: 2001-09-21; US20020402317P Applic. Date: 2002-08-09

Inventor: PINTO DONALD J P [US]; QUAN MIMI L [US]; ORWAT MICHAEL J [US]; LI YUN-LONG [US]; HAN WEI [US]; QIAO JENNIFER X [US]; LAM PATRICK Y S [US]; KOCH STEPHANIE L [US]


Application No.: US20080090907A1  Published: 17/Apr/2008

Title: Crystal Comprising (2R)-2-Propyloctanoic Acid and Amine

Applicant/Assignee: ONO PHARMACEUTICAL CO., LTD

Application No.: 11/579071   Filing Date: 27/Apr/2005

Abstract:Crystals comprising (2R)-2-propyloctoic acid and an amine which retain the pharmacological effect of (2R)-2-propyloctoic acid and can be safely used as a medicinal raw drug for peroral solid preparations. Of these crystals, the crystals especially with dibenzylamine are advantageous because not only the crystals themselves are useful as a medicinal raw drug but also use of the crystals as an intermediate can yield (2R)-2-propyloctoic acid having an optical purity exceeding 99.5% e.e., which has not been obtained hitherto.

Priority: JP20040134655 Applic. Date: 2004-04-28; WO2005JP08462 Applic. Date: 2005-04-27

Inventor: HASEGAWA TOMOYUKI [JP]; KAWANAKA YASUFUMI [JP]; KASAMATSU EIJI [JP]


Application No.: US20080097241A1  Published: 24/Apr/2008

Title: SAMPLING DEVICE

Applicant/Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY

Application No.: 11/874830   Filing Date: 18/Oct/2007

Abstract:This invention provides devices and methods for obtaining a sample.

Priority: US20060852830P Applic. Date: 2006-10-18

Inventor: MALTEZOS GEORGE [US]; SCHERER AXEL [US]


Application No.: US20080097242A1  Published: 24/Apr/2008

Title: Disposable Blood Sampling Device

Applicant/Assignee: KUN SHAN MEDSAFE MEDICAL TECH CO., LTD

Application No.: 11/781237   Filing Date: 21/Jul/2007

Abstract:A disposable blood sampling device is disclosed herein, which includes a plunger, a rubber stopper, a barrel, a sealing member, a needle holder, a protection sleeve, an anticoagulant storing tube and a needle sheath. In use, the disposable blood sampling device is deconstructed by removing each component therefrom and is unable to be assembled again for recycling. Furthermore, the needle can be hidden in the protection sleeve before it is detached from the blood sampling device, which effectively prevents a medical operator from being hurt or even infected by the needle.

Priority: TW20060218599U Applic. Date: 2006-10-20

Inventor: CAI JIAN [CN]


Application No.: US20080097243A1  Published: 24/Apr/2008

Title: HOLLOW NEEDLE ASSEMBLY

Applicant/Assignee:

Application No.: 11/466588   Filing Date: 23/Aug/2006

Abstract:Some embodiments of the invention provide a needle with a sharp open end and a blunt open end, housed in a barrel with an open anterior end and an open posterior end. The barrel can travel along the hub of the needle, for extending the needle for insertion into a blood vessel, and for retracting the needle into the barrel to avoid injury. The blunt open end can be fluidly connected to the inlet opening of a measurement apparatus, so that the blood can flow directly into the measurement apparatus, eliminating the traditional step of transferring the blood from a syringe to the measurement apparatus. The hollow needle assembly can remain attached to the measurement apparatus because of its small size, and the engagement of an optional safety cap to the open anterior end of the barrel, minimizes the risk of injury and blood contamination. Because a small blood sample is required, a very small needle shaft can be used, minimizing the discomfort experienced by the patient.

Priority:

Inventor: SAMSOONDAR JAMES [CA]


Application No.: US20080097592A1  Published: 24/Apr/2008

Title: Artificial Blood Vessel

Applicant/Assignee: VASCUTEK LIMITED TERUMO CORPORATION

Application No.: 11/792498   Filing Date: 14/Feb/2005

Abstract:There is described an artificial blood vessel for use in a region of a living body which needs to be repeatedly pierced with a needle. The artificial blood vessel includes a main section having a vessel wall which includes a laminated assembly comprising an inner layer, an outer layer, and an intermediate layer positioned therebetween, and a pair of anastomotic sections disposed on the respective opposite ends of the main section. Each of the anastomotic sections has an intermediate layer thinner than the intermediate layer of the main section or is free of an intermediate layer, so that the anastomotic section as a vessel wall thinner than the main section.

Priority: WO2005GB00521 Applic. Date: 2005-02-14

Inventor: FITZPATRICK CHARLES [GB]; OKUBO TADANORI [GB]


Application No.: US20080102115A1  Published: 01/May/2008

Title: Modified coagulation factor IX polypeptides and use thereof for treatment

Applicant/Assignee:

Application No.: 11/818985   Filing Date: 15/Jun/2007

Abstract:Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.

Priority: US20060815113P Applic. Date: 2006-06-19

Inventor: OYHENART JORGE [AR]; GALLET XAVIER [FR]; BORRELLY GILLES [FR]; GUYON THIERRY [FR]; VEGA MANUEL [FR]; DRITTANTI LILA [FR]


Application No.: US20080107678A1  Published: 08/May/2008

Title: Method for treating thrombotic disorders using sulfated polysaccharides

Applicant/Assignee:

Application No.: 11/789447   Filing Date: 24/Apr/2007

Abstract:Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed.

Priority: US20060797079P Applic. Date: 2006-04-27

Inventor: JOHNSON KIRK W [US]


Application No.: US20080107741A1  Published: 08/May/2008

Title: NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/928278   Filing Date: 30/Oct/2007

Abstract:Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US2003-392403 Applic. Date: 2003-03-20; US20020366542P Applic. Date: 2002-03-25; US20020365540P Applic. Date: 2002-03-20

Inventor: MERISKO-LIVERSIDGE ELAINE [US]; BOSCH H W [US]; CARY GRETA G [US]; PRUITT JOHN [US]; RYDE TUULA [US]; JAIN RAJEEV [US]; WALTERS AMY [US]


Application No.: US20080108122A1  Published: 08/May/2008

Title: Microchemical nanofactories

Applicant/Assignee: STATE UNIVERSITY

Application No.: 11/897998   Filing Date: 31/Aug/2007

Abstract:Embodiments of an apparatus, system, and method for chemical synthesis and/or analysis are disclosed. One embodiment of a disclosed apparatus comprises a laminated, microfluidic structure defining a reactor and a separator. Such apparatuses, or portions thereof, generally have dimensions ranging from about 1 micrometer to about 100 micrometers. To implement synthetic processes, disclosed embodiments of the apparatus generally include at least one unit operation, such as a mixer, a valve, a separator, a detector, and combinations thereof. Individual apparatuses may be coupled both in series and in parallel to form a system for making chemical compounds. An individual apparatus or a system also can be used in combination with known devices and processes.

Priority: US20060841778P Applic. Date: 2006-09-01

Inventor: PAUL BRIAN K [US]; CHANG CHIH-HUNG [US]; REMCHO VINCENT T [US]


Application No.: US20080108942A1  Published: 08/May/2008

Title: ANALYTE SENSOR

Applicant/Assignee: DEXCOM, INC

Application No.: 11/691426   Filing Date: 26/Mar/2007

Abstract:Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into communication with a host's circulatory system.

Priority: US2006-543396 Applic. Date: 2006-10-04; US2006-543490 Applic. Date: 2006-10-04; US2006-543404 Applic. Date: 2006-10-04

Inventor: BRISTER MARK [US]; SWANSON VANCE [US]; PETISCE JAMES R [US]; SAINT SEAN [US]; WONG DAVID K [US]; WOO KUM MING [US]


Application No.: US20080109070A1  Published: 08/May/2008

Title: BIODEGRADABLE ELASTOMERIC SCAFFOLDS CONTAINING MICROINTEGRATED CELLS

Applicant/Assignee:

Application No.: 11/837235   Filing Date: 10/Aug/2007

Abstract:Described herein are elastomeric materials, and in particular porous biodegradable elastomeric materials which optionally may have microintegrated cells. Also described herein are bioprosthetic devices that can be manufactured using the biodegradable elastomeric materials, non-limiting examples of such devices including pulmonary valves, vocal chords, and blood vessels.

Priority: US20060822073P Applic. Date: 2006-08-10

Inventor: WAGNER WILLIAM R [US]; STANKUS JOHN [US]; GUAN JIANJUN [US]; FUJIMOTO KAZURO L [US]; NIEPONICE ALEJANDRO [AR]; SOLETTI LORENZO [US]; VORP DAVID A [US]; SACKS MICHAEL S [US]; COURTNEY TODD [US]; MAYER JOHN E [US]


Application No.: US20080112955A1  Published: 15/May/2008

Title: METHOD AND COMPOSITION FOR PREVENTING PAIN IN SICKLE CELL PATIENTS

Applicant/Assignee: TRF PHARMA, INC

Application No.: 12/015885   Filing Date: 17/Jan/2008

Abstract:A method of preventing pain in a sickle cell patient is disclosed. The method includes orally administering to the patient, an amount of an active agent effective on oral administration to inhibit binding of the patient's sickle erythrocytes to P-selectin on the patient's vascular endothelium. The inhibition may be evidenced in a number of ways. The active agent administration inhibits the adhesion of sickle erythrocytes to vascular endothelium in the patient, thereby preventing patient pain associated with vascular occlusion. Also disclosed are compositions useful in practicing the method.

Priority: US2003-418653 Applic. Date: 2003-04-18; US20020373841P Applic. Date: 2002-04-18; US20020373842P Applic. Date: 2002-04-18; US20020373844P Applic. Date: 2002-04-18

Inventor: EMBURY STEPHEN H [US]; MATSUI NEIL M [US]


Application No.: US20080119703A1  Published: 22/May/2008

Title: Analyte sensor

Applicant/Assignee:

Application No.: 11/543396   Filing Date: 04/Oct/2006

Abstract:Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into a host's peripheral vein or artery.

Priority: US2006-543404 Applic. Date: 2006-10-04; US2006-543490 Applic. Date: 2006-10-04

Inventor: BRISTER MARK [US]; SAINT SEAN [US]; SWANSON VANCE [US]; PETISCE JAMES R [US]


Application No.: US20080119704A1  Published: 22/May/2008

Title: Analyte sensor

Applicant/Assignee:

Application No.: 11/543490   Filing Date: 04/Oct/2006

Abstract:Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into a host's peripheral vein or artery.

Priority: US2006-543396 Applic. Date: 2006-10-04; US2006-543404 Applic. Date: 2006-10-04

Inventor: BRISTER MARK [US]; SAINT SEAN [US]; SWANSON VANCE [US]; QUINTANA NELSON [US]


Application No.: US20080124280A1  Published: 29/May/2008

Title: Thyroid Hormone Analogs and Methods of Use

Applicant/Assignee:

Application No.: 11/663047   Filing Date: 15/Sep/2005

Abstract:Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Priority: US2004-943072 Applic. Date: 2004-09-15; US20030502721P Applic. Date: 2003-09-15; US20050670534P Applic. Date: 2005-04-13; WO2005US32813 Applic. Date: 2005-09-15

Inventor: MOUSA SHAKER A [US]; DAVIS FAITH B [US]; DAVIS PAUL J [US]


Application No.: US20080124700A1  Published: 29/May/2008

Title: Method and apparatus for controlling the flow rate of washing solution during the washing step in a blood centrifugation bowl

Applicant/Assignee:

Application No.: 11/604664   Filing Date: 27/Nov/2006

Abstract:A method of washing blood mixed with undesirable elements not normally found in healthy whole blood to remove the undesirable elements, the method comprising: separating the blood into components according to relative densities of the components with a rotating centrifuge bowl

providing a port through which fluid exits the bowl, the exiting fluid having a concentration of undesirable elements

flowing washing solution into the centrifuge bowl at an initial flow rate

monitoring the fluid exiting the bowl with an optical sensor having an output signal indicative of the composition of the exiting fluid

and increasing and decreasing the flow rate of the wash solution as a function of the output signal.

Priority:

Inventor: FORTINI MATTEO [IT]; REGGIANI STEFANO [IT]; PANZANI IVO [IT]


Application No.: US20080131423A1  Published: 05/Jun/2008

Title: Anti-TREM-like transcript-1 (TLT-1) antibodies, methods and compositions

Applicant/Assignee: GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES

Application No.: 11/634331   Filing Date: 04/Dec/2006

Abstract:The present invention relates to methods and compositions for modulating platelet activity, and methods and compositions for treating a disease or disorder associated with platelet activity in a subject, comprising administering a single chain anti-TREM-like transcript-1 (TLT-1) antibody or a functional fragment or variant thereof in an amount effective to modulate platelet activity.

Priority:

Inventor: MORI TOSHIYUKI [JP]; MCVICAR DANIEL W [US]; GIOMARELLI BARBARA [US]; WASHINGTON A V [US]


Application No.: US20080132499A1  Published: 05/Jun/2008

Title: PLATELET ADP RECEPTOR INHIBITORS

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 11/856616   Filing Date: 17/Sep/2007

Abstract:Compounds are provided which are useful as platelet ADP receptor inhibitors, for treating thrombosis and for reducing the likelihood and/or severity of a secondary ischemic event in a patient.

Priority: US20060846328P Applic. Date: 2006-09-20

Inventor: SCARBOROUGH ROBERT M [US]; SCARBOROUGH CARROLL ANNA CREW [US]; BAUER SHAWN M [US]; PANDEY ANJALI [US]


Application No.: US20080138277A1  Published: 12/Jun/2008

Title: Delivery systems and methods for diagnosing and treating cardiovascular diseases

Applicant/Assignee: MEDSTAR HEALTH INC GEORGETOWN UNIVERSITY

Application No.: 11/386513   Filing Date: 23/Mar/2006

Abstract:The invention relates to the treatment and prevention of atherosclerosis and cardiovascular diseases associated with atherosclerosis. The invention further relates to methods of diagnosing atherosclerosis and cardiovascular diseases associated with atherosclerosis. In certain embodiments, the invention provides biological systems and methods for delivering a therapeutic agent or an imaging agent to atherosclerotic lesions such as vulnerable plaques.

Priority: US20050664330P Applic. Date: 2005-03-23

Inventor: EPSTEIN STEPHEN E [US]; BURNETT MARY SUSAN [US]; MULLINS MARTIN A [US]


Application No.: US20080145423A1  Published: 19/Jun/2008

Title: Chewable tablet and method of formulating

Applicant/Assignee:

Application No.: 11/639016   Filing Date: 14/Dec/2006

Abstract:Processes for preparing a chewable tablet comprising a micronized form of an active ingredient, the method comprising the steps of combining the active ingredient with tablet excipients by geometric dilution to form a final mixture and applying direct compression to at least a portion of the final mixture to form at least one tablet.

Priority:

Inventor: KHAN AJMAL ALI [US]; BRUNSON EDDIE [US]


Application No.: US20080145438A1  Published: 19/Jun/2008

Title: Micro- and nano-particulate drugs and methods of making thereof

Applicant/Assignee:

Application No.: 11/823476   Filing Date: 26/Jun/2007

Abstract:A micro and nano-particulate drug comprising a drug substance and a surfactant in which the drug and surfactant form a eutectic mixture. The matrix formed between the drug substance and the surfactant has a melting point less than the decomposition temperature of the drug substance and thus provides the advantages of reduced irritation due to the melting process without the prior art problem of decomposition of the drug substance. In one embodiment, crystals are formed while the mixture is cooled at room temperature under high shear conditions. In a second embodiment, a flowable material may be formed which also contains the drug and that may be incorporated into a pharmaceutical delivery system is also disclosed. Methods of preparing the micro and nano-particulate drug crystals and non-crystalline substance are also contemplated in the inventive subject matter.

Priority: US2001-022799 Applic. Date: 2001-12-20

Inventor: BOGUE BEUFORD ARLIE [US]


Application No.: US20080152585A1  Published: 26/Jun/2008

Title: Low viscosity liquid dosage forms

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/979253   Filing Date: 31/Oct/2007

Abstract:The present invention relates to liquid dosage forms of nanoparticulate active agents having very low viscosities.

Priority: US2003-420927 Applic. Date: 2003-04-23; US2003-412669 Applic. Date: 2003-04-14; US20020371680P Applic. Date: 2002-04-12; US20020430348P Applic. Date: 2002-12-03

Inventor: RYDE TUULA [US]; RYDE NIELS [US]; BOSCH H WILLIAM [US]; PRUITT JOHN D [US]; WERTZ CHRISTIAN F [US]


Application No.: US20080153152A1  Published: 26/Jun/2008

Title: MICROFLUIDIC CHIP

Applicant/Assignee:

Application No.: 11/943380   Filing Date: 20/Nov/2007

Abstract:A microfluidic chip, includes: a first port for inputting: a sample liquid

and a first liquid

a second port for inputting a second liquid

a third port for supplying air pressure

a first channel (A) for mixing the sample liquid and the first liquid to generate a first mixed liquid

a second channel (B) for beating the first mixed liquid

a third channel (C) for allowing the second liquid to converge into the first mixed liquid to generate a second mixed liquid

a fourth channel (D) installing a first solid

a fifth channel (E) for promoting mixing of the first solid

a plurality of sixth channels (F) each having a second solid

and a seventh channel (G), which connects the fifth channel (E) and the plurality of sixth channels (F), for dispensing a fixed quantity of the second mixed liquid to each of the plurality of sixth channels (F).

Priority: JP20060316129 Applic. Date: 2006-11-22; JP20070297003 Applic. Date: 2007-11-15

Inventor: WAKABAYASHI AKIRA [JP]; KARAKI HIDEYUKI [JP]; SAWAYASHIKI YOSHIHIRO [JP]; KATO KOTA [JP]; IWAKI YOSHIHIDE [JP]


Application No.: US20080154181A1  Published: 26/Jun/2008

Title: Central nervous system ultrasonic drain

Applicant/Assignee:

Application No.: 12/008611   Filing Date: 11/Jan/2008

Abstract:The invention provides a method and apparatus for treating hemorrhage and maintaining catheter patency in the brain and spine through a new and minimally invasive technique. Ultrasound energy is delivered either through a catheter inserted directly into the hemorrhage and the delivered ultrasound energy dissolves the blood clot which is then drained through the catheter.

Priority: US2006-418849 Applic. Date: 2006-05-05

Inventor: KHANNA ROHIT K [US]


Application No.: US20080159984A1  Published: 03/Jul/2008

Title: Compositions Capable of Facilitating Penetration Across a Biological Barrier

Applicant/Assignee:

Application No.: 11/547568   Filing Date: 14/Apr/2005

Abstract:This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium The invention also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects.

Priority: US20040562345P Applic. Date: 2004-04-15; WO2005IB04183 Applic. Date: 2005-04-14

Inventor: BEN-SASSON SHMUEL A [IL]


Application No.: US20080161296A1  Published: 03/Jul/2008

Title: Compositions comprising nebivolol

Applicant/Assignee: FOREST LABORATORIES HOLDINGS LIMITED

Application No.: 11/273992   Filing Date: 15/Nov/2005

Abstract:Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.

Priority: US2005-141235 Applic. Date: 2005-05-31; US20040577423P Applic. Date: 2004-06-04

Inventor: DAVIS ERIC [US]; O'DONNELL JOHN P [US]; BOTTINI PETER BRUCE [US]; SHAW ANDREW [US]; MASON R PRESTON [US]


Application No.: US20080161793A1  Published: 03/Jul/2008

Title: Cooled ablation catheter with reciprocating flow

Applicant/Assignee:

Application No.: 11/646255   Filing Date: 28/Dec/2006

Abstract:The invention relates to an ablation catheter which controls the temperature and reduces the coagulation of biological fluids on an electrode of a catheter, prevents the impedance rise of tissue in contact with the electrode, and maximizes the potential energy transfer to the tissue, thereby allowing an increase in the lesion size produced by the ablation. The electrode includes passages positioned to allow blood and other biological fluids to flow into and out of an inner cavity of the electrode. This fluid flow produced the desired cooling effect and is accomplished, for example, by a reciprocating plunger or piston, or by a balloon that is alternately inflated and deflated.

Priority:

Inventor: WANG HUISUN [US]; DANDO JEREMY D [US]


Application No.: US20080161907A1  Published: 03/Jul/2008

Title: Stent coated with a sustained-release drug delivery and method for use thereof

Applicant/Assignee: PSIVIDA INC

Application No.: 11/906765   Filing Date: 02/Oct/2007

Abstract:An intraluminal medical device comprises a stent having a coating applied to at least part of an interior surface, an exterior surface, or both. The coating comprises a sustained release formulation of a combination of pharmaceutical compounds dispersed within a biologically tolerated polymer composition. The choice of the combination of pharmaceutical compounds are intended to reduce neointimal hyperplasia restenosis.

Priority: US2002-245840 Applic. Date: 2002-09-17; US20010322428P Applic. Date: 2001-09-17; US20020372761P Applic. Date: 2002-04-15

Inventor: CHEN JIANBING [US]; ASHTON PAUL [US]


Application No.: US20080166324A1  Published: 07/Dec/2006

Title: PLASMA-DEPLETED, NON-RED BLOOD CELL-DEPLETED CORD BLOOD COMPOSITIONS AND METHODS OF USE

Applicant/Assignee: STEMCYTE, INC

Application No.: 11/422017   Filing Date: 02/Jun/2006

Abstract:The umbilical cord blood (UCB) compositions of the present invention possess the unique features of having plasma that is substantially depleted from the UCB unit and red blood cells (RBC) that are not depleted from the UCB unit. Such UCB units can be prepared by a process that combines plasma depletion with cryopreservation, selection, thawing, and/or transplantation of hematopoietic stem cells to provide superior clinical outcome by maximizing post-processing cell recovery and post-thaw infusion cell dose. Methods for treating a wide variety of malignant diseases and benign diseases associated with the hematopoietic system by administering the UCB compositions of the present invention are also provided.

Priority: US2003-367339 Applic. Date: 2003-02-13; US20050733956P Applic. Date: 2005-11-03; US20050687127P Applic. Date: 2005-06-02; US20020357308P Applic. Date: 2002-02-14

Inventor: CHOW ROBERT [US]


Application No.: US20080166390A1  Published: 10/Jul/2008

Title: Biodegradable polyphosphazenes containing pyrrolidone side groups

Applicant/Assignee:

Application No.: 11/974528   Filing Date: 12/Oct/2007

Abstract:Biodegradable polyphosphazene polymers containing pyrrolidone side groups, and the biomedical use of such polyphosphazene polymers are disclosed.

Priority: WO2006US13661 Applic. Date: 2006-04-11

Inventor: ANDRIANOV ALEXANDER K [US]; MARIN ALEXANDER [US]


Application No.: US20080171972A1  Published: 17/Jul/2008

Title: Medical device package

Applicant/Assignee:

Application No.: 11/544503   Filing Date: 06/Oct/2006

Abstract:The present disclosure provides a medical device package including a container for receiving a medical device having an area configured for storing at least one agent and a port for permitting the passage of a contact material between the outside the container and the area configured for storing the agent.

Priority:

Inventor: STOPEK JOSHUA B [US]


Application No.: US20080175831A1  Published: 24/Jul/2008

Title: NEUROPROTECTION BY BLOOD FLOW STABILIZATION

Applicant/Assignee:

Application No.: 11/961835   Filing Date: 20/Dec/2007

Abstract:A treatment is disclosed for alleviation or prevention of abnormal blood flow to various organs such as the eye, brain, kidneys, heart, feet and other tissues of organs with fine vascular networks that can lead to neurodegeneration as is seen in wet age-related macular degeneration (AMD), epilepsy and diabetes, in which an effective amount of a blood flow regulatory drug is administered to a subject in need of it. Illustrative blood flow regulatory drugs include anticoagulants and vasodilators, and their mixtures.

Priority: US20060876354P Applic. Date: 2006-12-21; US20070977501P Applic. Date: 2007-10-04

Inventor: MACKNIK STEPHEN L [US]; MARTINEZ-CONDE SUSANA [US]


Application No.: US20080175878A1  Published: 24/Jul/2008

Title: Protease for activating clotting factor VII

Applicant/Assignee: CSL BEHRING GMBH

Application No.: 11/984058   Filing Date: 13/Nov/2007

Abstract:A protease for activating the blood clotting factor VII is described, which (a) is inhibited by the presence of aprotinin, (b) is increased in its activity by calcium ions and/or heparin or heparin-related substances, and (c) in SDS-PAGE, on subsequent staining in the non-reduced state, comprises one or more bands in the molecular weight range from 50 to 75 kDa

and in SDS-PAGE, on subsequent staining in the reduced state, comprises a band at 40 to 55 kDa, one or more bands in the molecular weight range from 10 to 35 kDa, and a band, which corresponds to a proenzyme, in the molecular weight range between 60 and 65 kDa.

Priority: DE19981018495 Applic. Date: 1998-04-24; DE19981027734 Applic. Date: 1998-06-22; DE19981051332 Applic. Date: 1998-11-06; DE19981051335 Applic. Date: 1998-11-06; DE19981051336 Applic. Date: 1998-11-06; DE19991003693 Applic. Date: 1999-02-01; US2005-118396 Applic. Date: 2005-05-02; US2002-319592 Applic. Date: 2002-12-16; US1999-295316 Applic. Date: 1999-04-21

Inventor: ROMISCH JURGEN [DE]; FEUSSNER ANNETTE [DE]; STOHR HANS-ARNOLD [DE]


Application No.: US20080188400A1  Published: 07/Aug/2008

Title: Methods For Treating Bleeding

Applicant/Assignee: MAXYGEN HOLDINGS LTD

Application No.: 11/912484   Filing Date: 25/Apr/2006

Abstract:Methods for the treatment of various bleeding disorders using variants of human Factor VII (hFVII) or activated FVII (FVIIa) having an altered activity compared to 5 recombinant FVIIa with the native human sequence.

Priority: US20050674815P Applic. Date: 2005-04-26; WO2006DK50016 Applic. Date: 2006-04-25

Inventor: ROPKE MADS [DK]; LATHROP STEPHANIE J [US]


Application No.: US20080190857A1  Published: 14/Aug/2008

Title: System and Methods of Producing Membranes

Applicant/Assignee: CASCADE MEDICAL ENTRPRISES, LLC

Application No.: 11/909191   Filing Date: 22/Mar/2006

Abstract:An apparatus and method of forming a solid-fibrin web. The apparatus includes a centrifuge ( 600 ) having a housing ( 604 ), and actuator ( 648 ), a wheel ( 660 ), and a flange ( 664 ). The housing includes a recessed area ( 616 ) and a base ( 608 ) supportable on a surface. The wheel is coupled to the actuator and extends into the recessed area and is adapted to contact a first end of a container ( 620 ). The flange extends into the recessed area opposite the wheel and defines an adjustable distance between the wheel and the flange. The flange is adapted to contact a second end of the container and the actuator is operable to rotate the container. The container is oriented substantially parallel with respect to the base.

Priority: US20050664004P Applic. Date: 2005-03-22; WO2006US10525 Applic. Date: 2006-03-22

Inventor: BERETTA ROBERTO [IT]; GRIPPI NICHOLAS A [US]


Application No.: US20080193414A1  Published: 14/Aug/2008

Title: Use of an Immunoglobulin Domain-Containing Cell Surface Recognition Molecule For Treating Diseases

Applicant/Assignee:

Application No.: 11/913620   Filing Date: 04/May/2006

Abstract:The invention relates to the use of INSP052 for treatment and/or prevention of infectious disease, properdin-related disease, MBL2-related disease, MASP1-related disease, MASP2-related disease, Antithrombin III-related disease, Complement factor H-related disease and/or Albumin-related disease. Combinations of INSP052 with an interferon, a TNF antagonist or a further anti-infectious or anti-blood clotting agent are also within the present invention.

Priority: EP20050103791 Applic. Date: 2005-05-06; US20050681651P Applic. Date: 2005-05-17; WO2006EP62063 Applic. Date: 2006-05-04

Inventor: PROUDFOOT AMANDA [FR]; ANTONSSON BRUNO [FR]; KONTULA LINDA [CH]; VILBOIS FRANCIS [FR]


Application No.: US20080194036A1  Published: 14/Aug/2008

Title: Method For Determining Coagulation Activation And Device For Carrying Out Said Method

Applicant/Assignee: TECHNOCLONE GESELLSCHAFT M.B.H

Application No.: 11/884966   Filing Date: 22/Feb/2006

Abstract:The invention relates to a method for determining the generation of thrombin or factor Xa, said generation of activated coagulation factors in various sample materials, such as whole blood or plasma with different thrombocyte quantities, being triggered by phospholipid micelles with different tissue factor contents (0 to 1000 pM). According to the invention, the generation of thrombin is determined in a coagulation machine, which can simultaneously determine classic conventional coagulation parameters. The device for carrying out the method for the parallel determination of thrombin generation and classic conventional coagulation parameters has a rotating cuvette plate, into which a cuvette ring and cuvette elements are inserted.

According to the invention, at least one section of the cuvette ring contains a test station for at least two fluorescent test sets and at least four conventional test sets for coagulation, chromogenic substrates and turbidimetric analysis.

Priority: AT20050000296 Applic. Date: 2005-02-22; AT20050001656 Applic. Date: 2005-10-11; WO2006AT00073 Applic. Date: 2006-02-22

Inventor: BINDER BERND [AT]


Application No.: US20080194868A1  Published: 14/Aug/2008

Title: HYDRODYNAMIC CAVITATION CRYSTALLIZATION DEVICE AND PROCESS

Applicant/Assignee:

Application No.: 11/782299   Filing Date: 24/Jul/2007

Abstract:A device and process for crystallizing a compound using hydrodynamic cavitation comprising the steps of mixing at least one stream of a solution of such compound to be crystallized with at least one stream of an anti-solvent and passing the mixed streams at an elevated pressure through a local constriction of flow to create hydrodynamic cavitation thereby causing nucleation and the direct production of crystals. The compound to be crystallized can be, for example, an active pharmaceutical ingredient.

Priority: US2006-330473 Applic. Date: 2006-01-12; US2003-382117 Applic. Date: 2003-03-04

Inventor: KOZYUK OLEG V [US]


Application No.: US20080195062A1  Published: 14/Aug/2008

Title: SAMPLING OF BLOOD ANALYTES

Applicant/Assignee: VANDERBILT UNIVERSITY

Application No.: 11/422748   Filing Date: 07/Jun/2006

Abstract:The present invention provides for devices and methods of sampling and analyzing body fluid analytes, including proteins, nucleic acids, drugs, carbohydrates and lipids. Body fluids include blood, serum, sputum, saliva, urine, cerebrospinal fluid, and ascites.

Priority: US20050688618P Applic. Date: 2005-06-08; US20050711019P Applic. Date: 2005-08-24

Inventor: CAPRIOLI RICHARD [US]


Application No.: US20080197024A1  Published: 21/Aug/2008

Title: ANALYTE SENSOR

Applicant/Assignee: DEXCOM, INC

Application No.: 12/055078   Filing Date: 25/Mar/2008

Abstract:Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into communication with a host's circulatory system.

Priority: US2007-691466 Applic. Date: 2007-03-26; US2007-691424 Applic. Date: 2007-03-26; US2007-691432 Applic. Date: 2007-03-26; US2007-691426 Applic. Date: 2007-03-26; US2006-543396 Applic. Date: 2006-10-04; US2006-543490 Applic. Date: 2006-10-04; US2006-543404 Applic. Date: 2006-10-04; US2006-543683 Applic. Date: 2006-10-04; US2004-004561 Applic. Date: 2004-12-03; US2007-865572 Applic. Date: 2007-10-01; US20030527323P Applic. Date: 2003-12-05; US20040587787P Applic. Date: 2004-07-13; US20040614683P Applic. Date: 2004-09-30

Inventor: SIMPSON PETER C [US]; KAMATH APURV ULLAS [US]; LEACH JACOB S [US]; BRISTER MARK [US]; SWANSON VANCE [US]; HANSON CURTIS [US]; PRYOR JACK [US]; WIGHTLIN MATTHEW [US]; SAINT SEAN [US]; NOLTING JOHN [US]


Application No.: US20080199900A1  Published: 21/Aug/2008

Title: Disposable Device For One Or More Introductions, Treatment And Sampling Of Biological Material From At Least One Of The Separation Phases Present Within The Device, Under Sterility Conditions and Constant Pressure

Applicant/Assignee: UNIVERSITA' DEGLI STUDI DI ROMA "LA SPIENZA"

Application No.: 11/659076   Filing Date: 07/Jul/2005

Abstract:A disposable device ( 1 ) for introduction, treatment and sampling of biological material from at last one of the separation phases under sterility and constant pressure conditions includes a sealed sterile test tube ( 2 ), having a first opening ( 4 ), or sampling opening, a second opening ( 7 ) or inlet opening, and a third opening ( 8 ), the first opening ( 4 ) providing the passage of a needle ( 5 ), coupling between the needle ( 5 ) and the first opening ( 4 ) being a sealing coupling by an elastic element ( 6 ) allowing translation in a substantially vertical direction and inclination of the needle ( 5 ). The second opening is sealed by a membrane ( 7 ) made of a material allowing the piercing by a syringe needle and closing back after the removal of the needle, the third opening ( 8 ) providing a sealing valve ( 8 ) balancing the pressure inside the test tube and environmental pressure.

Priority: IT2004RM00397 Applic. Date: 2004-08-04; WO2005IT00390 Applic. Date: 2005-07-07

Inventor: SIGNORE ALBERTO [IT]; ANNOVAZZI ALESSIO [IT]


Application No.: US20080200533A1  Published: 21/Aug/2008

Title: Drug or Pharmaceutical Compounds and a Preparation Thereof

Applicant/Assignee:

Application No.: 11/994752   Filing Date: 29/Jun/2006

Abstract:The administration of pharmaceuticals of drugs which are having less solubility, lower bioavailability, lower bioabsorbability, less rate of absorption has become a big challenge in day to day life. Therefore an attempt has been made to prepare a complex modified form of the said pharmaceutical or drug such that the modified complex drugs or pharmaceuticals exhibits the enhanced properties of solubility, bioavailability, bioabsorbability and rate of absorption despite the increased complexity of the molecule. Surprisingly such modification was found to enhance retentivity of the active drug ingredient in the blood. Higher amounts of the active drug ingredient has shown lower toxicity.

Priority: IN2005CH00861 Applic. Date: 2005-07-04; WO2006IN00222 Applic. Date: 2006-06-29

Inventor: KRISHNAN RAMU [IN]


Application No.: US200802008038A1  Published: 21/Aug/2008

Title: WEARABLE, PROGRAMMABLE AUTOMATED BLOOD TESTING SYSTEM

Applicant/Assignee:

Application No.: 11/469586   Filing Date: 01/Sep/2006

Abstract:The present invention is a programmable, automated device for measurement and analysis of blood analytes and blood parameters. The device components are preferably combined in a single housing and either programmed to initiate automatic, periodic blood sampling or initiate automatic blood sampling via operator input or in response to a predefined event or in response to a signal from another instrument. The device operates automatically to draw blood samples and analyze the drawn blood samples to obtain the desired blood readings.

Priority: US2005-287897 Applic. Date: 2005-11-28

Inventor: GOLDBERGER DANIEL [US]; SHREVE ERIC [US]; SIEBRECHT WAYNE [US]; PESACH BENNY [IL]; PESACH GIDI [IL]; BITTON GABBY [IL]; NAGAR RON [IL]; ARGAMAN DALIA [IL]; BELLOMO STEPHEN [IL]; LARSON ROBERT [US]; JOHNSON LARRY [US]; KLOMHAUS JILL [US]


Application No.: US20080213743A1  Published: 04/Sep/2008

Title: Method for adjusting sedimentation rates

Applicant/Assignee:

Application No.: 12/071234   Filing Date: 19/Feb/2008

Abstract:One or more chemicals are added to a physiological fluid to alter the density and/or shape of cells in the fluid to provide a desired sedimentation rate of the cells. In a preferred embodiment, the chemical to be added is an anticoagulant, preferably ACD.

Priority: US20070901660P Applic. Date: 2007-02-16

Inventor: ELLSWORTH JAMES R [US]; KEVY SHERWIN [US]; JACOBSON MAY [US]


Application No.: US20080214978A1  Published: 04/Sep/2008

Title: METHOD OF TREATING A BODILY FLUID

Applicant/Assignee: INTEGRATED SENSING SYSTEMS, INC

Application No.: 12/106642   Filing Date: 21/Apr/2008

Abstract:A method of treating a bodily fluid withdrawn and then returned to a living body. The method involves withdrawing the bodily fluid from the living body and causing the bodily fluid to flow through a treatment system, altering at least the density of the bodily fluid through the action of a second fluid as the bodily fluid flows through the treatment system, sensing at least the density and flow rate of the bodily fluid before the density thereof is altered by the second fluid, sensing at least the density and flow rate of the bodily fluid after the density thereof is altered by the second fluid, sensing at least the density and flow rate of the second fluid, controlling the density and/or flow rate of the second fluid based on the sensed densities and flow rates, and returning the bodily fluid to the living body.

Priority: US2005-160403 Applic. Date: 2005-06-22; US20040582976P Applic. Date: 2004-06-28

Inventor: SPARKS DOUGLAS RAY [US]; NAJAFI NADER [US]


Application No.: US20080215136A1  Published: 04/Sep/2008

Title: DIFFERENTIAL DRUG RELEASE FROM A MEDICAL DEVICE

Applicant/Assignee:

Application No.: 11/953969   Filing Date: 11/Dec/2007

Abstract:The invention relates to a medical device, such as an intravascular stent, useful for delivering two or more therapeutic agents to a body tissue of a patient at different rates, and methods for making and using such medical device. The medical device includes a substrate and/or coating having a plurality of pores, dispersed in said pores are a plurality of a first and second therapeutic agents, wherein said first therapeutic agent is bonded to one or more molecule(s) of a first material and the second therapeutic agent bonded to one or more molecule(s) of a second material, such that when the medical device, is in use (e.g., implanted into a body lumen such as a blood vessel), bonded first therapeutic agent is released from the medical device at a rate that is slower than the rate at which the bonded second therapeutic agent is released from the medical device.

Priority: US20060877266P Applic. Date: 2006-12-26

Inventor: GREGORICH DANIEL J [US]; MEYER MIKE [US]


Application No.: US20080219998A1  Published: 11/Sep/2008

Title: Anti-Thrombotic Agents

Applicant/Assignee:

Application No.: 10/486159   Filing Date: 08/May/2002

Abstract:The present invention embodies: methods

compounds, their pharmaceutically acceptable analogs, isomer, salts, hydrates, solvates and prodrug derivatives, and pharmaceutically acceptable compositions thereof that have particular biological properties

devices

diagnostic and other assays

and the uses of such methods, compounds, devices and assays. Common throughout these embodiments is specific selective reduction of intravascular thromboplastin antecedent activity, which results in a safe antithrombotic effect. A particularly prominent application or the invention relates to diagnosis and treatment of patients which have, or are at risk of, developing thrombosis, thrombotic injury, or vaso-occlusive diseases, such as myocardial infarction, stroke, restenosis after angioplasty, thrombotic diseases, etc. Another particularly prominent feature of the present invention is its high level of hemostatic safety at optimal efficacy. Also, the present invention is compatible for use in combination with other traditional therapeutic agent such as another antithrombotic, antiplatelet, thrombolytic, or anticoagulant agents.

Priority: US20010340294P Applic. Date: 2001-12-07; WO2002US14510 Applic. Date: 2002-05-08

Inventor: GRUBER ANDRAS [US]


Application No.: US20080220075A1  Published: 11/Sep/2008

Title: Nanoparticulate compositions of angiogenesis inhibitors

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 12/076247   Filing Date: 14/Mar/2008

Abstract:Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US2003-392403 Applic. Date: 2003-03-20; US20020365540P Applic. Date: 2002-03-20; US20020366542P Applic. Date: 2002-03-25

Inventor: MERISKO-LIVERSIDGE ELAINE [US]; BOSCH H WILLIAM [US]; CARY GRETA G [US]; PRUITT JOHN [US]; RYDE TUULA [US]; JAIN RAJEEV [US]; WALTERS AMY [US]


Application No.: US20080226732A1  Published: 18/Sep/2008

Title: NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/928289   Filing Date: 30/Oct/2007

Abstract:Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Priority: US2003-392403 Applic. Date: 2003-03-20; US20020366542P Applic. Date: 2002-03-25; US20020365540P Applic. Date: 2002-03-20

Inventor: MERISKO-LIVERSIDGE ELAINE [US]; BOSCH H WILLIAM [US]; CARY GRETA G [US]; PRUITT JOHN [US]; RYDE TUULA [US]; JAIN RAJEEV [US]; WALTERS AMY [US]


Application No.: US20080227083A1  Published: 18/Sep/2008

Title: OPTICAL DETECTOR FOR ENZYME ACTIVATION

Applicant/Assignee:

Application No.: 12/127908   Filing Date: 28/May/2008

Abstract:Activation of an enzyme in a bodily fluid is detected based on the amount of cleavage of a substrate for the enzyme. The substrate is tagged with two fluorescent dyes-a donor and an acceptor. The tagged substrate is presented to the bodily fluid. A device emits energy at a first wavelength into the bodily fluid, and detects energy at second and third wavelengths emitted by the dyes in response to the energy at the first wavelength. Prior to enzymatic cleavage of the substrate, the acceptor emits energy at the third wavelength in response to energy at the second wavelength received through fluorescent resonant energy transfer (FRET) from the donor. After enzymatic cleavage of the substrate, the donor emits energy at the second wavelength. The device can determine the concentration of activated enzyme within the bodily fluid based on the relative intensities of energy, at the second and third wavelengths.

Priority: US2003-423112 Applic. Date: 2003-04-25

Inventor: SOYKAN ORHAN [US]; DONOVAN MAURA G [US]


Application No.: US20080233554A1  Published: 25/Sep/2008

Title: COMPOSITION FOR PRESERVING PLATELETS AND METHOD OF USING THE SAME

Applicant/Assignee: BIOVEC, LLC

Application No.: 12/109784   Filing Date: 25/Apr/2008

Abstract:The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Priority: US2006-330132 Applic. Date: 2006-01-12; US20050643107P Applic. Date: 2005-01-12

Inventor: SEHGAL LAKSHMAN R [US]; MOUSA SHAKER [US]


Application No.: US20080241001A1  Published: 02/Oct/2008

Title: Protease Inhibitor Sample Collection System

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 11/937954   Filing Date: 09/Nov/2007

Abstract:A collection container and a method for collecting a biological sample, particularly whole blood, includes at least one stabilizing agent in an amount effective to stabilize and inhibit protein degradation and/or fragmentation. The stabilizing agent is able to stabilize proteases in the biological sample, particularly at the point of collection, by inhibiting protein degradation and/or fragmentation in the sample when the sample is stored. The stabilizing agent comprises or consists of one or more protease inhibitors.

Priority: US2003-436263 Applic. Date: 2003-05-13; US20020379399P Applic. Date: 2002-05-13

Inventor: HAYWOOD BRUCE [US]; DASTANE AJIT [US]; LIN FU-CHUNG [US]


Application No.: US20080241289A1  Published: 02/Oct/2008

Title: PREPARATION AND UTILITY OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/035763   Filing Date: 22/Feb/2008

Abstract:Disclosed herein are non-nucleoside reverse transcriptase inhibitors having structural Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and the methods of their use thereof.

Priority: US20070891436P Applic. Date: 2007-02-23

Inventor: GANT THOMAS G [US]; SARSHAR SEPEHR [US]


Application No.: US20080241349A1  Published: 02/Oct/2008

Title: PROCESS FOR PREPARING A SUBSTRATE COATED WITH A BIOMOLECULE

Applicant/Assignee: ENSION, INC

Application No.: 12/061212   Filing Date: 02/Apr/2008

Abstract:Processes are provided for preparing a substrate coated with a biomolecule, comprising: a) providing a substrate

b) coating the substrate with a polysiloxane, typically by exposing the substrate to a reactive gas containing siloxane functional groups and to plasma energy to yield a plasma-deposited polysiloxane surface on the substrate

c) rendering the polysiloxane surface amino functional

and d) contacting the amino-functional polysiloxane surface with a biomolecule under conditions effective to attach the biomolecule to the substrate. The coated substrate may be a medical device that demonstrates an ability to maintain gas permeability when in contact with blood or blood components, compared to a substantially identical medical device that has not been coated with a biomolecule using this process.

Priority: US20070909553P Applic. Date: 2007-04-02

Inventor: CAHALAN PATRICK [US]; CAHALAN LINDA [US]; JOHNSON GREG [US]; GARTNER MARK [US]


Application No.: US20080248107A1  Published: 09/Oct/2008

Title: Controlled Release Formulation

Applicant/Assignee: RUBICON RESEARCH PVT. LTD

Application No.: 12/064687   Filing Date: 24/Aug/2006

Abstract:The present invention provides a controlled release formulation comprising an therapeutically effective amount of pharmacologically active substance having high water solubility, at least one non-polymeric release retardant, and at least one pH independent non-swelling release retarding polymer. The said dosage form provides controlled release of the active agent with reduced initial burst release.

Priority: IN2005MU01001 Applic. Date: 2005-08-24; WO2006IN00309 Applic. Date: 2006-08-24

Inventor: PILGAONKAR PRATIBHA S [IN]; RUSTOMJEE MAHARUKH T [IN]; GANDHI ANIKUMAR S [IN]; KELKAR ATUL A [IN]; BAGDE PRADNYA [IN]


Application No.: US20080254036A1  Published: 16/Oct/2008

Title: COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR

Applicant/Assignee: MILLENNIUM PHARMACEUTICALS, INC

Application No.: 12/101644   Filing Date: 11/Apr/2008

Abstract:The present invention is directed to methods of using combination therapies containing [2-({4-[(dimethylamino)iminomethyl]phenyl}carbonylamino)-5-methoxyphenyl]-N-(5-chloro(2-pyridyl))carboxamide for the treatment of thrombotic disease(s) and pharmaceutical compositions thereof.

Priority: US20070911852P Applic. Date: 2007-04-13

Inventor: SINHA UMA [US]; HOLLENBACH STANLEY J [US]; ANDRE PATRICK [US]


Application No.: US20080254146A1  Published: 16/Oct/2008

Title: METHOD OF PROVIDING HEMOSTASIS IN ANTI-COAGULATED BLOOD

Applicant/Assignee: Z-MEDICA CORPORATION

Application No.: 12/101336   Filing Date: 11/Apr/2008

Abstract:A method of clotting blood includes the step of administering a therapeutically effective amount of a composition comprising zeolite as the active ingredient to a wound from which the blood emanates. A method of arresting blood flowing from a wound includes the steps of providing a patient being inflicted with a bleeding wound and administering a therapeutically effective amount of a composition comprising zeolite as the active ingredient to the bleeding wound. A method of facilitating the formation of blood clots includes the step of contacting blood with a negatively charged surface wherein upon contacting the blood with the negatively charged surface a clotting mechanism is initiated. In any of the foregoing methods, the blood has a compromised ability to form clots. The blood may be from a person diagnosed with hemophilia or von Willebrand disease.

Priority: US20070923416P Applic. Date: 2007-04-13

Inventor: HUEY RAYMOND J [US]; BASADONNA GIACOMO [US]


Application No.: US20080254147A1  Published: 16/Oct/2008

Title: METHOD OF PROVIDING HEMOSTASIS IN ANTI-COAGULATED BLOOD

Applicant/Assignee: Z-MEDICA CORPORATION

Application No.: 12/101346   Filing Date: 11/Apr/2008

Abstract:In a method of clotting blood in which the blood exhibits a reduced tendency to clot and may be from a person undergoing an anticoagulant therapy or having type A or B hemophilia or von Willebrand disease, a therapeutically effective amount of a composition comprising clay as the active ingredient is administered to a wound from which the blood emanates. Upon contacting the blood, this clay, which may be kaolin, bentonite, or any type of layered clay, causes the blood to clot. In a method of arresting blood flowing from a wound, a therapeutically effective amount of a composition comprising clay as the active ingredient is administered to the bleeding wound. In this method, the blood has a reduced tendency to clot and may be from a person undergoing an anticoagulant therapy or having at least one of hemophilia A or B or von Willebrand disease.

Priority: US2008-101336 Applic. Date: 2008-04-11; US20070923416P Applic. Date: 2007-04-13

Inventor: HUEY RAYMOND J [US]; BASADONNA GIACOMO [US]


Application No.: US20080255352A1  Published: 16/Oct/2008

Title: Cyclic amide derivative, and its production and use

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 12/157574   Filing Date: 11/Jun/2008

Abstract:The present invention provides a cyclic amide derivative useful as a drug for treating thrombosis, which is represented by the formula (I): wherein R<1 >represents an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group, W represents a bond or an optionally substituted divalent chain hydrocarbon group, a represents 0, 1, or 2, X<1 >represents an optionally substituted lower alkylene or an optionally substituted lower alkenylene, Y<1 >represents -C(O)-, -S(O)- or -S(O)2-, A represents a piperazine ring which may be further substituted or a piperidine ring which may be further substituted, X<2 >represents a bond or an optionally substituted lower alkylene, Y<2 >represents -C(O)-, -S(O)-, -S(O)2- or -C(-NR<7>)-, X<3 >represents an optionally substituted C1-4 alkylene or an optionally substituted C2-4 alkenylene, Z<3 >represents -N(R<4>)-, -O- or a bond, Z<1 >represents -C(R<2>)(R<2'>)-, -N(R<2>)-, etc., and Z<2 >represents -C(R<3>)(R<3'>)-, -N(R<3>)-, etc., or a salt thereof.

Priority: JP20040152000 Applic. Date: 2004-05-21; US2006-596089 Applic. Date: 2006-11-09; WO2005JP09711 Applic. Date: 2005-05-20

Inventor: KUBO KEIJI [JP]; IMAEDA YASUHIRO [JP]


Application No.: US20080260710A1  Published: 23/Oct/2008

Title: Method for Suppressing Surgical Site Infection and Column to be Used for the Method

Applicant/Assignee: ASAHI KASEI MEDICAL CO., LTD

Application No.: 11/572405   Filing Date: 23/Jun/2005

Abstract:An object of the present invention is to provide a method for suppressing surgical site infections (SSI) that have occurred at extremely high incidence rates at the time of surgical operations and particularly surgical operations on digestive system organs, and to provide a column to be used for the method. According to the present invention, a method is provided for suppressing surgical site infections, which comprises the steps of: (a) administering a chemotherapeutic drug for treating and/or preventing a surgical site infection

and (b) collecting blood from a surgical subject and removing leukocytes that comprise neutrophils from the blood during or within 24 hours after surgical operation, and then returning the blood from which the leukocytes have been removed to the surgical subject. The present invention also provides a column for blood circulation which is filled with a carrier having affinity for leukocytes comprising neutrophils, which is used for suppressing a surgical site infection during or within 24 hours after surgical operation on a digestive system organ.

Priority: JP20040213998 Applic. Date: 2004-07-22; JP20050009201 Applic. Date: 2005-01-17; WO2005JP11501 Applic. Date: 2005-06-23

Inventor: KUSUNOKI MASATO [JP]; MIKI CHIKAO [JP]; YOSHIYAMA SHIGEYUKI [JP]


Application No.: US20080261861A1  Published: 23/Oct/2008

Title: 2-Micron Family Plasmid and Use Thereof

Applicant/Assignee: DELTA BIOTECHNOLOGY LIMITED

Application No.: 10/584486   Filing Date: 23/Dec/2004

Abstract:The present invention provides a 2 mum-family plasmid comprising a polynucleotide sequence insertion, deletion and/or substitution between the first base after the last functional codon of at least one of either a REP2 gene or an FLP gene and the last base before the FRT site in an inverted repeat adjacent to said gene.

Priority: GB20030029722 Applic. Date: 2003-12-23; WO2004GB05435 Applic. Date: 2004-12-23

Inventor: SLEEP DARRELL [GB]; FINNIS CHRISTOPHER JOHN ARTHUR [GB]


Application No.: US20080268021A1  Published: 30/Oct/2008

Title: Adhesive bioerodible ocular drug delivery system

Applicant/Assignee: QLT USA, INC

Application No.: 12/215101   Filing Date: 24/Jun/2008

Abstract:The present invention provides bioerodible, water-soluble pharmaceutical carriers for ocular (e.g., transconjunctival or transcorneal) delivery of pharmaceuticals for either systemic or local therapy.

Priority: US2003-706603 Applic. Date: 2003-11-12; US20020425508P Applic. Date: 2002-11-12

Inventor: WARREN STEPHEN L [US]; OSBORNE DAVID W [US]; HOLL RICHARD [US]


Application No.: US20080268483A1  Published: 30/Oct/2008

Title: Methods for a Global Assay of Coagulation and Fibrinolysis

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO

Application No.: 11/575853   Filing Date: 22/Sep/2005

Abstract:The present disclosure concerns methods of analyzing both clot formation and fibrinolysis in a sample, preferably simultaneously. In certain embodiments, the methods may comprise adding a small amount of at least one activator of coagulation and at least one activator of fibrinolysis to a sample and analyzing the sample for kinetic parameters related to clot formation and fibrinolysis. In another embodiment, the methods may comprise analyzing a sample from a subject for clot formation and fibrinolysis and detecting or diagnosing a disease or condition and/or applying information obtained from analyzing clot formation and fibrinolysis to determine a treatment for a medical condition of the subject.

Priority: US20040612580P Applic. Date: 2004-09-22; WO2005US33999 Applic. Date: 2005-09-22

Inventor: GOLDENBERG NEIL A [US]; MANCO-JOHNSON MARILYN J [US]; JACOBSON LINDA [US]; HATHAWAY WILLIAM E [US]


Application No.: US20080269176A1  Published: 30/Oct/2008

Title: New Salts

Applicant/Assignee: ASTRAZENECA AB

Application No.: 11/839842   Filing Date: 16/Aug/2007

Abstract:There is provided pharmaceutically-acceptable acid addition salts of compounds of formula (I), wherein R<1 >represents C1-2 alkyl substituted by one or more fluoro substituents

R<2 >represents C1-2 alkyl

and n represents 0, 1 or 2, which salts are useful as prodrugs of competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required.

Priority: SE20020001661 Applic. Date: 2002-05-31; US2005-516422 Applic. Date: 2005-05-20; WO2003SE00859 Applic. Date: 2003-05-27

Inventor: AHLQVIST MATTI [SE]; BOHLIN MARTIN [SE]; INGHARDT TORD [SE]; LUNDBLAD ANITA [SE]; SIGFRIDSSON CARL-GUSTAF [SE]


Application No.: US20080269762A1  Published: 30/Oct/2008

Title: METHOD AND DEVICE FOR REPAIR OF CARTILAGE DEFECTS

Applicant/Assignee: BIOMET MANUFACTURING CORP

Application No.: 11/740014   Filing Date: 25/Apr/2007

Abstract:Methods for repairing a cartilage defect in a subject, such methods comprising placing a tissue specimen into a container, centrifuging the container to separate the specimen into at least three fractions, drawing a selected fraction from the container, processing the fraction into a therapeutic composition, and treating the cartilage defect with the therapeutic composition.

Priority:

Inventor: SIMON BRUCE [US]; WOODELL-MAY JENNIFER E [US]


Application No.: US20080274477A1  Published: 06/Nov/2008

Title: Forms of Factor Xiia

Applicant/Assignee:

Application No.: 11/795074   Filing Date: 10/Jan/2006

Abstract:A 53 Kd novel form of factor XIIa and related products, including nucleic acid molecules, monoclonal and polyclonal antibodies and hybridoma cell lines. Also assays for a 53 Kd form of factor XIIa and uses of said assays in diagnostic and prognostic methods, for example in the prediction of survival following myocardial infarction.

Priority: GB20050000487 Applic. Date: 2005-01-11; WO2006GB00072 Applic. Date: 2006-01-10

Inventor: PRITCHARD DAVID JOHN [GB]


Application No.: US20080286290A1  Published: 20/Nov/2008

Title: Anti-Cd14 Antibody Fusion Protein

Applicant/Assignee:

Application No.: 11/791888   Filing Date: 05/Jun/2006

Abstract:A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.

Priority: JP20050164901 Applic. Date: 2005-06-03; WO2006JP11255 Applic. Date: 2006-06-05

Inventor: FURUSAKO SHOJI [JP]; NAKAYAMA KAZAYUKI [JP]; HOSAKA YOSHITAKA [JP]; KAWAHARA TETSUSHI [JP]; NAKAMURA MASAKI [JP]; TAKEUCHI TAKASHI [JP]


Application No.: US20080286327A1  Published: 20/Nov/2008

Title: THOMBOLYSIS AND CHRONIC ANTICOAGULATION THERAPY

Applicant/Assignee:

Application No.: 11/949752   Filing Date: 03/Dec/2007

Abstract:Method and systems of treating a patient with at least one of a myocardial infarction, a stroke, and a pulmonary embolism include providing a stimulator coupled to at least one electrode and a catheter, configuring one or more stimulation parameters to treat at least one of a myocardial infarction, a stroke, and a pulmonary embolism, programming the stimulator with the one or more stimulation parameters, delivering with the stimulator via the catheter at least one drug to at least one tissue in accordance with the one or more stimulation parameters, and limiting perfusion of the at least one tissue by delivering electrical stimulation with the stimulator via the at least one electrode to the at least one tissue.

Priority: US2002-285803 Applic. Date: 2002-11-01; US20010340076P Applic. Date: 2001-11-01

Inventor: WHITEHURST TODD K [US]; MCCLURE KELLY H [US]; THACKER JAMES R [US]


Application No.: US20080286329A1  Published: 20/Nov/2008

Title: Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom

Applicant/Assignee: CARNEGIE MELLON UNIVERSITY ALLEGHENY-SINGER RESEARCH INSTITUTE CARMELL, LLC

Application No.: 12/104728   Filing Date: 17/Apr/2008

Abstract:Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts

methods of making and using the same

methods for assessing the concentration of a biological response modifier in an article

and systems for preparing blood-derived plastic articles are provided.

Priority: US2007-873751 Applic. Date: 2007-10-17; US2006-495115 Applic. Date: 2006-07-28; US2003-391458 Applic. Date: 2003-03-18; US20060852368P Applic. Date: 2006-10-17; US20070961580P Applic. Date: 2007-07-23; US20050703206P Applic. Date: 2005-07-28; US20020365451P Applic. Date: 2002-03-18

Inventor: CAMPBELL PHIL G [US]; BURGESS JAMES E [US]; WEISS LEE E [US]; SMITH JASON [US]


Application No.: US20080287829A1  Published: 20/Nov/2008

Title: COLLECTION MEANS AND A METHOD FOR COLLECTING CORD BLOOD

Applicant/Assignee:

Application No.: 12/062500   Filing Date: 03/Apr/2008

Abstract:The invention provided herein comprises a kit, where the kit includes at least one collecting receptacle for collecting cord blood, and a pre-measured non-liquid anticoagulant which is optionally pre-loaded into the receptacle. The anticoagulant is preferably selected from the group consisting of heparin or heparin type additives, citrates, EDTA (ethylenediaminetetraacetic acid), and oxalates and any other anticoagulant that can be used to decrease the clotting ability of the blood. The invention provided herein also comprises a method for collecting cord blood, where the method comprises collecting a desired amount of cord blood from the umbilical cord using a collection receptacle of the invention, wherein the collection receptacle is pre-loaded with a pre-measured amount of non-liquid anticoagulant.

Priority: US2005-186415 Applic. Date: 2005-07-20; US20040590386P Applic. Date: 2004-07-20

Inventor: MOORE THOMAS E [US]; MAPOTHER BETH [US]


Application No.: US20080292707A1  Published: 27/Nov/2008

Title: Pharmaceutical Compositions of Adsorbates of Amorphous Drug

Applicant/Assignee: PFIZER INC

Application No.: 12/180769   Filing Date: 28/Jul/2008

Abstract:Pharmaceutical compositions comprise a low-solubility drug adsorbed onto a high surface area substrate to form an adsorbate. The compositions in some embodiments include a concentration-enhancing polymer.

Priority: US2002-173987 Applic. Date: 2002-06-17; US20010300260P Applic. Date: 2001-06-22

Inventor: BABCOCK WALTER C [US]; FRIESEN DWAYNE T [US]; SHANKER RAVI M [US]; SMITHEY DANIEL T [US]; TADDAY RALPH [US]


Application No.: US20080293628A1  Published: 27/Nov/2008

Title: Methods and Compositions for the Inhibition of Thrombus Formation

Applicant/Assignee:

Application No.: 11/579291   Filing Date: 27/Apr/2005

Abstract:The present invention is directed to anti-platelet peptides that may be used in various methods for the treatment or prophylaxis of thrombosis. More specifically, the specification describes methods and compositions for making and using compositions GPIbalpha fragments as anti-platelet agents. The present invention is also directed to peptides that inhibit intracellular function of 14-3-3.

Priority: US20040568042P Applic. Date: 2004-05-04; WO2005US14528 Applic. Date: 2005-04-27

Inventor: DAI KESHENG [US]; DU XIAOPING [US]


Application No.: US20080299186A1  Published: 04/Dec/2008

Title: COATINGS FOR APPLYING SUBSTANCES ONTO SUBSTRATE CARRIER

Applicant/Assignee: SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC

Application No.: 12/130225   Filing Date: 30/May/2008

Abstract:Compositions of matter containing an active agent, and methods of manufacturing thereof, wherein the method comprises the step of coating a substrate with a coating composition comprising the active agent formulated for immediate release, wherein the coating composition does not contain an appreciable amount of cellulosic materials and preferably comprises polyvinyl alcohol or a polyvinyl alcohol derived copolymer.

Priority: US20070941577P Applic. Date: 2007-06-01

Inventor: FRITZ GLENN E [US]; REO JOSEPH P [US]; KABIR MOHAMMED A [US]


Application No.: US20080299587A1  Published: 04/Dec/2008

Title: METHODS OF MEASURING INHIBITION OF PLATELET AGGREGATION BY THROMBIN RECEPTOR ANTAGONISTS

Applicant/Assignee:

Application No.: 12/114498   Filing Date: 02/May/2008

Abstract:A method is provided for measuring inhibition of platelet aggregation by a thrombin receptor antagonist. First, a blood sample is obtained from a patient treated with a thrombin receptor antagonist. The blood sample is mixed in combination with particles including an immobilized GPIIb/IIIa receptor ligand and a thrombin receptor activator. The combination is then incubated under conditions suitable for agglutinating the particles, and platelet-mediated agglutination is assessed in the mixture. The absence of agglutination indicates that the patient has reduced ability to form platelet thrombi in response to the thrombin receptor antagonist treatment. Also provided is a kit for measuring inhibition of platelet aggregation by a thrombin receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, a thrombin receptor activator, an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.

Priority: US20070915820P Applic. Date: 2007-05-03

Inventor: DURBIN DENNIS [US]


Application No.: US20080300489A1  Published: 04/Dec/2008

Title: Cable and connector system for an ultrasound probe

Applicant/Assignee:

Application No.: 11/895613   Filing Date: 24/Aug/2007

Abstract:A finger-mounted ultrasound probe assembly having an ultrasound probe, adapted to be mounted on a finger and a multi-conductor cable, attached to the ultrasound probe. In addition, a forearm unit is connected to the multi-conductor cable and includes a physical connector to bind the forearm unit to a user's forearm. Also, the ultrasound probe and the forearm unit are adapted to cooperatively engage so that the ultrasound probe may be engaged to and retained by the forearm unit, to stow the ultrasound probe when not in immediate use.

Priority: US20070923323P Applic. Date: 2007-04-13

Inventor: SCHUTZ RONALD W [US]; CORBETT III SCOTT S [US]; BATES KENNETH N [US]; MCDONOUGH WILLIAM [US]; KRAUSE ALBERT H [US]


Application No.: US20080305160A1  Published: 11/Dec/2008

Title: Oral Medicament For The Modified Release Of At Least One Active Principle, In Multimicrocapsule Form

Applicant/Assignee: FLAMEL TECHNOLOGIES

Application No.: 11/791466   Filing Date: 02/Nov/2005

Abstract:The field of the invention is that of oral medicaments or pharmaceutical compositions, in particular of the type including one or more active principles. The aim of the invention is to provide an improved oral medicament to be administered in one or several daily doses and enabling the modified release of active principles (in particular of one active principle), whereby the prophylactic and therapeutic effectiveness of said medicament is improved. This aim is achieved by the oral multimicrocapsule galenic form according to the invention, in which the active principle release is controlled by a dual release trigger mechanism: "time-dependent trigger" and "pH-dependent trigger". Said medicament includes microcapsules providing the modified release of the active principle, each comprising a core containing

Priority: FR20040052748 Applic. Date: 2004-11-24; WO2005FR50922 Applic. Date: 2005-11-02

Inventor: GUIMBERTEAU FLORENCE [FR]; CASTAN CATHERINE [FR]; MEYRUEIX REMI [FR]; SOULA GERARD [FR]


Application No.: US20080312576A1  Published: 18/Dec/2008

Title: PLUNGER-LESS SYRINGE FOR CONTROLLING BLOOD FLOW

Applicant/Assignee:

Application No.: 12/140181   Filing Date: 16/Jun/2008

Abstract:A plunger-less syringe, method of manufacture and system of use is disclosed wherein the syringe includes a barrel that has an interior receptacle for receiving a quantity of blood. The syringe has at least one filter that controls fluid flow within the syringe. The syringe may be fabricated from a material that prevents diffusion of the gas from the blood. Different syringes may comprise different fluid flow characteristics. In addition, the components of the syringe may include indicia so a syringe having particular characteristics can be selected for patients with different blood pressure.

Priority: US20070944315P Applic. Date: 2007-06-15

Inventor: MCKINNON ROBERT J [US]; BICKLEY JAMES DALE [US]


Application No.: US20080318259A1  Published: 25/Dec/2008

Title: Hematocrit and Analyte Concentration Determination

Applicant/Assignee: ZAFENA AKTIEBOLAG

Application No.: 10/581094   Filing Date: 02/Dec/2004

Abstract:A method to determine an analyte concentration of an anticoagulated plasma by performing at least two different measurements on a mixture of a blood sample corresponding to said anticoagulant plasma and of liquid reagent is described. The method comprises a) mixing a volume of said blood sample with a five-fold, or more, volume of said liquid reagent, b) performing said at least two measurements on said mixture, at least one of which correlates with the hematocrit of said blood sample and at least one of which correlates with said analyte concentration, and c) computing the results from the measurements when the volumes in a) are precise and accurate or when the hematocrit of said blood sample in b) is known to determine said analyte concentration of said anticoagulated plasma. In addition, a measurement and determination device for performing measurements on blood, anticoagulated blood and/or anticoagulated plasma samples, and an equipment kit are described.

Priority: SE20030003249 Applic. Date: 2003-12-02; WO2004SE01798 Applic. Date: 2004-12-02

Inventor: RANBY MATS [SE]


Application No.: US20090000630A1  Published: 01/Jan/2009

Title: Instant Face-Lifter

Applicant/Assignee:

Application No.: 11/986714   Filing Date: 26/Nov/2007

Abstract:Following are six improvements on the prior art entitled "Instant Face-Lifter". "Intra-scalp TV/Radio/Stereo-Music-Reproducing Device Face-Lifter": uses an intra-scalp silicone Face-Lifter as stand for an implanted TV set and/or AM-FM Radio and/or an Open Platform Stereo Music device (MP3, MP4 Ipod(R), Walkman(R), WMA(R)). "Intra-scalp GPS-Face-Lifter": a Face-Lifter as a stand for a GPS device. "Intra-scalp Heart Pace-Maker-Face-Lifter": a Face-Lifter as a stand for a heart pace-maker device. "Intra-scalp Artificial Hair Anchoring Base Face-Lifter": a Face-Lifter as an anchoring base for permanently implanting small bundles of artificial hair on balding people. "Intra-scalp Bullet-Proof Head-Armor Face-Lifter": a Face-Lifter as bullet-proof head armor. "Intra-scalp Orgasm-inducer Face-Lifter": a Face-Lifter as a stand for an orgasm-inducing electric device.

Priority: US20070905057P Applic. Date: 2007-03-05; US20070904996P Applic. Date: 2007-03-05; US20070995258P Applic. Date: 2007-09-25

Inventor: ARAY RICARDO ALFREDO FUENMAYOR [VE]


Application No.: US20090004281A1  Published: 01/Jan/2009

Title: MULTIPARTICULATE OSMOTIC DELIVERY SYSTEM

Applicant/Assignee: BIOVAIL LABORATORIES INTERNATIONAL S.R.L

Application No.: 11/768764   Filing Date: 26/Jun/2007

Abstract:The present invention relates to a multiparticulate osmotic delivery system. The system is a modified release composition suitable for oral administration. The composition includes a core that includes at least one drug in combination with at least one pharmaceutically acceptable excipient. The composition further includes an osmotic subcoat surrounding the core, and a modified release overcoat surrounding the osmotic subcoated core.

Priority:

Inventor: NGHIEM TIEN [IE]; JACKSON GRAHAM [IE]


Application No.: US20090010886A1  Published: 08/Jan/2009

Title: Method for the Treatment of Myeloproliferative Diseases Using(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methylsulfonylethyl]-4- Acetylaminoisoindoline-1,3- Dione

Applicant/Assignee: CELGENE CORPORATION

Application No.: 11/579355   Filing Date: 22/Sep/2008

Abstract:Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agent is capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of MPD. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Priority: WO2004US14001 Applic. Date: 2004-05-05

Inventor: ZELDIS JEROME B [US]


Application No.: US20090011024A1  Published: 08/Jan/2009

Title: Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers

Applicant/Assignee: PFIZER INC

Application No.: 12/217700   Filing Date: 08/Jul/2008

Abstract:A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.

Priority: US2002-175640 Applic. Date: 2002-06-19; US20010300261P Applic. Date: 2001-06-22

Inventor: BABCOCK WALTER C [US]; CURATOLO WILLIAM J [US]; FRIESEN DWAYNE T [US]; KETNER RODNEY J [US]; LO JULIAN B [US]; NIGHTINGALE JAMES A S [US]; SHANKER RAVI M [US]; WEST JAMES B [US]


Application No.: US20090011451A1  Published: 08/Jan/2009

Title: MICROFLUIDIC DEVICE AND LEUCOCYTE ANTIGEN MEDIATED MICROFLUIDIC ASSAY

Applicant/Assignee:

Application No.: 11/568832   Filing Date: 13/May/2005

Abstract:The present invention relates to an leucocyte antigen mediated microfluidic assay and a microfluidic device for analyzing a subjects' body fluids containing leucocytes to determine if the subject has been previously exposed to a predetermined antigen.

Priority: US20040570543P Applic. Date: 2004-05-13; WO2005US16974 Applic. Date: 2005-05-13

Inventor: RODRIGUEZ RODOLFO R [US]; DARR DOUGLAS J [US]


Application No.: US20090012426A1  Published: 08/Jan/2009

Title: Intravascular Line and Port Cleaning Methods, Methods of Administering an Agent Intravascularly, Methods of Obtaining/Testing Blood, and Devices for Performing Such Methods

Applicant/Assignee: HYPROTEK, INC

Application No.: 12/211723   Filing Date: 16/Sep/2008

Abstract:An intravascular port access device includes a first component having a chamber configured to attach reversibly to an intravenous line port. A second component reversibly attaches to the first component and contains a disinfecting agent and an applicator material. The second component is configured to be reversibly received over external surfaces of the intravenous line port. A method of cleansing an intravenous line port includes providing a port cleaning device having a first component with a chamber containing a first cleaning agent. A second component includes a second cleaning agent. A third component has a microbiocidal agent and is reversibly attached to the first component. The second component is removed from the device, the external surfaces of the port are contacted with the second cleaning agent, the first cleaning agent is ejected from the chamber into the port, and the third component is used to cap the port.

Priority: US2007-745843 Applic. Date: 2007-05-08; US20060747606P Applic. Date: 2006-05-18; US20060842194P Applic. Date: 2006-08-31; US20070895621P Applic. Date: 2007-03-19

Inventor: TENNICAN PATRICK O [US]


Application No.: US20090012606A1  Published: 08/Jan/2009

Title: BIOBENEFICIAL POLYAMIDE/POLYETHYLENE GLYCOL POLYMERS FOR USE WITH DRUG ELUTING STENTS

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 12/207419   Filing Date: 09/Sep/2008

Abstract:This disclosure provides a method device and a method of forming the medical device. The medical device comprises a coating comprising a polymer. The polymer comprises at least two different blocks, at least one L1 block with the formula and at least one L2 block with the formula Medical devices comprising these polymers, mixtures of these polymers with therapeutic agents, and methods of making these polymers and mixtures are within the scope of this disclosure.

Priority: US2003-741214 Applic. Date: 2003-12-19

Inventor: PACETTI STEPHEN D [US]


Application No.: US20090022706A1  Published: 22/Jan/2009

Title: SUBSTITUTED CYCLOHEXENES

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/176163   Filing Date: 18/Jul/2008

Abstract:Disclosed herein are substituted cyclohexene TLR4 signaling pathway modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20070951067P Applic. Date: 2007-07-20

Inventor: GANT THOMAS G [US]; SARSHAR SEPEHR [US]; ZHANG CHENGZHI [US]


Application No.: US20090028873A1  Published: 29/Jan/2009

Title: SUBSTITUTED CYCLOHEXANOLS

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/180421   Filing Date: 25/Jul/2008

Abstract:Disclosed herein are substituted cyclohexanol opioid receptor modulators and/or neurotransmitter reuptake modulators of Formula I or Formula II, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20070952292P Applic. Date: 2007-07-27

Inventor: GANT THOMAS G [US]; SARSHAR SEPEHR [US]


Application No.: US20090028948A1  Published: 29/Jan/2009

Title: NANOPARTICLE COMPOSITION AND METHODS OF SYNTHESIS THEREOF

Applicant/Assignee: ICEUTICA PTY LTD

Application No.: 11/813116   Filing Date: 30/Dec/2005

Abstract:The present invention relates to improved therapeutically active nanocomposite microstructure compositions, including nanoparticle compositions and nanoparticle preparations. Preferred embodiments include nanoparticle compositions comprising nanoparticles of a therapeutically active agent dispersed in a carrier matrix. The invention also relates to a method for preparing said compositions and preparations using solid-state mechanochemical synthesis. Further, it relates to therapeutic products produced using said compositions and to methods of treatment using the compositions.

Priority: AU20040907377 Applic. Date: 2004-12-31; WO2005AU01977 Applic. Date: 2005-12-30

Inventor: PAYNE TREVOR [AU]; MEISER FELIX [AU]; POSTMA ALMAR [AU]; CAMMARANO RAFFAELE [AU]; WILLIAMS JAMES [AU]; MCCORMICK PAUL [AU]; DODD AARON [AU]; CARUSO FRANK [AU]


Application No.: US20090029342A1  Published: 29/Jan/2009

Title: Medium and method for preserving platelets, red blood cells, and other non-nucleus cells and platelets-containing composition

Applicant/Assignee:

Application No.: 12/232482   Filing Date: 18/Sep/2008

Abstract:The present invention provides a platelet-containing composition prepared by contacting platelets with a medium for preserving. The medium comprises anticoagulant, cryoprecipitate and thrombin. The present invention also provides a method for long-term preservation of platelets, comprising the steps of: (a) adding an anticoagulant, cryoprecipitate, thrombin in normal saline

(b) adding a platelet-containing medium into the solution formed in step (a)

and (c) lyophilizing the platelet-containing solution formed in step (b). Moreover, the present invention yet provides a medium for preserving non-nucleus cells.

Priority: TW20040119184 Applic. Date: 2004-06-29; US2005-157838 Applic. Date: 2005-06-22

Inventor: SU CHENG YAO [TW]; LIN CHENG CHIH [TW]


Application No.: US20090029829A1  Published: 29/Jan/2009

Title: NOSE TO BACK NECK AND EYE MUSCLES EXERCISE

Applicant/Assignee:

Application No.: 11/828458   Filing Date: 26/Jul/2007

Abstract:A nose to back neck and eye muscles exercise for improved facial enhancement, resulting in a more youthful appearance because of reduced or eliminated wrinkling of the face, is one representation of this invention. This exercise affects all of the facial muscle area beginning at the nose and going upward, ending at the back of the neck area. Notable improvement results in a tightened, smaller slenderized nose and reduced or eliminated wrinkling around facial eye area and forehead. Not only is a more youthful appearance achieved, but eyesight (vision) is greatly improved from strengthened supportive facial muscles surrounding eyes and independently strengthened muscles of the eyes as a result of this exercise. It is not possible to receive one natural benefit of the muscles exercise of this present invention of reduced wrinkling and a more youthful appearance without receiving its naturally intertwined second benefit of improved eyesight, and vice versa.

Priority:

Inventor: FERRARA YOLANDA CARMEN [US]


Application No.: US20090030071A1  Published: 29/Jan/2009

Title: Treatment of Cardiovascular Disease in Mexican Americans Using Nebivolol

Applicant/Assignee:

Application No.: 12/173125   Filing Date: 15/Jul/2008

Abstract:Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such as, but not limited to, hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention relates to methods for treating and/or preventing cardiovascular disorders in persons of Hispanic descent, particularly Mexican Americans, using compositions comprising nebivolol.

Priority: US20070952015P Applic. Date: 2007-07-26

Inventor: SHAW ANDREW A [US]; MASON R PRESTON [US]; RIGGS BETTY [US]


Application No.: US20090036764A1  Published: 05/Feb/2009

Title: FLUID INJECTION AND SAFETY SYSTEM

Applicant/Assignee: OPTISCAN BIOMEDICAL CORPORATION

Application No.: 12/123422   Filing Date: 19/May/2008

Abstract:Various medical systems and methods are described, including a medical monitoring system. The medical monitoring system can have a fluid system configured to receive bodily fluid and optically analyze said fluid to determine analyte concentration. The fluid system can have a removable portion. The removable portion can have an opening with a port. The system can also have a container configured to contain anticoagulant. The container can have a portion configured to mate with the port of the removable portion. The container can be further configured to not fit into a conventional luer fitting. An anti-coagulant insertion apparatus is also described. The apparatus can have a syringe, a dock with a port, and an adapter configured to connect the syringe to the port. The dock can also have a tab configured to move with the port.

Priority: US20070939023P Applic. Date: 2007-05-18; US20070979374P Applic. Date: 2007-10-11

Inventor: RIVAS GIL [US]; BUTLER MICHAEL [US]; CHIOU JEFFREY T [US]; LIM EUGENE [US]


Application No.: US20090036841A1  Published: 05/Feb/2009

Title: COATINGS FOR BLOOD AND BONE MARROW-CONTACTING DEVICES

Applicant/Assignee:

Application No.: 12/184869   Filing Date: 01/Aug/2008

Abstract:Medical devices having an anticoagulant coating are described. The devices may be needles, syringes and blood processing devices. The anticoagulant coating can be any of heparin, heparin salts, citric acid salts, ethylenediaminetetraacetic acid salts, hirudin, sodium pentosan polysulfate, cumarin, derivatives of cumarin, warfarin, or phenprocoumon acenocoumarolor.

Priority: US20070953356P Applic. Date: 2007-08-01

Inventor: MCKALE JAMES M [US]; GIBBS BARBARA S [US]


Application No.: US20090042217A1  Published: 12/Feb/2009

Title: Methods and Kits for Determining Blood Coagulation

Applicant/Assignee: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES

Application No.: 12/223290   Filing Date: 23/Jun/2008

Abstract:A method of determining a coagulation status of a blood sample is provided. The method comprising determining an expression and/or activity ratio of Tissue Factor (TF) to Tissue Factor Pathway Inhibitor (TFPI) in cellular microparticles of the blood sample, wherein the ratio is indicative of the coagulation status of the blood sample.

Priority: US20060762519P Applic. Date: 2006-01-27; WO2007IL00110 Applic. Date: 2007-01-28

Inventor: BRENNER BENJAMIN [IL]; AHARON ANAT [IL]


Application No.: US20090042916A1  Published: 12/Feb/2009

Title: [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 12/114742   Filing Date: 02/May/2008

Abstract:The present invention provides novel sulfonylurea salts of a salt of formula (I) and polymorph forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a salt of formula (I) or a pharmaceutically acceptable form thereof.

Priority: US20070927328P Applic. Date: 2007-05-02

Inventor: SHARP EMMA [GB]; QUEGAN LOUISA JANE [GB]; PANDEY ANJALI [US]; WANG JUAN [US]; NIEDER MATTHEW [US]; HUANG WOLIN [US]


Application No.: US20090043380A1  Published: 12/Feb/2009

Title: Coatings for promoting endothelization of medical devices

Applicant/Assignee: SPECIALIZED VASCULAR TECHNOLOGIES, INC

Application No.: 12/128533   Filing Date: 28/May/2008

Abstract:A unique method and coatings are provided for promoting tissue encapsulation of medical devices, especially before antiproliferative drug therapy within a body of a patient in order to prevent excessive restenosis and while avoiding thrombosis (including late stage/stent thrombosis). The method involves delaying the activation of restenosis suppressing (i.e. antiproliferative) drugs in the vicinity of the medical device until a thin layer of geometrically streamlined tissue has deposited itself upon the device. Coatings of one or more layer that provide an aligned scaffolding (i.e. via aligned fibers or aligned grooves) may be used in the method to encourage tissue deposition and/or to delay elution of drug(s) stored beneath or within. The delay phase prior to degradation, erosion, and/or absorption of the coating to release an active drug should last until an optimal amount of controlled restenosis has provided a thin endothelial layer to encapsulate the device.

Priority: US20070964142P Applic. Date: 2007-08-09; US20070993328P Applic. Date: 2007-09-11; US20070002343P Applic. Date: 2007-11-08

Inventor: BLAHA CHARLES MATTHEW [US]; TO JOHN [US]; PHAN LOC X [US]


Application No.: US20090047209A1  Published: 19/Feb/2009

Title: Novel nifedipine compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 11/980720   Filing Date: 31/Oct/2007

Abstract:The present invention is directed to nanoparticulate compositions comprising nifedipine. The nifedipine particles of the composition have an effective average particle size of less than about 2 microns.

Priority: US2003-712259 Applic. Date: 2003-11-14; US2003-276400 Applic. Date: 2003-01-15; WO2001US15983 Applic. Date: 2001-05-18; US1999-337675 Applic. Date: 1999-06-22; US2003-345312 Applic. Date: 2003-01-16; US2000-715117 Applic. Date: 2000-11-20; US2002-075443 Applic. Date: 2002-02-15; US2000-666539 Applic. Date: 2000-09-21

Inventor: MERISKO-LIVERSIDGE ELAINE [US]


Application No.: US20090047366A1  Published: 19/Feb/2009

Title: Inorganic Coagulation Accelerators for Individuals taking Platelet Blockers or Anticoagulants

Applicant/Assignee:

Application No.: 11/839041   Filing Date: 15/Aug/2007

Abstract:The present invention is a method to accelerate the coagulation of blood through the application of inorganic materials to the wound of a patient on anticoagulant or platelet blocker therapy. The method comprises contacting such wounds with a substance selected from the group consisting of zeolitic molecular sieves and non-zeolitic molecular sieves, diatomaceous earth, glass powder or fibers, precipitated or fumed silica, kaolin and montmorillonite clays and Ca exchanged permutites.

Priority:

Inventor: BEDARD ROBERT L [US]; ZENZ CARL N [US]


Application No.: US20090053245A1  Published: 26/Feb/2009

Title: Pharmacokinetics and Efficacy of Anti-Angiogenic Drugs and Drugs Treating Diseases of the Blood

Applicant/Assignee:

Application No.: 12/129487   Filing Date: 29/May/2008

Abstract:A method for modulating at least one pharmacokinetic property of an anti-angiogenic or blood disease or steroid therapeutic and efficacy upon administration to a host is provided. One administers to the host an effective amount of a bifunctional compound of less than about 5000 Daltons comprising the anti-angiogenic or blood disease or steroid therapeutic or an active derivative thereof and a pharmacokinetic modulating moiety. The pharmacokinetic modulating moiety binds to at least one intracellular protein. The bifunctional compound has at least one modulated pharmacokinetic property upon administration to the host as compared to a free drug control that comprises the anticancer therapeutic as well as enhanced efficacy not due to compound degradation. It is preferred that the pharmacokinetic modulating moiety has a mass of less than 1100 Daltons.

Priority: US20070932359P Applic. Date: 2007-05-29

Inventor: MUTZ MITCHELL W [US]; MARQUIS ANDRE L [US]


Application No.: US20090054352A1  Published: 26/Feb/2009

Title: BENZENE DERIVATIVE OR SALT THEREOF

Applicant/Assignee: ASTELLAS PHARMA INC

Application No.: 12/091099   Filing Date: 07/Nov/2006

Abstract:Problem: To provide compounds which have an anticoagulation effect based on their ability to inhibit the activated blood coagulation factor X and are useful as coagulation inhibitors or agents for prevention or treatment for diseases caused by thrombi or emboli. Means for Solution: Benzene derivatives or their salts having a characteristic chemical structure with a phenol ring and a benzene ring bonding to each other via an amide bond, in which the phenol ring further bonds to a benzene ring or a heteroaryl ring via an amide bond. They have an excellent effect of inhibiting the activated blood coagulation factor X, and especially have an excellent oral activity.

Priority: JP20050323491 Applic. Date: 2005-11-08; WO2006JP322133 Applic. Date: 2006-11-07

Inventor: HIRAYAMA FUKUSHI [JP]; FUJIYASU JIRO [JP]; KAGA DAISUKE [JP]; NEGORO KENJI [JP]; SASUGA DAISUKE [JP]; SEKI NORIO [JP]; SUZUKI KEN-ICHI [JP]


Application No.: US20090061468A1  Published: 05/Mar/2009

Title: REAGENT AND METHOD FOR MEASURING COAGULATION TIME OF BLOOD SAMPLE

Applicant/Assignee: SYSMEX CORPORATION

Application No.: 12/195028   Filing Date: 20/Aug/2008

Abstract:A reagent kit for measuring coagulation time is described herein. This reagent comprises calcium chelator which interferes with the reaction between calcium and substance other than a coagulation factor in a blood sample, and which substantially does not interfere with coagulation reaction. A method for measuring coagulation time is also described herein. The method comprises a contacting step and a measuring step. The contacting step is to contact a blood sample, calcium and compound selected from the group consisting of partial thromboplastin, tissue thromboplastin, and complex of tissue factor and phospholipid, in the presence of calcium chelator. This calcium chelator can interfere with the reaction between calcium and substance other than a coagulation factor in the blood sample and substantially does not interfere with coagulation reaction. The measuring step is to measure coagulation time of the blood sample.

Priority: JP20070226463 Applic. Date: 2007-08-31

Inventor: HOSHIKO SUSUMU [JP]; KOBAYASHI KATSUSHI [JP]


Application No.: US20090068168A1  Published: 12/Mar/2009

Title: SUBSTITUTED AMINO ALCOHOLS

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/203581   Filing Date: 03/Sep/2008

Abstract:Disclosed herein are substituted amino alcohol anti-mycobacterial agents and/or chelation therapy agents of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20070970376P Applic. Date: 2007-09-06

Inventor: GANT THOMAS G [US]; SARSHAR SEPEHR [US]


Application No.: US20090074718A1  Published: 19/Mar/2009

Title: Avian derived erythropoietin

Applicant/Assignee:

Application No.: 11/973853   Filing Date: 10/Oct/2007

Abstract:Erythropoietin obtained from eggs laid by transgenic avians having avian N-linked and O-linked glycosylation patterns.

Priority: US2007-708598 Applic. Date: 2007-02-20; US2006-370555 Applic. Date: 2006-03-08; US2003-351196 Applic. Date: 2003-01-24; US1998-173864 Applic. Date: 1998-10-16; US20070918504P Applic. Date: 2007-03-16; US20060857896P Applic. Date: 2006-11-09; US20060877601P Applic. Date: 2006-12-28; US20060783648P Applic. Date: 2006-03-17; US20060840291P Applic. Date: 2006-08-25; US19970062172P Applic. Date: 1997-10-16

Inventor: IVARIE ROBERT D [US]; HARVEY ALEX J [US]; MORRIS JULIE A [US]; LIU GUODONG [CA]; RAPP JEFFREY C [US]


Application No.: US20090074829A1  Published: 19/Mar/2009

Title: Novel Heparin Alternative Material and Method for Producing the Same

Applicant/Assignee:

Application No.: 12/224950   Filing Date: 13/Mar/2007

Abstract:The object is to provide a novel heparin alternative material, which is excellent in safety and in vivo degradability. Disclosed are: a novel heparin alternative material, which comprises an enzymatically synthesized alpha-1,4-glucan derivative and has functions substituting those of heparin, such as an anticoagulation activity and functions of a material for storage or sustained release of a heparin-binding growth factor

a method for production of the substitute material

and a preparation or article for medical applications or a cosmetic produced using the heparin alternative material.

Priority: JP20060069479 Applic. Date: 2006-03-14; WO2007JP54935 Applic. Date: 2007-03-13

Inventor: TANIHARA MASAO [JP]; HOSOYA KAYO [JP]; TAKAHA TAKESHI [JP]; TAKAHARA JUNICHI [JP]; SUNAKO MICHIHIRO [JP]


Application No.: US20090074875A1  Published: 19/Mar/2009

Title: Nanoparticulate compositions having lysozyme as a surface stabilizer

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 12/292091   Filing Date: 12/Nov/2008

Abstract:The present invention is directed to nanoparticulate active agent compositions comprising lysozyme as a surface stabilizer. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention and methods of making and using such nanoparticulate and pharmaceutical compositions.

Priority: US2003-357514 Applic. Date: 2003-02-04; US20020353230P Applic. Date: 2002-02-04

Inventor: WERTZ CHRISTIAN F [US]; RYDE NIELS P [US]


Application No.: US20090081297A1  Published: 26/Mar/2009

Title: Use of surface tension reducing agents in aerosol formulations

Applicant/Assignee:

Application No.: 11/412523   Filing Date: 27/Apr/2006

Abstract:The present disclosure describes aerosol formulations that are particularly effective for pulmonary aerosol delivery. The aerosol formulations comprise an aqueous dispersion of active agent particles, said aqueous dispersion having an excess of a surface tension reducing agent. As a result of the reduced surface tension of the aqueous dispersion, the resulting aerosol droplets formed have a particle size less in one embodiment of than 10 microns in size or in an alternate embodiment of less than 6 microns in size. The present disclosure also provides for a method for forming an aerosol from said aerosol formulation, a method of treating a mammal in need of said treatment using said aerosol formulation, and a method of diagnosing a mammal in need of such diagnosis using said aerosol formulation.

Priority: US20050675375P Applic. Date: 2005-04-27

Inventor: COOK ROBERT O [US]; ARMER THOMAS A [US]


Application No.: US20090081703A1  Published: 26/Mar/2009

Title: METHOD FOR DETECTING DEEP VENOUS THROMBOSIS

Applicant/Assignee:

Application No.: 12/238011   Filing Date: 25/Sep/2008

Abstract:A method for detecting deep vein thrombosis (DVT) in humans includes the steps of assaying a collected blood sample and measuring the amount of Lp-PLA2. The detected amount of Lp-PLA2 is then compared and correlated with known risk values of Lp-PLA2. A diagnosis of a patient's likelihood, risk, or development of DVT may be made by comparing the measured value with values known to correlate to a particular risk or development of DVT.

Priority: US20070975043P Applic. Date: 2007-09-25

Inventor: YALE STEVEN H [US]


Application No.: US20090082800A1  Published: 26/Mar/2009

Title: Distal Embolic Protection Devices With A Variable Thickness Microguidewire And Methods For Their Use

Applicant/Assignee: INSERA THERAPEUTICS LLC

Application No.: 11/859272   Filing Date: 21/Sep/2007

Abstract:A distal embolic protection device for dedicated use in cerebral arterial blood vessels is described. The distal embolic protection device comprises a variable-thickness micro-guidewire and a collapsible filtering device mounted on the microguidewire over two mobile attachment points so that in its collapsed configuration, the thickness of the microguidewire and the filtering device at this region is less than or equal to 0.017 inch (0.432 mm) in thickness to be able to pass through existing conventional microcatheters. The mobile attachment points allow for rotatory and longitudinal mobility of the microguidewire while the filtering device is stable thereby decreasing the risk of trauma to the fragile cerebral arterial blood vessels. Preferably, the filtering device comprises an expansion assembly, e.g., a plurality of struts attached to a filter membrane that are in a folded position which self expand to the desired dimensions within the cerebral blood vessels. Also described are methods of using the distal embolic protection devices of this invention.

Priority:

Inventor: JANARDHAN VIKRAM [US]


Application No.: US20090084717A1  Published: 02/Apr/2009

Title: MODULAR HEMOFILTRATION APPARATUS WITH REMOVABLE PANELS FOR MULTIPLE AND ALTERNATE BLOOD THERAPY

Applicant/Assignee: TRANSVIVO INC

Application No.: 12/183527   Filing Date: 31/Jul/2008

Abstract:An apparatus for performing blood therapy having a plurality of pumps for engaging blood and fluid tubing is characterized by a plurality of manually mounted and disengagable panels installed on the sides of the apparatus housing, the panels having pump engaging tubing mounted on the inside of the respective panels.

Priority: US20070953577P Applic. Date: 2007-08-02

Inventor: DELMAGE J MICHAEL [US]; PETERS HAROLD [US]; COOPER TOMMY [US]


Application No.: US20090087421A1  Published: 02/Apr/2009

Title: Novel Recombinant Staphylokinase Derivatives and the Preparations and Applications thereof

Applicant/Assignee: FUDAN UNIVERSITY

Application No.: 12/185601   Filing Date: 04/Aug/2008

Abstract:The present invention relates to the biotechnology field, more particularly, to novel recombinant staphylokinase (RGD/KGD-Sak) derivatives and the preparation the thereof. The derivatives, have a low polymerizing ability, low immunogenicity and a bifunctionality of thrombolytics and anticoagulant. Based on the line, structural analysis of the monomer and dimer of recombinant staphylokinases and their biochemical properties, we designed two novel bifunctional staphylokinase molecular structures. Mutant genes were constructed by PCR site-directed mutagenesis which were then recombined with a prokaryotic vector and used to transform E. coli. Engineered strains with a high expression level were selected by screening and propagated by fermentation, followed by disruption of the cells, centrifugation to collect inclusion bodies, renaturation, and purification of RGD/KGD-SAK through a two-step method. After lyophilized, the polymerizing ability and immunogenicity of the products decreased significantly. The derivatives can not only activate fibrinogen to lyse thrombus, but also significantly inhibit the platelet aggregation induced by ADP, suggesting that they have the bifunctionality of thrombolytics and anticoagulant.

Priority: CN20001011627 Applic. Date: 2000-01-28; US2003-182160 Applic. Date: 2003-01-22; WO2001CN00102 Applic. Date: 2001-01-23

Inventor: SONG HOUYAN [CN]; SONG GANG [CN]


Application No.: US20090088613A1  Published: 02/Apr/2009

Title: CONTINUITY CIRCUITS FOR DETECTING ACCESS DISCONNECTION

Applicant/Assignee: BAXTER INTERNATIONAL INC BAXTER HEALTHCARE S.A

Application No.: 11/862984   Filing Date: 27/Sep/2007

Abstract:A monitor for an extracorporeal therapy access site is disclosed. The monitor includes a bandage atop or adjacent the access site and a sensor for monitoring the bandage. The bandage includes a layer of polymer that expands when wetted with blood. The expansion causes a break in continuity of the sensor, or in an alternate embodiment, causes a sensor to cease detecting a target. When the break occurs, the control circuit monitoring the bandage sends a signal that a break has occurred, and a remote monitor then takes appropriate action, such as ceasing therapy, sending an alert, or sounding an alarm. In another embodiment, connecting wires in a continuity circuit are held apart by a polymer that dissolves when contacted by blood. If a leak occurs and a small portion of the polymer dissolves, the wires make contact, thus detecting a blood leak.

Priority:

Inventor: MARTTILA ALAN W [US]; CHAN WILLIAM W [US]; BHAGTANI REEMA A [US]


Application No.: US20090093697A1  Published: 09/Apr/2009

Title: MEMS INTERSTITIAL PROTHROMBIN TIME TEST

Applicant/Assignee:

Application No.: 12/189509   Filing Date: 11/Aug/2008

Abstract:A method of determining a prothrombin time is disclosed. A mediator is applied to a stratum corneum. The stratum corneum is penetrated to allow the mediator to enter a region containing interstitial fluid and interact with at least one capillary, causing blood and/or blood components to leak from the at least one capillary into the region containing interstitial fluid. A characteristic affected by the blood and/or blood components is measured in the region containing interstitial fluid which correlates to the prothrombin time. A system for measuring prothrombin time is also disclosed. The system has a mediator, one or more microneedles, and a processor directly or indirectly coupled to the one or more microneedles and configured to determine a coagulation change in blood or blood components in a region around the one or more microneedles after the one or more microneedles penetrate a stratum corneum.

Priority: US20070955054P Applic. Date: 2007-08-10

Inventor: MIR JOSE [US]; KOWARZ MAREK W [US]; SARBADHIKARI KAMAL K [US]; ASHE PHILIP RYAN [US]


Application No.: US20090093754A1  Published: 09/Apr/2009

Title: Device for Treatment of Venous Congestion

Applicant/Assignee:

Application No.: 12/335304   Filing Date: 15/Dec/2008

Abstract:A device for treatment of venous congestion provides for subcutaneous introduction of anticoagulant through an incision positioned within a collection shell for withdrawal of an effused material. A widened delivery tip provides dispersal of the anticoagulant and may be agitated to disrupt clot formation.

Priority: US2002-273215 Applic. Date: 2002-10-16; US2000-745298 Applic. Date: 2000-12-20; US19990171351P Applic. Date: 1999-12-22

Inventor: HARTIG GREGORY K [US]; CONNOR NADINE P [US]; CONFORTI MICHAEL L [US]


Application No.: US20090095679A1  Published: 16/Apr/2009

Title: HEMODIALYSIS SYSTEMS AND METHODS

Applicant/Assignee: DEKA PRODUCTS LIMITED PARTNERSHIP

Application No.: 12/199452   Filing Date: 27/Aug/2008

Abstract:Hemodialysis dialysis systems are disclosed. Hemodialysis systems of the invention may include a dialysate flow path including a balancing circuit, a mixing circuit, and/or a directing circuit. The circuits may be defined within one or more cassettes. The fluid circuits may be at least partially isolated, spatially and/or thermally, from electrical components of the system. A gas supply may be provided in fluid communication with the dialysate flow path and/or the dialyzer to urge dialysate through the dialyzer and blood back to the patient. The hemodialysis systems may include fluid handling devices, actuated using a control fluid, optionally delivered using a detachable pump. Fluid handling devices may be generally rigid and of a spheroid shape, optionally with a diaphragm dividing the device into compartments.

Priority: US2008-072908 Applic. Date: 2008-02-27; US20070903582P Applic. Date: 2007-02-27; US20070904024P Applic. Date: 2007-02-27

Inventor: DEMERS JASON A [US]; WILT MICHAEL J [US]; BALLANTYNE TODD A [US]; GRANT KEVIN L [US]; DALE JAMES D [US]


Application No.: US20090098104A1  Published: 16/Apr/2009

Title: Method for Diagnosing Cardiovascular Diseases

Applicant/Assignee: MEDIZINISCHE UNIVERSITAT WIEN

Application No.: 12/298209   Filing Date: 16/Apr/2007

Abstract:Method for diagnosing a cardiovascular disease in an individual comprising the steps of: providing a sample of an individual

determining the amount of cytokeratin-18 (CK-18) or fragments thereof and/or interleukin-1beta precursor (IL-1beta precursor) in said sample

comparing the amount of CK-18 or fragments thereof and/or IL-1beta precursor in said sample to the amount of CK-18 or fragments thereof and/or IL-1beta precursor present in a reference control of at least one individual not suffering from a cardiovascular disease

and diagnosing a cardiovascular disease if the amount of CK-18 or fragments thereof in the sample is increased in comparison to the amount of CK-18 or fragments thereof in the reference control and/or the amount of IL-1beta precursor in the sample is decreased in comparison to the amount of IL-1beta precursor in the reference control.

Priority: AT20060000694 Applic. Date: 2006-04-24; WO2007AT00173 Applic. Date: 2007-04-16

Inventor: ANKERSMIT HENDRIK JAN [AT]


Application No.: US20090098119A1  Published: 16/Apr/2009

Title: ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME

Applicant/Assignee: PORTOLA PHARMACEUTICALS, INC

Application No.: 12/239651   Filing Date: 26/Sep/2008

Abstract:The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Priority: US20070976343P Applic. Date: 2007-09-28; US20080090574P Applic. Date: 2008-08-20

Inventor: LU GENMIN [US]; PHILLIPS DAVID R [US]; ANDRE PATRICK [US]; SINHA UMA [US]


Application No.: US20090098185A1  Published: 16/Apr/2009

Title: Method for treating thrombotic disorders using sulfated polysaccharides

Applicant/Assignee: AVIGEN, INC

Application No.: 12/316632   Filing Date: 15/Dec/2008

Abstract:Methods for treating thrombotic disorders using sulfated polysaccharides such as fucoidans are disclosed.

Priority: US2007-789447 Applic. Date: 2007-04-24; US20060797079P Applic. Date: 2006-04-27

Inventor: JOHNSON KIRK W [US]


Application No.: US20090098585A1  Published: 16/Apr/2009

Title: REAGENT KIT FOR DETECTING LUPUS ANTICOAGULANT

Applicant/Assignee: SYSMEX CORPORATION

Application No.: 12/269719   Filing Date: 12/Nov/2008

Abstract:A reagent kit capable of distinguishing between a blood sample containing lupus anticoagulant and blood samples from individuals having other anticoagulant diseases is disclosed. The reagent kit comprises two coagulation time reagents containing phosphatidylserine in a different phosphatidylserine content ratio to the total content of phospholipids from each other, threreby giving different coagulation times with use of corresponding coagulation time reagent.

Priority: JP20020216782 Applic. Date: 2002-07-25; US2003-622736 Applic. Date: 2003-07-21

Inventor: OKUDA MASAHIRO [JP]


Application No.: US20090099639A1  Published: 16/Apr/2009

Title: METHOD FOR EXPANSION AND DEPLOYMENT OF POLYMERIC STRUCTURES INCLUDING STENTS

Applicant/Assignee: ARTERIAL REMODELING TECHNOLOGIES, S.A

Application No.: 12/282738   Filing Date: 24/Oct/2007

Abstract:The invention is to methods of deploying polymeric biodegradable or non biodegradable stents by use of stepwise creases in the pressure placed upon the inner diameter of the stent to slowly increase the stent diameter. In one embodiment, the pressure on the interior stent diameter is slowly increased. The stent is allowed to acclimate to this diameter for a set period of time, and then the pressure is again increased. This series of steps continues until the stent reaches its final diameter and a final period of acclimatization is maintained prior to the removal of the deployment/delivery device.

Priority: US20060854075P Applic. Date: 2006-10-25; WO2007IB03195 Applic. Date: 2007-10-24

Inventor: SABARIA PATRICK [FR]


Application No.: US20090104273A1  Published: 23/Apr/2009

Title: Novel nifedipine compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 12/292395   Filing Date: 18/Nov/2008

Abstract:The present invention is directed to nanoparticulate compositions comprising nifedipine. The nifedipine particles of the composition have an effective average particle size of less than about 2 microns.

Priority: US2003-712259 Applic. Date: 2003-11-14; US2003-276400 Applic. Date: 2003-01-15; WO2001US15983 Applic. Date: 2001-05-18; US1999-337675 Applic. Date: 1999-06-22

Inventor: MERISKO-LIVERSIDGE ELAINE [US]


Application No.: US20090105629A1  Published: 23/Apr/2009

Title: BLOOD CIRCUIT ASSEMBLY FOR A HEMODIALYSIS SYSTEM

Applicant/Assignee: DEKA PRODUCTS LIMITED PARTNERSHIP

Application No.: 12/199077   Filing Date: 27/Aug/2008

Abstract:A blood circuit assembly for a dialysis unit may include an organizing tray, a pair of pneumatic pumps mounted to the organizing tray for circulating blood received from a patient through a circuit including a dialyzer unit and returned to the patient, an air trap mounted to the organizing tray arranged to remove air from blood circulating in the circuit, a pair of dialyzer connections arranged to connect to the inlet and outlet of a dialyzer unit, and a pair of blood line connectors, one inlet blood line connector for receiving blood from the patient and providing blood to the pneumatic pumps and the other outlet blood line connector for returning blood to the patient.

Priority: US2008-120729 Applic. Date: 2008-02-27; US2008-038474 Applic. Date: 2008-02-27; US2007-871821 Applic. Date: 2007-10-12; US2008-038648 Applic. Date: 2008-02-27; US2007-871803 Applic. Date: 2007-10-12; US2007-871793 Applic. Date: 2007-10-12; US2007-871787 Applic. Date: 2007-10-12; US2007-871712 Applic. Date: 2007-10-12; US2007-871680 Applic. Date: 2007-10-12; US20070903582P Applic. Date: 2007-02-27; US20070904024P Applic. Date: 2007-02-27; US20070921314P Applic. Date: 2007-04-02

Inventor: GRANT KEVIN L [US]; DALE JAMES D [US]; WILT MICHAEL J [US]; DEMERS JASON A [US]; COLLINS DAVID E [US]


Application No.: US20090107903A1  Published: 30/Apr/2009

Title: Anticoagulant-coated dipstick for use with a blood centrifuge rotor

Applicant/Assignee: IDEXX LABORATORIES, INC

Application No.: 12/290205   Filing Date: 28/Oct/2008

Abstract:An anticoagulant-coated dipstick is selectively receivable by the central fill port of a rotor of a blood centrifuge. The dipstick includes an elongated, rod-like member having a first axial end and an opposite second axial end, and a cap affixed to the second axial end. At least a portion of a surface of the rod-like member is coated with an anticoagulant. The elongated rod-like member of the dipstick is dimensioned in length and diameter to be receivable through the central fill port of the rotor to contact a blood sample contained therein. The cap is circular in shape, with a diameter that is greater than that of the rotor fill port to entirely cover and seal the fill port to prevent leakage therethrough of a blood sample contained in the rotor, especially when the rotor is gently agitated or inverted.

Priority: US20070000849P Applic. Date: 2007-10-29

Inventor: DASSA ALYSSA J [US]


Application No.: US20090110683A1  Published: 30/Apr/2009

Title: MONOCLONAL ANTIBODIES AGAINST ACTIVATED PROTEIN C

Applicant/Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION

Application No.: 12/257706   Filing Date: 24/Oct/2008

Abstract:The present invention provides monoclonal antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Other antibodies inhibit both activated protein C and activation of unactivated protein C. Methods of treatment employing these antibodies are described herein as are methods of screening for and detecting these antibodies.

Priority: US20070983092P Applic. Date: 2007-10-26

Inventor: XU JUN [US]; ESMON CHARLES [US]


Application No.: US20090110740A1  Published: 30/Apr/2009

Title: Materials and Methods for Modulating Metabolism

Applicant/Assignee:

Application No.: 12/265447   Filing Date: 05/Nov/2008

Abstract:The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a cysteamine compound is administered to a patient to treat hypercholesterolemia and/or complications associated with hypercholesterolemia. In another embodiment, a cysteamine compound is administered to a patient to prevent the onset of diabetes in an at-risk patient and/or treat or prevent the onset of diabetes-associated complications.

Priority: US2005-118737 Applic. Date: 2005-04-29; US20040567899P Applic. Date: 2004-05-03; US20040637618P Applic. Date: 2004-12-20

Inventor: CHAN BILL PIU [CN]; WONG GARY KWAN PO [HK]; XU JINXIAN [CN]; CHI FRANCIS [HK]


Application No.: US20090112049A1  Published: 30/Apr/2009

Title: HEART PUMP APPARATUS AND METHOD FOR BEATING HEART SURGERY

Applicant/Assignee: SAUDI ARABIAN OIL COMPANY

Application No.: 11/927160   Filing Date: 29/Oct/2007

Abstract:Apparatus for assisting a surgeon in procedures involving the heart and methods of employing such apparatus are provided. The apparatus can include a pump, and a first fluid conduit having a distal end adapted to be inserted into the superior vena cava of a beating heart, a second fluid conduit having a distal end adapted to be inserted into the inferior vena cava, and a third fluid conduit having a distal end adapted to be inserted into the pulmonary artery of the beating heart, each in liquid fluid communication with the pump, which in combination can be operatively positioned to form a closed cardiac pathway extending from the vena cavae and to the pulmonary artery to thereby convey blood collected from the vena cavae into the pulmonary artery, operatively bypassing the right side of the heart. The pump is positioned to both convey blood flow from each vena cavae and to the third fluid conduit and to provide a blood reservoir which enables the provision of manual assistance to the blood flow to the lungs when blood flow is insufficient.

Priority:

Inventor: AHMED FAYAZ [SA]


Application No.: US20090118660A1  Published: 07/May/2009

Title: APPARATUS AND METHOD FOR IN-VIVO PLASMAPHERESIS USING PERIODIC BACKLUSH CONTAINING ANTICOAGULANT

Applicant/Assignee: TRANSVIVO INC

Application No.: 12/353209   Filing Date: 13/Jan/2009

Abstract:Method for in-vivo plasmapheresis utilizing a plurality of elongated hollow microporous filter fibers periodically interrupt diffusion of blood plasma from a patient, and, for a selected time, directing backflush fluid into the fibers at a pressure and interval sufficient to cleanse the fiber pores, after which plasma diffusion is resumed. The backflush fluid, preferably a normal saline solution, may contain an anticoagulant such as heparin, citrate or NO donor in suitable concentration for systemic anti-coagulation or for treating the fiber for thromboresistance.

Priority: US2005-320866 Applic. Date: 2005-12-29; US2003-408657 Applic. Date: 2003-04-04; US2001-754773 Applic. Date: 2001-01-04

Inventor: GORSUCH REYNOLDS G [US]; COOPER TOMMY GENE [US]; HANDLEY JR HAROLD H [US]; PETERS HAROLD W [US]


Application No.: US20090123437A1  Published: 14/May/2009

Title: METHODS FOR COLLECTING AND USING PLACENTA CORD BLOOD STEM CELLS

Applicant/Assignee:

Application No.: 12/268319   Filing Date: 10/Nov/2008

Abstract:An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.

Priority: WO2007US11359 Applic. Date: 2007-05-11; US20060799734P Applic. Date: 2006-05-11

Inventor: TAKEBE NAOKO [US]


Application No.: US20090123907A1  Published: 14/May/2009

Title: LYSINE CITRATE FOR PLASMA PROTEIN AND DONOR PROTECTION

Applicant/Assignee: SHANBROM TECHNOLOGIES, LLC

Application No.: 11/914532   Filing Date: 22/Jul/2005

Abstract:An improved anticoagulant or additive is based on a higher level of citric acid than is usual (at least about 1.0% weight by volume). The higher citrate is combined with an amino acid as a counterion. The amino acid prevents cellular damage often caused by elevated citrate levels. The amino acid citrate mixture also serves to preserve platelet concentrates and platelet rich plasma during room incubation. Not only does the amino acid citrate combination enhance platelet integrity, it completely inhibits or kills bacteria such as Staphylococcus epidermidis. Collecting blood of plasma into such higher levels of citrate prevents activation of blood proteins so that fractions made from the blood or plasma have superior characteristics.

Priority: US2004-897632 Applic. Date: 2004-07-22; WO2005US26308 Applic. Date: 2005-07-22

Inventor: SHANBROM EDWARD [US]


Application No.: US20090124954A1  Published: 14/May/2009

Title: APPARATUS AND METHOD FOR AUTOLOGOUS NORMOVOLEMIC HEMODILUTION

Applicant/Assignee: UNIVERSITY HOSPITALS OF CLEVELAND

Application No.: 12/355275   Filing Date: 16/Jan/2009

Abstract:A system and method for autologous normovolemic hemodilution (ANH) are disclosed. The system can include a vacuum canister, which is sized to accept donor bags of a predetermined capacity. The vacuum canister is connected to a vacuum source which applies a suction to the donor bag within the canister. The system can include a canister having a self-generated vacuum, which includes compressible sidewalls that are spring-loaded to provide negative pressure needed to collect blood from a patient without the use of a gravity-induced siphon gradient. Also disclosed are ANH systems and kits that rely on a gravity-induced siphon gradient for blood collection.

Priority: US2005-318286 Applic. Date: 2005-12-23; US20040639246P Applic. Date: 2004-12-27

Inventor: TRICKETT JAMES R [US]


Application No.: US20090129976A1  Published: 21/May/2009

Title: Circuit For Collecting Blood Component And Apparatus For Collecting Blood Component

Applicant/Assignee:

Application No.: 11/988105   Filing Date: 04/Jul/2006

Abstract:A circuit for collecting a blood component includes a blood collection device provided with a blood collection needle through which blood is collected from a blood donor, a blood separator in which the blood collected by the above blood collection device is separated, a blood component collection bag in which a predetermined blood component separated by the above blood separator is collected, a blood line in which the blood collection needle is connected to an inlet of the blood separator, a line for removing an initial blood flow, which branches from a first branching portion formed in the blood line, and in which an initial flow of blood collected from the blood donor is removed, and an anticoagulant-injection line that branches from a second branching portion, formed in the line for removing the initial blood flow, and into which an anticoagulant is injected.

Priority: JP20050200623 Applic. Date: 2005-07-08; WO2006JP313328 Applic. Date: 2006-07-04

Inventor: HOSHINO YOSHITERU [JP]; YOKOO YOSHIHIRO [JP]; YAMAZAKI YUUSUKE [JP]


Application No.: US20090130104A1  Published: 21/May/2009

Title: FUSION PROTEINS FOR INHIBITION AND DISSOLUTION OF COAGULATION

Applicant/Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Application No.: 12/089250   Filing Date: 05/Oct/2006

Abstract:Fusion proteins containing a ligand which specifically binds to a selected vascular bed linked to an anti-thrombotic molecule are provided. Also provided are methods for use of these fusion proteins to prevent coagulation, to dissolve blood clots and to protect against the risk of iatrogenic side effects including those arising from cancer therapy and specific vascular occluding agents.

Priority: US20050723899P Applic. Date: 2005-10-05; WO2006US38989 Applic. Date: 2006-10-05

Inventor: MUZYKANTOV VLADIMIR R [US]; GOTTSTEIN CLAUDIA [US]; DING BI-SEN [US]; CINES DOUGLAS B [US]


Application No.: US20090130293A1  Published: 21/May/2009

Title: BIOCOMPATIBLE COATINGS FOR MEDICAL DEVICES

Applicant/Assignee:

Application No.: 11/941834   Filing Date: 16/Nov/2007

Abstract:Biocompatible coatings for implantable medical devices are disclosed. Embodiments of the invention provide plasma etch processes, surface silanization processes, and protein coating processes. Embodiments of the invention provide tropoelastin coatings and methods of creating tropoelastin coatings for implantable medical devices. Optionally, the biocompatible coating can be a drug eluting coating.

Priority:

Inventor: SHYKIND DAVID [US]; YOUNKIN TODD [US]; BURGHARD JOHN [US]; KUHN MARKUS [US]; CAMPBELL CARMEN [US]; MAIZ JOSE [US]


Application No.: US20090131847A1  Published: 21/May/2009

Title: System and device for medically treating an individual

Applicant/Assignee:

Application No.: 12/288905   Filing Date: 24/Oct/2008

Abstract:A system for medically treating/vaccinating an individual comprising a first syringe, containing an anticoagulant material therein, for drawing a sample of blood from the individual. A centrifuge means for centrifuging the sample of blood contained within the first syringe to obtain a buffy coat. A second syringe comprising a second plunger and at least one microtubule member containing one of a treatment agent and a vaccine antigen. At least one open end formed within the at least one microtubule member for drawing a portion of the buffy coat therein and exposing the buffy coat to one of the treatment agent and vaccine antigen. A second needle capable of being attached onto the second syringe for introducing the exposed sample into the individual to effect treatment/vaccination thereof.

This system is capable of allowing a plurality of treatment agents and/or vaccine antigens to be simultaneously applied to an individual.

Priority: US2006-507876 Applic. Date: 2006-08-22

Inventor: NALIN DAVID R [US]


Application No.: US20090138070A1  Published: 28/May/2009

Title: Stent Apparatuses for Treatment Via Body Lumens and Methods of Use

Applicant/Assignee: INSPIREMD LTD

Application No.: 11/920972   Filing Date: 24/May/2006

Abstract:An enhanced stent apparatus, comprising: a support element, wherein the support element is constructed to be positioned in a body lumen

and, a porous structure, the porous structure located on a surface of the support element, and wherein the porous structure is comprised of at least one fiber under 30 microns in diameter, has a coverage area of less than 30% and is provided with apertures.

Priority: US20050683788P Applic. Date: 2005-05-24; US20050716100P Applic. Date: 2005-09-12; US20050742460P Applic. Date: 2005-12-05; WO2006IB51874 Applic. Date: 2006-05-24

Inventor: HOLZER ZEEV ASHER [IL]; PAZ OFIR [IL]; BAR ELI [IL]; COHEN ILANA [IL]


Application No.: US20090143572A1  Published: 04/Jun/2009

Title: METHOD FOR SEPERATING AND PURIFYING RNA

Applicant/Assignee:

Application No.: 11/995310   Filing Date: 30/Aug/2006

Abstract:A method for separating and purifying RNA including the steps of passing a sample solution containing a nucleic acid, a washing solution and a recovering solution through a nucleic acid-adsorbing porous membrane to adsorb nucleic acid, adsorbing, washing and recovering, in which the nucleic acid adsorbing porous membrane is a porous membrane capable of adsorbing a nucleic acid by interaction involving substantially no ionic bond, and the sample solution is obtained by a process, comprising the steps of (I) injecting a test sample containing at least one of blood and leukocyte, and further containing an anticoagulant to a container, (II) adding a hemolytic agent to the container to obtain a leukocyte pallet, (III) adding a nucleic acid-solubilizing reagent to the leukocyte pallet to obtain a mixture solution and (IV)

adding a water-soluble organic solvent to the mixture solution to obtain the sample solution containing the nucleic acid.

Priority: JP20050249694 Applic. Date: 2005-08-30; JP20060229142 Applic. Date: 2006-08-25; WO2006JP317584 Applic. Date: 2006-08-30

Inventor: INOMATA HIROKO [JP]; MORI TOMOKO [JP]


Application No.: US20090148383A1  Published: 11/Jun/2009

Title: Anticoagulation Agent and Uses Thereof

Applicant/Assignee: BAKER MEDICAL RESEARCH INSTITUTE BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LIMITED

Application No.: 11/988196   Filing Date: 05/Jul/2006

Abstract:The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.

Priority: AU20050903570 Applic. Date: 2005-07-05; AU20050905522 Applic. Date: 2005-10-06; WO2006AU00943 Applic. Date: 2006-07-05

Inventor: PETER KARLHEINZ [AU]


Application No.: US20090148502A1  Published: 11/Jun/2009

Title: COMPOSITIONS AND METHODS FOR TREATING LACERATIONS, ABRASIONS, AVULSIONS, BURNS, ULCERS, AND CASES OF EXCESSIVE BLEEDING

Applicant/Assignee: HEMO NANOSCIENCE, LLC

Application No.: 11/876343   Filing Date: 22/Oct/2007

Abstract:Described herein are compositions and methods related to wound treatment. Compositions are multi-components admixed in amounts and ratios to meet specific objectives for optimally treating various types of wound injury.

Priority: US20060853621P Applic. Date: 2006-10-23

Inventor: PRONOVOST ALLAN D [US]


Application No.: US20090149728A1  Published: 11/Jun/2009

Title: BLOOD CONTACTING SENSOR

Applicant/Assignee: MEDTRONIC MINIMED, INC

Application No.: 12/264810   Filing Date: 04/Nov/2008

Abstract:The invention provides methods and apparatus for detecting an analyte in blood. The apparatus is particularly suited for bringing a sensor into direct contact with blood in vivo. The apparatus comprises a sensor that detects the presence of an analyte and an assembly means. The assembly means has a sensor end, wherein the sensor end of the assembly means is affixed to the sensor, and the assembly means is adapted for coupling with a venous flow device. By coupling with a venous flow device, the assembly means brings the sensor into direct contact with blood flowing through the venous flow device. Examples of venous flow devices that bring the sensor into direct contact with the blood of a subject include, but are not limited to, intravenous catheters and external blood loops, such as are used in extra corporeal membrane oxygenation or hemodialysis.

Priority: US2004-935954 Applic. Date: 2004-09-08

Inventor: VAN ANTWERP NANNETTE M [US]; ENEGREN BRADLEY J [US]; MASTROTOTARO JOHN J [US]; SHAH RAJIV [US]; HOSS UDO [US]; ZHANG YANAN [US]; WANG JENN-HANN [US]; CLARK KENT L [US]


Application No.: US20090155838A1  Published: 18/Jun/2009

Title: Devices, systems and methods for the collection, stimulation, stabilization, and analysis of a biological sample

Applicant/Assignee: SMART TUBE, INC

Application No.: 12/315186   Filing Date: 28/Nov/2008

Abstract:Devices, systems, methods and kits for the collection, stimulation, stabilization and analysis of biological samples, including blood samples, are disclosed. An embodiment of the invention includes a container having a side wall, a bottom wall and a closure member defining an internal compartment having arranged therein a partition defining and fluidly separating first and second chambers in the internal compartment, the first chamber positioned in association with the closure member to receive the biological sample

in which at least one wall is constructed of an elastically deformable material

in which the first chamber contains at least one stimulating agent

in which the second chamber contains at least one stabilizing agent

and in which the first and second chambers can be placed in fluid communication by a user without opening or otherwise compromising the fluid integrity of the internal compartment.

Priority: US20070990626P Applic. Date: 2007-11-28

Inventor: HALE MATTHEW [US]


Application No.: US20090156504A1  Published: 18/Jun/2009

Title: METHODS OF TREATING BLOOD CELL DEPLETION

Applicant/Assignee: IMMUNEREGEN BIOSCIENCES, INC

Application No.: 12/179409   Filing Date: 24/Jul/2008

Abstract:Provided herein are methods and compositions useful for the replenishment of blood cells in a mammal after exposure to therapeutic radiation or drugs. Radiation illness can be reduced in animals by treatment with substance P analogs. In one embodiment, granulocytes can be regenerated after therapeutic radiation by the administration of a substance P analog. In one embodiment, substance P analogs are useful for reducing PARP activity or PARP expression. In one embodiment, substance P analogs are useful for preventing, reducing or ameliorating adverse effects of drugs. In one embodiment, drug induced blood dyscrasias can be ameliorated by the methods and compositions provided herein.

Priority: US20070966948P Applic. Date: 2007-08-29; US20070965580P Applic. Date: 2007-08-20; US20070952691P Applic. Date: 2007-07-30; US20080039866P Applic. Date: 2008-03-27; US20080039860P Applic. Date: 2008-03-27

Inventor: SIEGEL HAL [US]; WILHELM MICHAEL K [US]


Application No.: US20090157057A1  Published: 18/Jun/2009

Title: Circulatory monitoring systems and methods

Applicant/Assignee: SEARETE LLC, A LIABILITY CORPORATION OF THE STATEOF DELAWARE

Application No.: 12/154140   Filing Date: 19/May/2008

Abstract:Systems and methods are described for obtaining and acting upon information indicative of circulatory health and related phenomena in human beings or other subjects. Some involve implementing or deploying therapeutic administration systems, for example, for obtaining a priori implant information and signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants

or obtaining a flow-change-indicative measurement and signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement

or obtaining one or more indications of a lytic material in a vicinity of one or more body lumens and accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens

or one or more capture components configured to accelerate a decrease in a local concentration of one or more therapeutic structures along a downstream portion of a vasculature and one or more dispensation components configured to release the one or more therapeutic structures into an upstream portion of the vasculature.

Priority: US2007-004107 Applic. Date: 2007-12-18; US2008-154138 Applic. Date: 2008-05-19; US2008-154162 Applic. Date: 2008-05-19; US2008-152669 Applic. Date: 2008-05-14; US2008-152846 Applic. Date: 2008-05-15; US2008-154654 Applic. Date: 2008-05-22

Inventor: FERREN BRAN [US]; HAGEN JEFFREY JOHN [US]; HYDE RODERICK A [US]; ISHIKAWA MURIEL Y [US]; LEUTHARDT ERIC C [US]; RIVET DENNIS J [US]; WOOD JR LOWELL L [US]; WOOD VICTORIA Y H [US]


Application No.: US20090163548A1  Published: 25/Jun/2009

Title: Method of using and comopositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases

Applicant/Assignee:

Application No.: 11/579352   Filing Date: 22/Sep/2008

Abstract:Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

Priority: WO2004US14003 Applic. Date: 2004-05-05

Inventor: ZELDIS JEROME B [US]


Application No.: US20090163856A1  Published: 25/Jun/2009

Title: Treatment indications informed by a prior implant information

Applicant/Assignee: SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE

Application No.: 12/004453   Filing Date: 19/Dec/2007

Abstract:Systems and methods are described for implementing or deploying therapeutic administration systems for obtaining a priori implant information and signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants

or obtaining a flow-change-indicative measurement and signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement

or obtaining one or more indications of a lytic material in a vicinity of one or more body lumens and accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens

or one or more capture components configured to accelerate a decrease in a local concentration of one or more therapeutic structures along a downstream portion of a vasculature and one or more dispensation components configured to release the one or more therapeutic structures into an upstream portion of the vasculature.

Priority:

Inventor: FERREN BRAN [US]; HYDE RODERICK A [US]; ISHIKAWA MURIEL Y [US]; LEUTHARDT ERIC C [US]; RIVET DENNIS J [US]; WOOD JR LOWELL L [US]; WOOD VICTORIA Y H [US]


Application No.: US20090169545A1  Published: 02/Jul/2009

Title: 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE

Applicant/Assignee: SERODUS AS

Application No.: 12/372592   Filing Date: 17/Feb/2009

Abstract:This invention provides the use of a 5-HT4 receptor antagonist in the manufacture of a medicament for treating or preventing heart failure. Particular heart disorders to be treated are selected from the group comprising chronic heart failure, congestive heart failure, chronic congestive heart failure and heart failure resulting from ischaemic heart disease. Methods of treating heart failure using 5-HT4 receptor antagonists and pharmaceutical compositions containing 5-HT4 receptor antagonists are also provided.

Priority: GB20020011230 Applic. Date: 2002-05-16; US2005-514386 Applic. Date: 2005-08-26; WO2003GB02134 Applic. Date: 2003-05-16

Inventor: LEVY FINN OLAV [NO]


Application No.: US20090169620A1  Published: 02/Jul/2009

Title: ORALLY DISINTEGRATING TABLET COMPOSITIONS OF TEMAZEPAM

Applicant/Assignee:

Application No.: 12/339908   Filing Date: 19/Dec/2008

Abstract:The compositions of the present invention are orally disintegrating tablet compositions comprising a therapeutically effective amount of at least one drug such as temazepam, 0.5-3% of an ODT binder polymer, a sugar alcohol and/or saccharide, and a disintegrant.

Priority: US20070015931P Applic. Date: 2007-12-21

Inventor: VENKATESH GOPI M [US]; CLEVENGER JAMES M [US]; LAI JIN-WANG [US]; PUROHIT VIVEK [US]


Application No.: US20090169714A1  Published: 02/Jul/2009

Title: BIOCOMPATIBLE COATINGS FOR MEDICAL DEVICES

Applicant/Assignee:

Application No.: 11/964428   Filing Date: 26/Dec/2007

Abstract:Biocompatible coatings for implantable medical devices are disclosed. Embodiments of the invention provide methods for coating an object with a biocompatible coating wherein the device is suspended using a flowing gas during the coating process. Embodiments of the invention provide tropoelastin coatings and methods of creating tropoelastin coatings for implantable medical devices. Optionally, the biocompatible coating can be a drug eluting coating.

Priority:

Inventor: BURGHARD JOHN [US]; CAMPBELL CARMEN [US]; YOUNKIN TODD R [US]; KUHN MARKUS [US]; SHYKIND DAVID [US]; MAIZ JOSE [US]


Application No.: US20090170932A1  Published: 02/Jul/2009

Title: DISINFECTANT COMPOSITIONS, METHODS AND SYSTEMS

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 12/347073   Filing Date: 31/Dec/2008

Abstract:Disinfectant compositions comprising N-Acetyl Cysteine (NAC) and Vitamin C are disclosed. The disinfectant compositions have also demonstrated activity in inhibiting as well as killing micro-organisms responsible for generating biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to reduce the proliferation of and/or eliminate existing or established infections.

Priority: US20070006201P Applic. Date: 2007-12-31

Inventor: AGGARWAL DINESH [US]; SHAH CHIRAG [US]


Application No.: US20090171303A1  Published: 02/Jul/2009

Title: Fixed- or Variable-Length, Wire-Reinforced Catheter and Method of Adaptation

Applicant/Assignee:

Application No.: 12/343888   Filing Date: 24/Dec/2008

Abstract:This disclosure relates to a fixed- or variable-length, wire-reinforced catheter for use in a human body or connected to a subcutaneous port implanted in a human body for use under a cyclical internal load and method of adaptation thereof, and more particularly, to a wire-reinforced catheter of increased internal diameter or reduced external diameter of fixed or variable lengths for the optimized transportation of blood under cyclical internal load and without damage.

Priority: US20070017095P Applic. Date: 2007-12-27

Inventor: LOITERMAN DAVID A [US]; LOITERMAN MICHAEL G [US]


Application No.: US20090171448A1  Published: 02/Jul/2009

Title: Implantable device with miniature rotating portion for energy harvesting

Applicant/Assignee:

Application No.: 11/976434   Filing Date: 24/Oct/2007

Abstract:A miniature rotating portion, anchored to and used within the human body. Optionally and preferably, the device may be used to generate energy for sensors or other implantable devices.

Priority: US20070924041P Applic. Date: 2007-04-27

Inventor: ELI URI [IL]


Application No.: US20090173158A1  Published: 09/Jul/2009

Title: MEASUREMENT CHAMBER AND RESONATOR

Applicant/Assignee: ANDREAS HETTICH GMBH & CO., KG

Application No.: 12/294959   Filing Date: 28/Mar/2007

Abstract:The invention relates to an apparatus comprising a measurement chamber and a resonator, which can be integrated in the measurement chamber via a quick-action closure, for the liquid sensor system and for verification and measurement of the concentration of materials, substances, particles and/or microorganisms in liquids. The invention is characterized in that the resonator is held only on its outer circumference by a thin elastomer ring, and in that at the radial distance of the external diameter of the resonator, the elastomer ring on the one hand rests on an upper sealing ring of the measurement chamber, forming a seal, and on the other hand rests on a holding ring.

Priority: DE200610015512 Applic. Date: 2006-03-31; WO2007EP02729 Applic. Date: 2007-03-28

Inventor: GEHRING FRANK K [DE]


Application No.: US20090173641A1  Published: 09/Jul/2009

Title: AUTOMATED METHOD AND APPARATUS FOR DETECTING ERRONEOUS SAMPLE COLLECTION IN CLINICAL ASSAYS

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 12/339886   Filing Date: 19/Dec/2008

Abstract:A method for identifying biological samples that are collected using the wrong anticoagulant for subsequent analytical testing. The method also provides for identification of certain analytical test results that are substantially or partly adversely affected.

Priority: US20070015582P Applic. Date: 2007-12-20

Inventor: BROUWER ERIC [CA]; TIRINATO JODY ANN [US]; ZELIN MICHAEL P [US]


Application No.: US20090176758A1  Published: 09/Jul/2009

Title: LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 12/401401   Filing Date: 10/Mar/2009

Abstract:The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4 I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

Priority: US2007-955678 Applic. Date: 2007-12-13; US2005-198801 Applic. Date: 2005-08-05; US2004-850587 Applic. Date: 2004-05-20; US2002-245122 Applic. Date: 2002-09-17; US20010324165P Applic. Date: 2001-09-21; US20020402317P Applic. Date: 2002-08-09

Inventor: PINTO DONALD J P [US]; QUAN MIMI L [US]; ORWAT MICHAEL J [US]; LI YUN-LONG [US]; HAN WEI [US]; QIAO JENNIFER X [US]; LAM PATRICK Y S [US]; KOCH STEPHANIE L [US]


Application No.: US20090176792A1  Published: 09/Jul/2009

Title: SUBSTITUTED DIBENZHYDRYLPIPERAZINES

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/350032   Filing Date: 07/Jan/2009

Abstract:The present invention relates to new dibenzhydrylpiperazine modulators of histamine receptors, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080019520P Applic. Date: 2008-01-07

Inventor: GANT THOMAS G [US]; SARSHAR SEPEHR [US]


Application No.: US20090181895A1  Published: 16/Jul/2009

Title: Stabilised Compositions of Factor VII Polypeptides

Applicant/Assignee: NOVO NORDISK HEALTH CARE AG

Application No.: 12/407266   Filing Date: 19/Mar/2009

Abstract:The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.

Priority: DK20030001901 Applic. Date: 2003-12-19; US2006-450783 Applic. Date: 2006-06-09; WO2004EP53587 Applic. Date: 2004-12-17; US20030531728P Applic. Date: 2003-12-22

Inventor: HANSEN BIRTHE LYKKEGAARD [DK]; JENSEN MICHAEL BECH [DK]; KORNFELT TROELS [DK]


Application No.: US20090191177A1  Published: 30/Jul/2009

Title: Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026

Applicant/Assignee:

Application No.: 12/359323   Filing Date: 25/Jan/2009

Abstract:The present invention relates to enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid or pharmaceutically acceptable salts thereof, it being in a solid state, its use in medical therapy, pharmaceutical composition comprising it, its use in the preparation of a medicament for use in a method for preventing or treating diseases, and its use in method for preventing or treating disease. The present invention relates to a selective inhibitor of phosphoinositide (PI) 3-kinase beta and use of the selective inhibitor in e.g. anti-thrombotic therapy.

Priority: US20080023498P Applic. Date: 2008-01-25

Inventor: FJELLSTROM OLA [SE]; GUSTAFSSON DAVID [SE]; LINDBERG JAN A [SE]; JACKSON SHAUN [AU]


Application No.: US20090191183A1  Published: 30/Jul/2009

Title: SUBSTITUTED INDOLES

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/181929   Filing Date: 29/Jul/2008

Abstract:Disclosed herein are substituted indole cysteinyl leukotriene receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20070952862P Applic. Date: 2007-07-30

Inventor: GANT THOMAS G [US]; SARSHAR SEPEHR [US]


Application No.: US20090191637A1  Published: 30/Jul/2009

Title: Method and apparatus for determining anticoagulant therapy factors

Applicant/Assignee:

Application No.: 12/378456   Filing Date: 14/Feb/2009

Abstract:Methods and apparatus are disclosed for determining a new anticoagulant therapy factors for monitoring oral anticoagulant therapy to help prevent excessive bleeding or deleterious blood clots that might otherwise occur before, during or after surgery. New anticoagulant therapy factors maybe based upon the time to maximum acceleration from the time of reagent injection (TX) into a plasma sample, Embodiments include methods and apparatus for determining an anticoagulant therapy factor without requiring use of a mean normal prothrombin time determination or ISI, and may be carried out with the patient sample and a coagulation reagent.

Priority: US2007-906325 Applic. Date: 2007-10-01; US2006-359667 Applic. Date: 2006-02-22; US2003-662043 Applic. Date: 2003-09-12; US2003-428708 Applic. Date: 2003-05-02; US20050679423P Applic. Date: 2005-05-10

Inventor: CARROLL WALLACE E [US]; JACKSON R DAVID [US]


Application No.: US20090192597A1  Published: 30/Jul/2009

Title: Surgical implant, method for the production and use thereof

Applicant/Assignee: AESCULAP AG & CO. KG

Application No.: 12/385045   Filing Date: 30/Mar/2009

Abstract:A surgical implant is made from biocompatible fiber material as a woven textile fabric, in particular in the form of a vascular prosthesis, the woven fabric being so configured that its permeability to blood is so low that the blood impregnates the textile fabric upon implantation and seals it off by coagulating, but does not flow through it.

Priority: DE20011025712 Applic. Date: 2001-05-21; US2004-478128 Applic. Date: 2004-04-30; WO2002EP05544 Applic. Date: 2002-05-21

Inventor: BENTELE FRANZ [DE]; GOLDMANN HELMUT [DE]


Application No.: US20090196928A1  Published: 06/Aug/2009

Title: Biocompatible hydrogel compositions

Applicant/Assignee:

Application No.: 12/384699   Filing Date: 08/Apr/2009

Abstract:Compositions, instruments, systems, and methods are providing for creating families of materials having diverse therapeutic indications and possessing enhanced biocompatibility. One genus platform for the families includes a biocompatible synthetic electrophilic component mixed with a nucleophilic component. The electrophilic component can include a functionalized electrophilic poly (anhydride ester) material. The nucleophilic material can include a natural, autologous protein. The components, when mixed in a liquid state, react by cross-linking, forming a solid matrix composition, or hydrogel.

Priority: US2005-233737 Applic. Date: 2005-09-23; US2004-948765 Applic. Date: 2004-09-23

Inventor: HNOJEWYI OLEXANDER [US]


Application No.: US20090202540A1  Published: 13/Aug/2009

Title: SUBSTITUTED OXAZAPHOSPHORINES

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/368754   Filing Date: 10/Feb/2009

Abstract:The present invention relates to new oxazaphosphorine alkylating agents and/or immuno-suppressive agents, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080027775P Applic. Date: 2008-02-11

Inventor: GANT THOMAS G [US]


Application No.: US20090203656A1  Published: 13/Aug/2009

Title: Method for the Reduction of Dangerous Blood Sugar Levels

Applicant/Assignee:

Application No.: 12/069505   Filing Date: 11/Feb/2008

Abstract:The present invention relates to a method and procedure for reducing immediate serum glucose levels without resort to drugs. Specifically, the invention discloses a regular regimen comprising modest exercise, daily nutritional supplements and a series of specific, time sensitive steps, which, when followed will optimize the effects of the invention.

Priority:

Inventor: RUSSEL KENNETH O [US]


Application No.: US20090203763A1  Published: 13/Aug/2009

Title: SUBSTITUTED BENZHYDRYLETHERS

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/357996   Filing Date: 22/Jan/2009

Abstract:Disclosed herein are substituted benzhydrylethers of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of their use thereof.

Priority: US20080022667P Applic. Date: 2008-01-22

Inventor: GANT THOMAS G [US]


Application No.: US20090209031A1  Published: 20/Aug/2009

Title: MEDICAL DEVICE PACKAGE

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 12/431837   Filing Date: 29/Apr/2009

Abstract:A package for a medical device, the package capable of sustaining viable cells, wherein the package includes a first container, which is configured to receive a medical device and to sustain at least one viable cell, and a fluid port in communication with the first container for allowing sterile passage of an agent to the medical device and for maintaining cell viability.

Priority: US2007-954426 Applic. Date: 2007-12-12; US2006-340912 Applic. Date: 2006-01-26; US20080049504P Applic. Date: 2008-05-01

Inventor: STOPEK JOSHUA B [US]


Application No.: US20090209550A1  Published: 20/Aug/2009

Title: SUBSTITUTED TRIAZOLOPYRIDINES

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/389561   Filing Date: 20/Feb/2009

Abstract:Disclosed herein are substituted triazolopyridine serotonin reuptake modulators and/or 5-HT receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080029960P Applic. Date: 2008-02-20

Inventor: GANT THOMAS G [US]; SARSHAR SEPEHR [US]


Application No.: US20090209933A1  Published: 20/Aug/2009

Title: WHOLE BLOOD COLLECTION KIT AND METHOD

Applicant/Assignee: ASSUREIMMUNE, LLC

Application No.: 12/032124   Filing Date: 15/Feb/2008

Abstract:A blood collection device includes a collection container, a flexible conduit permanently affixed at a proximal end to the collection container, and a needle permanently affixed to a distal end of the flexible conduit. The collection container, flexible conduit and needle can be provided within a package. A method for collecting blood products is also disclosed.

Priority:

Inventor: ZYLBERBERG JAVIER [US]; ZYLBERBERG CLAUDIA [US]; GILCHER RONALD O [US]


Application No.: US20090214675A1  Published: 27/Aug/2009

Title: 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof

Applicant/Assignee: BAYER HEALTHCARE AG

Application No.: 11/989279   Filing Date: 14/Jul/2006

Abstract:The present application relates to novel 4-chromenonyl-1,4-dihydropyridinecarbonitriles, processes for their preparation, pharmaceutical compositions containing them, and their use for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

Priority: DE200510034264 Applic. Date: 2005-07-22; WO2006EP06905 Applic. Date: 2006-07-14

Inventor: KUHL ALEXANDER [DE]; KOLKHOF PETER [DE]; HECKROTH HEIKE [DE]; SCHLEMMER KARL-HEINZ [DE]; FLAMME INGO [DE]; FIGUEROA PEREZ SANTIAGO [DE]; GIELEN-HAERTWIG HEIKE [DE]; GROSSER ROLF [DE]; ERGUEDEN JENS-KERIM [DE]; LANG DIETER [DE]


Application No.: US20090215181A1  Published: 27/Aug/2009

Title: Multi-Analyte Reference Solutions

Applicant/Assignee: INSTRUMENTATION LABORATORY COMPANY

Application No.: 12/203486   Filing Date: 03/Sep/2008

Abstract:The present invention provides a reference solution for use in instruments that determine hematocrit levels in biological samples by measuring the resistance and/or conductivity of the biological samples. A reference solution according to the invention achieves conductivities representative of known hematocrit levels in blood, while maintaining tolerable levels of interference with the measurement of other analytes in the reference solution.

Priority: US2003-733871 Applic. Date: 2003-12-11; US20020432373P Applic. Date: 2002-12-11

Inventor: CONLON DENNIS ROBERT [US]; MANSOURI SOHRAB [US]; VAGO GIANNANTONIO [IT]


Application No.: US20090216246A1  Published: 27/Aug/2009

Title: ULTRASOUND CATHETER DEVICES AND METHODS

Applicant/Assignee: FLOWCARDIA, INC

Application No.: 12/428183   Filing Date: 22/Apr/2009

Abstract:Ultrasound catheter devices and methods provide enhanced disruption of blood vessel obstructions. Generally, an ultrasound catheter device includes an elongate flexible catheter body with one or more lumens, an ultrasound transmission member extending longitudinally through the catheter body lumen and a distal head coupled with the transmission member and positioned adjacent the distal end of the catheter body for disrupting occlusions. A proximal housing of the catheter device may include one or more features for dissipating heat from the ultrasound transmission wire, such as a fluid inlet aperture for passage of fluid, use of heat conductive materials in the proximal housing, surface features to increase the housing's surface area, heat conductive members disposed adjacent the transmission member and the like. Various irrigation fluids may be used, such as cooled, oxygen supersaturated or lubricious fluids.

Priority: US2004-927966 Applic. Date: 2004-08-26

Inventor: NITA HENRY [US]; SARGE JEFF [US]; SPANO RICHARD [US]


Application No.: US20090216317A1  Published: 27/Aug/2009

Title: Delivery of Highly Lipophilic Agents Via Medical Devices

Applicant/Assignee:

Application No.: 11/886815   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US20050664328P Applic. Date: 2005-03-23; WO2006US10307 Applic. Date: 2006-03-22

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]


Application No.: US20090220482A1  Published: 03/Sep/2009

Title: METHODS AND COMPOSITIONS FOR DELIVERING INTERLEUKIN-1 RECEPTOR ANTAGONIST

Applicant/Assignee: BIOMET BIOLOGICS, LLC

Application No.: 12/394723   Filing Date: 27/Feb/2009

Abstract:Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.

Priority: US20080031803P Applic. Date: 2008-02-27; US20080116940P Applic. Date: 2008-11-21; US20090155048P Applic. Date: 2009-02-24

Inventor: HIGGINS JOEL C [US]; WOODELL-MAY JENNIFER E [US]; HOEPPNER JACY C [US]


Application No.: US20090221570A1  Published: 03/Sep/2009

Title: Uses of 2-Phenyl-Substituted Imidazotriazinone Derivatives for Treating Pulmonary Hypertension

Applicant/Assignee: BAYER HELTHCARE AG

Application No.: 11/918312   Filing Date: 27/Mar/2006

Abstract:The present invention relates to the use of PDE 5 inhibitors generally and in particular of known 2-phenyl-substituted imidazotriazinone derivatives for manufacturing medicaments for the treatment of pathological states which can be treated by raising cGMP levels in certain tissues, such as, for example, of, for example: primary pulmonary hypertension, secondary pulmonary hypertension, pulmonary arterial hypertension, portopulmonary hypertension, hepatopulmonary syndrome, pulmonary hypertension caused by medicaments (amphetamines), interstitial lung disease, pulmonary hypertension occurring with HIV, thromboembolic pulmonary hypertension, pulmonary hypertension in children and neonates, pulmonary hypertension induced by atmospheric hypoxia (altitude sickness), COPD, emphysema, chronic bronchial asthma, mucoviscidosis-related pulmonary hypertension, right heart failure, left heart failure and global failure, and which can be treated by raising cGMP levels in certain tissues, such as, for example, isolated systiolic hypertension (ISH) and hardening of blood vessels, specifically of arterial blood vessels, and combination of PDE 5 inhibitors generally and in particular of known 2-phenyl-substituted imidazotriazinone derivatives with further therapeutic agents in the said indications.

Priority: DE200510016345 Applic. Date: 2005-04-09; WO2006EP02774 Applic. Date: 2006-03-27

Inventor: HANING HELMUT [DE]; SERNO PETER [DE]; BISCHOFF ERWIN [DE]; ULBRICH ERNST [DE]


Application No.: US20090221948A1  Published: 03/Sep/2009

Title: SYSTEM AND METHOD FOR DELIVERY OF REGIONAL CITRATE ANTICOAGULATION TO EXTRACORPOREAL BLOOD CIRCUITS

Applicant/Assignee: HENRY FORD HEALTH SYSTEM

Application No.: 12/280450   Filing Date: 22/Feb/2007

Abstract:The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable soultes.

Priority: US20060845646P Applic. Date: 2006-09-19; US20060790882P Applic. Date: 2006-04-11; US20060791055P Applic. Date: 2006-04-11; US20060775728P Applic. Date: 2006-02-22; US20060775729P Applic. Date: 2006-02-22; WO2007US62589 Applic. Date: 2007-02-22

Inventor: SZAMOSFALVI BALAZS [US]; FRINAK STANLEY [US]; YEE JERRY [US]


Application No.: US20090225316A1  Published: 10/Sep/2009

Title: Systems for Measuring Properties of a Physiological Fluid Suspension

Applicant/Assignee:

Application No.: 12/398480   Filing Date: 05/Mar/2009

Abstract:A method of evaluating a property of a physiological fluid suspension comprises measuring a value of the property of a liquid portion of the physiological fluid suspension via light scattering, and comparing the measured value with a reference value to evaluate the property of the liquid portion of the physiological fluid suspension.

Priority: US20080068354P Applic. Date: 2008-03-05

Inventor: SUKAVANESHVAR SIVAPRASAD [US]; TEITEL EDWARD R [US]; MOHAMMAD SYED F [US]


Application No.: US20090226412A1  Published: 10/Sep/2009

Title: AGENT FOR REDUCTION OF BLEEDING IN CEREBROVASCULAR DISORDER

Applicant/Assignee: ONO PHARMACEUTICAL CO., LTD.,

Application No.: 11/993917   Filing Date: 23/Jun/2006

Abstract:The present invention relates to a hemorrhage reducing agent in cerebrovascular disorder containing a poly (ADP-ribose) polymerase inhibitor (PARP inhibitor). The PARP inhibitor provides an inhibitory effect of vascular endothelial cell disorder so that it may reduce hemorrhage in cerebrovascular disorder. In addition, the PARP inhibitor inhibits the hemorrhage that is concerned about in thrombolytic agent use by using together with a thrombolytic agent, and an effect of extending therapeutic time window of a thrombolytic agent may be further expected. Furthermore, the PARP inhibitor can be a safe hemorrhage reducing agent with fewer side effects because it does not affect the blood coagulation system and the fibrinolytic system.

Priority: JP20050185606 Applic. Date: 2005-06-24; WO2006JP312569 Applic. Date: 2006-06-23

Inventor: YASUHIRO TETSUYA [JP]; KITAJIMA TAKASHI [JP]; WAKAMATSU DAISUKE [JP]; KAMOSHIMA WATARU [JP]


Application No.: US20090226415A1  Published: 10/Sep/2009

Title: MODIFIED TRIDEGINS, PRODUCTION AND USE THEREOF AS TRANSGLUTAMINASE INHIBITORS

Applicant/Assignee:

Application No.: 12/406745   Filing Date: 18/Mar/2009

Abstract:The invention relates to modified tridegins, polypeptides derived from SEQ ID No. 1, in which the modification is replacement of a cysteine residue and/or one of the following amino acids-Lys2, Lys7, His10, Gly12, Leu24, Tyr31, Phe34, Arg39, Ile45, Met48, Asp50, Pro55, Phe58, Asn60, Pro65, Arg66, by another amino acid and/or N- or C-terminal deletion, whereby the remaining polypeptide comprises at least the amino acid sequence DDIYQRXVXFPXLPL (SEQ ID NO.89) and/or a covalent bonding to polyethylene glycol. Said polypeptides are novel inhibitors of transglutaminases, in particular of Factor XIIIa, of the terminal enzymes in the blood coagulation cascade. The invention further relates to methods for production of said inhibitors and the use thereof as transglutaminase inhibitors.

Priority: DE20011063333 Applic. Date: 2001-12-21; DE20021058159 Applic. Date: 2002-12-12; US2005-498752 Applic. Date: 2005-02-10; WO2002EP14684 Applic. Date: 2002-12-20

Inventor: GIERSIEFEN HELMUT [DE]; STOECKEL JOHANNES [DE]; PAMP TANJA [DE]; OHLMANN MARION [DE]


Application No.: US20090227504A1  Published: 10/Sep/2009

Title: Pegylated Factor VII Glycoforms

Applicant/Assignee: NOVO NORDISK A/S

Application No.: 12/371156   Filing Date: 13/Feb/2009

Abstract:The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked oligosaccharide chains, and wherein at least one oligosaccharide group is covalently attached to at least one polymeric group.

Priority: DK20020000964 Applic. Date: 2002-06-21; US2007-845175 Applic. Date: 2007-08-27; US2003-609701 Applic. Date: 2003-06-30; WO2003DK00420 Applic. Date: 2003-06-20; US20020394778P Applic. Date: 2002-07-01

Inventor: KLAUSEN NIELS KRISTIAN [DK]; BJORN SOREN [DK]; BEHRENS CARSTEN [DK]; GARIBAY PATRICK WILLIAM [DK]


Application No.: US20090238852A1  Published: 24/Sep/2009

Title: METHODS FOR CONTROLLING INTRACELLULAR CALCIUM LEVELS ASSOCIATED WITH AN ISCHEMIC EVENT

Applicant/Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Application No.: 12/408377   Filing Date: 20/Mar/2009

Abstract:Described herein are methods for controlling the intracellular calcium concentration in a subject prior to experiencing an ischemic event, while experiencing an ischemic event, or while suffering from ischemia. The methods comprise administering an effective amount of O-desulfated heparin to the subject. The methods described herein are also useful in treating the symptoms associated with ischemic events or ischemia.

Priority: US20080038446P Applic. Date: 2008-03-21

Inventor: KENNEDY THOMAS P [US]; BARRY WILLIAM H [US]


Application No.: US20090238874A1  Published: 24/Sep/2009

Title: BIOMIMETIC COMPOSITION REINFORCED BY A POLYELECTROLYTIC COMPLEX OF HYALURONIC ACID AND CHITOSAN

Applicant/Assignee: TISSUE ENGINEERING CONSULTANTS, INC

Application No.: 12/410537   Filing Date: 25/Mar/2009

Abstract:The present invention relates to a three dimensional, malleable cell culture composition and method of forming the same comprising hyaluronic acid, chitosan and a polyelectrolytic complex of hyaluronic acid and chitosan. These three components in combination constitute an initial microenvironment for support of stromal cells, and their undifferentiated mesenchymal cell progeny. The tissue engineering device and method of forming the same comprising hyaluronic acid and chitosan and the use of said device with compositions of pluripotent cells and various formulations of cell culture media for repair of tissues is disclosed.

Priority: US2004-999848 Applic. Date: 2004-11-30; US20030525965P Applic. Date: 2003-12-01

Inventor: BREKKE JOHN H [US]


Application No.: US20090239857A1  Published: 24/Sep/2009

Title: TRIAMINE DERIVATIVE

Applicant/Assignee: DAIICHI SANKYO COMPANY, LIMITED

Application No.: 11/909802   Filing Date: 31/Mar/2006

Abstract:An object of the present invention is to provide a novel compound which has a potent inhibitory effect on FXa and exhibits an excellent antithrombotic effect when orally administered. The present invention provides a compound represented by the following general formula (1): wherein R1 and R2 each independently represent a hydrogen atom, a hydroxy group, an alkyl group or an alkoxy group

Q1 represents a saturated or unsaturated bicyclic or tricyclic fused hydrocarbon group which may be substituted, a saturated or unsaturated bicyclic or tricyclic fused heterocyclic group which may be substituted, or the like

Q2 represents a single bond, a straight-chained or branched alkylene group having 1 to 6 carbon atoms, a straight-chained or branched alkenylene group having 2 to 6 carbon atoms, or the like

R3 and R4 each represent an alkyl group, or the like

m and n each represent an integer from 0 to 3

Q4 represents an aryl group

and T0 and T1 each represent a carbonyl group or the like, and a medicine containing the compound.

Priority: JP20050100335 Applic. Date: 2005-03-31; WO2006JP306930 Applic. Date: 2006-03-31

Inventor: MOCHIZUKI AKIYOSHI [JP]; NAGATA TSUTOMU [JP]


Application No.: US20090246866A1  Published: 01/Oct/2009

Title: READY-TO-USE WHOLE BLOOD COLLECTION VESSEL

Applicant/Assignee:

Application No.: 12/327854   Filing Date: 04/Dec/2008

Abstract:The present invention relates to a sampling tube for collecting and processing a whole blood sample. The sampling tube contains a reagent for differential hemolysis of whole blood, wherein said reagent for differential hemolysis comprises a chemical for differential hemolysis and an anti-coagulant, and wherein said sampling tube is a ready-to-use and single-use sampling tube. It also relates to the use of said sampling tube in the processing of a whole blood sample for liquid chromatography and also to the use of a blood sample processed in such sampling tube in a liquid chromatography-based analysis.

Priority: EP20060011606 Applic. Date: 2006-06-06; WO2007EP04925 Applic. Date: 2007-06-04

Inventor: NASER WERNER [DE]; DUELFFER THOMAS [DE]; HERRMANN RUPERT [DE]; KOBOLD UWE [DE]; VON DER ELTZ HERBERT [DE]


Application No.: US20090247628A1  Published: 01/Oct/2009

Title: SUBSTITUTED PHENYLCYCLOHEXYLGLYCOLATES

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/409420   Filing Date: 23/Mar/2009

Abstract:Disclosed herein are substituted phenylcyclohexylglycolate-based muscarinic acetylcholine receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080039166P Applic. Date: 2008-03-25

Inventor: GANT THOMAS G [US]; SARSHAR SEPEHR [US]


Application No.: US20090254117A1  Published: 08/Oct/2009

Title: Venous Filter with Detachable Anchors

Applicant/Assignee:

Application No.: 12/417990   Filing Date: 03/Apr/2009

Abstract:A venous filter including anchors that detach from the struts and that remain attached to the vein wall after retrieval of the other parts of the filter is described. Anchors may be detachably connected to struts of the filter via a detachably connected ridge and groove, a detachably connected clip and ridge, a friction fit, a detachable locking pin connection, or a combination thereof.

Priority: US20080123043P Applic. Date: 2008-04-03

Inventor: PAKTER ROBERT L [US]


Application No.: US20090258337A1  Published: 15/Oct/2009

Title: Thawed organ or tissue or thawed cell group to be donated, transplanted, added, or administered to living body, production process thereof, supercooled solution therefor, and production apparatus of the organ or tissue

Applicant/Assignee: ELLIE CORPORATION

Application No.: 12/383582   Filing Date: 25/Mar/2009

Abstract:The present invention aims to freeze and store organs or tissues taken from human bodies or animals and after thawing, use the resulting organs or tissues, or cells taken and extracted therefrom for medical treatment. The present invention is characterized in that the organs or tissues taken from human bodies or animals are regenerated through the steps of freezing, storing and thawing

the cells taken from the organs or tissues undergo cell division and colonization.

Priority: JP20080098782 Applic. Date: 2008-04-04

Inventor: YAGI SHUNICHI [JP]


Application No.: US20090259162A1  Published: 15/Oct/2009

Title: System and Method for Plasma Reduced Platelet Collection

Applicant/Assignee:

Application No.: 12/102486   Filing Date: 14/Apr/2008

Abstract:A method and apparatus for collecting plasma reduced platelets potentially suspended in a synthetic solution from a donor. Whole blood is drawn from the donor and introduced into a separation chamber. Platelets are extracted from the separation chamber into a container, using, for example, surge (with anticoagulated plasma or a synthetic solution) or push methodologies. The remaining blood components in the separation chamber are returned back to the donor. The steps of drawing whole blood and introducing the whole blood into the separation chamber, extracting platelets from the separation chamber into the container, and returning the remaining components in the chamber back to the donor are repeated. The sequestered platelets in the container are reintroduced into the separation chamber, whereupon a plasma reduced platelet product is extracted.

Priority:

Inventor: OHASHI TOSHIYASU [JP]; PAGES ETIENNE [FR]; UHLMANN DOMINIQUE [US]; MAILLARD PASCAL [CH]; RAGUSA MICHAEL [US]


Application No.: US20090259163A1  Published: 15/Oct/2009

Title: Three-Line Apheresis System and Method

Applicant/Assignee:

Application No.: 12/102407   Filing Date: 14/Apr/2008

Abstract:A blood processing system for collecting and exchanging blood components includes a venous-access device for drawing whole blood from a subject and returning blood components to the subject. The system may also include three lines connecting the venous access device to a blood component separation device and an anticoagulant source. A blood draw line fluidly connects to the venous-access device to the blood component separation device. An anticoagulant line connected to an anticoagulant source, introduces anticoagulant into the drawn whole blood. A return line, fluidly connected to the venous-access device and the blood component separation device, and returns uncollected blood component to the subject. A draw pump, an anticoagulant pump, and a return pump, respectively control the flows through the draw line, anticoagulant line, and the return line. The blood component separation device separates the drawn blood into a first blood component and a second blood component. The blood component separation device also may be configured to send the first blood component to a first blood component bag.

Priority:

Inventor: PAGES ETIENNE [FR]; RAGUSA MICHAEL [US]


Application No.: US20090259164A1  Published: 15/Oct/2009

Title: System and Method for Optimized Apheresis Draw and Return

Applicant/Assignee:

Application No.: 12/102427   Filing Date: 14/Apr/2008

Abstract:A blood processing device for collecting and exchanging blood components includes a venous-access device for drawing whole blood from a subject and returning unused blood components to the subject. The system may also include a blood component separation device that separates the drawn whole blood into a first blood component and a second blood component. The blood component separation device may also be configured to send the second blood component to a second blood component storage container. The system may use a return line that fluidly connects the venous-access device and the blood component separation device to return the first blood component to the subject. The system may also have a first and second pressure sensor located on the return line. The first pressure sensor may be located between the blood component separation device and the venous-access device and may determine a first pressure within the return line. The second pressure sensor may be located on the return line between the first pressure sensor and the venous-access device and may determine a second pressure within the return line. A pump connected to the return line may control the return flow rate within the return line based on a subject access pressure determined based on the first pressure and the second pressure.

Priority:

Inventor: PAGES ETIENNE [FR]; RAGUSA MICHAEL [US]


Application No.: US20090263903A1  Published: 22/Oct/2009

Title: METHOD FOR DETERMINING PROTHROMBIN TIME

Applicant/Assignee:

Application No.: 11/909208   Filing Date: 20/Mar/2006

Abstract:The present invention relates to tests for monitoring oral anticoagulation therapy and hepatocellular carcinoma (HCC). Particularly, the invention provides a method for determining prothrombin time of a plasma or whole blood sample taking account the effect which protein induced by vitamin K absence or antagonists (Pivka) has on clotting time and INR result. The primary object of the invention is to harmonise prothrombin time methods for international normalized ratio (INR) results and measure INRpivka.

Priority: FI20050000298 Applic. Date: 2005-03-21; WO2006FI50104 Applic. Date: 2006-03-20

Inventor: HORSTI JUHA [FI]


Application No.: US20090265182A1  Published: 22/Oct/2009

Title: Method and system for point-of-dispensing management of anticoagulation agent therapy

Applicant/Assignee:

Application No.: 12/081794   Filing Date: 22/Apr/2008

Abstract:A method and system for point-of-dispensing, point-of-sale, or retail pharmacy management of an anticoagulation agent therapy for a subject, includes reviewing an anticoagulation regimen and obtaining data for a subject relating to anticoagulation therapy, determining an International Normalized Ratio (INR) level for the subject, determining any potential interaction of the anticoagulation agent with one or more non-anticoagulation agents that the subject intends to take or is taking, evaluating in real time any need to adjust the anticoagulation regimen, and adjusting in real time, if needed, the anticoagulation regimen based on one or both INR level and any interaction determinations, to maintain the subject's INR level within a desired range.

Priority:

Inventor: PETERSON BRENT W [US]; DAY ALLEN M [US]; NUNN CHARLES E [US]


Application No.: US20090269325A1  Published: 29/Oct/2009

Title: Methods for treating bleeding disorders using sulfated polysaccharides

Applicant/Assignee: BAXTER INTERNATIONAL INC BAXTER HEALTHCARE S.A BAXTER HEALTHCARE S. A

Application No.: 12/386026   Filing Date: 13/Apr/2009

Abstract:Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.

Priority: US2005-140504 Applic. Date: 2005-05-27; US20040574845P Applic. Date: 2004-05-27

Inventor: JOHNSON KIRK W [US]


Application No.: US20090269418A1  Published: 29/Oct/2009

Title: Compositions and Methods for Inducing Hair Growth

Applicant/Assignee: BIOMAS LTD

Application No.: 11/662743   Filing Date: 15/Sep/2005

Abstract:Novel therapeutic methods and pharmaceutical compositions utilizing tellurium-containing compounds for inducing hair growth for the treatment of various types of alopecia and other conditions associated with hair loss.

Priority: US20040610660P Applic. Date: 2004-09-17; WO2005IL00991 Applic. Date: 2005-09-15

Inventor: ALBECK MICHAEL [IL]; SREDNI BENJAMIN [IL]


Application No.: US20090270332A1  Published: 29/Oct/2009

Title: GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF

Applicant/Assignee: CELERA CORPORATION

Application No.: 12/403552   Filing Date: 13/Mar/2009

Abstract:The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Priority: US20080069687P Applic. Date: 2008-03-13

Inventor: BARE LANCE [US]; DEVLIN JAMES J [US]; ROSENDAAL FRITS R [NL]; REITSMA PIETER H [NL]; BEZEMER IRENE D [NL]


Application No.: US20090270469A1  Published: 29/Oct/2009

Title: SUBSTITUTED OXAZOLIDINONES

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/428275   Filing Date: 22/Apr/2009

Abstract:The present invention relates to new oxazolidinone modulators of skeletal muscle function and tone, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080048028P Applic. Date: 2008-04-25

Inventor: GANT THOMAS G [US]; SARSHAR SEPEHR [US]


Application No.: US20090276039A1  Published: 05/Nov/2009

Title: Implantable Prosthetic Valve

Applicant/Assignee: CLINASYS LLC

Application No.: 12/158747   Filing Date: 22/Dec/2006

Abstract:An implantable prosthetic valve for regulating fluid flow through a body vessel is provided. The prosthetic valve comprises an anchoring member, at least one leaflet, and a restraining member capable of temporarily preventing substantial movement of the leaflet between and open and closed position so as to allow fluid flow in the antegrade and retrograde directions. In various embodiments, the prosthetic valve reduces the risk of thrombosis. In various embodiments, the prosthetic valve reduces the appearance of potentially thrombogenic abnormal flow patterns at the site of implantation immediately following the implantation, allows cell deposition making the valve more biocompatible, less thrombogenic before flow changes resulting from valving action set in and allows tissue growth so that a partially or completely biological functioning valve may form on the scaffold provided by the implant.

Priority: US20050753716P Applic. Date: 2005-12-23; WO2006US48799 Applic. Date: 2006-12-22

Inventor: MERETEI ATTILA [US]


Application No.: US20090280570A1  Published: 12/Nov/2009

Title: METHOD FOR TESTING EFFICACY OF ANTITHROMBOTIC AGENT

Applicant/Assignee:

Application No.: 11/915273   Filing Date: 08/Nov/2005

Abstract:The present invention provides a method for testing quickly and easily the manner in which an antithrombotic agent inhibits the acceleration of blood coagulation when a platelet agonist causes acceleration of blood coagulation. The invention is a test method wherein a system in which an anticoagulant is added to a portion of blood sampled from a patient being administered an antithrombotic agent (X system blood), and a system in which an anticoagulant and adenosine diphosphate or collagen are added to a portion of the abovementioned blood (Y system blood) are simultaneously measured by thromboelastograph

and the efficacy of the antithrombotic agent is assessed by comparing the R values of the X system blood and the Y system blood. If the R value of the Y system blood is not found to differ significantly from the R value of the X system blood, the drug is judged to be working. Adenosine diphosphate and collagen can be used as the anticoagulant. The present invention provides a heretofore unknown method for easily assessing the efficacy of an antithrombotic agent.

Priority: JP20050149183 Applic. Date: 2005-05-23; WO2005JP20421 Applic. Date: 2005-11-08

Inventor: KAWASAKI JUN [JP]; TANAKA KENICHI [JP]


Application No.: US20090281455A1  Published: 12/Nov/2009

Title: BLOOD TEST APPARATUS

Applicant/Assignee: MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD

Application No.: 12/159904   Filing Date: 28/Dec/2006

Abstract:A blood test apparatus wherein a blood collection needle and a blood sensor can be easily attached and detached so that a burden or pain of a patient can be relieved. More specifically speaking, a blood test apparatus wherein a holder, a lancet, a blood collection needle and a blood sensor are united together as a blood sampling cartridge that is detachably mounted to the apparatus body. When this blood sampling cartridge is attached, a plunger involved in the apparatus body holds the lancet and connectors involved in the apparatus body come into contact with the blood sensor. It is preferable that the contact points with the blood sensor of the individual connectors are located at intervals at the same angle centering on a definite point.

Priority: JP20060000354 Applic. Date: 2006-01-05; JP20060000355 Applic. Date: 2006-01-05; JP20060000356 Applic. Date: 2006-01-05; JP20060000357 Applic. Date: 2006-01-05; JP20060000358 Applic. Date: 2006-01-05; JP20060022040 Applic. Date: 2006-01-31; WO2006JP326262 Applic. Date: 2006-12-28

Inventor: FUJIWARA MASAKI [JP]; AKIYAMA TOSHIHIRO [JP]; AMANO YOSHINORI [JP]


Application No.: US20090281516A1  Published: 12/Nov/2009

Title: MULTILAYER CONTAINERS

Applicant/Assignee: BECTON, DICKINSON AND COMPANY

Application No.: 12/270399   Filing Date: 13/Nov/2008

Abstract:A multilayer evacuated blood collection tube is provided having a first tube layer, and a second tube layer formed on the first tube layer and a closure, the second tube layer being a nanocomposite barrier layer. Such containers include but are not limited to blood collection tubes, evacuated blood collection tubes, centrifuge tubes, culture bottles, and syringe barrels.

Priority: US2004-480540 Applic. Date: 2004-07-02

Inventor: AHERN BRIAN F [US]; GRIPPI NICHOLAS A [US]; SOSKEY PAUL R [US]; CARANO DONALD J [US]; HUTTON NORMAN J [US]; DESALVO DANIELLE M [US]; LUSARDI GREGORY L [US]


Application No.: US20090285722A1  Published: 19/Nov/2009

Title: Collection container assembly with nanocomposite barrier coating

Applicant/Assignee:

Application No.: 12/383058   Filing Date: 19/Mar/2009

Abstract:An evacuated container assembly suitable for use in connection with blood collection including: (a) a container member formed of a first polymeric material and having a sidewall and one or more openings

(b) a nanocomposite barrier coating disposed on the container member having a thickness of up to about 30 microns and being derived from an aqueous dispersion including (i) a dispersed barrier matrix polymer

and (ii) a substantially exfoliated silicate filler having an aspect ratio of more than 50

and (c) one or more sealing members disposed in the opening(s) operative to hermetically seal the cavity

wherein the cavity is evacuated and maintains a pressure below atmospheric pressure and exhibits a draw volume loss lower than that of a like assembly without a nanocomposite barrier film by a factor of at least 1.5.

Priority: US20080070128P Applic. Date: 2008-03-20

Inventor: SOSKEY PAUL R [US]; PARMER JR JEROME F [US]; GOLDBERG HARRIS A [US]; KARIM DOUGLAS P [US]; SAMANTARA LAXMI [US]; FEENEY CARRIE A [US]; FARRELL MICHELE [US]


Application No.: US20090285786A1  Published: 19/Nov/2009

Title: METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH

Applicant/Assignee: CHILDREN'S MEDICAL CENTER CORPORATION

Application No.: 12/294344   Filing Date: 26/Mar/2007

Abstract:The present invention provides for compositions and methods for modulating hematopoietic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo.

Priority: US20060785968P Applic. Date: 2006-03-24; WO2007US07419 Applic. Date: 2007-03-26

Inventor: ZON LEONARD I [US]; NORTH TRISTA E [US]; GOESSLING WOLFRAM [US]


Application No.: US20090285811A1  Published: 19/Nov/2009

Title: ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE GLUCOCORTICOID STEROIDS

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: 12/464150   Filing Date: 12/May/2009

Abstract:The present invention relates to new glucocorticoid steroid modulators of glucocorticoid receptor, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20080052872P Applic. Date: 2008-05-13

Inventor: GANT THOMAS G [US]; SHAHBAZ MANOUCHER M [US]; MEJORADO LUPE [US]


Application No.: US20090285892A1  Published: 19/Nov/2009

Title: METHODS AND SYSTEMS FOR EXPANDING AC133+ CELLS AND DIRECTING DIFFERENTIATION

Applicant/Assignee:

Application No.: 12/351630   Filing Date: 09/Jan/2009

Abstract:The invention provides, among other things, methods and systems for expanding CD133+ cells. The invention further provides methods and systems for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides methods and systems for directing differentiation of expanded CD133+ cells. The invention further provides methods and systems for treating a subject with differentiated cells in a subject in need thereof.

Priority: US2007-975492 Applic. Date: 2007-10-18; US20060852598P Applic. Date: 2006-10-18; US20080010917P Applic. Date: 2008-01-10; US20080190544P Applic. Date: 2008-08-28

Inventor: SAKTHIVEL RAMASAMY [US]; BROWN DONALD J [US]; MAO HAI-QUAN [US]; DOUAY LUC [FR]; POMPILI VINCENT J [US]; MCLNTOSH KEVIN [US]; DAS HIRANMOY [US]; ZHAO YUKANG [US]


Application No.: US20090286251A1  Published: 19/Nov/2009

Title: Enzyme Reagents for Amplification of Polynucleotides in the Presence of Inhibitors

Applicant/Assignee: NEW ENGLAND BIOLABS, INC

Application No.: 12/466856   Filing Date: 15/May/2009

Abstract:Compositions and methods are provided for amplifying polynucletoides from samples containing inhibitors that normally inhibit amplification using an enzyme blend containing a plurality of polymerases. The ability to amplify polynucleotides efficiently in the presence of inhibitors allows the enzyme reagent to be used in both routine amplification and real-time amplification from inhibitor-containing samples.

Priority: US20080053740P Applic. Date: 2008-05-16

Inventor: XU YAN [US]


Application No.: US20090287305A1  Published: 19/Nov/2009

Title: Wholly implantable non-natural heart for humans

Applicant/Assignee:

Application No.: 12/152896   Filing Date: 19/May/2008

Abstract:A wholly implantable non-natural heart for humans is a double pump configuration provided with two auricles and two ventricles. Both the said auricles and ventricles are driven by solenoid actuators interacting with high energy magnets

the auricles and ventricles which are hollow chambers are provided with one-way valves in the usual manner, for the purpose of effectively and rhythmically moving blood to and from the said chambers

power generation for driving said solenoid actuators, as well as an electronic control unit is accomplished by a power generating module which could be a simple battery, a miniature spring-driven generator, a mems generator or a redundant self-sustaining generator or a combination of all of the above

the self-sustaining generator has been proposed and designed to power this present artificial heart and will be presented in a separate patent application in the near future as a follow up to this present one

the aforementioned electronic control unit is preferably configured to amplify the signals from the power generating unit as well as utilizing input/output signals from temperature and pressure sensors embedded in the heart to vary contractile force and frequency of beats, based on bodily requirements, thereby mimicking some functions of the natural heart

the electronic unit is also preferably provided with a translator chip that converts signals from the cardiac/vargus trunks (sympathetic and parasympathetic nerves) via electrodes into clear electric currents for varying actuator outputs

the heart would be implanted in the normal position in the chest, atop the diaphragm, while the electronic control unit and the power generation module would preferably be implanted behind the breastbone and lower abdomen respectively

all components of the present invention are amenable to current mass production techniques and miniaturization for the purpose of fitting into individuals of various sizes

as is clearly shown in FIG. 1, this present invention is an integral three-tiered configuration constituted of pumping unit I, the power generating unit II and the controller III. Also, as aforementioned, additional signals from the embedded temperature and pressure sensors, as well as nerve connecting electrodes are used to manipulate instantaneous outputs. The said electrodes are in the form of cuffs and are to be implanted on the vargus nerves (sympathetic and parasympathetic)

Texas Instruments (TI) manufactures reliable operational and instrumentation amplifiers which can detect condition, and amplify nerve signals. The VCO in the controller uses the signals to manipulate instantaneous outputs of the actuating solenoids.

Priority:

Inventor: AMALAHA LEONARD D [US]


Application No.: US20090288178A1  Published: 19/Nov/2009

Title: INSECT CELL LINE FOR PRODUCTION OF RECOMBINANT GLYCOPROTEINS WITH SULFATED COMPLEX N-GLYCANS

Applicant/Assignee:

Application No.: 12/421977   Filing Date: 10/Apr/2009

Abstract:A transgenic insect cell line for production of recombinant glycoproteins possessing sulfated, complex N-glycans is provided.

Priority: WO2007US80997 Applic. Date: 2007-10-10; US20060850573P Applic. Date: 2006-10-10

Inventor: JARVIS DONALD L [US]


Application No.: US20090297596A1  Published: 03/Dec/2009

Title: Nanoparticulate and Controlled Release Compositions Comprising a Platelet Aggregation Inhibitor

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LIMITED

Application No.: 11/568835   Filing Date: 23/May/2006

Abstract:The present invention provides a composition comprising a platelet aggregation inhibitor, for example, cilostazol, or a salt or derivative thereof, useful in the treatment and prevention of ischemic symptoms. The invention provides a composition which comprises nanoparticulate particles comprising the platelet aggregation inhibitor and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a platelet aggregation inhibitor, or nanoparticles comprising the same, in a pulsatile or continuous manner.

Priority: US20050683620P Applic. Date: 2005-05-23; WO2006US19905 Applic. Date: 2006-05-23

Inventor: DEVANE JOHN [IE]; STARK PAUL [IE]; FANNING NIALL [IE]; REKHI GURVINDER [US]; JENKINS SCOTT [US]; LIVERSIDGE GARY [US]


Application No.: US20090298060A1  Published: 03/Dec/2009

Title: METHODS FOR DIAGNOSING AND MONITORING THE STATUS OF SYSTEMIC LUPUS ERYTHEMATOSUS

Applicant/Assignee: XDX, INC

Application No.: 11/938227   Filing Date: 09/Nov/2007

Abstract: and diagnosing or monitoring the status of SLE in the subject or patient by applying at least one statistical method to the expression of the genes of the diagnostic set.

Priority: US20060858147P Applic. Date: 2006-11-09

Inventor: LAL PREETI G [US]; WILLIAMS GAVIN E [US]; FRY KIRK E [US]; SUN JINGTAO [US]; DEDRICK RUSSELL L [US]


Application No.: US20090298078A1  Published: 03/Dec/2009

Title: METHOD FOR THE DETECTION OF AN ACTIVATION OF THE IMMUNE SYSTEM OR THE EXTENT OF CELL DEATH

Applicant/Assignee: LEUKOCARE AG

Application No.: 12/442383   Filing Date: 01/Oct/2007

Abstract:The present invention relates to a method for the detection of an activation of the immune system, preferably in the sense of an NET formation, or the extent of cell death in a non-tumorous tissue or in a body fluid, wherein free DNA is measured in a sample from an individual. Furthermore, the invention relates to a method for the production of a kit for the detection of an activation of the immune system or the extent of cell death in an individual, comprising the packaging of a fluorescent dye and a DNA standard in at least one container.

Priority: US20060827571P Applic. Date: 2006-09-29; WO2007EP08523 Applic. Date: 2007-10-01

Inventor: MARGRAF STEFAN [DE]


Application No.: US20090298090A1  Published: 03/Dec/2009

Title: METHODS TO MEASURE IMMUNOSUPPRESSIVE TACROLIMUS, SIROLIMUS, AND CYCLOSPORIN A COMPLEXES IN A BLOOD SAMPLE

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/539825   Filing Date: 12/Aug/2009

Abstract:The present invention provides methods, diagnostic assays, and diagnostic kits based on said methods, to determine levels of immunosuppressive complexes containing immunosuppressive drugs tacrolimus, sirolimus and cyclosporine A separately and in combination, formed in the blood of a drug-treated patient or in a patient candidate to immunosuppressive drug therapy. These methods, assays and kits are especially useful when using automated systems.

Priority: US2006-398997 Applic. Date: 2006-04-06; US20050668714P Applic. Date: 2005-04-06

Inventor: DRENGLER SUSAN M [US]; BAUGHER BENNETT W [US]


Application No.: US20090298103A1  Published: 03/Dec/2009

Title: Predicting hemostatic risk

Applicant/Assignee: THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE

Application No.: 12/454677   Filing Date: 20/May/2009

Abstract:Featured are methods for assessing hemostatic risk including the risk for ACS. Such methods include acquiring blood/plasma composition based on a biological sample obtained from a subject, determining parameters associated with blood clotting, simulating in silico blood clotting using the determined parameters and comparing the results of such simulation to a reference and to determine the hemostatic risk from said comparing. In further embodiments, such methods further include selecting a treatment regime or protocol based on the results of such comparing. In yet further embodiments, such methods further include assessing the efficacy of medicants, drugs and the like of a given treatment protocol such as by simulating in silico the application of such medicants, drugs and the like.

Priority: US20080054503P Applic. Date: 2008-05-20

Inventor: MANN KENNETH G [US]; ZIEDINS KATHLEEN B [US]; ORFEO THOMAS [US]; HOCKIN MATTHEW F [US]; EVERSE STEPHEN J [US]


Application No.: US20090299223A1  Published: 03/Dec/2009

Title: BLOOD COMPONENT COLLECTION APPARATUS AND METHOD

Applicant/Assignee: TERUMO KABUSHIKI KAISHA

Application No.: 12/488649   Filing Date: 22/Jun/2009

Abstract:A blood component collection apparatus comprises a blood component collecting circuit which includes an anticoagulant line for feeding an anticoagulant and a line for collecting an initial flow of collected blood. In the blood component collection apparatus, air is intermediately present between the anticoagulant and the blood in the passage of a blood collection needle side line, after a priming operation is performed in which anticoagulant is supplied from the anticoagulant line toward the side of a centrifugal separator in the blood collection needle side line through a branch connector and after an initial flow collecting operation is performed in which the initial flow of blood is collected.

Priority: JP20050178316 Applic. Date: 2005-06-17; US2006-453840 Applic. Date: 2006-06-16

Inventor: HIRABUKI MAKOTO [JP]


Application No.: US20090304577A1  Published: 10/Dec/2009

Title: Peptides for Treatment and Diagnosis of Autoimmune Disease

Applicant/Assignee:

Application No.: 11/990281   Filing Date: 09/Aug/2006

Abstract:There are provided peptides derived from antibodies with reactivity against a GPI linkage epitope and functionally equivalent ligands. These peptides can be used in the therapy and diagnosis of a variety of diseases, all of which are considered to be caused by the inappropriate presence in the body of autoantibodies which are reactive with GPI linkage epitopes. There is also described a mechanism of action of these autoantibodies which compromises the organism, so causing disease, and a method of prevention of disease and detection of the autoantibody.

Priority: GB20050016527 Applic. Date: 2005-08-11; GB20060009920 Applic. Date: 2006-05-18; GB20060009921 Applic. Date: 2006-05-18; WO2006GB02977 Applic. Date: 2006-08-09

Inventor: MATOSSIAN-ROGERS ARPI [GB]


Application No.: US20090305315A1  Published: 10/Dec/2009

Title: HUBBED DUAL CANNULA DEVICE FOR CLOSED CONTAINER SAMPLING SYSTEMS

Applicant/Assignee:

Application No.: 12/480476   Filing Date: 08/Jun/2009

Abstract:The present invention provides a hubbed dual cannula device for extracting a fluid sample from a closed container. The device comprises a housing hub, two substantially parallel needles, a venting valve and a hydrophobic membrane, and may be used effectively to extract a fluid sample from a sealed container, such as a vacuum tube, without damaging the cellular components or activating platelets in the fluid sample. Also provided are methods for using the disclosed device to extract a fluid sample from a closed container and kits for measuring platelet aggregation using such a device.

Priority: US20080060076P Applic. Date: 2008-06-09

Inventor: GANDOLA KENT RAPHAEL [US]; KAPLAN DAVID ELLIOTT [US]; BARE REX O [US]; JOHNSON CHRISTOPHER JOHANN [US]


Application No.: US20090305325A1  Published: 10/Dec/2009

Title: Method for Preservation of Human Hematopoietic Stem or Progenitor Cells

Applicant/Assignee: DEPARTMENT OF BIOTECHNOLOGY NATIONAL CENTRE FOR CELL SCIENCE INDIAN INSTITUTE OF SCIENCES

Application No.: 12/096292   Filing Date: 27/Jun/2006

Abstract:Maintenance of quiescent hematopoietic stem and progenitor cells (HSPC) in culture without the addition of exogenous growth factors is an important aspect in clinical hematology. A recent report described the ability of Flt3 receptor-interacting lectin (FRIL) in the maintenance of cord blood (CB) derived progenitors in vitro. Since FRIL is a mannose binding lectin, the effectiveness of four such lectins of well-characterized specificities on the preservation of HSPC of CB origin have been examined. The HSPC preservation activity of lectins was assessed by in vitro colony forming unit (CFU) and long-term culture initiating cell (LTC-IC) assays. It was found that all four lectins had a HSPC preservation activity at least up to 30 days in culture without addition of exogenous growth factors. The results indicate that use of such lectins may provide a cost effective method of HSPC maintenance for clinical use.

Priority: IN2005DE03284 Applic. Date: 2005-12-06; WO2006IN00215 Applic. Date: 2006-06-27

Inventor: KALE VAIJAYANTI P [IN]; LIMAYE LALITA S [IN]; HINGE ASHWINI [IN]; SUROLIA AVADHESHA [IN]


Application No.: US20090305407A1  Published: 10/Dec/2009

Title: Devices and Methods for Sampling Biological Fluids

Applicant/Assignee:

Application No.: 12/406815   Filing Date: 18/Mar/2009

Abstract:Devices, instruments, systems and methods are provided in which a primary line that receives a biological fluid is selectively sampled by a plurality of collection chambers. Selective sampling occurs by selectively accessing the primary line and selective engagement of a sampling pump under control of a microprocessor. Further, the instrument housing reversibly houses a drive assembly and sample collection housing to permit the interchangeability of drive assemblies and collection housings and thus enhance sterility or reduction of cost.

Priority: US20080037587P Applic. Date: 2008-03-18

Inventor: TEMPLE JOHN [US]


Application No.: US20090306623A1  Published: 10/Dec/2009

Title: Multiple ratio fluid dispenser

Applicant/Assignee: ARTERIOCYTE MEDICAL SYSTEMS, INC

Application No.: 12/462885   Filing Date: 10/Aug/2009

Abstract:A double syringe delivery system is disclosed for holding a pair of syringes in a manner so as to accommodate the simultaneous activation of the plunger of each syringe in order to effect simultaneous delivery of the contents of each syringe. The delivery system includes a delivery mechanism for delivering the contents of both syringes to a site of application. The delivery system further includes a support member that is positioned between the two syringe bodies. The elongated support member has resilient, C-shaped clamps on one end of the support member. The clamps are designed to be removably clamped onto the applicator so that the syringe barrels will be held together in a parallel manner. The elongated support member further comprises finger grips. A plunger connects the two syringe plungers so that they can also be simultaneously activated.

Priority: US2004-876147 Applic. Date: 2004-06-24; US2002-212430 Applic. Date: 2002-08-05; US20020388822P Applic. Date: 2002-06-14

Inventor: MCINTOSH KEVIN D [US]; ALBRECHT RICHARD M [US]


Application No.: US20090307179A1  Published: 10/Dec/2009

Title: Genetic analysis

Applicant/Assignee:

Application No.: 12/383110   Filing Date: 18/Mar/2009

Abstract:The present invention provides methods for generating genetic profiles or analyses. Included are methods for conducting comprehensive, dynamic genetic analysis. Also provided are methods for determining genetic health scores for specific phenotypes, such as diseases, disorders, traits, and conditions, as well as for organ systems, for certain medical specialties, and for overall health.

Priority: US20080037959P Applic. Date: 2008-03-19; US20080050126P Applic. Date: 2008-05-02; US20080091342P Applic. Date: 2008-08-22; US20080136266P Applic. Date: 2008-08-22; US20080198765P Applic. Date: 2008-11-07

Inventor: COLBY BRANDON [US]; SLATER BATHANY [US]; COLBY MELVYN [US]; COLBY BRYON [US]


Application No.: US20090307180A1  Published: 10/Dec/2009

Title: Genetic analysis

Applicant/Assignee:

Application No.: 12/383117   Filing Date: 18/Mar/2009

Abstract:The present invention provides methods for generating genetic profiles or analyses. Included are methods for conducting comprehensive, dynamic genetic analysis. Also provided are methods for determining genetic health scores for specific phenotypes, such as diseases, disorders, traits, and conditions, as well as for organ systems, for certain medical specialties, and for overall health.

Priority: US20080037959P Applic. Date: 2008-03-19; US20080050126P Applic. Date: 2008-05-02; US20080091342P Applic. Date: 2008-08-22; US20080136266P Applic. Date: 2008-08-22; US20080198765P Applic. Date: 2008-11-07

Inventor: COLBY BRANDON [US]; SLATER BETHANY [US]; COLBY MELVYN [US]; COLBY BRYON [US]


Application No.: US20090307181A1  Published: 10/Dec/2009

Title: Genetic analysis

Applicant/Assignee:

Application No.: 12/383122   Filing Date: 18/Mar/2009

Abstract:The present invention provides methods for generating genetic profiles or analyses. Included are methods for conducting comprehensive, dynamic genetic analysis. Also provided are methods for determining genetic health scores for specific phenotypes, such as diseases, disorders, traits, and conditions, as well as for organ systems, for certain medical specialties, and for overall health.

Priority: US20080037959P Applic. Date: 2008-03-19; US20080050126P Applic. Date: 2008-05-02; US20080091342P Applic. Date: 2008-08-22; US20080136266P Applic. Date: 2008-08-22; US20080198765P Applic. Date: 2008-11-07

Inventor: COLBY BRANDON [US]; SLATER BETHANY [US]; COLBY MELVYN [US]; COLBY BRYON [US]


Application No.: US20090311309A1  Published: 17/Dec/2009

Title: Novel Tissue Support

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 12/544735   Filing Date: 20/Aug/2009

Abstract:The present disclosure provides tissue supports which may be utilized by themselves or in combination with other tissue closure means to enhance wound closure and healing. The tissue supports are made of a material which shrinks upon application of heat or light to further support the tissue and/or wound to which it is applied.

Priority: US2007-825478 Applic. Date: 2007-07-06; US20060819152P Applic. Date: 2006-07-07

Inventor: PROMMERSBERGER STOPEK MEGAN [US]


Application No.: US20090311706A1  Published: 17/Dec/2009

Title: QUANTITATIVE ANALYSIS OF IN VIVO MUTATION AT THE PIG-A LOCUS

Applicant/Assignee: LITRON LABORATORIES, LTD

Application No.: 12/483829   Filing Date: 12/Jun/2009

Abstract:The invention relates to methods and kits for the quantitative analysis of in vivo mutation frequencies of the Pig-A gene in individuals exposed to a genotoxicant, particularly using peripheral blood samples of vertebrates.

Priority: US20080061031P Applic. Date: 2008-06-12

Inventor: DERTINGER STEPHEN D [US]


Application No.: US20090317329A1  Published: 11/Jun/2009

Title: Anticoagulation Agent and Uses Thereof

Applicant/Assignee: BAKER MEDICAL RESEARCH INSTITUTE BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LIMITED

Application No.: 11/988196   Filing Date: 05/Jul/2006

Abstract:The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.

Priority: AU20050903570 Applic. Date: 2005-07-05; AU20050905522 Applic. Date: 2005-10-06; WO2006AU00943 Applic. Date: 2006-07-05

Inventor: PETER KARLHEINZ [AU]


Application No.: US20090317468A1  Published: 24/Dec/2009

Title: MULTICOMPARTMENT GRANULATE FORMULATIONS FOR ACTIVE SUBSTANCES

Applicant/Assignee: BAYER TECHNOLOGY SERVICES GMBH

Application No.: 12/374568   Filing Date: 07/Jul/2007

Abstract:The invention relates to molded article that contains active substances and comprises at least two compartments that have a different material composition. Each compartment is independently provided with at least one active substance that is contained in a matrix. Each matrix encompasses at least one filler at a concentration of >=20 percent by weight to <=100 percent by weight relative to the total weight of the respective matrix. The invention further relates to a method for producing such molded articles as well as the use thereof.

Priority: DE200610033723 Applic. Date: 2006-07-21; WO2007EP06046 Applic. Date: 2007-07-07

Inventor: LETMATHE CLAUDIA [DE]; EBLE AXEL [DE]; BORK OLAF [DE]


Application No.: US20090317471A1  Published: 24/Dec/2009

Title: CONTROLLED-RELEASE FORMULATIONS, METHOD OF MANUFACTURE, AND USE THEREOF

Applicant/Assignee: MUTUAL PHARMACEUTICAL COMPANY, INC

Application No.: 12/330280   Filing Date: 08/Dec/2008

Abstract:The present invention includes a controlled-release composition having a matrix. The matrix contains a pharmaceutically effective amount of an active agent or a pharmaceutically acceptable salt or solvate thereof, an ionic non-gelling matrix polymer, and a pH modifier. The ionic non-gelling matrix polymer is practically insoluble and unswellable at a first aqueous fluid pH and is soluble at a second aqueous fluid pH. The pH modifier is present in an amount to control the release of the active agent from the composition. The controlled-release composition is substantially free of a gelling or swellable excipient and does not contain a functional coating or a lipophilic component. The present invention also provides methods of making and using the controlled-release compositions.

Priority: US2008-143460 Applic. Date: 2008-06-20

Inventor: NARINGREKAR GANDHA V [US]; ARNOLD KRISTIN A [US]; ERKOBONI DAVID [US]


Application No.: US20090317473A1  Published: 24/Dec/2009

Title: CONTROLLED-RELEASE FORMULATIONS, METHOD OF MANUFACTURE, AND USE THEREOF

Applicant/Assignee:

Application No.: 12/143460   Filing Date: 20/Jun/2008

Abstract:The present invention includes a controlled-release composition having a matrix. The matrix contains a pharmaceutically effective amount of an active agent or a pharmaceutically acceptable salt, solvate, ester, and/or prodrug thereof, an ionic non-gelling matrix polymer, and a pH modifier. The ionic non-gelling matrix polymer is practically insoluble and unswellable at a first aqueous fluid pH and is soluble at a second aqueous fluid pH. The pH modifier is present in an amount to control the release of the active agent from the composition. The controlled-release composition is substantially free of a gelling or swellable excipient. The present invention also provides methods of making and using the controlled-release compositions.

Priority:

Inventor: NARINGREKAR GANDHA V [US]; ARNOLD KRISTIN A [US]; ERKOBONI DAVID [US]


Application No.: US20090317790A1  Published: 24/Dec/2009

Title: Method for the Production of Frozen Blood or Frozen Blood Cells for Biological Assays

Applicant/Assignee:

Application No.: 12/443302   Filing Date: 27/Sep/2007

Abstract:The present invention relates to an improved method for cryo-preservation of human whole blood containing monocytes and lymphocytes at temperatures of between -40 DEG C. and -60 DEG C., preferably at -60 DEG C., whereby the function of monocytes and lymphocytes is preserved. The present invention, particularly relates to a method for cryo-preservation of human whole blood containing monocytes and lymphocytes without the need for an isolation of peripheral blood mononuclear cells (PBMCs), or blood cells.

Priority: EP20060020256 Applic. Date: 2006-09-27; WO2007EP08439 Applic. Date: 2007-09-27

Inventor: MONTAG-LESSING THOMAS [DE]; SPREITZER INGO [DE]; LOESCHNER BETTINA [DE]


Application No.: US20090317843A1  Published: 24/Dec/2009

Title: METHOD FOR MEASURING PLASMA LEVELS OF LONG PENTRAXIN PTX3

Applicant/Assignee:

Application No.: 12/520059   Filing Date: 22/Jun/2009

Abstract:The present invention relates to a method for measuring PTX3 in a biological fluid, particularly in human or animal plasma. Particularly, the present invention relates to a method for measuring PTX3 levels in a human or animal derived plasma sample, comprising a stage of the treatment of said plasma sample with a red blood cell agglutinating agent and a subsequent stage of determining the plasma levels of PTX3.

Priority: WO2006IT00872 Applic. Date: 2006-12-22

Inventor: MANTOVANI ALBERTO [IT]; PERI GIUSEPPE [IT]; PASQUALINI FABIO [IT]


Application No.: US20090326510A1  Published: 31/Dec/2009

Title: Drug Delivery Methods and Systems

Applicant/Assignee:

Application No.: 12/165328   Filing Date: 30/Jun/2008

Abstract:Drug delivery methods and systems that include a determination of whether a cardiac condition is normal or abnormal, so that a drug may be administered in accordance with that determination. In one implementation, a drug delivery device may be controlled to reduce or stop the drug administration when a normal cardiac condition is detected. In another implementation, a patient monitoring device determines the duration that a cardiac condition is normal and provides an output indicative of the determination so that the patient may alter a therapy accordingly.

Priority:

Inventor: HAEFNER PAUL A [US]; MOON LOELL BOYCE [US]

...or search a US patent No (ex:
7666555) or a US patent
application (ex: 2003123456)
or a World (PCT) No (Ex:
2007666555)
Search for anything. Simply
type the words in the box..
US Applications Published in 2010
US Applications Published from 2001 -2005
US PROVISIONAL PATENT APPLICATIONS IN BLOOD ANTICLOT TECHNOLOGY PUBLISHED FROM 2006 TO 2009
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms
included drugs, medications, formulation and devices related to blood anticlotting; blood thinners, anticoagulants, protease enzymes, coumadin and thrombin drugs, thrombin inhibitors,
heparin, warfarin and related technologies. The document search strategy of Formula Scan™ includes proprietary direct and proximity data mining algorithms to retrieve and select highly
relevant documents.
Clck to enlarge and view details